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Anterior gradient-2 (AGR2) is an endoplasmic reticulum (ER)-resident protein that 
belongs to a member of protein disulphide isomerase (PDI) superfamily. AGR2 
initially emerged as a dominant effector of basic biological properties in vertebrates 
such as specifying forebrain integrity and limb generation. Subsequent studies in 
mammals implicated the role of AGR2 as a pro-metastatic protein essential to cancer 
progression and drug resistance, asthma and inflammatory bowel disease. AGR2 
protein is mainly overexpressed in a number of human cancers and involved in 
pathways for ER stress, protein folding, transcription regulation, and exosome 
formation. Hence, AGR2 protein represents a clinically-relevant oncoprotein in 
tumour emergence and survival.  
 
The aim of this thesis is to shed more light on the role of AGR2 in cancer development. 
AGR2 was previously shown that it could bind sequence-specifically to a linear 
peptide motif. In this study, hydrogen/deuterium exchange mass spectrometry was 
used to identify the dominant peptide-binding site on AGR2 by comparing the 
deuterium uptake between AGR2 and AGR2 with its ligand (linear peptide motif). The 
binding of the peptide was probed by making mutant series in the identified peptide 
‘docking site’ region on AGR2.  A consensus peptide-binding motif was then 
developed to identify potential cellular proteins that harbour this motif as potential 
AGR2 client proteins.  Database mining using this consensus binding peptide 
demonstrated that transmembrane proteins were dominant class of proteins. Epithelial 
cell adhesion molecule (EpCAM), an oncogenic transmembrane protein, was chosen 
as putative AGR2 client proteins and their interaction was verified using both cell-free 
and cell-based assays. The AGR2 and EpCAM pathway dynamics were reconstituted 
and investigated in cells that do not endogenously express both proteins. Further, the 
expression of AGR2 and EpCAM were assessed in clinical tumour samples using 
immunohistochemistry. Proteomics screen using quantitative tandem mass tag (TMT) 
mass spectrometry on cells transiently overexpressing AGR2 were used to identify 
potential AGR2 client proteins and to find relevant dominant pathways affected by 
AGR2 signalling. Additionally, synthetic tools were devised to further dissect the 
function, regulation and ‘druggability’ of AGR2 protein. These tools include: i) 
 
 v 
isolation of high-affinity AGR2-binding synthetic antibodies from a phage-scFv 
(single-chain variable fragment) library; ii) engineering synthetic mini-protein 
(synPRO) containing copies of wild-type and mutated AGR2 linear peptide motif and; 
iii) engineering synthetic membrane protein model that bind to AGR2.  
 
In conclusion, the data presented hereby demonstrated a novel role of an ER-resident 
protein AGR2 which possess an intrinsic sequence-specific peptide binding for a 
subset of its client proteins and one function of this motif is to ensure proper maturation 
of client proteins to their final destination. Development of synthetic tools in this study 
can be further manipulated to disrupt AGR2 signalling and the fate of its binding 
proteins which in turn highlights a potentially ‘druggable’ stage in the oncogenic 




AGR2 is an endoplasmic reticulum (ER)-resident protein that belongs to a member of 
protein disulphide isomerase (PDI) superfamily. AGR2 protein has emerged as a 
clinically-relevant protein as it is upregulated in various types of cancer and 
demonstrated tumour-promoting features.  
 
The role of AGR2 is not fully understood, and it is the aim of this thesis to elucidate 
the role of AGR2 in cancer development. We focused on identifying novel AGR2 
interacting proteins (termed interactome) as by looking at functional consequences of 
some of these interactions, we can deduce the role of AGR2. We used two approaches 
to identify AGR2 interacting proteins; 1) database mining of AGR2 sequence-specific 
peptide motif; 2) quantitative mass spectrometry analysis of cell models with a 
controlled expression of AGR2. We validated the key AGR2 client proteins using both 
in-vitro and cell-based assays. 
 
Finally, we developed synthetic tools to further dissect the pro-oncogenic role of 
AGR2. These tools include: 1) developing AGR2 monoclonal antibodies in the format 
of the scFv fragment; 2) engineering synthetic mini-protein containing AGR2 
sequence-specific peptide motif and; 3) engineering synthetic membrane protein that 
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 xx 
FASP   Filter Aided Sample Preparation 
FBS   Foetal bovine serum 
FL   Full-length 
gRNA  Guide RNA 
GST   Glutathione S-transferase 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC  High-performance liquid chromatography 
HRP   Horseradish peroxidase 
HSP   Heat shock protein 
IF  Immunofluorescence 
IP   Immunoprecipitation 
IPTG   Isopropyl β-D-thiogalactopyranoside 
kDa   Kilo Dalton 
mAb  Monoclonal antibody 
pAb  Polyclonal antibody 
MDM2  Murine Double Minute 2 
ml   Mililiter 
mM  Milimolar  
MOPS  3-(N-morpholino)propanesulfonic acid 
mRNA  Messenger RNA 
MS   Mass spectrometry 
MUC  Mucin 
OAC   Oesophageal adenocarcinoma 
OD   Optical density 
PBS   Phosphate-buffered saline 
PBS-T  PBS Tween-20 
PCR   Polymerase chain reaction 
PDI  Protein disulphide isomerase 
pfu   Plaque-forming unit 
pH  Potential of hydrogen 
PLA   Proximity ligation assay 
PPI   Protein-protein interaction 
 
 xxi 
RING   Really Interesting New Gene 
RLU   Relative light unit 
RNA   Ribonucleic acid 
RPMI  Roswell Park Memorial Institute 
RT   Room temperature 
RT-PCR  Reverse Transcription PCR 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide pel electrophoresis 
siRNA  Small interfering RNA 
SP  Secretory pathway 
SRP  Signal recognition particle 
SWATH Sequential window acquisition of all theoretical mass spectra 
TEMED  Tetramethylethylenediamine 
TMT  Tandem mass tag 
Tris   Tris(hydroxymethyl)aminomethane 
UPR  Unfolded protein response 
WT  Wild type 
v/v   Volume/volume 
w/v   Weight/volume 
Y2H  Yeast two-hybrid 
µg  Microgram 
µl  Microliter 
µm  Micrometer 
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CHAPTER 1: Introduction 
 
1.1. Cancer 
1.1.1. Overview of cancer 
Cancer refers to a class of diseases in which cells exhibit abnormal growth and 
can invade surrounding healthy tissues or spread to distant part of the body. Cancer is 
also known as a malignant tumour, where it can be differentiated with a benign tumour 
which refers to a tumour that does not invade or spread to another part of the body [1]. 
According to World Cancer Report 2014, published by the World Health 
Organization’s International Agency for Research on Cancer1. Cancer is responsible 
for 8.2 million deaths which account for 13% of all deaths worldwide. This figure is 
expected to rise by about 70% over the next two decades. The world’s most common 
cancer is lung cancer, making up 13% of the total number in 2012. The five most 
common type of cancer for men are lung, prostate, colorectal, stomach, and liver 
cancer while the top five most common type of cancer for women are breast, 
colorectal, and lung, cervix, and stomach cancer.   
 
Cancer progresses from a single cell which transforms from normal into 
tumour cells through multi-stage processes, typically a progression from a pre-
cancerous lesion to malignant tumours and involves different and variable activation 
and inactivation pathways. The transformation of a ‘normal’ cell to a cancerous cell 
requires a cascade of genetic alteration of genes modulating cell cycle, which are being 
silenced or overexpressed. Cancer can spread from its original site by local spread, 
lymphatic spread to regional lymph nodes or through the bloodstream to distant sites, 
known as metastasis. When cancer cells metastasize, they usually do so to preferential 
organs, depending on the type of cancer as hypothesised in the ‘seed and soil’ theory of 
cancer metastasis [2]. The process of cancer metastasis consists of a long series of 
sequential, interconnected steps and is dependent on both the intrinsic properties of the 
tumour cells and the responses of the host [3]. The symptoms of metastatic cancers 
depend on the location of the tumour and can include among others enlarged lymph 
                                                 
1 http://www.who.int/cancer/en/ 
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nodes, enlarged liver or enlarged spleen, pain or fracture of affected bones, as well as 
neurological symptoms. 
 
There are many different kinds of cancer (more than 200 have already been 
classified) associated with almost every cell type, establishing cancer as a multistage 
and widely spread ‘disease’ 2. Genetic abnormalities cause most cancers which can be 
due to the effect of carcinogens, UV, radiation, chemicals, tobacco smoke or viruses. 
Genetic abnormalities, including DNA mutations, also involve inheritance of certain 
cancer-promoting oncogenes or cancer-protecting tumour suppressor genes.  
 
Classification of cancer is usually according to the organs or tissue from which 
the cells originate (primary tumour), as well as the specific type of cells that they 
originate from. Cancer diagnosis usually requires medical examinations such as blood 
tests, X-rays, endoscopy and computed tomography (CT) scans. This is followed by 
histological examination of a tissue biopsy or surgery specimen by a pathologist to 
determine the histological grade of the tumour along with other characteristics. This 
information helps the clinician to set prognosis of cancer patients. Prognosis is 
influenced by the type of cancer, as well as the stage, or extent of the disease. 
Additionally, the presence of specific molecular markers can also be useful in 
establishing a prognosis, as well as in determining individual treatments.  
 
1.1.2. Hallmarks of cancer 
The hallmarks of cancer, first defined in 2000 by Hanahan and Weinberg [4], 
provided a major foundation for the understanding of the complexity of this neoplastic 
disease (Figure 1.1). These traits that enable malignant growth include: (1) sustaining 
proliferative signalling, (2) evasion of programs that limit cell growth and (3) evade 
cell death, (4) unrestricted replicative potential, (5) induce angiogenesis and (6) trigger 
invasion and metastasis. An increasing research advance suggests that two additional 
emerging hallmarks of cancer are involved in the pathogenesis of some and perhaps 
all cancers [5]. These two emerging hallmarks involve (7) reprogramming energy 
metabolism (8) and circumventing the immune destruction. Additionally, two 
                                                 
2 http://www.cancerresearchuk.org 
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consequential characteristics of neoplasia facilitate the acquisition of both core and 
emerging hallmarks (enabling characteristics) which include (9) genome instability 
and (10) tumour promoting inflammation (Figure 1.1). 
 
1.1.3. Cancer targeted-therapy 
Cancer can be treated by surgery, chemotherapy, radiotherapy, 
immunotherapy, monoclonal antibody therapy, or even combination of some methods. 
The choice of therapy depends on the location and grade of the tumour and the stage 
of the disease, as well as the general state of the patient. Surgery is the most effective 
and extensive approach in the treatment of primary tumour and affected lymph nodes 
because surgery operates by excising the tumours that are eventually killed. With the 
introduction of radiation therapy in the 1920s and chemotherapy after the 1940s, 
cancer surgery has become conservative. In contrast to surgery, chemotherapy and 
radiation therapy are only capable of killing a fraction of tumour cells by each 
treatment, and often a combination of all methods are necessary to remove cancer cells 
effectively. 
 
Target-specific therapies have been developed for each emergence of 
hallmarks of cancer.  One of the most utilised approaches towards developing an 
effective drug has been to target a very specific property or signalling pathway in the 
cancer cell that discriminates it from the normal cell. Targeted therapy approaches aim 
to inhibit molecular pathways that are crucial for tumour growth and progression; 
whereas, immunotherapy purposes to stimulate a host immune response that can 
obliterate the prolonged tumour growth. The combination of both immunotherapy and 
targeted therapy have been proposed to improve clinical outcomes [6] efficiently. 
Moreover, as the body of research advances and understanding of human cancer 
landscape progresses, treatments are refined for effective cancer therapy. There has 
been significant progress in the development of targeted therapy drugs that act 
specifically on molecular abnormalities in certain tumours, and which minimise 
damage to normal cells. Antibody therapy, for example, is targeted therapy strategy in 
which the therapeutic agent binds specifically to a protein on the surface of the cancer 
cells. This approach is possible due to human cancer cells express specific cell surface 
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antigens that are either overexpressed, mutated or selectively expressed compared with 
normal tissues [6]. Examples include the anti-HER2/neu antibody trastuzumab 
(Herceptin) used in breast cancer, and the anti-CD20 antibody rituximab, used in a 
variety of β-cell malignancies (Table 1.1)[7] [8]. Targeted therapy can also involve 
small molecules that act as "homing devices" which can target various phases in the 
transduction of the growth signal and its execution [7, 9]. Inhibitors are also the type 
of small molecule targeted therapy that has catalytic activity on mutated, 
overexpressed, or otherwise critical proteins within the cancer cell. Well-known 
examples include the tyrosine kinase inhibitors imatinib and gefitinib (Table 1.1).  
 
Despite all the methodologies to treat cancer, the most deaths of cancer patients 
result from the progressive growth of metastases that are resistant to current therapies 
[10]. Metastatic cells can undergo an enormously high rate of spontaneous mutation 
in comparison to benign cells and hence, have a greater propensity to undergo rapid 
phenotypic modification that in turn become resistant to various therapeutic 
approaches [11]. 
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Figure 1.1 Hallmark capabilities of cancer. The six hallmarks of cancer originally proposed by 
Hanahan and Weinberg [4] acquired during the multistep progression of human tumours. The increasing 
form of research adds two additional emerging hallmarks [5]. Additionally, two enabling characteristics 
of cancer have been proposed that facilitate the acquisition of both core and emerging hallmarks [5] that 
altogether comprise a unifying principle for understanding the multiplicity of neoplastic disease. 
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THERAPEUTIC GROUP DRUG EFFECT ON TUMOUR 
MONOCLONAL 
ANTIBODIES 
Trastuzumab Blocks growth signalling through HER2 
 Bevacizumab Neutralising antibody against VEGF: 
blocks angiogenesis 
 Cetuximab Neutralising antibody against EGFR: 
blocks growth signals 
SMALL 
MOLECULES/INHIBITORS 
Sunitinib Blocks multiple tumour-associated 
tyrosine kinases, including VEGFR and 
PDGFR 
 Imatinib Blocks multiple tumour-associated 
tyrosine kinases, including ABL and KIT 
 Vemurafenib Blocks BRAF-V600E 
 Temsirolimus, rapamycin and 
other mTOR inhibitors 
Blocks mTOR pathway 
 Bortezomib Blocks 26S subunit of the proteasome 
 JAK2 inhibitors Block JAK2 signalling in tumour cells 
 HSP90 inhibitors Blocks HSP90, which increases unfolded 
protein-associated stress in tumour cells 
 PI3K–AKT inhibitors Decreases PI3K–AKT signalling in 
tumour cells 
 Lenalidomide Not well understood 
 GSK3β inhibitors Blocks GSK3β-mediated signalling of 
tumour cell growth 
 IAP inhibitors Sensitises tumour cells to apoptosis 
Table 1.1. Overview of targeted therapy group for cancer treatment and their targets. 
(Reproduced from [7, 9]) 
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1.2. Emerging strategy: targeting secretory pathway in cancer 
1.2.1. Overview of the secretory pathway  
The secretory pathway (SP) is a system to deliver proteins to the plasma 
membrane and specified membrane-bound organelles as well as to release material 
into extracellular space. Most of the cellular transmembrane proteins use this pathway 
to reach their final destination. Proteins destined for SP pass through membrane-bound 
compartments mediated by secretory vesicles that bud from one compartment and then 
fuse with the successive compartment. The SP consists of the rough endoplasmic 
reticulum (rough ER), ER exit sites (ERESs) the ER-to-Golgi intermediate 
compartment (ERGIC), the Golgi complex and secretory vesicles that transport 
proteins to final destination [12, 13].  
 
Approximately one-third of the proteins in eukaryotes are targeted to the 
secretory pathway. The first compartment encountered by the SP substrates is the ER 
[14]. The ER contains molecular chaperones that orchestrate different maturation steps 
including protein folding, glycosylation, disulphide bond formation and catalysed co- 
and post-translational modifications ensuring that secretory proteins are properly 
folded, modified and assembled into multi-protein complexes in the ER. ER quality 
control (ERQC) governs these multi-steps processed inside the ER  to ensure that the 
ER assembly line meets specific requirements [15]. ERQC comprises molecular 
chaperones that not only help proteins to fold but also assess the conformations of their 
substrates. If a protein has accomplished its native conformation, it might proceed to 
next subsequent step in the SP. 
 
Most of the proteins for secretory pathway contains signal peptide at their N-
terminus for targeting into ER and subsequent steps in the SP. This pathway is called 
the conventional secretory pathway (Figure 1.2). The conventional secretory pathway 
is the trafficking route that secretory proteins undertake when are transported from the 
ER to the Golgi apparatus network by successive fusion through the Golgi 
compartments, and subsequently to the plasma membrane via secretory vesicles or 
secretory granules. This process is mediated by many proteins, enzymes and co-
factors. Similarly, the principal mechanism by which integral and transmembrane 
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proteins mature and arrive at their resident location is also through the secretory 
pathway. Nascent proteins that are being synthesized by ribosomes in the ER must be 
inserted into the ER membrane. Most of the proteins for secretory pathway contains 
signal peptide at their N-terminus. The N-terminal signal peptide (or leader sequence), 
is an ER-targeting sequence and hydrophobic, which is recognised by the signal 
recognition particle (SRP) complex in the ER membrane, which then targets the 
nascent polypeptide to an ER membrane component known as a translocon. The ER 
membrane maintains its integrity through the action of the BiP chaperone on the 
lumenal side, which associates with the translocon, moving away when the ribosome 
that is synthesising the nascent polypeptide associated with the cytoplasmic side of the 
translocon [16]. In the ER, the N-terminal signal sequence is cleaved off, and proteins 
are folded and assembled by molecular chaperones whilst preventing unwanted protein 
aggregation due to exposure of hydrophobic patches to the aqueous environment 
[17].This is to ensure that the hydrophobic portions of the nascent polypeptide are 
shielded from the aqueous environment, whilst allowing the hydrophilic portions 
destined for the cytoplasm or the extracellular environment to pass through to the ER 
lumen or cytoplasm. The newly synthesised proteins then exit the ER at dedicated 
membrane domains, ERESs which are ribosome-free regions of the rough ER. The 
ERESs house the cargo-containing coat protein complex II (COPII)-coated vesicles 
form along with the association of plus end microtubules [18]. After formation, COPII 
vesicles can fuse homotypically to generate pre-Golgi intermediates [19]. 
Alternatively, COPII vesicles may heterotypically fuse with the pre-formed ERGIC 
[20]. Subsequently, the newly synthesised proteins reach the Golgi apparatus where 
they are further modified by glycosylation and/or processing, sorted and dispatched 
towards their correct final destinations. The Golgi apparatus comprises a collection of 
fused, flattened membrane-bound disks that are called cisternae. Golgi stacks are made 
up of a series of compartments consisting of two main networks: a reticular membrane 
network on the entry side of the Golgi that builds the cis-Golgi network (CGN) and 
the trans-Golgi network (TGN) on its exit side [21]. At the TGN, proteins destined to 
be secreted are sorted in secretory vesicles (SVs) or immature secretory granules 
(ISGs). SVs are constitutively delivered toward the PM, whereas ISGs accumulate in 
the cytoplasm. Upon the arrival of specific stimuli, ISGs form mature secretory 
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granules (MSGs) that are transported to the PM.Proteins can also be returned to the 
ER through COPI-coated vesicles via retrograde transport involving components in 
the Golgi and back to the ER [22]. COPI-coated vesicles also partake in the 
anterograde movement of certain components which occurring in ERGIC region [23]. 
One significant function of the COPI-coated vesicle is to facilitate the retrieval of 
escaped luminal proteins containing K/HDEL retrieval signals that are recognised by 
the K/HDEL receptor as well as other machinery required for optimal anterograde 
transport. The transport of secretory cargo between the ER and the Golgi occur bi-
directionally involving COPII and COPI protein complexes. Trafficking of the 
proteins within the SP also involves a series of fusion events that occur between 
secretory vesicles with their target membrane-bound compartments such as a lysosome 
and plasma membrane. These fusions are catalysed by SNAREs (soluble N-
ethylmaleimide-sensitive fusion protein (NSF) accessory protein (SNAP) receptors) 
which contain long regions that form helical structures[21]. Membrane fusion is 
mediated by the formation of tight trans-SNARE complexes that are formed by -
helical bundles of the cytoplasmic SNARE domains (v-SNAREs) and target SNAREs 
(tSNAREs) that interact when brought into proximity and appear to zipper up and 
eventually results in membrane fusion [21, 24]. 
 
Some signal-peptide-containing proteins have been shown not to follow this 
conventional secretory pathway. These processes are known as unconventional protein 
secretion (Figure 1.2) [25]. There are some evidences that some proteins do not seem 
to involve COPII vesicles. For example, in the case of yeast protein Heat-shock protein 
150 (Hsp150), the protein was seen transported to the plasma membrane upon exit the 
ER without COPII coat proteins Sec24 and Sec13 [26]. Some proteins also were shown 
to be inserted to ER but bypass the Golgi apparatus. For example, the cystic fibrosis 
transmembrane conductance regulator (CFTR) which reaches the plasma membrane 
by direct transport from the ER by COPII carriers [27]. However, the exact 
mechanisms and protein components of unconventional protein secretion are not 
known and are beginning to emerge [28].  
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Figure 1.2 Overview of the secretory pathway. Most of the proteins enter secretory pathway by 
possessing signal peptide at their N-terminus for targeting into ER followed by the ER-Golgi system 
and subsequent steps in SP. This is called the conventional secretory pathway. However, there are some 
signal-peptide-containing proteins not to follow this conventional secretory pathway. This is known as 
unconventional protein secretion which can occur by either bypassing the association of COPII vesicles 
during ER exit or bypassing Golgi apparatus (transport from the ER to the plasma membrane). 
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1.2.2. Unfolded protein response 
The SP involves multistep and active processes that are closely regulated and 
controlled to maintain ER protein homoeostasis or proteostasis [29, 30]. The ER 
particularly plays an important role in the folding and maturation of newly synthesised 
secretory and transmembrane proteins. The ER lumen governs a unique environment 
to establish a balance between the ER protein load and the capacity to handle this load 
in order to ensure proper protein-folding requests. This ER homeostasis can be 
perturbed by physiological as well as multiple environmental and cellular signals such 
as high protein demand, viral infections, environmental toxins, inflammatory 
cytokines, and mutant protein expression resulting to an accumulation of misfolded 
and unfolded proteins in the ER lumen, a condition termed as ER stress. It is known 
that under ER stress, cells activate a series of complementary adaptive mechanisms to 
cope with increased demands of protein folding in the ER. This adaptive system is 
called the unfolded protein response (UPR) which is a highly conserved signal 
transduction pathway. 
 
The UPR signals protein-folding status in the ER lumen to the nucleus and 
cytosol to buffer fluctuations in unfolded protein load [31]. When unfolded proteins 
accumulate in the ER, resident chaperones become occupied, releasing transmembrane 
ER proteins involved in inducing the UPR. These proteins engaged ER membranes, 
with their N-terminus in the lumen of the ER and their C-terminus in the cytosol, 
providing a bridge that connects these 2 compartments. Generally, in unstressed 
condition, the ER chaperone Grp78 (BiP) binds to the N-termini of these 
transmembrane ER proteins, preventing their aggregation. Upon accumulation of 
misfolded proteins, Grp78 dissociates from these transmembrane ER proteins, 
allowing aggregation of these sensors, and as a result activating the UPR. The UPR 
adaptive response includes upregulation of molecular chaperones and protein 
processing enzymes to increase folding and handling efficiency, translational 
attenuation to reduce ER workload and prevent further accumulation of unfolded 
proteins, and an increase in ER-associated protein degradation (ERAD) and autophagy 
components to promote clearance of unwanted proteins. The process of ER stress in 
cells can be irreversible [32], which can lead the cells being eliminated by apoptosis. 
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Cell damage due to chronic ER stress is widely common to a wide range of dominant 
human diseases, including cancer, neurodegeneration, stroke, pulmonary fibrosis, viral 
infections, inflammation, metabolic disorders, diabetes, and heart disease [33].  
 
 There are three main players in mammalian UPR which comprise the sensors 
IRE1α (endoribonuclease inositol-requiring enzyme 1-alpha), PERK (protein kinase 
RNA-like endoplasmic reticulum kinase) and ATF6α (activating transcription factor 
6) [34].These three arms of UPR activate stress signals from the ER lumen to the rest 
downstream signalling that allow cells to cope with protein workload and misfolding 
by provisionally reducing de novo protein synthesis and improving the folding and 
clearance capacity of the ER [35].  
 
The first UPR sensor IRE1α is an ER-resident type 1 transmembrane protein. 
It has two enzymatic activities in its cytosolic domain: a serine/threonine kinase and 
an endoribonuclease activity. Upon activation, IRE1α dimerizes to form homodimer 
followed by an auto transphosphorylation, which triggers an unconventional RNA 
splicing activity, which processes the mRNA transcription factor called unspliced X-
box-binding protein 1 (XBP1u) to produce an active transcription factor, spliced XBP1 
(XBP1s). XBP1s controls the transcription of genes encoding proteins involved in 
protein folding, ER-associated degradation (ERAD), protein quality control and 
phospholipid synthesis. IRE1α also degrades the mRNA of several secreted proteins, 
through a process called regulated IRE1-dependent decay (RIDD). Besides, IRE1α can 
signal through the recruitment of TRAF2 leading the activation of the ASK1–JNK 
cascade. 
 
PERK is a transmembrane protein with a specific kinase activity in its cytosolic 
domain. Its main substrate is the translation initiation factor eIF2α. Phosphorylation of 
eIF2α results in a decrease in translation as well as a preferential translation of key 
proteins such as CHOP and GADD34, two factors directly involved in the cellular 
decisions of life or death. PERK can also phosphorylate nuclear factor erythroid 2-
related factor 2 (NRF2), a transcription factor involved in redox metabolism.  
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Finally, ATF6 is a transmembrane protein and an ER transcription factor. 
Under normal ER condition, ATF6 has a basic Leu zipper (bZIP) transcription factor 
in its cytosolic domain and localises in the ER. When ER is under stress condition, 
ATF6 is exported to the Golgi apparatus, through interaction with the coat protein II 
(COPII) complex, and finally cleaved from its membrane by the proteases S1P and 
S2P, releasing its cytosolic domain fragment (ATF6f). ATF6f pedals the upregulation 
of genes encoding ERAD components and also XBP1.  
 
Together, integration signals from these three UPR arms determine cell 
survival by the regulation of distinct subsets of gene transcription and translation 
reorientation toward recovery of ER homoeostasis. One of the first responses from 
UPR is the downregulation of translation to reduce entry of newly synthesised proteins 
in the ER. Among other cellular processes include the activation of amino acid 
metabolism and upregulation of antioxidant capacity, increased clearance of misfolded 
proteins, and increase expression of ER chaperones/ER quality control proteins 
involved in protein folding. However, if these adaptive actions exceed ER protein 
folding capacity, ER stress shifts towards the terminal UPR response which is 
apoptosis [36]. 
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Figure 1.3 The three arms of UPR. (From [34]) All three of UPR arms (PERK, IRE1α, ATF6) are 
present in the ER membrane that initiates signalling events to maintain ER protein homoeostasis or ER 
proteostasis under ER stress. PERK phosphorylates eIF2α, which results in a decrease in translation as 
well as a preferential translation of key proteins such as CHOP and GADD34, two factors directly 
involved in the cellular decisions of life or death or concurrently increases the expression of the 
transcription factor ATF4. IRE1α form homodimer upon activation and signals through (i) the 
recruitment of TRAF2 leading to the activation of the ASK1–JNK cascade and (ii) through its RNase 
activity by splicing the XBP1 mRNA or the degradation of RNAs (RIDD activity), regulating gene 
expression at transcriptional and post-transcriptional levels. Finally, ATF6 normally localised at the ER 
in unstressed cells is exported from the ER to the Golgi complex upon activation through interaction 
with the coat protein II (COPII) complex, where it is cleaved by the proteases S1P and S2P, releasing 
its cytosolic domain releasing its cytosolic domain fragment (ATF6f). Depending on the severity and 
duration of ER stress, the signalling branches of the UPR can activate adaptive determine cell survival 
toward recovery or induce apoptotic cell death.  
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1.2.3. Cancer cell secretory pathway is addicted to protein secretion 
Cancers development are triggered by different hallmarks of cancer [5]. Cancer 
cells grow under oncogenic stress caused by hypoxia, nutrient deprivation, DNA 
damage, metabolic stress, and oxidative stress, leading to UPR as an adaptation 
strategy. However, most normal cells are not subjected to stress and the UPR pathways 
remain inactive in these cells. ER resident proteins display altered expression patterns 
in cancer. For example the ER chaperone protein Grp78 (BiP)  is one of the most active 
components of cancer cells and is overexpressed in different kinds of cancers [37]. 
Most cancers have to cope with the secretory crisis that demands secretory proteins to 
be secreted through SP. In recent years, an important link between ER carcinogenesis 
and tumour development has been established [38]. ER is the first compartment of the 
secretory pathway which orchestrate secretion and the cell microenvironment. In 
transformed cells like cancer, the SP is exposed to a strong environmental pressure 
such as hypoxia, oxidative stress or chemotherapies, aneuploidy, an increase in 
metabolic demand, and high proliferation rates which together contribute to 
tumorigenesis. This increased demand in tumours leads to the accumulation of 
misfolded proteins in the secretory pathway and more particularly in the ER. The 
requirement of a robust ER and secretory machinery are necessary for tumour cells, 
and the cellular challenges can trigger disturbance of ER homoeostasis and 
consequently causing UPR activation at the basal level or constitutively active [39]. 
The increase in secretion demand is also dependent on a substantial requirement of 
energy and amino acid supply which can be highly costly in cancer environment [39].  
 
There are several consequences of altered SP in transformed cells as described 
by Dejeans et al. (Figure 1.4) [40]. First, it can lead to microenvironment landscape 
destabilisation by remodelling of the extracellular matrix (ECM) through changes in 
ECM components abundance or matrix metalloproteinases (MMPs) expression which 
linked to cancer dissemination and invasion. Second, there is a modulation of 
signalling proteins or contact/adhesion protein abundance which can trigger cancer 
cell proliferation, migration or tumour angiogenesis. Third, it can lead to an alteration 
of the immune response by expanding the proinflammatory response of tumour cells. 
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Finally, it can remodel tumour immunogenicity by stimulating plasma membrane 
exposure of major ER -resident chaperones such as calreticulin (CRT). 
 
The activation of UPR signalling can attract both pro-survival and pro-
apoptotic cellular settings. Therefore, therapeutic intervention targeting the secretory 
pathway is a fascinating strategy to target cancer cells (Figure 1.5) [39, 41]. Cancer 
drugs or chemical probes can be designed for example by; (i) reducing the amount of 
protein load entering the secretory pathway or neutralizing the increased demand for 
secretory proteins mediated by hyperploidy or oncogene activation (ii) controlling the 
secretion of specific set of proteins, such as receptor tyrosine kinases, pro-
inflammatory messenger, by modulating protein processing at post-translational level 
(iii) targeting ER chaperones, such as BiP or GRP94 that show chemoresistance 
characteristic, (iv) upregulating macroautophagy or enhance the efficiency of the ER-
associated protein degradation (ERAD) pathway (v) and modulating the UPR 
(inhibitors and activator) to sensitize cancer cells to ER stress and cancer. Screening 
studies for example have identified several compounds that can inhibit key mediators 
of ER stress signalling [34]. For examples, 4μ8C, MKC-3946 and STF-083010 
compounds were identified by high-throughput screenings that can target IRE1α. 
These compounds are in pre-clinical trials which can interact IRE1α via one of two 
sites: the catalytic core of the RNase domain or the ATP-binding pocket of the kinase 
domain. Another example of IRE1α inhibitors are Sunitinib and APY29. Both 
molecules bind to the hinge region of the ATP-binding pocket and stabilize an active 
kinase domain conformation. Sunitinib and APY29 block IRE1α activity but can 
allosterically activate the IRE1α RNase domain in-vitro [42]. Sunitinib (also called 
Sutent) was approved by the United States Food and Drug Administration (FDA) for 
targeted therapy of renal cell carcinoma (RCC) kidney, gastrointestinal stromal 
tumours and pancreatic neuroendocrine tumours (GISTs). Screening studies also has 
identified compound that can inhibit PERK. One example is GSK2606414, a small 
molecule that inhibits PERK phosphorylation. While still in preclinical trial, 
GSK2606414 displayed a potent antitumor and antiangiogenic activities in a xenograft 
model of pancreatic cancer [43].  
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Figure 1.4 Cancer cell secretory pathway addiction to secrete. (From [40]) Protein secretion is 
dependent on both intrinsic (aneuploidy, increase in metabolic demand, and high proliferation rates) 
and extrinsic factors (environmental stress such as hypoxia or oxidative stress). In cancer cells, these 
factors are relatively high which leads to the accumulation of misfolded proteins in the secretory 
pathway and more particularly in the ER. There are several consequences of altered SP which include 
destabilisation of ECM, modulation of signalling proteins or contact/adhesion protein abundance, 
alteration of the immune response and remodelling of tumour immunogenicity. 
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Figure 1.5 Targeting the secretory pathway in cancer. (From [41]) Therapeutic interventions are 
possible at many time points in the secretory pathway of cancer. Cancer drugs can be designed for 
example by; (i) reducing the amount of protein load entering the secretory pathway, (ii) modulating the 
secretion of select proteins, such as receptor tyrosine kinases, growth factors, or cytokines, (iii) targeting 
ER chaperones, such as BiP or GRP94 that show chemoresistance characteristic, (iv) upregulating 
macroautophagy or enhance the efficiency of the ER-associated protein degradation (ERAD) pathway 
(v) modulating the UPR (inhibitors and activator) to sensitize cancer cells to ER stress and cancer. 
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1.2.4. ERAD and interplay with autophagy during ER Stress and UPR 
Despite the stringent requirements of ERQC, there is evidence to suggest that 
at least a third of all proteins entering the ER fail to satisfy the quality-control 
mechanisms that ensure proper folding, and for some proteins, the success rate is much 
lower[44]. Protein folding itself is prone to error because of the differences in protein 
folding and protein aggregation free energy landscapes[45]. Moreover, spontaneous 
errors during transcription and translation, genetic mutations, toxic compounds and 
cellular stresses, can contribute to folding efficiency. ERQC ensures that proteins are 
properly folded and ensure correct protein conformations. If folding is delayed or the 
specific protein conformations are not met, the proteins are either subjected to 
additional folding steps or selected for a process called ER-associated degradation 
(ERAD)[46]. As discussed above, ER stress for instance can lead to the build-up of 
unfolded, misfolded or damaged proteins that exceeds the capacity of chaperones 
available in the ER to correctly fold them. ERAD is a stringent quality-control system 
that involves in the clearance of these improperly folded proteins . During ERAD, 
molecular chaperones and associated factors recognise and target substrates for 
retrotranslocation and ubiquitination of misfolded proteins in the ER for proteasomal 
degradation in the cytosol to the cytoplasm for subsequent degradation by ubiquitin–
proteasome machinery  [47]. The ERAD system encompasses the transmembrane 
ubiquitin E3 ligase proteins that connect the substrate recognition machinery in the ER 
lumen and the ubiquitin-proteasome system in the cytosol. 
 
ERAD is a regulated process which is important for maintaining ER 
homoeostasis. Several studies showed that there is an interplay between ERAD and 
other pathways[47]. The transcription of a certain subclass factors required for ERAD 
was shown to be induced by the UPR[48, 49], which is activated through the directed 
interaction of misfolded proteins with a UPR sensor IRE1 in the ER or through BiP 
which is titrated away to bind to misfolded substrates. 
 
Autophagy is another pathway that reduces ER stress [47]. Substrates that 
accumulate over time are prone to aggregation which leads to ERAD inefficiency to 
clear this aggregation. This is where autophagy comes into play to reduce the 
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substrates aggregation by autophagy-mediated destruction. During this process, 
portions of the ER, along with proteins and protein aggregates, are surrounded in 
double-membrane structures called autophagosomes which will be then delivered to 
the lysosome or vacuole for degradation [50]. Similarly to the UPR, autophagy can 
result in either cell survival or cell death (167,168). The mechanisms by which the 
UPR induces autophagy are poorly understood, but possibly involve signalling through 
PERK–eukaryotic translation initiation factor 2α (eIF2α) and IRE1α169. The is an 
interplay between ERAD machinery with autophagy.  Proteasomes which involves in 
ERAD machinery are multi-protein complexes made up of an inner 20S cylindrical 
shaped core of subunits that have the proteolytic activity and a 19S regulatory cap of 
subunits on each end of the core which recognize ubiquitin-conjugated proteins and 
provide ATPase activity [36].  Proteasomes and autophagy are co-dependent system 
that partaken in the digestion of soluble proteins and releasing peptides into the 
cytoplasm and nucleus to be digested by peptidases, or to be transferred to the ER 
where they are bound by human leukocyte antigen (HLA) proteins to the surface of 
the cell [25, 64]. The proteasome degrades type I (short-lived) and type II 
(misfolded/dysfunctional) proteins, whereas autophagy degrades type II and type III 
(long-lived) proteins [14]. This suggests that there is a backup mechanism for ERAD 
for clearance of misfolded proteins especially those related to substrate aggregations. 
The cellular ubiquitination system specifies whether a protein will be transferred to the 
proteasome or an autophagosome for recycling. Proteins with attached polyubiquitin 
chains that are branched on Lys48 have a more closed conformation and are targeted 
for proteasomal degradation, while proteins with single ubiquitin moieties or 
polyubiquitin chains that are branched on other Lys residues are targeted to the 
autophagosomes as described above [98, 121]. Some proteins can be digested by both 
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1.3. Anterior gradient-2 
1.3.1. Discovery of AGR2 and its key biological description 
AGR2 belongs to the wider family of anterior gradient proteins including the 
ancestral member XAG-2. The anterior gradient XAG-1, XAG-2 and XAG-3, were 
first discovered in Xenopus laevis and named accordingly based on their specific 
expression patterns during early development [51]. XAG-2 was further investigated in 
a study to understand the patterning of anterior-posterior pattern formation in the 
neural plate. XAG-2 was described as a secreted proteins that are expressed in the 
anterior region of dorsal ectoderm from late gastrula stages onwards [52]. Gain-of-
function analysis showed that XAG-2 function in specifying the fate of the dorso-
anterior ectoderm that forms the mucus secreting cement gland and in inducing the 
forebrain’s fate. Another XAg-2 homologous gene, namely XAgr-2, was identified 
more recently in Xenopus embryos was also expressed in cement gland. Also, its 
expression was also found in the otic vesicles, specifically in the ventromedial region 
that later develops to the cochlea, and notochord, especially in the tailbud and neurula 
stages [53].  
 
A rather late key insight of AGR2 function came from the studies of limb 
regeneration in the salamander. Notophthalmus viridescens (newt) homologue of agr2 
(nAG) was found as candidate genes induced during limb regeneration following 
amputation [54]. nAG was discovered as a secreted ligand for the newt GPI-anchored 
three-finger protein (TFP) Prod1 using yeast-2-hybrid studies [54], where Prod1 is 
membrane receptor which critical in determining the proximodistal identity of 
regenerating limb [55]. It was later described that nAG may interact with Prod1 
through the activation of ERK1/2 MAP kinase signalling in blastema cells [56]. After 
newt amputation, nAG sequentially expressed in the Schwann cells of the distal nerve 
sheath and then in glands in the wound epidermis followed by release to the distal 
sheath and induces the formation of glands in the wound epidermis [54]. Further, when 
nAG is expressed via electroporation into denervated, and amputated limb was able to 
rescue denervated blastema and allow it to regenerate in the absence of the nerve. This 
indicates that nAG, secreted by nerve cells of the regenerating limb, specifically acts 
to differentiate limb shape and structure [54]. Surprisingly, no apparent homologs of 
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Prod1 were found in other vertebrates which lead to the question of whether nAG acts 
as a major regulator of regeneration in other vertebrates. The role of anterior gradient 
proteins in limb regeneration has since been broadened to other amphibians (namely 
Xenopus laevis tadpoles) and has been described as having a universal role in body 
appendage regeneration in amphibians [57]. Interestingly, human AGR2 (hAGR2) has 
been reported to interact with another GPI-anchored protein, metastasis protein C4.4 
(now known as LYPD3), which shares some structural similarity with Prod-1 inferring 
to their cysteine-rich domains and Ly6-type  domains [58]. This suggests that there 
might be a preserved, functional interaction pathway of protein complexes.  
 
Another key insight of biological description of AGR2 functions came from 
the studies of mice. In situ hybridization revealed that mouse AGR2 (Gob4/mAGR2) 
is localised in the goblet cells of the intestine.  Goblet cells, hence the name, are goblet-
like shape differentiated epithelial cells located in the lining of the small intestine. 
Northern blot analysis of showed mAGR2 expression in the small intestines, colon and 
stomach of the adult mouse [59]. Later study also described AGR2 expression in the 
goblet cells of the intestine in mice [60]. The amino acid sequence of mAGR2 is 
similar to Xenopus laevis (46% homology and both contain a putative cleavable leader 
sequence required for targeting proteins to the secretory pathway)[59]. This finding 
gives a hint that that AGR2 might be involved in the secretory pathway. Additionally, 
both mice and Xenopus study showed the involvement of AGR2 in cement gland 
which consists of mucus-secreting cells. The cement gland, as suggested by the name, 
forms a cone of columnar epithelium that mediates the attachment to a solid support, 
which allows the Xenopus embryo to attach before it can swim [51]. This ‘adhesion’ 
inducing property of AGR2 predicts its potential role in migration and adhesion in 
mammalian cancer metastasis [61].  
 
Studies using transgenic mice have begun to elucidate the role of mAGR2 in 
homoeostasis of the intestine. In normal intestine, AGR2 is found in several cell types 
of both proliferating and differentiated intestinal cells of secretory lineage which 
include mature goblet, Paneth and enteroendocrine cells goblet cell as well as goblet 
cell progenitors and MSI1-positive intestinal stem cells/early progenitors [62]. A null 
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mutation in the Agr2 gene (Agr2 -/-) in mice results in the loss of morphologically 
normal goblet cells and decreased intestinal mucus [60]. The null mutation of AGR2 
also revealed the association of AGR2 with intestinal mucin MUC2, a large, cysteine-
rich glycoprotein that forms the protective mucus gel lining the intestine, where there 
is no MUC2 synthesis detected [60, 63]. AGR2 co-immunoprecipitates with MUC2, a 
large, cysteine-rich glycoprotein that forms the protective mucus gel lining the 
intestine, and that this association depends on a conserved cysteine residue in the 
AGR2 thioredoxin-like domain [60]. The null mutation of AGR2 revealed the 
association of AGR2 with intestinal mucin MUC2, where there is no MUC2 synthesis 
detected [60, 63], suggesting that AGR2 protein remodels the cell to adapt to a demand 
for secretory protein synthesis. Mice lacking AGR2 were viable but were highly 
susceptible to colitis. Additional work by Zhao et al. using transgenic mice describes 
additional abnormalities causing symptoms in the small intestine of AGR2 knockout 
mice [63]. The Paneth cells morphology was significantly altered and showed severe 
intestinal inflammation consistent with the role of Paneth cells in the inflammatory 
response [64, 65]. Additionally, the Paneth cells display abnormal localisation, with 
differentiation away from the crypt base into the upper crypt and villi of the small 
intestine. Furthermore,  loss of AGR2 expression leads to disrupted enterocyte 
homoeostasis, reduced proliferation, increased apoptosis and reducing villi [63]. 
Interestingly, cell culture experiments showed that ER stress induces AGR2 
expression and that siRNA knockdown of AGR2 elevates ER stress response [63].  
 
Altogether, these studies present fundamental paradigms, indicating the role of 
AGR2 and its homologues can function in epithelial cells as dominant endoplasmic 
reticulum resident molecular chaperone that can mediate proper protein maturation 
and maintain secretory landscape even in the presence of stress. AGR2 property in 
maintaining the epithelial barrier is further indicative of how it can function in diseases 
like cancer.  
 
1.3.2. AGR2 and related family members 
AGR2 belongs to the wider family of the anterior gradient (AGR) proteins 
which include AGR1 and AGR3. Human AGR2 and AGR3 proteins affiliation to the 
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PDI family were based on the initial phylogenetic analysis performed by Persson et al. 
where it was shown that both proteins have high homology to ERp18/19 protein, which 
now also denoted as AGR1 [66]. Persson et al. used BLASTP and BLASTN searches 
using the different PDIs/ERps from Homo sapiens to search for individual thioredoxin 
domains have evolved among the PDI/ERp family members [66].  
 
Since there are more homologous Agr genes found in vertebrates, there is 
substantial confusion exists in the literature concerning the terminology and 
orthologous relationships between anterior gradient genes in different species. More 
recently, Ivanova et al. combined bioinformatics tools and expression analysis to gain 
more insight into the relationship [57]. Using a source from Ensembl and Genebank, 
they screened the sequences homologous to known anterior gradient genes and 
analysed local synteny of Agrs-containing loci in 17 amniotic and 6 anamniotic species 
while keeping the integrity of the orthologous relationships between members of Agr 
family in different species. They concluded that there are three subfamilies of Agrs; 
Ag1, Agr2 and Agr3 in which exist two syntenic fragments, Ag1 and Agr2/Agr3. 
Interestingly genes of TLP19 subfamily which encodes non-secreted PDI are the 
nearest homologs (Figure 1.6A). Importantly, Ag1 genes present in fishes and 
amphibians but lost in amniote ancestors (reptiles, birds, and mammals) which suggest 
a decreased ability to regenerate body appendages in higher vertebrates (Figure 1.6B). 
Using  Xenopus laevis tadpoles as a model, amputation of the animals' hind limb buds 
and tails causes a substantial increase in expression which represents the two revealed 
syngenic groups of Agr: Xag2, Xagr2a and Xagr3a [57]. This finding was further 
complement with their in-situ hybridisation with Xag2 and Xagr2a probes and by the 
in-vivo monitoring of regeneration in transgenic tadpoles expressing EGFP under the 
control of the Xag2 promoter. Together with the data obtained in salamanders, indicate 
that Agrs have a universal role in body appendage regeneration in amphibians.  
 
In addition, in a more recent study, Ivanova et al. the biological role of Ag1 
[67]. It has been postulated that higher vertebrates have only Agr2 and Agr3, but lack 
Ag1 that is apparently lost from their ancestors which explain why higher vertebrates 
have a low ability to regenerate the body appendages. Therefore the loss of Ag1 in 
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evolution could be an important event that led to a decline of the regenerative capacity 
in higher vertebrates. Using the dish Dario rerio, a group of lower vertebrates as a 
model, Ivanova et al. demonstrated that Dario Ag1 (DAg1) expression, like the 
expression of its Xenopus ortholog Xag1, increases after amputation of the body 
appendages which in this case the fins [67]. In concordance with this result, 
downregulating DAg1 using Vivo-morpholino antisense oligonucleotides, resulted in 
an impedance of the fin regeneration [67]. This suggests that the loss of Ag1 in higher 
vertebrates' ancestors could be a cause of the reduction of regenerative capacity in their 
modern descendants. 
 
Another phylogenetic analyses through database mining of both transcriptomic 
and genomic databases have identified a novel group of Caudata (salamander) AG 
proteins, which were named AG4 [68]. The phylogenetic analyses suggested that AG 
proteins are vertebrate-specific and cluster in four groups each of which has a different 
distribution of vertebrate classes and has thioredoxin active site/C-terminus profile. 
AG4 sequences are slightly more similar to mammalian AGR2 than nAG (e.g. 75% 
vs. 69% identity between human AGR2 and Notophthalmus AG4 and nAG, 
respectively). The expression and secretion of the newly found gene AG4 were 
assessed using Western blot. AG4 along with constructs expressing wild-type nAG, or 
human AGR2 were transfected into cancer cells, and the media were collected after 
three days, concentrated, and analysed by western blotting in parallel with the cell 
lysates. The results showed that secreted  AG4 was approximately 20-fold lower than 
that for nAG, while that for AGR2 was nearly 6-fold lower suggesting a significant 
difference in secretion between newt AG4 and nAG[68]. The author suggested that the 
resilt may be due to the co-existence of multiple AG proteins that might have 
moderately overlapping functions and each AG protein subfamilies have novel 
activities through evolution by modulating the cellular localisation and/or the degree 
of ER retention.  
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Figure 1.6 Phylogeny of Agr genes and evolution of different subfamilies of Agrs in vertebrates. 
(From [57]). (A) Analysis of local synteny of Agrs-containing loci in 17 amniotic and 6 anamniotic 
species with assembled genomes (from www.ensembl.org). The following species were analysed in this 
way: fishes (Danio rerio, Gasterosteus aculeatus, Oryzias latipes, Takifugu rubripes, Tetraodon 
nigroviridis); amphibians (Xenopus tropicalis); reptiles (Anolis carolinensis, Pelodiscus sinensis, 
Chrysemys picta bellii); birds (Gallus gallus, Meleagris gallopavo, Melopsittacus undulatus, 
Taeniopygia guttata); and mammals (Bos taurus, Gorilla gorilla, Homo sapiens, Ictidomys 
tridecemlineatus, Macropus eugenii, Monodelphis domestica, Mus musculus, Ornithorhynchus 
anatinus, Pan troglodytes, Sus scrofa). B) Evolution of Agrs subfamilies showed Agr2 and Agr3, are 
present only in amphibians and higher vertebrates. Ag1 are apparently absent in reptiles, birds and 
mammal but are present in fishes and amphibians.  
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1.3.3. Human AGR2 
1.3.3.1. Gene architecture and expression of AGR2 
The human agr2 (hAgr2) gene spans a region of 50 kb in genomic DNA and 
is located on chromosome 7p21.3 [69]. Two mRNA isoforms were detected and 
contained eight exons and seven introns, and both isoforms contain the same open 
reading frame [70]. The sequence of both cDNA clones revealed that they have the 
same open-reading frame and exhibits an additional 5’ exon. Zheng et al. investigated 
the promoter activity of hAgr2 gene using a luciferase reporter gene construct driven 
by the agr2 promoter assay [71]. The results indicated that the forkhead box 
transcription factors FOXA1 and FOXA2 which maintains goblet cell function 
increased luciferase activity thus may regulate the transcription of agr2 mRNA [71]. 
Additionally, the agr2 promoter region also exhibits a binding site for hepatic nuclear 
factor 1, related to the same family as FOXA1 and FOXA2 [71]. Further work by Krig 
and co-workers using chromatin immunoprecipitation (ChIP) and database mining 
approach identified binding sites for the oncogene ZNF217, and relevant NF-κB and 
SOX9 within the agr2 promoter region  [72].  
 
AGR2 promoter regulations also have been implicated in hormonal response. 
AGR2 was significantly upregulated in response to estradiol [73] using both cell and 
animal models and showed a time and dose dependent manner induction by androgens 
[70]. Moreover, AGR2 can be regulated by pathophysiological stresses. When breast 
cancer cell line is subjected to serum starvation and oxygen deprived, agr2 mRNA 
transcription increased approximately fivefold [74]. Several known inhibitors for 
ERK1/2, JNK, p38 and PI3K regulatory pathway was tested in this model, but only 
ERK1/2 inhibition resulted in reduced AGR2 mRNA expression using RT-PCR, 
suggesting that AGR2 contributes to the survival of cells undergoing physiological 
stress in the microenvironment of the tumor. The AGR2 induction response could be 
blocked effectively by a synthetic inhibitor of ERK1/2, suggesting that the activation 
signal for AGR2 induction during stress is mediated through an ERK1/2-dependent 
pathway. AGR2 expression is controlled by the UPR upon ER stress and most likely 
depends on both IRE1 and ATF6 signaling [75]. IRE1α and ATF6α knockdowns 
resulted in decreased basal Agr2 mRNA expression using RT-PCR and also prevented 
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Agr2 induction upon ER stressor, Tunicamycin treatment (an inhibitor of N-linked 
glycosylation). In contrast, PERK knockdown had no effect on Agr2 expression. The 
study also showed that Agr2 expression was partly under the control of the IRE1α-
Xbp1s pathway where Xbp1 mRNA splicing was attenuated in IRE1α dominant 
negative expressing cells. Other ER stress inducers like a reducing agent dithiothreitol 
(DTT) and thapsigargin (calcium pump inhibitor), were also found to upregulate agr2 
transcription [70, 75]        which supports the idea of the gene as protein disulphide 
isomerase (PDI) in maintaining ER homoeostasis. Further, AGR2 has been shown to 
be associated with tumour growth factor-β (TGF-β) responsive in pancreatic cells, 
whose expression can be downregulated by SMAD4 induction [76].  
 
1.3.3.2. AGR2 protein structure 
The AGR2 protein consists of 175 amino acid residues (Figure 1.7A), with a 
predicted molecular mass of 19,979.2 Da and a predicted pI of 9.03 3. AGR2 gene 
consists of 7 transcripts in total as shown in Ensemble4. However, only 4 of them has 
the open reading frame and protein coding: AGR2 001, AGR2 005, AGR2 006, and 
AGR2 007, where AGR2 001 is commonly used as the reference sequence. A sequence 
alignment of AGR2 reveals 54% identity and 71% similarity to XAG-2, and 91% 
identity and 96% similarity to murine AGR2 [77]. The availability of bioinformatics 
software to predict structural motif highlights several important characteristics of the 
expressed protein.  Based on the secondary structure prediction (PSIPRED v 3.3)5 the 
full-length AGR2 was shown to possess α- β-α- β- α- α- β- β- β- α arrangement (Figure 
1.7B). The N-terminal 45 amino acid residues exhibit high levels of predicted disorder 
using DISOPRED3 tools (Figure 1.7C) [78]. Regions of intrinsic disorder were 
described to particularly enriched in proteins involved in protein-protein interactions, 
cell signalling and transcription [79]. A more recent approach using the powerful 
Nuclear Magnetic Resonance (NMR) to study the crystal structure of mature AGR2 
(without the 20-amino-acid signal peptide) revealed that N-terminal amino acid region 
21– 40 is unfolded which was consistent with the predicted disorder region data [61]. 
The N-terminal unstructured region also showed an enhanced rate of adhesion of rat 
                                                 
3 ExPASy Compute pI/Mw.  (http://web.expasy.org/compute_pi/) 
4 http://www.ensembl.org 
5 PSIPRED v 3.3 http://bioinf.cs.ucl.ac.uk/psipred/ 
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mammary tumour cells which supports the impression that intrinsic disorder region 
plays a role in protein’s function. Structural analysis of AGR241–175 (PDB code: 2LNS) 
showed that it has α- β- α- α- β- β- β- α arrangement which was consistent with its 
secondary structure prediction (Figure 1.8A). Each AGR2 monomer subunit consists 
of a four-stranded β -sheet core surrounded by four α - helices: α 1 (residues 58– 67), 
β 1 (residues 72– 77),α 2 (residues 82– 93), α 3 (residues 95– 103), β 2 (residues 105– 
108), β 3 (residues 127– 132), β 4 (residues 135–138) and α4 (residues 157–168) [61]. 
The NMR structure analyses also showed that AGR241–175 exists as homodimer 
which occurs via antiparallel rearrangement of the α1 helix (Figure 1.8B). The 60-
EALYK-64 within the α1 helix is shown to be the dimeric interface where the 
intersubunit salt bridge between the carboxylate group of E60 and the ammonium 
group of K64 forms the major interaction.  
 
There are three major structural determinants of AGR2. First, AGR2 harbours 
hydrophobic signal peptide sequences in its N-terminus (amino acids 1-20) directing 
AGR2 into the endoplasmic reticulum. The putative cleavage sites for signalling 
peptides predicted by Signal-P program6 is between amino acids Ala20 and Lys21. 
The N-terminal leader sequence target nascent polypeptides directly from the 
ribosome to the ER membrane via a signal recognition particle (SRP) and later cleaved 
by signal peptidase in the ER lumen, yielding a mature, processed form of a protein 
[16]. However, there is very little information on regulation at the level of cleavage of 
the signal peptides by enzymes such as signal peptide peptidase [80]. Cell-based 
analysis using immunofluorescence of localisation of AGR2 with and without signal 
peptide suggested differential subcellular localisation where the full-length protein is 
localising predominantly to the ER and the shorter, mature AGR2 lacking the N-
terminal leader sequence localising primarily to the nucleus [81]. As described by 
Vitale and Denecke, co-translational cleavage by signal peptidase of protein 
harbouring signal peptide is essential for protein folding and maturation [16]. Thus 
protein with an absence of the signal peptide would not be directed to the ER lumen, 
and instead, would demonstrate subcellular mislocalisation. Further, it has been 
indicated that signal peptide peptidase can cleave intramembrane signal sequences 
                                                 
6 http://www.cbs.dtu.dk/services/SignalP/ 
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which can lead to perturbation of endoplasmic reticulum-associated protein 
degradation (ERAD) to control the unfolded protein response (UPR) modulators [82]. 
Studying whether AGR2 involves in proteolysis by signal peptide peptidases and 
impact upon endoplasmic reticulum quality control, unfolded protein responses, and 
disease mechanisms would gain more insights in AGR2 signalling.   
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Figure 1.7 Structural elements of AGR2. (A) Schematic illustrating structure of the full-length AGR2 
protein. The panel highlights the functional motifs human AGR2; signal peptide, an N-terminal 
intrinsically disordered region; a dimerization motif; a thioredoxin fold, and the ER retention site. (B) 
Schematic illustrating predicted secondary structure of AGR2 (PSIPRED v 3.3)  (C) The N-terminal 45 
amino acid residues indicate a high level of predicted protein disorder using DISOPRED3 [78].  
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Figure 1.8  Crystal structure of AGR241-175 (PDB code: 2LNS). A) Ribbon representation of the 
subunit structure of AGR241–175 using NMR showing secondary structures (β-sheet in yellow and α-
helix in red) (reproduced from [61]). B) Ribbon representation of homodimer model of AGR241–175 
showing the antiparallel arrangement of the α1 helix. Dimeric interface 60-EALYK-64 is highlighted 
in red with the residues of E60 and K64 showed as sticks. The intersubunit salt bridge between the 
carboxylate group of E60 and the ammonium group of K64 forms the major interaction between the 
subunits. Ribbon representation were generated using PyMOL v1.8.0 
 
  
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 1 - Introduction 33 
The second key motif of AGR2 primary structure is the extreme C-terminus 
ER retention motif containing tetrapeptide sequence of lysine (K) – threonine (T) – 
glutamic acid (E) – leucine (L) abbreviated as KTEL [83]. This motif is a non-
optimized form of the classic ER retention motif, whose classical form is H/KDEL 
[84]. More recent studies have suggested the role of extra amino acids at position 5 
and 6 from the C-terminus in determining ER residency [85]. The ER retrieval motif 
KDEL, complemented with N-terminal signal peptide, also targets proteins to ER, 
where it mediates retrograde transport of proteins in endoplasmic reticulum during the 
protein secretion process into the extracellular space [85]. Early studies showed that 
proteins possessing H/KDEL or similar motif interact with Golgi-resident KDEL 
receptors in intermediary compartments of cis-Golgi complex [86]. Having H/KDEL 
been well described as an ER retrieval motif, a few examples of human proteins exist 
where proteins exhibiting this motif demonstrate a non-ER localisation such as the 
cytosolic and nuclear localisation of the KDEL-containing protein calreticulin [86]. 
The underlying mechanism of how these proteins can evade ER retention remain 
unknown, whether it is through an error rate of the KDEL receptor molecules, active 
secretion or whether KDEL-expressing proteins are released by necrotic cells. 
Variations in the sequence have been described [66, 83], including KTEL which is 
possessed by AGR2, which has reduced binding affinity for the KDEL receptor [85, 
86]. Hence, this might explain why KTEL motif of AGR2 provides some flexibility in 
the subcellular localisation where it can ‘leak’ outside the ER, which may be essential 
for dynamic protein function in response to physiological conditions [81, 83]. 
Modulating the motif in AGR2 has shown effects in cell-based systems where deletion 
of KTEL result in secretion of AGR2, and while KTEL mutagenesis to the optimised 
canonical KDEL increases the magnitude of endoplasmic reticulum localisation [81].  
Gupta et al. also showed that AGR2 induce the expression of amphiregulin  (AREG) 
only when the wild-type carboxyl-terminal KTEL only with the highly conserved 
KTEL but not with KDEL [83]. Hence, variants of ER retention sequence may serve 
a specific functional role, and in the case of AGR2, this role is served specifically by 
KTEL. In addition, deletion of the motif eliminates its ability to stimulate cell growth 
in clonogenic assays and to attenuate the p53 transcriptional response to DNA damage 
[87] which suggest an AGR2 function in cancer cell survival that is just not limited to 
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localisation in the ER. Also, a recent study showed surprising results. In newt AG 
(nAG), when myc-tag is introduced at its C-terminal, the nAG protein after 
transfection into cells was highly secreted into media which was observed by chance 
by Grassme et al. [68]. When the proteins were further extended for 25 residues after 
the myc-tag, the levels of secretion were even higher. This maybe due to the KTEL is 
hidden with the addition of the extra myc-tag which may have a lower binding affinity 
to KDEL receptor, and therefore the protein is not retained inside the cell but rather 
secreted into the media. The newt protein nAG was identified as a binding partner of 
the salamander-specific protein Prod1, a member of the three-finger protein (TFP) 
superfamily that is GPI-anchored at the cell surface. secreted nAG acts on blastemal 
cells via the GPI-linked Prod1 receptor [4]. nAG acted to promote S phase entry of 
cultured newt blastemal cells, possibly by binding to Prod1 on the cell surface. This 
study showed that the wt nAG and its extended variant (myc+25) had comparable 
activity in promoting S phase entry of cultured blastemal cells.  
 
Another key structural motif of AGR2 which is shared with its orthologue 
AGR3 is the CXXS motif or thioredoxin fold which taxonomically classify the protein 
as a member of protein disulphide isomerase (PDI). Thioredoxin fold is classically 
described as having the CXXC motif with dual cysteines mediate oxidoreductase 
which is important in shuffling disulphide bonds during protein maturation [66]. 
Having the sole cysteine residues in CXXS motif of AGR2 possesses lower 
oxidoreductase activity but may, however, contribute to isomerization of already 
existing disulphide bridges and possibly perform specialised functions in the ER [88, 
89]. Other oxidoreductases also harbour CXXS motifs including ERP44 [90, 91].  The 
founding gene of the AGR family exists in invertebrates and is named ERP18 (also 
named AGR1) [92, 93].  This protein contains the classic di-cysteines thioredoxin fold 
with the CxxC motif and demonstrates through the covalent trapping of disulphide 
bonds in ER [93].  Though ERp18 and AGR2 are highly similar along with having the 
thioredoxin fold, ERP18 did not emerge as oncogenic signalling molecule using 
OMICS discovery platforms like AGR2 [94]. Interestingly, studies using transgenic 
mice showed different phenotypes between AGR2 knockout mice compared to its 
ortholog AGR3; where animals in the absence of AGR3 showed lower ciliary beat 
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frequency in the airway [95].  This indicates the non-reductant function of AGR2 and 
AGR3 function in development and gives a hint that the single cysteine in AGR2 is 
vital in its substrate binding succession. Surprisingly, Bergstrom et al. have recently 
demonstrated that in addition to the KTEL ER-retention signal, the presence of a single 
cysteine within the AGR2 thioredoxin-like domain is required for the control of protein 
secretion [96].  
 
Apart from these three classic biochemical determinants that drive AGR2 
functions, recent studies have brought another compelling insight about AGR2 protein 
architecture.  The NMR studies showed AGR241-175 can exist in homodimer structure 
through a novel amino acid motif at position E60-K64 in an antiparallel arrangement 
of the 1 helix [61]. The salt bridge between the carboxylate group of Glu60 and the 
ammonium group of Lys64 forms the major interaction between the subunits in an 
anti-parallel fashion. Mutagenesis at this dimerization motif abolished the dimeric 
structure. Sequence alignment showed that E60 is conserved in all 21 species from 
zebrafish to humans, and K64 is conserved in amphibians, marsupials and mammals 
but as R in mouse and, in general, tryptophan in fish [61]. It is important to note that 
the dimerization interface of AGR2 is held far from the catalytic CPHS motif 
(opposing faces), where enhanced disulphide exchange in client proteins might occur. 
Another study showed that the N-terminal disordered region (amino acids 20-40) is 
another determinant in AGR2 dimeric structure where deletion in that region 
significantly stabilises the dimer [97]. Remarkably, AGR2 can form an alternatively 
shaped dimeric structure in which oxidation-dependent homo-dimerisation occurs 
through Cysteine-81 mediated disulphide bond formation which would re-orientate the 
dimer into a different conformation [98]. Hupp group also contributed to the molecular 
arrangement of AGR2 in a recent study. The study showed that mutation of Cysteine-
81 to alanine prevents peroxide catalysed dimerization of AGR2 in vitro, suggesting a 
reactive cysteine is central to covalent dimer formation. Using an ESI mass 
spectrometry Clarke et al. demonstrated that low levels of a chemical oxidant promote 
an intermolecular disulphide bond through the formation of a labile sulfenic acid 
intermediate [99]. However, higher levels of oxidant promote sulfinic or sulfonic acid 
formation thus preventing covalent dimerization of AGR2. Thus single cysteine (C81) 
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of the AGR2 act as an oxidant-responsive moiety that regulates its tendency for 
oxidation and its monomeric-dimeric state. Physiologically, this suggests that the 
monomer to dimer equilibrium is important in AGR2 signalling and dictates the 
protein geometry and synergy between the dimer interface and the catalytic 
thioredoxin motif given the fact that AGR2 has only sole Cysteine-81 for thiol-
disulphide interchange to assemble correctly folded disulphide bridges in client cargo 
proteins. 
 
1.3.4. Functions of AGR2  
Functions of AGR2 are not well defined since AGR2 is not only found in ER 
but also in other subcellular localisation such as nucleus [81, 83], cell surface and 
extracellular space [100]. Human AGR2 is strongly expressed in tissues of the lung, 
stomach, colon, prostate and small intestine, organs which contain mucus-secreting 
cells, or function as endocrine organs (Table 1.2) [101]. Likewise, human AGRs are 
predominantly expressed in endoderm-derived organs [102]. In normal tissues, AGR 
proteins could contribute to the regulation of the total protein load in the cell. For 
instance, in normal mammary gland AGR2 highly expressed during late pregnancy 
and lactation [103], a period during which high volumes of milk protein are produced 
in the secretory alveolar buds. During this period, AGR2 promotes epithelial cell 
proliferation and milk protein production from the assistance of additional protein-
folding and secretory factors to cope with the increased protein load. Moroever, milk 
protein expression at the mRNA level is downregulated in a mammary-specific Agr2 
knockout mouse model and upregulated in a mammary-specific Agr2 overexpression 
mouse model [103], suggesting that AGR2 may play a role as a gatekeeper at both the 
protein and mRNA level to regulate the total protein load a cell can withstand without 
entering proteotoxic-induced cell death pathways. Another line of evidence is 
thatAGR2 is required for the production of airway epithelial MUC5AC and MUC5B 
in respiratory system tissues after allergen challenge [104].AGR2 may also be 
involved in epithelial barrier function since the AGR2 promoter regulators are grouped 
into a family which are typical for epithelial goblet cells [71]. Here, possible roles of 
AGR2 function based on its different localisation and its interacting proteins are 
described.    
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Organ system Normal tissues IHC Cell type Protein expression 
Liver and pancreas Prostate Glandular cells Strong 
 Gallbladder Glandular cells Strong 
Digestive tract Stomach Glandular cells Strong 
 Duodenum Glandular cells Strong 
 Small intestine Glandular cells Strong 
 Appendix Glandular cells Strong 
 Colon Glandular cells Strong 
 Rectum Glandular cells Strong 
Urinary tract Urinary bladder Urothelial cells Strong 
 Kidney Cells in tubules Moderate 
Male reproductive system Epididymis Glandular cells Strong 
 Prostate Glandular cells Strong 
 Seminal vesicle Glandular cells Strong 
Breast and female reproductive 
system 
Breast Glandular cells Weak 
 Cervix, uterine Glandular cells Strong 
 Fallopian tube Glandular cells Strong 
 Endometrium Glandular cells Strong 
 Placenta Trophoblastic cells Moderate 
Skin and soft tissues Skin Melanocytes Weak 
Blood and Immune System Tonsil Squamous epithelial cells Moderate 
 Cerebral cortex Neuronal cells Moderate 
Respiratory system Lung Alveolar cells Moderate 
 Nasopharynx Respiratory epithelial cells Strong 
 Pancreas Exocrine glandular cells Moderate 
 Tonsil Squamous epithelial cells Moderate 
Table 1.2 AGR2 expression in normal tissues (derived from Human Protein Atlas7 as described 
in [101]). IHC= Immunohistochemistry. 
 
  
                                                 
7 http://www.proteinatlas.org  
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1.3.4.1. Interactomics of AGR2 defining its function 
Identifying the interacting proteins (termed interactomics) is one of many ways 
to understand how the protein works. Several studies have used a variety of techniques 
to uncover the protein interaction network of AGR2 (Table 1.3). Yeast-two hybrid 
(Y2H) and co-immunoprecipitation, two commonly used assays to study protein-
protein interaction, have largely driven the comprehensive discovery of AGR2 binding 
proteins. Studies using Y2H that human AGR2 can interact with the metastasis-
associated GPI-anchored C4.4a protein and extracellular alpha-dystroglycan (DAG-1) 
[58] and previously described membrane receptor Prod1 [54]. These data showed that 
AGR2 plays a pivotal role in the secretion of the receptor protein that is linked to 
adhesion and cell growth. Further Y2H analyses shown that AGR2 interactome is not 
clouded to only membrane receptor but to nuclear binding proteins such as 
Chromodomain Helicase DNA Binding Protein 6 (CHD6) and Reptin [94, 105]. 
Reptin is the AAA+ ATPase protein and the only AGR2 client protein that has been 
well studied [105]. The AGR2: Reptin interaction was mapped to a peptide interface, 
comprising the proposed substrate-binding loop on AGR2, within amino acids F104 
to Y111. Amino acid mutagenesis at that positions attenuates Reptin binding to the 
AGR2. Later it was shown that Reptin participated in the cytosolic regulatory protein-
folding complexes through the chaperone-dependent R2TP activity  [106] and in cilia 
complex assembly at the plasma membrane [107] which could drag the involvement 
of AGR2. Studies thus far assumed that AGR2 acts as a monomer, but recent NMR 
studies recently showed that AGR2 is predominantly in dimeric form with a 
dissociation constant 8.83 μM where high concentrations will be maintained in its 
resident location, ER. There is very little information about the dimeric function of 
AGR2 towards binding to its client protein. Gray et al. work showed that AGR2 in this 
condition has gain-of-function towards binding to its client protein. The study revealed 
that a stable dimer Δ45-AGR2 was more active in binding to Reptin than either wt-
AGR2 or the monomeric AGR2 (E60A) mutant [97]. Another study by Ryu et al. 
showed that AGR2 dimerization is required for the interaction with BiP/GRP78 in 
mediating the unfolded protein response (UPR) signalling pathway in ER [98]. In 
addition, it has been shown that PDI oligomerization was associated with chaperonin 
activity independent of isomerase activity [108] which could foreshadow dimeric 
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AGR2 function. Therefore, as also discussed in AGR2 protein structure1.3.3.2, 
studying the relationship between the equilibrium of monomer to a dimer of AGR2 
and its interactome will open the door for more research niche in the future 
 
Although CoIP is considered to be the gold standard assay for protein-protein 
interactions and has been the driving force in determining AGR2 client proteins, there 
are some limitations for this assay. First, the interaction partners may not bind directly, 
since they can be part of larger complexes thus may interact via one or more bridging 
molecules [109]. Second, co-precipitation is insensitive compared to other methods 
such as protein affinity chromatography, because the concentration of the antigen is 
lower than it is in protein affinity chromatography. There are also several setbacks for 
Y2H system. For example, Y2H is limited to proteins that can be localized to the 
nucleus, which may prevent its use with certain extracellular proteins [110]. The 
proteins must also exist and stably expressed in yeast cells and to retain activity as 
fusion proteins for detection. Furthermore, the environment of the yeast nucleus 
inhibits interactions of some proteins. The use of protein fusions also means that the 
site of interaction may be blocked by one of the transcription factor domains. In 
addition, posttranslational modification that does not occur in yeast cells therefore 
interaction that is dependent on this cannot be detected. While both CoIP and Y2H 
system as well as other protein-protein interaction methods can identify real protein-
protein interactions, they cannot tell where does the interaction occur in the cell. 
Several new techniques of identifying client proteins and ways to overcome these 
drawbacks will be discussed later in the thesis which can further expand AGR2 
interactome.  
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Gene name Function Method Reference 
DAG1 Links the cytoskeleton and the extracellular 
matrix 
Y2H Fletcher et al. (2003) 
[58] 
REPTIN AAA+ ATPase—DNA repair and 
transcription 
Y2H Maslon et al. (2010) 
[105] 
KDELR KDEL receptors CoIP Raykhel et al. (2007) 
[86] 
C4.4 Metastasis-associated GPI-anchored protein Y2H Fletcher et al. (2003) 
[58] 
MUC2 Mucin 2 CoIP Park et al. (2009) [60] 
PROD1 Axolotl homolog for human CD59 Y2H Kumar et al. (2007) [54] 
EGFR Epidermal Growth Factor Receptor CoIP Dong et al. (2015) [111] 
ARGHAP29 GTPase-activating protein Y2H Unpublished data [94] 
CKAP2 Cytoskeletal-linked protein involved in 
mitosis 
Y2H Unpublished data [94] 
CHD6 Chromatin-remodelling factor Y2H Unpublished data [94] 
GPSM2 Regulates G-protein activation Y2H Unpublished data [94] 
HECTD1 E3 ubiquitin ligase Y2H Unpublished data [94] 
LYPD3 Regulates cell migration Y2H Unpublished data [94] 
HIVEP1 DNA binding protein Y2H Unpublished data [94] 
NRIP1 Binds hormone-dependent receptors Y2H Unpublished data [94] 
NRXN3 Controls adhesion and receptor signalling Y2H Unpublished data [94] 
Table 1.3 Published AGR2-interacting proteins identified from classical protein-protein 
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1.3.4.2. AGR2 as an endoplasmic reticulum protein disulphide isomerase 
AGR2 has been classified as a member of PDI family of molecular chaperone 
due to the presence of thioredoxin-like fold based on phylogenetics analyses [66]. 
Coupled with the degenerative ER retrieval motif and hydrophobic N-terminal signal 
peptide, it is obvious to say that ER is AGR2 native resident where it is most 
functional. Though AGR2 functions have been both speculated intra and 
extracellularly, its protein disulphide isomerase function might be pertinent as a 
protein folding catalyst. The ER contains a network of chaperones which processes 
proteins targeted for membrane insertion or extracellular secretion by performing 
folding, disulphide bond introduction, and N-glycosylation through distinct 
complementary pathways. The ER consists of chaperones that belong to several 
classical chaperone families, such as heat shock protein (Hsp) 40, Hsp70 and Hsp90 
[15]. The ER also houses unique chaperones and folding enzymes such as calnexin 
and calreticulin and the family of PDIs and Peptidyl-prolyl isomerases (PPIases) [15]. 
These chaperones and folding enzymes are part of the ER quality control (QC) system 
that ensures protein are properly folded before entering the subsequent secretory 
pathway.  
 
The main function of the PDI family members is to catalyse the formation or 
rearrangement of the disulphide bonds between two cysteine residues of nascent 
proteins in the lumen of the ER for their proper folding and maturation prior to the 
release for cellular transport [112]. The presence of the canonical thioredoxin fold, 
CXXC, contains two free thiol groups at each of the cysteine residues allows these 
oxidoreductase activities to take place. The thioredoxin fold is thought to be the 
minimum requirement for PDI family membership. Most of PDI family members have 
between one to three dithiol redox motif (CXXC) [113]. To date, 21 members varying 
in size, structure, tissue distribution and enzymatic activity were identified [114]. 
AGR2 is a class of PDI with one divergent CXXS (CPHS) active site sequence which 
means it lacks the fully oxidoreductase CXXC motif activity. It is notable that the 
cysteine to serine substitution is common for some PDI family members, however, the 
activity of CPHS active site is unknown [115]. Some PDIs also has chaperone activity 
to fold denatured proteins which are independent of its thiol activity. This activity is 
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thought to occur via the exposed hydrophobic residues, intrinsically unfolded loops, 
or conceivably exposed aromatic residues which suggest substrate specific client 
proteins are required [113].  
 
AGR2 has been described as a dominant component of ER homoeostasis [75]. 
AGR2 was identified in proteomics analysis of ER-bound ribosome that bound to 
newly synthesised cargo proteins. Further, it was shown that AGR2 expression could 
be controlled by the unfolded protein response (UPR) and that silencing of AGR2 
disrupts the components of the ER-associated degradation machinery (ERAD), 
resulting in a reduction in cells ability to cope with acute ER stress [75]. This showed 
that AGR2 can act as a switch, whether it can act as a catalyst in protein folding of 
nascent proteins or involve in control ERAD which are both important in the stringent 
requirement of ERQC exit [116] (Figure 1.9). 
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Figure 1.9 Functions of AGR2 in the ER. (From [116]) AGR2 can respond to classic unfolded protein 
response pathways controlled by PERK, ATF6, and IRE1 or can act through ERAD pathways. 
However, co-factors through which AGR2 can facilitate receptor maturation and secretion are yet to be 
investigated. The AGR2 expression is elevated in response to ER stress in disease landscape like cancer 
that demands mutant protein production and protein synthesis. AGR2 may also act outside the ER 
(classical leak due to possession of non-canonical ER retention motif) through an unknown mechanism.  
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1.3.5. AGR2 associated diseases 
1.3.5.1. Asthma 
AGR2 gene has been discovered as a biomarker for asthma in murine models 
of acute and chronic asthma [117]. Gene expression microarray in the lung of these 
models and confirmed with RT-PCR identified AGR2 as one of the overexpressed 
genes. Immunohistochemistry showed that AGR2 primarily localised to the goblet 
cells of the lung of these models [117]. Further study in human lung epithelial cells 
exhibited that knocking down interleukin-13 (IL-13), an “inducer” that causes the 
proliferation of goblet cells and over-production of mucus in the air- way, had a 
downstream effect on AGR2 and MUC5AC levels through a signal transducer and 
activator of transcription 6 (STAT6)-dependent pathway [118].  
 
These results were succeeded by the study to determine the relationship of 
AGR2 with other airway mucins, namely MUC5AC and MUC5B [104]. AGR2 was 
shown to colocalise in the same cells as MUC5AC and MUC5B and was able to co-
immunoprecipitate with immature form of MUC5AC.  AGR2 was found to express in 
the ER of MUC5AC- and MUC5B-producing mucus cells in the airway epithelium 
and submucosal glands. Mice deficient in AGR2 (agr2 -/-) have impaired production 
of MUC5AC and MUC5B as well as MUC2. Interestingly, AGR2 mice had 
compromised export of mucins which found accumulated in the ER that in turns 
activate the unfolded protein response. These findings implicated AGR2 role in the 
elevating production of respiratory mucins MUC5AC and MUC5B responsible for 
mucus production. Consequently, overproduction of mucus results in airway closure 
that is one of the prominent features of asthma [119, 120]. Further studies also 
demonstrated that AGR2 expression was higher in asthmatic mice and showed a 
positive linear relationship with the expression of IL-13 and MUC5AC [118]. 
Dexamethasone, a glucocorticoid drug induced silencing of IL-13 attenuated AGR2, 
MUC5B, and IL13 levels in epithelia of the airway suggesting a direct role of AGR2 
in disease penetrance [121]. 
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1.3.5.2. Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a group of autoimmune disorders of the 
gastrointestinal tract. This disease is categorised into two principal: Crohn's disease 
(CD) and ulcerative colitis (UC). The chromosomal location of AGR2 and its 
homologue AGR3, 7p21.3 [69], is mapped to a key susceptibility region of 
inflammatory bowel disease in a genome-wide linkage analysis [122, 123] which lead 
to the investigation of AGR2 as a candidate gene for inflammatory bowel disease [71]. 
It was demonstrated that single nucleotide polymorphism (SNP) were associated with 
the 5' region of the AGR2 gene to UC phenotype in two independent populations (The 
UK and German cohort) [71]. The expression level of AGR2 in UC patients was 
significantly lower than in healthy controls. In addition, carriers of the risk alleles also 
showed lower expression of AGR2. The study also found that AGR2 promoter is 
activated by forkhead box transcription factors FOXA1 and FOXA2 responsible for 
goblet cell function maintenance. These findings are consistent in the study of 
transgenic mice described above, where the mice that are null for AGR2 found to be 
susceptible to ulcerative colitis [60, 63]. Further, the intestines of patients suffering 
from inflammatory bowel disease often exhibit significant symptoms of ER stress 
[124] [125], suggesting that dysregulation of the ER stress response associated with 
low levels of AGR2 may pose a secondary pathway for increased susceptibility to IBD. 
Altogether these results support the hypothesis that AGR2 involve in maintenance 
epithelial barrier integrity [124, 125]. 
 
It seems that diseases associated with AGR2 is completely overlapped with 
those associated with UPR diseases as UPR has been implicated in diseases similar to 
AGR2 discussed above . However the scope UPR-associated is broader which include 
metabolic disease, and neurodegenerative disease. One example that links AGR2 and 
UPR is that in the AGR2 knockout mice studies which showed that there is a decreased 
expression of MUC2  in goblet cells and abnormal localization of Paneth cells in the 
small intestine, which overlaps with UPR activation and the development of 
spontaneous ileocolitis [63]. 
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The role of AGR2 in the secretory pathway, and relief or ER stress, reviewed 
above, support the finding that in the normal functioning of the cell controlled AGR2 
expression is a requirement for the appropriate maturation, localisation and secretion 
of extracellular proteins. AGR2 alteration through mutation, overexpression and 
underexpression has indicated significant pathological effects.  
 
1.3.6. AGR2 in cancer 
1.3.6.1. AGR2 pro-oncogenic features  
Human AGR2 gene was first described in the oestrogen receptor (ER)-positive 
MCF-7 cell line [126]. Regulation of AGR2 protein expression by oestrogen was later 
confirmed by both in-vivo [73] and in-vitro experiments [127]. AGR2 also was found 
in other types of cancer pertaining to hormone-dependent such as [58, 74, 101, 103, 
126-132] prostate [70, 101, 133, 134] and ovarian [135-138], as well as in non-
hormone dependent cancers such as tumours of the oesophagus [87, 139], 
gastrointestinal tract [140] and lungs [141, 142]. AGR2 exhibits the basic features of 
a pro-oncogenic protein and cell survival enhancing activity. Clonogenic assays were 
used to demonstrate that AGR2 overexpression can enhance cancer cell survival, rather 
than inhibit cell growth in the premalignant Barrett oesophagus and oesophageal 
cancer models [87]. Deletion of the last 10 amino acids of AGR2, harbouring the ER 
retention site of AGR2, prevented clonogenic growth stimulation and influencing p53 
phosphorylation indicating a role in tumourigenesis of the ER localised protein and 
survival factor. Further, AGR2 silencing was shown to inhibit proliferation, invasion 
and survival in-vitro in pancreatic [143] and breast cancer cell lines [144]. Moreover, 
conditioned media from cells silenced in AGR2 have a reduced ability to stimulate 
proliferation of pancreatic cancer cells [143]. On the contrary, short interfering RNA- 
or short hairpin RNA-mediated AGR2 knockdown prevents colony and subcutaneous 
growth in oesophageal and pancreatic cancer models [62, 143].  
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1.3.6.1. AGR2 overexpression in cancers 
Large-scale cancer genomics data sets8  and as described in [145] showed that 
most AGR2 were amplified in cancer landscape (Figure 1.10). Only a few mutations 
were reported in the dataset which mainly exhibited missense mutations (one amino 
acid change), suggesting that mutants AGR2 had little effect in cancer development. 
In human,  AGR2 had previously been first identified as an overexpressed gene in 
breast cancer cell lines [126] and breast cancer patients especially in association with 
oestrogen positivity [58]. In fact, the top literature findings using data from Pubmed9 
showed that AGR2 was most associated with breast cancer. The overexpression in 
breast cancer is clinically relevant as high levels of AGR2 are associated with poor 
prognosis in ER-positive breast cancer [127, 146]. The expression of AGR2 in poor-
prognosis tumours may be due to multiple regulatory mechanisms whether an AGR2 
expression can be induced in an ER-dependent manner early in tumorigenesis, leading 
to an inherent therapeutic resistance, or its expression can be induced in response to 
anti-hormone treatment, leading to an acquired resistance to therapies. Furthermore, 
the high AGR2 expression is sometimes found in ER-negative breast cancers [58], 
indicating a different mechanism of upregulation, such as physiological stress [74]. 
Breast tumours can be classified into the basal-like, Her2, luminal A, luminal B, and 
normal breast-like subtypes by their intrinsic gene expression profiles [147]. AGR2 is 
expressed significantly higher in the ER-positive luminal A and B subtypes compared 
with the ER-negative basal-like, Her2, and normal-like subtypes, supporting the 
previously reported overexpression of AGR2 in ER-positive breast cancer [146].  
 
  
                                                 
8 http://www.cbioportal.org/ 
9 http://www.cancerindex.org/geneweb/AGR2.htm 
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Figure 1.10  AGR2 expression from cBioportal large-scale cancer genomics data sets as described in [145].   This portal contains data from 147 cancer genomics 
studies that reduces molecular profiling data from cancer tissues and cell lines into user-friendly and interactive genetic, epigenetic, gene expression, and proteomic 
events. Data showed the top genomic studies in AGR2 cases. A large number of cancers showed overexpression of AGR2 with few cases of mutations, where mostly 
missense mutation.
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AGR2 has been also implicated in a various type of cancers as summarised in 
(Table 1.4). In ovarian cancers, mucinous cancer biopsies showed overexpression of 
AGR2 expression by immunohistochemistry [137], as well as in endometrioid 
cancers[148], and high-grade serous tumours [149]. A high concentration of AGR2 in 
the extracellular plasma has been associated with both serous and non-serous ovarian 
cancer [135]. In prostate carcinomas, AGR2 has been reported in high concentration  
[150, 151], both intracellularly and extracellularly in the blood [151] and urine [152], 
and AGR2 is now has been selected as possible candidate for a biomarker for prognosis 
of prostate cancer. Increased level of AGR2 is associated with poor prognosis of 
prostate cancer patients [134]. 
 
AGR2 overexpression is also associated with the normal biliary tree in both 
fetal and adult normal liver. Strong AGR2 expression was seen in the tall epithelial 
cells covering the large bile ducts as well as gallbladder epithelial cells [153].  
 
Elevated levels of AGR2 have also been linked to non-hormone related 
oncogenesis and cancer progression, and this includes oesophageal adenocarcinoma. 
Oesophageal adenocarcinoma is different from other types of cancer where the 
environmental stress of bile acid reflux plays a seemingly important role in disease 
progression [154]. In addition, p53 tumour suppressor gene mutation can occur very 
early in the disease sequence; during the conversion of squamous epithelium with 
metaplastic epithelium, also called ‘Barrett’s oesophagus’. Proteomics screen in the 
preneoplastic Barrett’s epithelium identified AGR2 as overexpressed proteins, which 
was validated as a strong inhibitor of p53-dependent transcription and a growth-
promoting pro-oncogene [87]. Since Barret’s oesophagus is damaged by reflux of 
stomach acid into the oesophagus, it is interesting to see if acid can influence AGR2 
expression since it is upregulated in this type of disease. 
 
Additionally, high levels of AGR2 mRNA have been found in pancreatic 
cancer tissue compared to paired normal tissue [143]. Further investigation 
complement this study where AGR2 was described as a transforming growth factor-β 
(TGF-β)-responsive gene in human pancreatic cancer cells, whose downregulation is 
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SMAD4 dependent [76]. In this study also, AGR2 exhibited chaperone activity in 
which it involves in the maturation of the cancer-associated mucin, MUC1 and that 
AGR2 is both sufficient and required for MUC1 expression in pancreatic cancer cells 
[76]. AGR2 also has been implicated in another various type of cancers, among others, 
gastric cancer cells [140], colorectal cancer [155], lung cancer [142] [156] as well as 
head and neck cancers [157]. AGR2 implications in the cancer landscape are 
summarised in Table 1.4. 
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Cancer Type AGR2 Implication Reference 
Breast Cell proliferation and migration 
Overexpression 




Li et al., 2015 [158] 
Fletcher et al., 2003[58] 
Duran et al., 2008 [159] 
Barraclough et al., 2009; 
Hrstka et al., 2010 [127, 130] 
Fletcher et al., 2003; Liu et 
al., 2005; Barraclough et 
al., 2009 [58, 129, 130] 
Ovarian (mucinous) Overexpression 
Overexpression 
High plasma concentration 
 
Park et al., 2011 [137] 
Gray et al., 2012 [136] 
Edgell et al., 2010 [135] 
Ovarian (other) Poor prognosis 
Overexpression 
Darb-Esfahani et al., 2012 [149] 
Armes et al., 2013 [148] 







Kani et al., 2013 [151] 
Kristiansen et al., 2005; Bu 
et al., 2011 [133, 150] 
Kani et al., 2013; Zhang et al., 
[151, 160] 
Hu et al., 2012 [161] 
Zhang et al., 2007 [134] 
Oesophageal Overexpression Pohler et al., 2004 [87] 
Pancreatic Overexpression in serum 
 
Secreted into pre-malignant 
neoplastic juice 
 
Promotes pancreatic intraepithelial 
neoplasia 
Barry et al., 2012; 
Ramachandran., 2008 [143, 162] 
Chen et al., 2010; 
Makawita et al., 2011 [163, 164] 
 
Norris et al., 2012 [76] 
Lung Overexpression 
 
Fritzsche et al., 2007 
Chung et al., 2011 [142, 156] 
Gastric Metastasis Lee do et al., 2011 [140] 
Colorectal Poor prognosis Valladares-Ayerbes et al., 
2012 [155] 
Head and neck Metastasis Sweeny et al., 2012 [157] 
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1.3.6.2. AGR2 implication in metastasis and excretory system 
The AGR2 metastatic role is intensively studied in many cancer types 
including breast carcinomas [58, 129, 130], prostate adenocarcinomas [151], head and 
neck squamous cell carcinomas [157] or gastrointestinal cancers [140]. A key nature 
of AGR2 highlighted in many studies is, not only the effect of AGR2 in growth 
promotion, but also the detection of AGR2 in excretory systems such as blood serum 
and urine, suggesting that AGR2 may act in a paracrine or autocrine manner [165]. 
AGR2 was identified as a candidate marker for metastasis in a gene expression screen 
of cancer cell lines [166]. Further interactomic studies have demonstrated that AGR2 
directly interacts with two transmembrane proteins involved in metastasis-associated 
GPI-anchored protein cell-cell contact or cell-matrix interactions in C4.4A and alpha-
dystroglycan (DAG1) respectively (Table 1.3) [58]. cDNA microarray analysis of 
ovarian tumour tissue revealed AGR2 overexpression and its overexpression 
upregulates the expression of genes involved in cell proliferation, invasion and 
angiogenesis, which are very important for tumour progression and metastasis [137]. 
Moreover, overexpression of AGR2 in benign rodent mammary cell line transformed 
the cells to the metastatic phenotype and showed enhanced adhesive properties, 
suggesting AGR2 significance on the in vivo tumour biology [129]. In head and neck 
squamous cell carcinoma cells model, AGR2 silencing (and also silencing of CD147) 
reduced cell proliferation, migration and invasion [157]. Thus, these results suggest 
that AGR2 does not only promote cell migration but can also control the cell adhesion 
rates of detached cells, which may relate to the metastatic properties. The differences 
in whether migration or adhesion dominates through an AGR2 signal are likely 
because of different cancer cell models were used in distinct experiments and that each 
cell type exploits distinct pathways that mediate cancer survival.  
 
AGR2 also has been shown to be associated with metastatic in prostate cancer. 
AGR2 overexpressing cells in non-metastatic prostate cancer cells promotes the 
motility and invasiveness, whereas silencing of AGR2 eliminates this behaviour [160]. 
While AGR2 promotes migration and invasion of prostate cancer cells as well as other 
types of cancers, it has the opposite phenotype in prostate cancer, it reduces cell-cycle 
progression [152].  In this study, overexpression of AGR2 led to cell growth inhibition 
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and reduce colony formation of prostate cells, conceivably brought by a cell cycle 
arrest [152]. This suggests that AGR2 may involve in regulating epithelial–
mesenchymal transition (EMT) in development and cancer and cell-proliferation effect 
of overexpressed AGR2 is dependent on cell type. It has been reported that SIP, a 
transcription factor which induced an invasion phenotype but at the same time 
attenuates cell growth control EMT. EMT is a process by which epithelial cells lose 
their cell polarity and adhesion and gain migratory and invasive properties to become 
mesenchymal cells. EMT was a major programme used in cell differentiation during 
embryogenesis, but parts of this genetic programme are believed to be reactivated 
during metastasis to transform malignant epithelial cells into increase motility to travel 
to the distant site [167, 168]. Possibly, AGR2 is suppressed during EMT but 
reactivated again once metastasized to distant organs. 
 
The cellular mechanism by which AGR2 promotes proliferation are poorly 
understood, but there are several hints from AGR2 studies on the role it plays in cell 
signalling networks. One pathway that AGR2 has been implicated in is the EGFR 
pathway. Dong et al. demonstrated that AGR2 induced expression of AREG, a growth 
promoting EGFR ligand [169] which functionally associated AGR2 and AREG and 
supported a significant role for AGR2 in lung adenocarcinomas and the regulation of 
cell growth. AREG induced by AGR2 expression may stimulate the EGFR signalling 
pathway and may be responsible for the increased cell proliferation and anchorage-
independent growth observed in transformed cells [62, 143]. It was also shown that 
the induction was specific for AREG, as there was no detection of other known EGFR 
ligands and that activation resulted in increased phosphorylation of both EGFR itself 
and AKT downstream of the receptor. AREG expression has also been shown to be 
regulated by the Hippo pathway, which involve in the regulation of cell growth and 
apoptosis, and functions in dictating organ size [170]. Suppression of the Hippo 
pathway results in YAP dephosphorylation followed by transport to the nucleus, where 
it inhibits apoptosis and promotes cell division. Nuclear YAP protein is associated 
with neoplasia and has been observed in lung, colon, ovarian and breast 
adenocarcinoma [169]. 
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Further, AGR2 was differentially expressed in metastatic gastric cancer cells, 
compared to non-metastatic cells using proteomics approach [140]. The role of AGR2 
in metastasis is of significant interest, as successful metastases require activation of 
genes that promote cell survival in environments of stress, therefore the necessity to 
characterise this metastatic marker proved to be clinical significance. 
 
1.3.6.3. AGR2 and cancer drug resistance 
The clinical relevance of AGR2 is strengthened by the finding that AGR2 
showed resistance to major cancer drug therapies (as summarised in Table 1.5). For 
example, AGR2 is one of the genes found to be mediating the resistance of breast 
cancer drug, Tamoxifen.  Tamoxifen is an anti-oestrogen that can be used successfully 
to treat human breast cancers but the treatment has become a problem due to intrinsic 
or acquired to the drug. This led to the hypothesis of some genes paradoxically act as 
agonists of Tamoxifen and might mediate this resistance. As such, identification of 
oestrogen responsive genes induced by Tamoxifen was performed to identify key 
players in the field of drug resistance [171]. AGR2 expression is elevated in response 
to tamoxifen treatment [172]. In cancer patients treated with the oestrogen suppressor 
Letrazole, the AGR2 gene was one of the top downregulated genes in biopsies from 
patients’ post-treatment that respond well to the drug [127]. This observation suggests 
that resistance to anti-oestrogens might be due to failure to suppress AGR2. Another 
study using label-free quantitative proteomics screen, PaCIFIC to search for dominant 
proteins induced by Tamoxifen demonstrated that AGR2 was the second most 
upregulated protein [173]. The study also showed that AGR2 gene can promote 
resistance to cell death induced by the common DNA-damaging agent doxorubicin and 
AGR2 grown in xenograft system confer resistance to cisplatin [173]. It was also 
demonstrated that induction of AGR2 was a direct effect of ERα activation using 
chromatin immunoprecipitation and reporter assay in the presence of oestradiol or 
Tamoxifen [127]. Later, it was found that AGR2 involve in the phosphoinositidine-
dependent protein kinase 1-AKT (PDPK1-AKT) signalling pathway in response to 
tamoxifen treatment [174].  
 
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 1 - Introduction 55 
Additionaly, AGR2 has been associated in an  anti-oestrogen resistance 
comparing fulvestrant-sensitive and –resistant T47D breast cell lines in proteomic and 
genomic studies  [175]. Conversely, AGR2 expression is reduced in docetaxel-
resistant hormone-refractory prostate cancer using proteomic screens [176].  
 
Tumour cells may overexpress AGR2 to promote cell survival by allowing the 
cell to withstand excess protein production associated with transformed cells. Major 
histocompatibility complex-1 (MHC-1) molecules, important for tumour surveillance, 
are potential targets of AGR2 as other PDIs have been shown to play a role in their 
folding and antigen loading[177]. Most cancer cells show an increased expression of 
proteins of the secretory machinery, including ER chaperones that contribute to the 
ability of cancer cells to confer resistance against a wide range of therapies. For 
example, it is known that the simple overexpression of the central chaperone BiP has 
been shown to be protective against a wide range of chemotherapeutic agents 
[178].Since AGR2 can exist intracellularly and also extracellularly, AGR2 may 
involve in the secretory machinery and thus upregulation of AGR2 in cancer can lead 
to overexpression of other the secretory machinery. Thus, understanding the molecular 
details of why certain cancer drug selectively induces or reduce AGR2 expression 
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DRUG INVOLVEMENT OF AGR2  REFERENCE 
TAMOXIFEN Induced by tamoxifen, overexpressed in 
tamoxifen-resistant tumours 
Hrstka et al., 2010[127]; Hengel 
et al. 2011 [173] 
CISPLATIN Mediates resistance in xenograft models Hengel et al 2011[173]; Gray et 
al. 2012 [136] 
DOXORUBICIN Overexpressed in doxorubicin-resistant 
tumours 
Hrstka et al., 2010 [127]; 
Hengel et al. 2011 [173] 
DOCETAXEL Reduced expression in docetaxel-
resistance tumours 
Zhao et al. 2009 [176] 
FULVESTRANT AGR2 and Cathepsin D mRNA 
upregulated in resistant cell line 
Huber et al. 2004 [175] 
Table 1.5. Studies underlining AGR2 in drug resistance.  
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1.3.7. AGR2 in the early secretory pathway and extracellular gain-of-
function. 
Enhanced AGR2 expression is observed in many cancers as described 
previously and this can be termed to intracellular AGR2 (iAGR2) expression. iAGR2 
overexpression could represent a mechanistic intermediate between the endoplasmic 
reticulum and tumour development. For example, Higa et. al showed that iAGR2 
expression could enhance ER protein homoeostasis and or proteostasis to increase the 
capacity of tumour cells to handle the demands for protein production and secretion 
thereby contributing to the aggressiveness of cancer [75]. Although the iAGR2-
mediated ER proteostasis control model is interesting, it was also observed that in 
cancer, AGR localises in a different part of the cells and is secreted (Figure 1.11 [94]). 
AGR2 can escape ER retrieval machinery and can be found in the cytoplasm as well 
as in the extracellular environment probably due to possession of the non-optimized 
ER retention site (KTEL) at its C-terminal [58]. AGR2 was found to be secreted during 
the development of pancreatic cancer [143] and was detected in the urine of prostate 
cancer patients [152] as well as in the blood of ovarian cancer patients [135]. These 
non-endoplasmic reticulum locations define broader functions of that may be based on 
different redox potential based on the localisation [179]and thereby opening other 
openings for its role in tumour microenvironment quality control and tumour 
development. 
  
More interestingly, a recent study describes the physiological role of 
extracellular AGR2 (eAGR). Fessart et al.  used an organoid model derived from 
human lung epithelial cell to address whether eAGR2 could act as a pro-oncogenic 
molecule in the extracellular matrix[180]. The study showed that eAGR2 present in 
the extracellular medium of non-tumoural organoids can convert non-tumoural 
organoids to tumour organoid and enhanced their growth about ten-fold [180]. 
Interestingly, eAGR2 is sufficient by itself, to disrupt cell polarisation and to promote 
the acquisition of invasive and metastatic properties and this is independent of its 
thioredoxin-like domain (CXXS) and of its ER-retention domain (KTEL). This study 
highlights a gain-of-function of AGR2 in extracellular milieu of the tumour 
microenvironment. Therefore, it can be postulated that there is a dual role of AGR2 in 
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cancer development. First, there is an intracellular AGR2 whose function previously 
described as a catalyst in the ER-homeostasis to cope with cancer cells secretory 
demands an. Second, an extracellular AGR2 that involves in pro-oncogenic signalling 
in epithelial tumorigenesis. Altogether these findings underscored AGR2 as an 
appealing target for novel therapeutic strategies against cancer.  
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Figure 1.11 The intracellular and extracellular role of AGR2. (From [116]) Although AGR2 
normally reside in the ER (ER homoeostasis), studies have shown that AGR2 can be identified outside 
the ER and secreted in extracellular space (autocrine/paracrine role or proteostasis). There are very few 
AGR2 “binding proteins” identified; one of which can bind AGR2 cytosolically in a complex with the 
AAA+ protein Reptin where the dimeric AGR2 shows enhanced affinity. Another AGR2 client proteins 
includes the exosomal and ubiquitin ligase family member TSG101 that can play a direct role in 
suppressing p53 function.  
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1.4. Aims 
The main aim of this study was to expand the AGR2 interactome and to 
understand the functional consequences of some of these interactions. Chapter 3 
discussed the use of linear peptide motif that specifically binds to AGR2 in which; i) 
the peptide binding site was mapped using hydrogen-deuterium mass spectrometry; 
and ii) the consensus peptide-binding motif was developed to search for human 
proteins that harbour this motif as potential AGR2 client proteins. When the potential 
AGR2 client proteins were grouped based on their subcellular localisations, 
transmembrane proteins were dominant class of proteins. This leads to another aim in 
the project which is to study AGR2 involvement in secretory pathway since AGR2 has 
the propensity to bind to these secretory proteins and AGR2 itself can be secreted for 
extracellular gain-of-function. The key AGR2 client protein represented by a 
membrane-bound protein EpCAM was validated in-depth using in-vitro biochemical 
approaches and mass spectrometric analysis. Chapter 4 was built around the key AGR2 
client protein (EpCAM) validated from Chapter 3 where the chapters aim; i) to further 
understand AGR2-EpCAM interaction using cell-based assays; ii) to understand how 
AGR2 can regulate EpCAM expression using molecular and cellular biology 
techniques; iii) and to examine the relevance of its expression in tumour clinical 
samples. Chapter 5 discussed the attempts to deplete AGR2 and to control AGR2 
overexpression in tumour cells as means to study its function which is then used to 
screen for global protein changes using quantitative utilised quantitative proteomics. 
This also serves as the second method to identify AGR2 client proteins and to support 
the working paradigms that AGR2 largely binds to membrane-bound secretory 
proteins. Finally, synthetic tools were utilised to further understand the function, 
regulation and ‘druggability’ of AGR2 in Chapter 6. These synthetic tools include the 
i) isolation of high-affinity AGR2-targeting monoclonal antibodies in the format of the 
scFv fragment, ii) engineering synthetic mini-protein containing copies of wild-type 
and mutated AGR2 linear peptide motif and iii) engineering synthetic membrane 
protein model that bind to AGR2. These synthetic tools were modified to express in 
mammalian cells and assessed how their expression is regulated by AGR2 to gain 
information regarding AGR2 signalling and to highlight potentially ‘druggable’ stage 
in the oncogenic secretory pathway. 
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CHAPTER 2: Materials and Methods 
 
2.1. Chemicals 
All chemicals and solvents were obtained from commercial sources and of high 
purity and HPLC spectral grade unless otherwise stated. 
 
2.2. Microbiological techniques 
All procedures using bacteria were carried out under aseptic techniques.  
 
2.2.1. Bacterial growth culture 
Small DNA preparation (miniprep) extraction from bacterial cell culture 5 ml 
Luria-Bertani (LB) medium (Table 2.1) containing the appropriate antibiotic (Table 
2.2) was inoculated with a single bacterial colony from a freshly streaked selective 
plate or from a glycerol stock store in -800C and incubated overnight at 370C with 
shaking at 200 rpm. For larger scale DNA preparation (maxiprep) 1-5 ml LB medium 
containing the appropriate antibiotic was inoculated with a bacterial colony grown on 
agar or from a glycerol stock and incubated for 8 hours at 200 rpm. The starter culture 
is diluted 1/500 to 1/1000 into a larger volume 200 ml LB containing appropriate 
antibiotic before incubation at 370C with shaking at 200 rpm and grown to saturation 
(16 hours). The flasks used were of at least four times greater than the volume of 
medium for proper aeration. Glycerol stocks were prepared as appropriate by 
transferring 0.8 ml of saturated culture to 0.2ml of sterile 80% (v/v) glycerol using a 
sterile cryovial (Nunc) before storing at -800C freezer. 
LB Broth LB plates 
1% (w/v) Tryptone 1% (w/v) Tryptone 
0.5% (w/v) Yeast extract 0.5% (w/v) Yeast extract 
1% (w/v) NaCl 1% (w/v) NaCl 
 1.5 % (w/v) Agar 
Table 2.1. Bacterial culture medium and plates 
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Antibiotics Stock concentration Storage Working dilutions 
Ampicillin (Sigma) 100 mg/ml -200C 100μg/ml 
Kanamycin (Sigma) 50 mg/ml -200C 50μg/ml 
Table 2.2. Antibiotics selection for bacterial growth 
2.2.2. Preparation of competent cells 
Bacteria cells (DH5α, BL21 DE3 or BL21 AI) from glycerol stocks were 
inoculated into 5 mL of LB medium and incubated overnight in an incubator-shaker at 
37oC, 200 rpm. LB broth (5 ml) was inoculated with a glycerol stock of DH5α cells 
and shaken overnight at 370C. 250 μl of starter culture was used to inoculate 100 ml 
of LB broth in a 250 ml flask and shaken at 370C until the culture reached an OD600nm 
of 0.4. After this step, all procedures were done on ice or in cold room. Cells were 
pelleted by centrifuging at 4000rpm (Sorvall Legend X1R) for 15 minutes at 40C, and 
the pellet was gently resuspended in 32 ml ice-cold competent buffer I (Table 2.3  ) 
and left on ice for 10 minutes. The cells were centrifuged as above, and the cell pellet 
was gently resuspended in 4 mL of ice-cold competent buffer II (Table 2.3) and 
quickly aliquoted (50 μL) into pre-chilled sterile microcentrifuge tubes. The aliquots 
were snap-frozen in liquid nitrogen and stored at -80oC. Transformation efficiency of 
each batch was checked afterwards by transformation of a competent cell aliquot with 
plasmid DNA using the heat shock method (see below). 
 
Competent Buffer I Competent Buffer II 
100 mM RbCl 10 mM MOPS  
40 mM MgCl2.6H2O 10 mM RbCl 
60 mM CH3COOK 75m M CaCl2.2H2O 
100 mM CaCl2.2H2O 
15% (v/v) glycerol 
Adjust to pH 5.8 with CH3COOH and sterilise by 
filtration using 0.22 µm filter 
15% (v/v) glycerol 
Adjust to pH 6.5 with NaOH and sterilise by 
filtration using 0.22 µm filter 
 
Table 2.3. Buffers for making competent cells  
2.2.3. Transformation of competent cells 
Transformation was performed using heat-shock method unless otherwise 
stated. 100 to 200 ng of plasmid DNA or 10 µL of the ligation reaction was added to 
50 µL of ice-thawed DH5α E. Coli competent cells prepared above (for plasmid 
propagation purposes or BL21 DE3/AI for protein expression) in a microcentrifuge 
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tube. The mixture was incubated 30 min on ice before incubating at 42C for 40 sec. 
Then the tube was quickly cooled on ice for 2 min. Using aseptic techniques, 450 µL 
of LB broth was added to the tube. Then bacterial cells were incubated with shaking 
at 37C for 1 hour. Between 50μl to 100μl of recovered bacterial cells were plated onto 
10-cm LB agar plates with appropriate antibiotic and incubated upside down overnight 
in 37C incubator.  If bacterial cells were less turbid, the cells were centrifuged at 3000 
rpm for 5 min, 450 L of the supernatant was removed and the pellet was gently 
resuspended in the remaining LB by pipetting up and down before plating on LB plate 
to get more cells on the plate. Plates were then kept upside down with parafilm around 
the edge at 4ºC.  
 
 
2.3. Molecular biology techniques 
Plasmids used in this study are listed below. 
Plasmid Name Description Reference 
FL-EPCAM Encodes Full-length EPCAM with 
pCMV6-XL5 backbone vector AmpR 
Origene 
pmAGR2  Mature AGR2 (aa 21-175). N-term 
6xHis-Tag. AmpR 
Dr Euan Murray 
pEHISTEV N-Term 6xHis-tag. KanR Dr Euan Murray 
pmEPEX-CO Human codon-optimised extracellular 
part of EpCAM (aa 24-265) cloned 
into pET151/D-TOPO N-Term 6xHis-
tag. AmpR 
Life Technologies 
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Plasmid Name Description Reference 
pEGFP-N1 Encodes the GFPmut1 variant which contains the 
double-amino-acid substitution of Phe-64 to Leu and 
Ser-65 to Thr. 
 KanR 
Clontech 
pmCherry-N1 Encodes mCherry, a mutant fluorescent protein 
derived from the tetrameric Discosoma sp. red 
fluorescent protein (DsRed), KanR 
Clonetech 
pSF-RSV (OG146) Rouse sarcoma virus (RSV) promoter upstream of the 
MCS, contains the pUC high-copy origin of 
replication. KanR 
Oxford Genetics 
pSF-CMV (OG2) CMV promoter upstream of the MCS contains the 
pUC high-copy origin of replication. AmpR 
Oxford Genetics 
FL-AGR2-C-Cherry FL-AGR2 cloned into pcDNA3/GW-Cherry. AmpR Brno,Czech 
Republic 
FL-AGR2-C-GFP FL-AGR2 cloned into pcDNA3/GW-GFP. AmpR Brno, Czech 
Republic 
FL-EPCAM-C-GFP FL-EPCAM cloned into pEGFP-N1. KanR Cloned in-house 
FL-EPCAM-C-Cherry FL-EPCAM cloned into pmCherry-N1. KanR Cloned in-house 
pAM1L 
pAM1H 
Synthetic FL-AGR2 WT  




Synthetic FL-AGR2 KDEL (Thr173 to Asp). 
Enhanced ER localisation. 




Synthetic mature AGR2 (Δ aa 1-20 aa signal peptide) 
and ΔKTEL (Δ aa 172-175). Enhanced AGR2 
secretion. 




Synthetic, deletion of N-term AGR2 intrinsically 
region (Δ aa 20-40) and ΔKTEL (Δ aa 172-175). 
Enhanced dimer. 




Synthetic FL-EpCAM WT 




Synthetic mature EpCAM (Δ aa1-23 signal peptide) 
L= Cloned into pSF-RSV; H=Cloned into pSF-CMV 
Cloned in-house 
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Plasmid Name Description Reference 
pAM7  Synthetic human codon-optimised FL-EPCAM 
cloned into pcDNA3.1(+).AmpR.  
Life 
Technologies 
pAM8 Synthetic human codon-optimised AGR2 scFv4 
antibody fragment with 20 aa AGR2 signal peptide 
fused at N-terminal, CD20 epitope tag and KDEL 
motif fused at its C-terminal. 
Cloned in-house 
pAM9 Synthetic human codon-optimised AGR2 scFv4 
antibody fragment with truncated AGR2 signal 
peptide fused at N-terminal, CD20 epitope tag without 
KDEL motif. 
Cloned in-house 
pAM10  Synthetic human codon-optimised CHIP scFv (11F) 
antibody fragment with 20 aa AGR2 signal peptide 
fused at N-terminal and KDEL motif fused at its C-
terminal. 
Cloned in-house 
pAM11 synPROwt. Synthetic human codon-optimised AGR2-
binding protein containing 3x PTTIYY motifs with 20 
aa AGR2 signal peptide fused at N-terminal, CD20 
epitope tag and KDEL motif fused at its C-terminal. 
Cloned in-house 
pAM12 synPROmut. Synthetic human codon-optimised 
AGR2-mutant binding protein containing 3x PKTIGS 
motifs with 20 aa AGR2 signal peptide fused at N-
terminal, CD20 epitope tag and KDEL motif fused at 
its C-terminal 
Cloned in-house 
pAM13 synMEMwt. Synthetic human codon-optimised 
membrane protein containing AGR2-binding protein 
containing 3x PTTIYY motifs with 20 aa AGR2 
signal peptide fused at N-terminal, CD20 epitope tag, 
EpCAM transmembrane domain (aa266-288) and 
KDEL motif fused at its C-terminal. 
Cloned in-house 
pAM14 synMEMmut. Synthetic human codon-optimised 
membrane protein containing mutant AGR2-binding 
protein containing 3x PKTIGS motifs with 20 aa 
AGR2 signal peptide fused at N-terminal, CD20 
epitope tag, EpCAM transmembrane domain (aa266-
288), and KDEL motif fused at its C-terminal. 
Cloned in-house 
Table 2.5. List of plasmid constructs for mammalian expression used in this study. All synthetic 
cDNA was obtained from GeneArt® Gene Synthesis, Life Technologies. 
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2.3.1. Plasmid DNA Purification and Quantification 
Bacterial cultures were prepared as above (2.2.1) where 5 ml and 200 ml of 
overnight bacterial cultures were used for small (miniprep) and large (maxiprep) scale 
plasmid DNA purification respectively. For small-scale plasmid DNA purification, 
QIAprep Spin Miniprep Kit (Qiagen) instructions were followed to extract and purify 
plasmid DNA. For the larger scale of plasmid DNA purification, HiSpeed Plasmid 
Maxi Kit (Qiagen) or GeneJET Plasmid Maxiprep Kit (LifeTechnologies) instructions 
were followed for extraction and purification of plasmid DNA, and DNA was eluted 
with 0.5 to 1 mL of TE Buffer (Qiagen) and stored at -20C. DNA concentration and 
purity was measured with a NanoDrop 2000 spectrophotometer (absorbance at 260 
nm). 
 
2.3.2. Agarose Gel Electrophoresis 
Agarose gel (1-2% (w/v) ultrapure agarose (Life Technologies) in 1X TAE (40 
mM Tris pH 7.5, 2 mM Na2EDTA.2H2O, 0.114% (v/v) acetic acid) was warmed up in 
a microwave to dissolve the agarose. If the DNA fragment is less than 500 bp , 1X 
TBE (890mM Tris, 890mM Boric acid, 20mM EDTA pH8.0) was used. SYBR® Safe 
DNA gel stain (Life Technologies) was added to the agarose solution at a final 
concentration of 1X. The agarose solution was then poured in a gel cast and let solidify 
by cooling at room temperature. DNA samples were mixed with 6X DNA loading 
buffer (0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene cyanol, 15% (v/v) 
glycerol) at a 5:1 ratio of DNA sample to loading dye. Samples were loaded onto the 
gel alongside Quick-Load 100 bp DNA ladder (NEB) and/or 1 kb DNA ladder (NEB) 
and were subsequently run at 100 V until the migration front reached the third quarter 
of the gel. The gel was then visualised under an ultraviolet lamp imaging system 
(Syngene Chemi Genius 2 Bio Imaging system, Syngene) with a built-in camera (Fluor 
Cam 210). For samples requiring DNA extraction from the gel, appropriate bands were 
excised and recovered using the QIAquick Gel Extraction Kit (Qiagen) according to 
manufacturer’s instructions. 
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2.3.3. Cloning using restriction enzymes 
2.3.3.1. PCR amplification  
  The DNA insert was amplified using a holding plasmid DNA containing the 
gene of interest. Directional cloning was used where the DNA insert and vector were 
digested with two different restriction enzymes to create two different complementary 
ends, thus ensuring only one possible orientation for the insert to effectively ligate to 
the vector cut with the same pair of restriction enzymes. When designing the primers, 
one restriction enzyme site is incorporated at each 5’ (forward) and 3’ (reverse) ends 
of the DNA insert sequence on the primer. A list of primers with their restriction sites 
and which template was used for each PCR are given in (Table 2.6). The primer was 
ensured to be in frame with any open reading frame or tag on the vector. Generally, 
the primers were 20-30 bp long with melting temperature (Tm) of 65°C and 75°C and 
GC content between 40-60%. 
 


























Table 2.6 Primers for DNA amplification 
 
PCR reactions were set up on ice in nuclease-free microtubes according to (Table 2.7). 
PCR reactions were performed in an Agilent SureCycler 8800 or DNA Engine DyadTM 
machine. PFU® Turbo DNA polymerase was used for amplification because it is a 
high fidelity polymerase and possesses a 3' to 5' exonuclease proof-reading activity 
that enables the polymerase to correct nucleotide-misincorporation errors. This means 
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that Pfu DNA Polymerase-generated PCR fragments will have fewer errors than Taq-
generated PCR inserts. Three µl of PCR products mixed with DNA loading buffer was 
electrophoresed on 1% agarose gel or 2% if the DNA size is lower than 500 bp to 
check for specific amplification product. Where appropriate the PCR products were 
cleaned using QIAquick PCR Purification Kit (Qiagen) according to the 
manufacturer’s protocol. 
 
Component Final Concentration 
2x Pfu Turbo Master Mix (Rovalab) 1x 
10 µM Forward primer 0.5 µM 
10 µM Reverse primer 0.5 µM 
DNA Template  100ng 
 Total volume 20 µl 
Table 2.7. PCR reactions 
PCR cycles protocol   
Step 1 95°C 2 min 
Step 2 95°C 30 sec 
Step 3 58°C 30 sec 
Step 4 72°C 1 min 30 sec 
Step 5 Repeat step 2-4 30 times  
Step 6 72°C 10 min 
Step 7 4°C ∞ 
Table 2.8. PCR cycles protocol for conventional cloning 
2.3.3.2. Restriction digestions 
PCR products, which have been cleaned up, by either QIAquick PCR 
Purification Kit or QIAquick Gel Extraction Kit (Qiagen) were double digested using 
restriction enzymes (NEB) and their compatible buffers according to the 
manufacturer’s guideline. The vector into which the gene was to be inserted into was 
digested in parallel. The digestion was set up as in table and incubated 2-3 hours at 
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Component Final Concentration 
Insert/vector 0.5ug - 2μg 
NEBBuffer 1x 
Restriction enzyme 1 10 units (1μl) 
Restriction enzyme 2 10 units (1μl) 
 Total volume 20 μl 
Table 2.9. DNA Double digestions reaction 
The digested products were then mixed with DNA loading buffer and electrophoresed 
onto 1-2% agarose gel, and single bands corresponding to the double-digested vector 
and double-digested insert were cut out under ultraviolet light. DNA was extracted 




Ligation of the double-digested gel-extracted insert and vector was carried out 
using T4 DNA ligase (NEB) according to the manufacturer’s instructions. The amount 
of insert to be added was calculated using the formula: 
 
ng of insert = ng of vector x kb size of insert   x   molar ratio of insert 
              kb size of vector                      vector 
 
Different molar ratios of vector: insert DNA as 1:1 to 1:4 were attempted to increase 
the chance of successful ligations. Ligation reactions were set up on ice as shown in 
Table 2.10 and were incubated 3 hours in 370C water bath or overnight at room 
temperature. 
 
Component Final Concentration 
Vector 100 ng 
Insert Calculated molar ratio 
10x Buffer (NEB) 1x 
T4 DNA ligase (NEB) 10 units (1μl) 
 Total volume 20 μl 
Table 2.10. DNA ligation reaction 
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Ten μL were transformed into competent DH5α cells as described before and plated 
out on LB-Agar plates containing appropriate antibiotic. Single colonies were picked 
for plasmid DNA isolation. Glycerol stocks were made from the bacterial culture if 
positive clones are identified later. To verify the presence of the insert in the selected 
clones, the purified DNA clones were either i) PCR amplified with the same primers 
used for cloning to see if the insert is successfully ligated or ii) double digested with 
the same restriction enzymes used for cloning to see if the insert band is visible on 
agarose gel. Positive clones will be further confirmed by DNA sequencing (2.3.5) to 
ensure the insert has no mutation and in-frame with the open reading frame or tag. 
 
2.3.4. Site-directed mutagenesis 
Mutants of the wild type AGR2 and wild-type EPCAM were made based on 
the protocol described in QuickChange site-directed mutagenesis (Stratagene). This 
method is based on a linear PCR amplification whereby mutation-containing primers 
are incorporated but not copied using high-fidelity Pfu DNA polymerase. The desired 
single point mutation was designed to be in the middle of the primers as shown in 





Primer Names  Template  Sequence 5’-3’ 
AGR2-D132A-F 
 
pmAGR2 CC AGG ATT ATG TTT GTT GCC CCA TCT CTG 
ACA GTT AG 
AGR2-D132A-R 
 
 CT AAC TGT CAG AGA TGG GGC AAC AAA CAT 
AAT CCT GG 
AGR2-P133A-F pmAGR2 C AGG ATT ATG TTT GTT GAC GCA TCT CTG ACA 
GTT AGA GC 
AGR2-P133A-R  GC TCT AAC TGT CAG AGA TGC GTC AAC AAA 
CAT AAT CCT G 
AGR2-S134A-F pmAGR2 ATT ATG TTT GTT GAC CCA GCT CTG ACA GTT 
AGA GCC G 
AGR2-S134A-R  C GGC TCT AAC TGT CAG AGC TGG GTC AAC AAA 
CAT AAT 
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 2 – Materials and Methods 71 





T CAT CAC TTG GAT GAG AGC CCA CAC AGT CAA 
GC 





G GAT CTG GAT CCT GGT CAA ACT TTA ATT TAT 
GCT GTT GAT GAA AAA GCA CCT 
FLEPCAM_Y251A_R  AGG TGC TTT TTC ATC AAC AGC ATA AAT TAA 






R   
 GGCCTTCTCGTCCACGGCGTAGATCAGGGTCTGG 
 
Table 2.11. Site-directed mutagenesis primers 
The reactions were setup using 2x Pfu Turbo Master Mix (Rovalab) as in Table 2.12 
and cycling conditions are described in Table 2.13. All constructs were confirmed and 
analysed by DNA sequencing. 
 
Component Final Concentration 
2x Pfu Turbo Master Mix (Rovalab) 1x 
10 µM Forward primer 0.5 µM 
10 µM Reverse primer 0.5 µM 
DNA template 100-150 ng 
 Total volume 20 µl 
Table 2.12 PCR reactions for site-directed mutagenesis 
 
Step 1 95°C 2 min 
Step 2 95°C 20 sec 
Step 3 58°C 40 sec 
Step 4 72°C 7 min 
Step 5 Repeat step 2-4 18 times  
Step 6 72°C 10 min 
Step 7 4°C ∞ 
Table 2.13 PCR cycles protocol for site-directed mutagenesis 
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2.3.5. DNA sequencing 
In a small microcentrifuge tube, 10 µl of the sample and 10 µl of primers were 
prepared as in Table 2.14. The samples were sent to SourceBioscience Scotland for 
Sanger sequencing. The facility’s stock primers were used if available. Where the 
stock primers are not available, either the forward or the reverse primers used for 
cloning was used. 
 
Type of samples Concentration 
Plasmid DNA 100 ng/μl 
PCR product 1 ng/μl per 100bp 
Primers 3.2 pmol/μl 
Table 2.14. DNA and primer concentrations for DNA sequencing 
The DNA sequence analysis was performed using Chromas v1.45 or SnapGene v3.0 
software and aligned using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
 
2.4. Cell culture and handling 
All cell culture work was performed in a laminar flow hood using standard 
aseptic tissue culture procedures. Only molecular biology grade reagents and 
plasticware were used, otherwise sterilising by filtering or autoclaving was carried out. 
 
2.4.1. Cell lines and maintenance 
Cell lines were grown in humidified incubators equipped with CO2 gas 
cylinders. Media was supplemented with fetal bovine serum with or without the 
presence of antibiotics as described in Table 2.15. Cells were maintained in 10-cm 
tissue culture dishes (Greiner CELLSTAR®, Sigma) and were subcultured 1 to 3 times 
per week. The medium was removed and cells were washed using 10 mL of sterile 1X 
phosphate-buffered saline (PBS).  Cells were then trypsinised using 1 to 2 mL of 1X 
Trypsin-EDTA 0.5% (Gibco, Life Technologies) warmed up to 37C in a water bath 
beforehand, and cells were returned to the incubator until they detached (3 to 5 min).  
Warmed medium supplemented described below was added up to a final volume of 10 
mL and cells were then seeded in new tissue culture dishes at a dilution of 1:5 to 1:20. 
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When cells need to be counted before sub-culturing, trypsinised cells were mixed 1:1 
with Trypan Blue Stain 0.4%  (Labtech) to stain for dead cells and loaded into Luna 
cell counting slides (Labtech) and counted using Luna Automated BF Cell Counter 
(Labtech). 
 
Cell Lines Description Growth 
Conditions 
Media 




5% CO2, 370C RPMI 1640, 10% FBS, 1% 
Penicillin-Streptomycin 
when not transfecting 
OE33 Adenocarcinoma of the 
lower oesophagus 
(Barrett′s metaplasia) 
5% CO2, 370C RPMI 1640 10% FBS, 1% 
Penicillin-Streptomycin 
when not transfecting 
FLO-1 Primary distal 
oesophageal 
adenocarcinoma 
5% CO2, 370C DMEM, 10% FBS, 1% 
Penicillin-Streptomycin 
when not transfecting 
MCF-7 Ductal carcinoma of the 
breast 
5% CO2, 370C DMEM, 10% FBS, 1% 
Penicillin-Streptomycin 
when not transfecting 
Table 2.15 Cell lines and growth conditions 
 
1.4.1. Cell storage  
Cell lines were grown to 90% confluence in 10cm dishes and trypsinised as 
described above (2.4.1)before diluting the trypsinised cells in a final volume of 10ml. 
Cells were pelleted by centrifuging at 1000rpm (Sorvall Legend X1R) for 5 minutes 
in sterile 15ml falcon tubes. The cell pellet was resuspended in freezing medium (50% 
FBS, 20% DMSO and 30% serum-free media). Cells were aliquoted in 1ml aliquots 
into cryotubes (Nunc) and placed in gradient freezing containers (Nalgene) for 24 
hours at -80C, before transferring to liquid nitrogen containers for long-term storage. 
 
2.4.2. Cell recovery 
Cells in cryotubes stored in liquid nitrogen were placed into a water bath at 37C 
by swirling the tube until a tiny amount of ice remaining before being transferred into 
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10 cm dish containing 9 ml of complete media (Table 2.15) and incubated into 37C. 
Media was replaced the following day to remove DMSO and cells were grown and 
maintained as described above (2.4.1). 
 
2.4.3. Transient Transfection of Plasmid DNA 
Cells were grown as above to 80-90% confluency before plating according to 
cell type and experimental conditions. Per 6 well-plate, cells were normally split 1:4 
to 1:10 (MCF-7 1:10, OE33-1:5 OE19, 1:5 FLO-1 1:10) or counted one day before the 
transfection and incubated into 37C to achieve between 40-70% cells confluency the 
following day. The following the day, transfection were carried out using Attractene 
Transfection Reagent (Qiagen) or Lipofectamine 2000 (Thermo Fisher Scientific). For 
transfection using Attractene, per 6-well plate, 1 μg DNA (only DNA from Maxi-prep) 
was diluted in a total of 100 μl of serum free media without any antibiotics in a sterile 
microcentrifuge tube. Five μl of Attractene was added to the tube and mixed before 
incubating at room temperature for 15 minutes for complex formation to take place. 
For transfection using Lipofectamine 2000, cells were split prior with normal media 
without antibiotics. Per 6-well plate, 2 μg DNA was diluted in a total of 250 μl OPTI-
MEM® reduced-serum medium (Thermo Fisher Scientific) in a sterile 
microcentrifuge tube. Five μl of Attractene was added to the tube and incubated 5 
minutes before mixing with diluted DNA in OPTI-MEM®. Then the mixture was 
incubated for 20 minutes at room temperature for complex formation to take place. 
Media in wells split the day before was replaced with 2ml fresh media. The 
transfection complexes were then added dropwise to the wells and swirled before 
incubating at 37C for 24-48 hours or as stated. For experiment using other than 6 well 
plate, manufacturer’s protocol was followed. 
 
2.4.4. Transient transfection of short interfering RNA (siRNA) 
MCF7 cells were counted and plated at 200,000 cells per 6-well plate on the 
day before the transfection. The cells were transfected with siRNA, control siRNA, or 
mock transfected as above using Attractene (2.4.3). The siRNA to AGR2 used was 
from FlexiTube GeneSolution GS10551 for AGR2 (#1027416, Qiagen) and control 
AGR2 siRNA used was AllStars Negative Control siRNA (#SI03650318 , Qiagen). 
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For siRNA to AGR2 in MCF-7, 60nM final concentration of siRNA was used and 
incubated for 72h at 37C before analysing by SDS-PAGE and western blot.  
 
2.4.5. Harvesting cells  
Cell culture dishes were placed on ice to prevent proteolysis. Cell culture 
medium was discarded and cells were gently and quickly washed with 2x ice-cold PBS 
(1 mL for a well of a 6-well dish, 2 mL for a 6-cm dish or 5 mL for a 10-cm dish).  In 
the final wash, the cells were scraped on ice in a small volume of fresh PBS (100 µL 
for a well of a 6-well dish, 200 µL for a 6-cm dish or 500 µL for a 10-cm dish) then 
transferred to a microcentrifuge tube before centrifuging cells at 3000 rpm for 5 min 
at 4C. The supernatant was discarded and the cell pellet was either snap-frozen in 
liquid nitrogen and stored at -80C, or immediately lysed using the appropriate buffer 
(see below 2.4.6). In some cases detailed when relevant, cells were directly scraped 
into lysis buffer. 
 
2.4.6. Cell lysis 
2.4.6.1. Denaturing Lysis  
Frozen cell pellets were lysed in approximately 4 volumes (with respect to the 
size of the cell pellet) of denaturing lysis buffer (Table 2.16) by pipetting up and down 
10 times.  Lysates were then incubated on ice for 30 min, followed by centrifugation 
at 13,000 g for 15 min at 4C. The supernatant (lysate) was transferred to a new tube 
and then snap-frozen and stored at -80C before protein concentration determination. 
Denaturing lysis Buffer Non-denaturing lysis buffer 
7M Urea  0.1 mM EDTA 
0.1M DTT 2mM DTT 
0.1% Triton X-100 0.1% NP40 (IGEPAL) 
25mM NaCl 150mM NaCl 
20 mM HEPES-KOH pH 7.6 50 mM HEPES-KOH pH 7.6 
1mM Benzamidine 1mM Benzamidine 
1X Protease inhibitor mix (Table 2.17) 1X Protease inhibitor mix (Table 2.17) 
Table 2.16 Cell lysis buffers 
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10X Protease inhibitor mix 
200 µg/ml Leupeptin 
10 µg/ml Aprotinin 
20 µg/ml Pepstatin 
10 mM Benzamidine 
100 µg/ml Soybean trypsin inhibitor 
20 mM Pefabloc 
10mM EDTA 
Table 2.17 Protease inhibitor mix 
2.4.6.2. Non-Denaturing Lysis  
Frozen cell pellets were lysed in approximately 4 volumes (with respect to the 
size of the cell pellet) of non-denaturing lysis buffer (Table 2.16) were added to the 
harvested cell pellet. Alternatively, adherent cells were scraped directly into lysis 
buffer. Samples were vortexed briefly, incubated on ice for 20 min, and then 
centrifuged at 13,000 g for 15 min at 4ºC. The supernatant (lysate) was transferred to 
a fresh tube, snap-frozen in liquid nitrogen and stored at -80º. 
 
2.5. Biochemical techniques 
2.5.1. Protein quantification 
Protein concentration was quantified using the Bradford assay. Bradford 
reagent was obtained from Bio-Rad Protein assay dye reagent 5x (Bio-Rad; 
#5000006). The Bradford reagent was diluted to 1x with water prior to use.  Bovine 
serum albumin (BSA; #A9647, Sigma) was used as protein standards from 0 to 4 
mg/ml. Two hundred μl of Bradford reagent was added into a 96-well plate. Then 1 μl 
of protein lysate was added to the Bradford reagent. The plate was shaken for 5 min at 
room temperature and the OD595nm was measured using VICTOR3 Multilabel Plate 
Reader (Perkin Elmer) with WorkOut v2.0 (Dazdaq) software. Readings were 
automatically converted to concentrations in mg/mL and concentrations were 




Polyacrylamide gels were prepared in the laboratory. The gels were cast using 
Mini-PROTEAN 3 Cell apparatus (Bio-Rad). Stacking and separating gels were 
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prepared as described in (Table 2.18) with either 1.0mm-gap glass plates or 1.5mm 
gap glass plates dependent on the volume required for loading and allowed to 
polymerise at room temperature. Upon addition of stacking gel, 10-well or 15 well 
combs were used depending on assay and number of samples. For analysis of proteins 
of high molecular weight 10% polyacrylamide gels were used, 12-15% gels were used 
for lower molecular weight proteins.  
 









375mM Tris pH8.8 375mM Tris pH8.8 375mM Tris pH8.8 125mM Tris pH8.8 
0.1% SDS (w/v) 0.1% SDS (w/v) 0.1% SDS (w/v) 0.1% SDS (w/v) 
0.1% APS (w/v) 0.1% APS (w/v) 0.1% APS (w/v) 0.1% APS (w/v) 
0.04% TEMED (w/v) 0.04% TEMED (w/v) 0.04% TEMED (w/v) 0.1% TEMED (w/v) 
Table 2.18. Separating and stacking gels for SDS-PAGE 
 
Generally 10-50μg (to adjust volume/quantity) protein lysate and 2 μg purified protein 
was mixed 1:1 with 2X SDS sample buffer (Table 2.19) and boiled at 85°C for 3-5 
minutes before loading onto the gels. Five μl of pre-stained protein standards were 
loaded as a marker (PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa, 
Thermo Fischer), and proteins were separated by electrophoresis at 180-200V using 
1x SDS running buffer (Table 2.19) for 45-60 minutes.  
 
2X SDS sample buffer 1X SDS running buffer 
250mM Tris pH6.8 192 mM Glycine 
50% Glycerol 25mM Tris base 
5% SDS (w/v) 0.1% SDS (w/v) 
Bromophenol blue to the desired colour  
200mM DTT or 10% ß-Mercaptoethanol (added 
fresh prior to use) 
 
Table 2.19 SDS sample buffer and running buffer 
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2.5.3. Western Blot 
After separating proteins by SDS-PAGE, proteins were transferred to 0.2 μM 
pore nitrocellulose blotting membrane (Amersham Protran Premium, GELifesciences) 
using The Mini Trans-Blot® wet electroblotting systems (Bio-Rad). The transfer was 
carried out electrophoretically in transfer buffer (Table 2.21) at 300 mA for 90 min or 
at 20mA overnight. Optionally, Membranes were stained using India ink (Pelican 
Black) to confirm the proteins were transferred properly. Membranes were washed 
briefly with PBS-Tween-20 (0.1%) (0.1% PBST) before blocking for 1h at room 
temperature or overnight at 4°C in blocking buffer (Table 2.21). Primary antibodies 
(Table 2.20) were diluted in blocking buffer as required and incubated 1 hour at room 
temperature or overnight at 4°C. Blots were then washed 3x 5 minutes in a shaker 
before incubation with appropriate secondary antibody diluted in blocking buffer for 
1h at room temperature. Blots were washed 3x 5 minutes again in wash buffer. Blots 
were then visualised by overlaying enhanced chemiluminescence (ECL) reagents 
(Table 2.22) in a 1:1 ratio for 1 minute. Excess ECL solution was removed using tissue 
paper and blots were exposed to film (Kodak, Hyperfilm) which was then developed 
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Primary 
Antibody 




Anti-AGR2* Rabbit polyclonal 1:1000 K47  
(Moravian 
Biotech) 










Anti-EpCAM Rabbit polyclonal 1:1000 HPA026761 
(Sigma) 
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Transfer Buffer PBS-Tween20 buffer Blocking buffer 
24 mM Tris 1x PBS 1x TBS 
191 mM glycine 0.1% Tween20 0.1% Tween20 
20% (v/v) methanol  5% Dried Skimmed Milk 
Table 2.21 Western Blot buffers 
 
ECL I ECL II 
2.5 mM Luminol 0.02% (v/v) Hydrogen peroxide 
0.4 mM p-Coumaric acid 0.1M Tris pH 8.8 
0.1M Tris pH8.8  
Table 2.22 Enhanced chemiluminescence reagents 
 
2.6. Protein Purification  
2.6.1. AGR2 purification 
The mature form of AGR221-134 was cloned into pDEST17 vector harbouring 
AGR2 having N-Terminal His-tag and was purified based on His-tag affinity 
chromatography. E. coli strains BL21-AI were transformed with the His-AGR2 
construct and were grown aerobically in a 10 ml starter culture overnight at 37 °C at 
200 rpm in LB medium supplemented with ampicillin (100 μg/ml). The cultures were 
then added into 1L LB medium supplemented with ampicillin (100 μg/ml) and 37 °C 
at 200 rpm. Cultures were induced at OD600nm of 0.6 by the addition of 0.2 % arabinose 
(w/v) for 3 hours at 37 °C. Cell pellets were collected by centrifugation 10,000 rpm 
for 10 minutes at 40C and resuspended in 10 ml buffer A (Table 2.23)(10ml/litre 
culture) into 50 ml falcon tube. The cells were then snap freeze using liquid nitrogen 
and stored at -20°C overnight. The frozen cell pellets were thawed in tap water and 
resuspended in buffer A with 0.1 mg/ml lysozyme. The resuspended cells were then 
sonicated 3 × 15 s (MSE Soniprep 150 Plus ultrasonic disintegrator) on ice with 30 sec 
interval to prevent overheat using a small probe at 10 amplitude. Sonicated cells were 
then centrifuged at 10,000 rpm for 10 minutes, 40C to remove cellular debris. Cell 
lysates were then mixed with 1 ml Ni-NTA agarose (Qiagen) that was previously 
washed with 10 ml buffer A wash, for 1 hour in rotating wheel at 40C before loading 
into 10 ml column with 35uM filter pore size (Mobitec) equilibrated with 10ml buffer 
A. The column was washed with 2x5 ml buffer A followed by 3x5ml with wash buffer 
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B (Table 2.23). Proteins were eluted with 15x0.5 ml elution buffer C (Table 2.23) in 
microcentrifuge tubes. AGR2 mutant derivatives His-AGR2 D132A, His-AGR2 
P133A and His –AGR2 S134A were purified under the same conditions as above. 
 
Buffers Components 
Buffer A 20mM Tris-HCL pH8, 150 mM NaCl, 10 mM MgCl2, 0.1%NP40, 10% 
glycerol 20 mM Imidazole 
Buffer B 20mM Tris-HCL pH8, 150 mM NaCl, 10 mM MgCl2, 0.1%NP40, 10% 
glycerol 40 mM Imidazole 
Buffer C 20mM Tris-HCL pH8, 150 mM NaCl, 10 mM MgCl2, 0.1%NP40, 10% 
glycerol 150 mM Imidazole 
Table 2.23 His-AGR2 purification buffers 
 
2.6.2. EPCAM purification 
Extracellular part of EpCAM24-265 was human codon optimised and synthesised 
into pET151/D-TOPO (GeneArt, LifeTechnologies) which contains N-Terminal His-
tag. E. coli strains BL21-DE3 were transformed with His-EPCAM construct and were 
grown aerobically in a 10 ml starter culture overnight at 37 °C at 200 rpm in LB 
medium supplemented with ampicillin (100 μg/ml). The cultures were then added into 
1L LB medium supplemented with 100 μg/ml and 37 °C at 200 rpm. Cultures were 
induced at OD600nm of 1.0 by the addition of 1mM IPTG for 4 hours at room 
temperature and 200rpm. Cell pellets were collected by centrifugation 10,000 rpm for 
10 minutes at 40C. The pellets were resuspended in 20 ml resuspension buffer 
(25ml/1L culture) (Table 2.24) in 50 ml falcon tube. The pellets were snap-frozen with 
liquid nitrogen and stored at -20°C overnight. The frozen pellets were thawed in tap 
water and added 0.5M NaCl, 1mM Benzamidine,1 mM DTT, 0,1% Triton X-100 
making up buffer 1 (Table 2.24) to bring the volume to 30 ml. One protease inhibitor 
tablet dissolved in 1 ml distilled water and 0.1 mg/ml lysozyme was added to the cells. 
Cells were then sonicated 3 × 15 s on ice with 30 sec interval to prevent overheat using 
a small probe at 10 amplitude. Solid urea powder (7M) was added directly to the 
sonicated cells and incubated in the rotating wheel at 4°C until the urea dissolves. Cells 
were then centrifuged at 10,000 rpm for 5 minutes, 40C to remove cellular debris 
before transferring into a new 50 ml falcon tube containing 0.3 ml Ni-NTA agarose 
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(Qiagen) that was washed with 50 ml sterile PBS. The beads and the lysate were 
incubated overnight in a rotating wheel at 40C. The Ni-NTA agarose beads were briefly 
spin down at 1000 rpm for 1 minute, and the unbound lysate was removed. The beads 
were resuspended in 1 ml wash buffer 2 (Table 2.24) and transferred into a clean 
microcentrifuge. The beads were washed by incubation in the rotating wheel for 30 
min 40C. The beads were allowed to sediment at the bottom of the tube by gravity. The 
buffer was replaced with new 1 ml buffer 2. Unbound proteins were monitored by 
taking 5 μl of the wash and added to 1X Bradford reagent and look for colour changes. 
The wash was repeated several times until there were no colour changes on Bradford 
reagent. To elute the proteins from the beads, the beads were then incubated with 150 
μl of elution buffer 3 (Table 2.24) for 45 minutes. The eluate was transferred to a clean 
microcentrifuge. The elution was repeated 5 times or until the eluate shows no colour 
changes on Bradford reagent.  
 
Buffers Components 
Resuspension buffer 10% Sucrose (w/v), 50 mM HEPES pH8.0 
Buffer 1 10% Sucrose (w/v), 50 mM HEPES pH8.0, 0.5M NaCl, 1mM 
Benzamidine ,1 mM DTT, 0,1% Triton X-100  
Buffer 2 50mM HEPES pH8.0, 0.5M NaCl, 1mM Benzamidine , 1 mM DTT,  2M 
Urea, 10mM Imidazole. 
Buffer 3 50mM HEPES pH8.0, 0.5M NaCl, 1mM Benzamidine , 100mM DTT,  
0.3M Imidazole. 
Table 2.24 His-EPCAM purification buffers 
 
2.7. In-vitro assays 
2.7.1. Protein-Protein interaction using ELISA 
2.7.1.1. Peptide ELISA.   
96-well polystyrene assay plate (Corning™ Costar™ 96-Well white solid, #07-
200-592) was coated with streptavidin by adding 1 μg in 50 μl of water per well and 
incubated at 37 o C overnight. The wells were washed 4x with 200 μl 0.1 % PBS-T 
before adding biotinylated peptides 1-5 µg in 50 μl water per well and incubated 1 
hour at room temperature. The wells were washed 6x with 200 μl PBS-T. The wells 
then were blocked for 1 hour with 200 µl of 3% BSA in PBS-T per well. The blocking 
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solution was removed and 50 μl of His-AGR2 diluted in 3% BSA in PBST was added 
to each well and incubated as required for 1 hour at room temperature. The wells were 
washed 6x with 200 μl PBS-T before probing with 50 μl of primary antibody diluted 
1:1000 in 3 % BSA in PBST for 1 hour at room temperature. After washing the wells 
6x with 200 μl 0.1% PBST, 50 μl of HRP-conjugated secondary antibody (1:1000 
dilution) in 3% BSA in PBS-T was added to each well and incubated for 1 hour at RT. 
The wells were washed 6x with 200 μl PBS-T before adding 50 μl of enhanced 
chemiluminescence (ECL) and reading the plate using Fluoroskan Ascent FL as a 
relative light unit (RLU). 
 
2.7.1.2. Protein binding ELISA.  
Protein of interest was coated directly to 96-well polystyrene assay plate using 
0.1M NaHC03 pH 8.6 overnight at 4
0C. Excess free protein in solution was 
subsequently removed and the wells were washed 4x with 200 μl of 0.1% PBST. The 
remaining available binding surfaces of the wells were blocked with 3% bovine serum 
albumin (BSA) in 0.1% PBST. The plate was then incubated with serial dilutions of a 
second protein of interest (binding partner to the protein coated on the solid phase) to 
the wells and incubated for 1 hour shaking at room temperature. Remaining free 
protein in solution was removed and washed 6x with 200 μl of 0.1% PBST, and the 
portion of the partner protein bound to the immobilised protein was quantified through 
detection via antibody against the protein in the mobile phase for 1 hour shaking at 
room temperature. The wells then were washed 6x with 200 μl of 0.1% PBST followed 
by the addition of HRP-conjugated secondary antibody. The wells of the plate were 
washed again 6x with 200 μl of 0.1% PBST to remove excess primary antibody and 
finally detected by adding ECL and reading using Fluoroskan Ascent FL (Labsystems) 
as relative light unit (RLU). 
 
2.8. Cell biology techniques 
2.8.1. Visualisation of fluorescently-tagged proteins  
For visualisation of fluorescent-tagged protein, cells were seeded onto glass 
coverslips in 6 well plate at 50% confluency and incubated at 37 °C incubator 
overnight. Cells were transiently transfected with DNA constructs encoding GFP or 
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Cherry-tagged proteins using Lipofectamine 2000 (Thermo Fisher Scientific) as 
described above (2.4.3) and incubated 37 °C for 24-48 hours. As controls, cells were 
either untransfected or transfected with GFP and Cherry expressing vector only. Cells 
on coverslips were then washed three times with sterile PBS before fixation with 4% 
paraformaldehyde for 15 min at room temperature. Coverslips were washed three 
times with PBS. Coverslips were mounted with DAPI nuclear stain (Invitrogen) 
diluted in Fluorescent Mounting Medium (Dako) and viewed using Zeiss Axioplan 2 
epifluorescent microscope or Leica TCS SP5 confocal microscope. Epifluorescent 
images were acquired using a Photometrics Coolsnap HQ2 CCD camera and a Zeiss 
Zeiss Axioplan II fluorescence microscope with Plan-neofluar objectives (Carl Zeiss, 
Cambridge, UK), a Mercury Halide fluorescent light source (Exfo Excite 120, 
Excelitas Technologies) and Chroma #83000 triple band pass filter set (Chroma 
Technology Corp., Rockingham, VT) with the excitation filters installed in a motorised 
filter wheel (Ludl Electronic Products, Hawthorne, NY). Image capture was performed 
using Micromanager10. For confocal microscope, images were acquired using a Leica 
SP5 confocal (Leica Microsystems Milton KeynesUK) using LAS-AF software. The 
microscope is equipped with a 405nm diode, Argon and, 561 and 648nm laser lines, 
three Photomultiplier tubes and one HyD GaSP detector. Images were scanned using 
a 63X or 40x objective.  
 
2.8.2. Immunofluorescence 
Cells were seeded onto glass coverslips in 6 well plate at 50% confluency and 
incubated at 37 °C incubator overnight. Cells were either not transfected (endogenous 
protein) or transiently transfected with DNA constructs using Lipofectamine 2000 
(Thermo Fisher Scientific) as described above (2.4.3) and incubated 37 °C for 24-48 
hours. Cells on coverslips were then washed three times with sterile PBS before 
fixation with 4% paraformaldehyde for 15 min at room temperature. Coverslips were 
washed three times with PBS and permeabilized with 0.1%Triton X-100 in PBS (v/v) 
for 10 minutes.  Coverslips were washed three times with PBS before incubating with 
primary antibodies (Table 2.20) in 3% BSA overnight at 4°C. Coverslips were washed 
three times and secondary antibodies conjugated with fluorophores (Table 2.25) were 
                                                 
10 https://open-imaging.com/ 
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added and incubated 1 hour at RT. Cells were washed three times with PBS and were 
mounted with DAPI nuclear stain (Invitrogen) diluted in Fluorescent Mounting 
Medium (Dako), and viewed using Zeiss Axioplan 2 fluorescent microscope or Leica 
TCS SP5 confocal microscope as described in 2.8.1.  
 
Secondary antibody name Dilution 
Alexa Fluor® 488 goat anti-mouse 1:1000 
Alexa Fluor® 488 donkey anti-rabbit 1:1000 
Alexa Fluor® 594 goat anti-mouse 1:1000 
Alexa Fluor® 594 donkey anti-rabbit 1:1000 
Table 2.25 List of secondary antibodies for immunofluorescence 
 
2.8.3. Proximity ligation assay.  
The proximity ligation assay was performed using the Duolink In-situ 
Detection Reagents Green kit (Sigma-Aldrich). Cells were prepared as described 
above for fluorescence microscopy. For in-situ AGR2-EPCAM interaction, the cells 
on cover slip were washed 3x with ice cold PBS and incubated overnight with a 
cocktail of rabbit polyclonal anti-EPCAM (Abcam) and 1:200 and mouse monoclonal 
anti-AGR3 3.1 1:200 or mouse monoclonal anti-EPCAM (Abcam) 1:250 and rabbit 
polyclonal anti-AGR2 K47 1:250 diluted in 3% BSA in PBS. Anti-rabbit PLUS probe 
(Sigma-Aldrich) and anti-mouse MINUS probe (Sigma-Aldrich) were then added to 
the sections for 1 h at 37 °C. Ligation, amplification, and detection of the probes were 
carried out according to the manufacturer's protocol. The sections were mounted with 
DAPI nuclear stain (Invitrogen) diluted in Fluorescent Mounting Medium (Dako) and 
viewed as described above. 
 
2.9. Single-chain variable fragment (scFv) phage-display 
2.9.1. Biopanning procedure 
A 96-well polystyrene assay plate (Corning™ Costar™ 96-Well white solid, 
#07-200-592) was coated with 1 μg of purified His-AGR2 protein or negative target 
(His-tag proteins) for pre-clearing step by diluting in 100 μl of coating buffer (0.1 M 
NaHCO3 pH 8.6) in three wells and incubated overnight at 4
0C. After 4x washes with 
200 μl PBST, the wells were then blocked with blocking solution (3% (w/v) BSA in 
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PBST), rocking for 1 h at RT. Blocking solution was removed followed by addition of 
50 μl of the scFv phage library and 50 μl blocking solution to the pre-clearing well 
containing His-tag protein and incubated 1h at RT with shaking. The scFv library was 
isolated from a canine naïve phage library provided by Dr Euan Murray. This library 
encodes both the VH and VL chains connected via a linker of 15 amino acids. The 
phages from the pre-clearing well were transferred into the panning well coated with 
the target His-AGR2 protein or non-coated well as negative control and incubated for 
1 h at RT with shaking. The phages were discarded and wells were washed 10 times 
with 200 μl PBST. The bound phages were eluted by incubating with 110 μl of 100mM 
trimethylamine (TEA) for 25 minutes at RT with gentle rocking and neutralised with 
22 μl of 1 M Tris pH 7.4. Eluted phages were stored at 4C for up to 1 week. The 
neutralised eluted phages were then amplified by infection of E.coli TG1 cells.  This 
was done by adding the phage to 1 ml of log-phase E.coli TG1 cells and incubated at 
37C for 15 min. The infected cells were transferred into 20 ml LB media 
supplemented with 100 μg/ml ampicillin and incubated at 37C for 1.5 h to select for 
the phage-infected cells. Twenty μl of helper phage M13KO7 (New England Biolabs, 
N0315S) was added and incubated for 15 min static followed by 1.5 h shaking at 37C. 
Kanamycin with a final concentration of 50 μg/ml was added and incubated at 30C 
overnight. To precipitate the phages, the overnight bacterial culture was pelleted at 
4000 rpm for 10 min. Supernatant containing the phage was added to 3.5 ml 
polyethylene glycol (PEG) 20% (w/v)  in 2.5 M NaCl and precipitated for 1 h on ice. 
The precipitated phages were pelleted at 4000 RPM for 15 min. The supernatant was 
discarded, re-centrifuged briefly and any remaining liquid was removed. The pellet 
was resuspended in 200 μl 1x PBS and used for the next biopanning round.  
 
The biopanning procedure was repeated two times to enrich for scFv binding 
to target. The precipitated phages were diluted 2:100 in blocking solution for each 
biopanning round and repeated as described above except after the incubation with the 
target; the wells were washed 20x instead of 10x with 200 μl PBST. 
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2.9.2. Isolation of scFv clones and expression of scFv 
The neutralised phage pools from each panning round were tittered by making 
serial dilution to give 10-3, 10-6 10-7, and 10-8 dilutions. From each dilution, 2 μl were 
infected to 98 μl E.coli TG1 cells culture and incubated for 15 min at 370C static. Fifty 
μl of the infected cells were plated into LB agar plates with ampicillin 100 μl/ml and 
incubated overnight at 370C incubator. Colonies were picked and grown into 100µl 
LB media with ampicillin 100 μl/ml (LB-amp) into a 96 well plate (Corning tissue 
culture plate) and grown for 4 hours at 370C. The culture was diluted 1:100 in LB-amp 
by adding 8µl culture into 792µl in a 96-deep well plate. To the remaining culture in 
the plate, sterile 80% glycerol was added to the first plate, and this plate was kept at -
800C to reuse in the future (scFV glycerol stocks). The culture was grown for two 
hours at 37 0C before adding 200µl of LB-ampicillin with 0.1% glucose (w/v) 
containing 5 mM IPTG (final concentration 1 mM) per well and grown overnight at 
30⁰C. The plates were spun down at 4000rpm for 10 minutes to obtain a supernatant 
containing secreted scFv. 
 
2.9.3. Detection of scFV phage pools or scFv clones binding by ELISA 
A 96-well polystyrene assay plate (Corning™ Costar™ 96-Well white solid, 
#07-200-592) was coated with 0.5 μg of purified His-AGR2 protein or non-coated 
(coating buffer only) in 50 μl of coating buffer (0.1 M NaHCO3 pH 8.6) in triplicates 
and incubated overnight at 40C. The wells were washed 4x with 200 μl PBST and 
incubated in blocking solution (3% (w/v) BSA in PBST), rocking for 1 h at RT. The 
precipitated phage-scFv pool or individual phage-scFv clone was diluted 1:50 in 50 μl 
blocking solution per well and incubated 1 h at RT shaking. The wells then were 
washed 6x with 200 μl of 0.1% PBST followed by the addition of anti-M13-HRP 
monoclonal (GE Healthcare, #27942101) conjugated antibody at 1:5000 dilution in 
blocking solution for 1 hour RT shaking. The wells of the plate were washed again 6x 
with 200 μl of 0.1% PBST to remove excess primary antibody and finally detected by 
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2.9.4. Extraction of phagemid for sequencing 
Glycerol stock of scFv clones stored at -800C was inoculated into 5 ml LB-amp 
and grown overnight (16-18 hours) at 370C shaking.  Alternatively, 1 µl of precipitated 
phage was infected into 1 ml log-phase E.coli TG1 cells and incubated in 370C static 
and incubated  15 minutes. Five ml of LB-amp were then added to the infected cells 
and incubated overnight at 370C overnight (16-18 hours). The phagemid was extracted 
using QIAprep Spin Miniprep Kit (Qiagen) as described in 2.3.1. The phagemid was 
sequencing using a gIIIFor reverse primer as described 2.3.5 to obtain a sequence of 
scFv. 
 
2.10. Gene editing using CRISPR/Cas9 technology 
2.10.1. Guide RNA design 
Guide RNAs (gRNA218 and gRNA219) for AGR2 knockout were obtained 
from Horizon Discovery and were cloned into a GE6-002 plasmid. This plasmid 
contains a U6 promoter, expressing wild-type Cas9 which is under the control of CMV 
promoter and also contains a 2A puromycin resistance gene for selection. The gRNA 
designed for AGR2 knockout was also designed for AGR2 knockin mutation (AGR2 
C81S), where this mutation will have defective oxidoreductase activity on its sole 
cysteine within the thioredoxin domain. The AGR2 knockout/knockin gRNA targets 
exon 4 of AGR2 (as the DNA sequence containing the Cys81 is in exon 4).  
 
2.10.2. Transfection of gRNA, expansion, and characterisation of clones 
MCF-7 cells were transfected with 1.2 µg of gRNA construct using Attractene 
as described in 2.4.3 a 6-well plate. The transfected cells were incubated 72 hours. The 
transfected cells were serially diluted and plated into 96-well plates at 1 cell per well 
in standard cell culture media. Ten 96-well plates containing single cell dilution were 
obtained. After several days, each well of 96-well plates were checked and marked if 
they contained a single colony, while wells containing more than one colony (which 
may contain contaminating clonal line) were excluded. The clonal lines were then 
incubated in the incubator for several weeks to expand and the media were changed 
every 3-5 days. The clones were expanded to 24-wells, then to 12-wells, and finally to 
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6-wells plates. Expanded clonal lines were harvested and analysed using western blot 
or genotyped using SURVEYOR nuclease assay described below. 
 
2.10.3. Functional validation of clonal line 
SURVEYOR® mutation detection kit (Integrated DNA technologies # 
706025) was used for genotyping AGR2 knockout clonal line or a pool of transfected 
cells with gRNA. First genomic DNA was isolated using Gentra Puregene Cell Kit 
(Qiagen #158745) following the manufacturer’s directions. SURVEYOR PCR primers 
for AGR2 knockout were designed from the genomic DNA region within AGR2 exon 
4 that will amplify 586 bp long, where one of the primers is roughly one-third of the 
Cas9 target so that the cleavage fragments can be clearly distinguished in 
electrophoresis (Table 2.26). PCR was performed as described in 2.3.3.1 using the 
condition in Table 2.27. PCR products were cleaned up by QIAquick PCR Purification 
Kit before sending for sequencing using AGR2 Exon 4 F as a primer (Table 2.26) or 
genotyping using SURVEYOR® mutation detection kit as per manufacturer’s 
protocol. Digested PCR fragments from SURVEYOR® assay were analysed using 2% 
DNA agarose gel electrophoresis.  
Plasmid Sequence  5’-3’ 
AGR2 Exon 4 F TCTTTAGTATAGGGTCTATTATCCCAGTCT 
AGR2 Exon 4 R TATTGAATGTGGACTGTAAGAGAAATCAAG 
Table 2.26 SURVEYOR primers for the AGR2 knockout. 
PCR cycles protocol   
Step 1 95°C 2 min 
Step 2 95°C 20 sec 
Step 3 60°C 30 sec 
Step 4 72°C 1 min  
Step 5 Repeat step 2-4 30 times  
Step 6 72°C 5 min 
Step 7 4°C ∞ 
Table 2.27 PCR cycles protocol for SURVEYOR nuclease assay. 
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2.11. Hydrogen-deuterium exchange mass spectrometry  
2.11.1. Proteins used for hydrogen-deuterium exchange mass 
spectrometry. 
The amino acid sequences of the AGR2 recombinant proteins with N-terminal 
His-tag are:  









The proteins were purified as described above and gel-filtered into a buffer with the 
composition of 20mM Tris pH8.0, 150mM NaCl and 10mM MgCl2. The 16mer 
AGR2-interacting peptide has the amino acid sequence SGSG-HLPTTIYYGPPG and 
the stock solution is at 5 mg/ml in DMSO. The peptide: AGR2 protein ratio was at 
10:1 to give a final concentration of the AGR2-binding peptide at 10 µM and a final 
concentration of DMSO was 1%.  
 
2.11.2. Sample preparation and statistical rationale for hydrogen-
deuterium exchange mass spectrometry 
Deuteration of the His-AGR2 WT and His-AGR2S134A proteins was initiated 
by a sequential 10-fold dilution into a deuterated buffer  (20 mM Tris-HCl, pD 7.6, 
150 mM NaCl, and 10 mM MgCl2). In the peptide mapping experiment, either His-
AGR2 WT at 3 µM final concentration was incubated with a final concentration of 
peptide at 10 µM [181]. This higher concentration of peptide was used as we had 
previously defined the Kd to be 45 µM using fluorescence polarisation [181].  
Deuteration of full-length MDM2 without or with Nutlin-3 was performed as 
described previously [182].  Samples were processed in biological replicates with 
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representative data from a time course of deuteration (AGR2 without and with peptides 
or wt-AGR2 compares to the AGR2S134A mutant) highlighted in each experiment. 
Multiple peptide replicates were used to selected data and the HD Examiner software 
selects peptides with high confidence meaning the selected peptides are identified in 
all submitted MS data of all samples (non-deuterated and deuterated time intervals).  
When peptides are not identified in all samples, then the deuteration of the peptide is 
not calculated. Protein was incubated with peptide for 30 minutes prior to the 
exchange.  The deuterium exchange was carried out at room temperature and was 
quenched by the addition of 1 M HCl in 1 M glycine at 30 s, 1 min, 3 min, 10 min, 30 
min, 1 h, and 3 h followed by rapid freezing in liquid nitrogen. Each sample was 
thawed and injected onto an immobilised pepsin column (15 µl bed volume, flow rate 
100 µl/min, 2% acetonitrile / 0.05% trifluoroacetic acid). Peptides were trapped and 
desalted on-line on a peptide microtrap (Michrom Bioresources, Auburn, CA) for 3 
min at flow rate 50 µl/min. Next, the peptides were eluted onto an analytical column 
(Jupiter C18, 1.0 x 50 mm, 5 µm, 300Å, Phenomenex, CA) and separated using a linear 
gradient elution of 10 % B for 2 min, followed by 17 min isocratic elution at 40 % B. 
Solvents were: A – 0.1% formic acid in water, B – 80% acetonitrile / 0.08% formic 
acid. The immobilised pepsin column, trap cartridge and the analytical column were 
kept at 1°C. Mass spectrometric analysis was carried out using an Orbitrap Elite mass 
spectrometer (Thermo Fisher Scientific) with ESI ionisation on-line connected with a 
robotic system based on the HTS-XT platform (CTC Analytics company). The 
instrument was operated in a data-dependent mode for peptide mapping (HPLC-
MS/MS). Each MS scan was followed by MS/MS scans of the top three most intensive 
ions from both CID and HCD fragmentation spectra. Tandem mass spectra were 
searched using SequestHT against the cRap protein database 
(ftp://ftp.thegpm.org/fasta/cRAP) containing sequences of the AGR2 proteins with the 
following search settings: mass tolerance for precursor ions of 10 ppm, mass tolerance 
for fragment ions of 0.6 Da, no enzyme specificity and no fixed or variable 
modifications were applied. The false discovery rate at peptide identification level was 
set to 1%. Sequence coverage was analysed with Proteome Discoverer software 
version 1.4 (Thermo Fisher Scientific).  Analysis of deuterated samples was done in 
HPLC-MS mode with ion detection in the orbital ion trap and the data were processed 
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using HDX Examiner (Sierra Analytics).  Graphs summarising deuteration kinetics 
were plotted using the Draw H/D Protection Plot [183]. All peptide plots (graphs 
showing % deuteration over a time course) are summarised in Appendix.  
 
2.12. Tandem mass tag (TMT) Mass Spectrometry 
2.12.1. Sample preparation 
FLO-1 cells were grown to 90% confluency. FLO-1 cells were split, counted 
and transfected in biological triplicates by electroporation using a Nucleofector® 
Device (Lonza) and the Amaxa Cell Line Nucleofector Kit T (Lonza; # VCA-1002) 
according to manufacturer’s instructions. Briefly, 2x 106 cells were used with 2 μg of 
each DNA constructs; 1) pAM1L (FL-AGR2 WT/RSV 2) pAM2L (FL-AGR2 
KDEL/RSV) or 3) pSF-RSV vector only. For the electroporation a high expression 
program (U-023 on Nucleofector® Device) was used. Electroporated cells were plated 
into a 6-well plate, allow to recover and the media was changed the following day. The 
cells were further incubated for 72 hours post-electroporation before harvesting. Media 
were removed, washed 3 times with PBS and harvested using urea lysis buffer (8M 
urea, 0.1 M Tris-HCl pH 8) by incubating 30 mins on ice. Cellular debris was spun 
down 14 000 rpm for 20 min at 40C. Cell lysates were then subjected to tryptic 
digestion using filter-aided sample preparation (FASP) digestion protocols as 
previously described [184]. The filter unit (Hydrosart—stabilised cellulose‐based 
membrane; Vivacon 500 μl (Sartorius Stedim Biotech, #VN01H02 with a 10 kDa 
cutoff). The filter unit was washed with 100 μl of same urea lysis buffer from 
harvesting, centrifuged at 14 000 rpm for 15 min at RT. Two hundred μg of the protein 
sample in urea lysis buffer was added to the filter unit followed by centrifugation for 
at 14 000 rpm for 15 min at RT. Urea lysis buffer containing 16.7 mM tris 2-
carboxyethly phosphine hydrochloride (TCEP) was then added followed by incubation 
in a thermomixer for 600 rpm for 30min at 37˚C followed by centrifugation at 14 000 
rpm for 15 min at RT. This is to reduce any disulphide bonds in the denatured proteins. 
To alkalize the proteins of free sulfhydryl groups to form S‐carboxyamidomethyl‐
cysteine for maximal tryptic digestion, the filter unit was incubated with urea lysis 
buffer containing 50 mM iodoacetamide in the dark for 20 min at room temperature 
before further centrifugation at 14 000 rpm for 15 min. The filter unit was washed with 
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a buffer containing 100 mM ammonium bicarbonate (NH4HCO3), centrifuged at 
14 000 rpm for 15 min at RT A buffer containing 50 mM NH4HCO3 (100 μl) and 
trypsin (Promega) in a mass ratio 1:30 (trypsin/protein) was added to the filter, the 
samples were mixed at 600 rpm for 1 min, and then incubated for 18 h in a wet chamber 
(37˚C). Two rounds of subsequent centrifugation 14 000 rpm/15 min (room 
temperature) eluted the peptides. Samples were centrifuged at 14000 g at 200C for 15 
minutes, the filters were discarded. The concentration of the digested peptides was 
measured using the Quantitative Colorimetric Peptide Assay (Pierce, ThermoFisher) 
following manufacturer’s instruction. The absorbance of the reaction was measured 
using a TECAM Spectrophotometer at 480 nm. A calibration curve was created and 
peptide concentration was determined. 25 μg of peptides were transferred in a new 
Eppendorf and dried in a SpeedVac at 350C for 1 hour or until the liquid had 
evaporated completely. Samples were stored at −800C. 
 
2.12.2. TMT labelling 
For the labelling of the peptides, the Thermo Scientific Tandem Mass Tag™ 
Labelling kit (TMTsixplex™ Isobaric Label Reagent Set # 90061) and reagents were 
used. This labelling allows the multiplex relative quantitation by mass spectrometry. 
The reagent set was used to label 6 different samples as described in Table 2.28. For 
each of them, a unique reporter mass in the low mass region of the MS/MS spectrum 
is used to measure relative protein expression levels during peptides fragmentation. 
 
Label Reagents Sample ID 
TMT6 -126 RSV CONTROL 1 (pSF_RSV) 
TMT6 -127 RSV CONTROL 2 (pSF_RSV) 
TMT6 -128 AGR2 WT 1 (pAM1L) 
TMT6 -129 AGR2 WT 2 (pAM1L) 
TMT6 -130 AGR2 KDEL 1 (pAM2L) 
TMT6 -131 AGR2 KDEL 2 (pAM2L) 
Table 2.28 TMTsixplex isobaric label reagent set. 
 
Twenty-five μg of peptides per sample were labelled with TMT labels, according to 
Thermo Fisher Scientific protocol. Peptides were separated using Thermo Scientific 
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UltiMate 3000 RSLCnano chromatograph. Sample was loaded on a precolumn 
(Thermo Scientific μ‐precolumn, 30 μm id, 5 mm length, C18 PepMap 100, 5 μm 
particle size, 100 Å pore size) and peptides further separated on a Thermo ScientificTM 
Acclaim PepMap RSLC column (75 μm id, length 500 mm, C18, particle size 2 μm, 
pore size 100 Å) using a 300 nL/min flow rate with a linear gradient of B (80% ACN 
in 0.08% aq. formic acid) in A (0.1% aq. formic acid (FA)). The gradient composition 
used for peptides separation was as follows highlighting time as a function of % B: 0 
min, 2%B; 10 min, 2%B, 200 min, 50%B, 210 min, 98%B, 228 min, 98%B, 255 min 
END. peptides were transferred into a newly labelled microcentrifuge tube and 
evaporated using a SpeedVac concentrator and were stored at −80◦C. Dried, desalted 
peptides were reconstituted in 0.1% FA  and introduced into Thermo ScientificTM 
Orbitrap EliteTM operating in Top10 data‐dependent acquisition mode. The data 
acquisition parameters setting for the Top10 method include: MS1 includes a mass 
range of 335–1800, a resolving power setting of 120 000, and a Max. in a time of 200 
ms; MS2 includes: HCD activation type; a min. The signal required of 5000, an 
isolation width of 1.2, NCE of 35, charge rejection state is unassigned; 1+; dynamic 
exclusion settings are ON; the exclusion width is 10 ppm; repeat count is set at 1; the 
exclusion list size is 500, and the exclusion duration is 30 s. 
 
2.12.3. Database searching and analysis 
Data analyses were processed with a Proteome Discoverer1.4 (Thermo 
ScientificTM), employing Mascot with the following search settings: database Swiss‐
Prot human (April 2015); enzyme trypsin; two missed cleavage sites; precursor mass 
tolerance 10 ppm; fragment mass tolerance 0.6 Da; dynamic modifications: formyl 
[peptide N‐terminus], oxidation [M], Gln to pyro‐Glu [peptide N‐terminus], acetyl 
[protein N‐terminus], TMT6plex [K], TMT6plex [N‐term], and static modification: 
carbamidomethyl [C]. The results of the search were further submitted to generate the 
final report using a cutoff of 1% FDR on peptide levels, and only unique peptides were 
used for protein quantitation. The quantitative option was enabled with the 
corresponding combination of labelled peptides in the sample type and the observed 
relative quantification ratio was normalised compared to the median.
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CHAPTER 3: Defining a Function for the Sequence-




AGR2 protein has emerged in the past ten years as a major pro-oncogenic and 
metastatic player in cancer largely due to the emergence of clinical-OMICS [94] [116]. 
AGR2 protein is highly upregulated in a various range of human cancers and has been 
shown to be involved in asthma, inflammatory bowel disease, cell transformation, 
cancer drug resistance and metastatic growth as previously discussed. However, the 
biological function of AGR2 is not fully understood, and scientists were unable to 
embed AGR2 in a specific pathway. Finding evidence of multifaceted roles of AGR2, 
and understanding its biological functions could cast mechanisms by which AGR2 
contributes to diseases. One way to understand the diverse biological functions of 
AGR2 is to understand how AGR2 interact with its client proteins. By suggesting 
features of binding partners, they provide a cellular framework that can give 
mechanistic insights about function. Current goals of this emerging AGR2 field are, 
therefore, to characterise and identify protein interactions that mediate its function 
which include identification of the signalling pathways through which it can stimulate 
cell growth or drug-resistance[185, 186], and determining whether these pathways are 
“druggable”[187].  
 
3.1.1. Linear peptide motif as tool to identify AGR2 binding protein 
There are approximately 22,000 protein-coding genes in the human genome 
which translated to roughly 35,000 instances of folded domains belonging to about 
10,000 families [188]. Their functions are often grasped through interactions with 
other proteins, mediated by an estimated 10,000 distinct interaction types [189], 
resulting in several hundred thousands of binary interactions [190-192] and 600–1,000 
distinct protein complexes [193-195]. Proteins have been assumed classically to bind 
each other via large discrete region called domain. However, with the recent advances 
in bioinformatics and genome sequencing have shown that majority of protein-protein 
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interactions in nearly all cellular processes are mediated by small interaction modules, 
referred to as peptide motifs (Figure 3.1). Peptide motifs are typically less than ten 
residues in length signify functional sites that often occur within intrinsically 
disordered regions of proteins, and there might be a million instances of peptide motifs 
in human proteome [196]. 
 
Peptide motifs are also referred to as linear motifs [LMs] or short/ eukaryotic 
linear motifs [ELMs/SLiMs]) in the literatures. Peptide motifs were originally 
discovered as conserved regions in rapidly growing regions and a substantial number 
of motifs with important functions are protected against deleterious mutations [197, 
198]. Peptide motifs can be categorised into two different classes which are binding 
motifs and post-translational modification sites (PTM). Regulatory role of the binding 
motif is to mediate interactions with globular domains which often function in the 
assembly of protein complexes as scaffolding modules. Due to its small size, they are 
widespread in key biological processes and are estimated to be millions in nature. 
Binding motif also can be further categorised into functional subsets which include 
trafficking motifs, targeting motifs, docking motifs and degron motifs. PTM are sites 
that only recognised when modifying enzymes alter them. PTM sites normally have 
weaker intrinsic specificity determinants [199, 200] and can be detected in a single 
residue range. PTM sites are classified into three sub categories which include moiety 
addition sites, cleavage sites and structural modification sites [196].  
 
Peptide motifs mediated interactions have very dissimilar properties from those 
interactions between two globular domains. Peptide motifs normally have low affinity 
for their binding partners and bind to much smaller interface areas [201, 202]. These 
properties help to clarify why peptide motifs frequently involved in signalling and 
other regulatory transient interactions and thus give them plasticity in the vast protein-
protein networks and lend themselves to rapid cellular perturbation and environmental 
changes [201]. They can either be switched on or off relatively easily, and their 
redundancy and weak affinity probably means that the loss or gain-of-function will 
rarely affect the system. 
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Although peptide motifs have the weaker disposition, interactions mediated by 
peptide motifs demonstrate high specificity with their binding partners. This can be 
achieved by eliminating certain interactions through the absence of other partners and 
the regions adjacent to peptide motifs. It has been shown that peptide motif flanking 
regions contribute 21% of the binding energy on average [203]. Further analysis 
demonstrated that flanking regions are often structurally conserved [204]. These 
flanking regions help peptide motifs fold into stable structure upon binding to their 
client domain. Mohan and colleagues described two types of structures adopted by 
peptide motifs upon binding [205]: formation of α helices, β strands; and formation of 
irregular structure elements. These structures normally involve the cooperation of 
multiple interactions and simultaneous presence of multiple weak low-affinity 
interactions that eventually gives structural rigidity to the overall complex. Peptide 
motifs can be an important tool in mediating the discovery of protein-protein 
interaction. Identifying peptide motifs that bind to proteins help to elucidate a group 
or class of proteins with which they interact, and thus determining their interactomes 
[206]. The fact that peptide motifs are rarely conserved makes them difficult to find. 
Most laboratory approaches such as the classical proteomics tandem affinity 
purification-tag (TAP-tag), yeast two-hybrid (Y2H) or combinatorial peptide-phage 
display experiments, are typically biased toward stable interactions [202, 206-208].  
 
The AGR2 protein was previously screened for peptide binding aptamers using 
combinatorial peptide-phage libraries. Briefly, phage-peptide display involves the 
expression of a peptide of the major coat protein of a phage virion which usually 
represented by an M15 or filamentous phage) (Phage display procedures is discussed 
further in details in Chapter 6). Large combinatorial phage peptide display libraries, in 
which a single random peptide is expressed on the surface of each virion can be built 
up (roughly 109 peptide sequences), and this library can be used to screen for potential 
binding peptides for a given protein or DNA. Using this approach, purified AGR2 was 
adsorbed onto a solid phase of an ELISA microtiter plate, a combinatorial peptide 
phage library was added, and unbound peptides were removed by several washing 
steps. Peptides bound selectively to AGR2 were released using low-pH and these 
selection and amplification processes were repeated four times to achieve high-affinity 
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binding peptides. Two peptides were found to bind AGR2 protein in high affinity; 
peptide A2 with the sequence YPWHHSWTHTTL and peptide A4 with the sequence 
HLPTTIYYGPPG [209]. These two peptides bind to two different epitopes on the 
protein [209]. Peptide A2 binds better to AGR2 when the protein is partially denatured 
or unfolded. On the other hand, peptide A4 binds better to AGR2 when the protein is 
native. Only peptide A4 was then further characterised as this peptide showed higher 
binding affinity to clinical tissue biopsy. Synthetic biotinylated peptide aptamers 
bound in an ELISA format to AGR2 and substitution mutagenesis further minimised 
one polypeptide aptamer to a hexapeptide core PTTIYY. 
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Figure 3.1 Functional Modules of Proteins. (Adapted from [196]) Typical length scale and estimated 
the number of cases of whole-protein elements (complexes and structural domains [folds]) and protein 
parts (binding motifs and modification sites) in the human proteome. 
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Figure 3.2 Phage-peptide display identifies peptide that binds to AGR2 in-vitro. (A) The phage-
peptide library was made by fusing random cDNA peptide to bacteriophage coa protein on the surface 
of the phage virion. Some peptides bind biotinylated to AGR2 adsorbed into wells of microtiter plate 
and- non-bound virion peptides are washed away. Bound virions are recovered and used to infect E.coli 
for amplification for use for the next round. Successive rounds of binding, selection, infection and 
replication enrich for peptides with high-affinity binding. (B) AGR2 binding peptide HLPTTIYYGPPG 
was identified and subjected to alanine scan and truncation series to find minimal binding peptide [209] 
(C) Coomasie Blue detection of the minimal binding hexapeptide  (PTTIYY) incubated from Barret’s 
esophagus tissue crude lysate (containing AGR2 proteins) which bind AGR2 to near homogeneity .   
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3.1.2. Aims of chapter 
The function of the AGR2 sequence-specific binding peptide has not been 
defined. In this chapter, we begin to investigate the biology of AGR2 by probing the 
specific peptide (peptide A4) binding function of AGR2 to define a possible cell 
biological role for this activity. Hydrogen-deuterium exchange mass spectrometry was 
employed to determine whether a specific peptide docking site can be mapped on 
AGR2 followed by generation of ‘docking site’ mutants. Subsequently, we developed 
AGR2 consensus peptide-binding motif in which we used it to search for human 
proteins containing this motif as potential AGR2 client proteins. We then targeted a 
key protein of interest as putative AGR2 client protein and perform in-vitro protein-
protein interaction assays to validate AGR2 binding. Accordingly, we proposed a 
model of how peptide-binding function directs the interaction of AGR2 with its client 
proteins. 
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3.2.1. Mapping AGR2 peptide docking sites using hydrogen- deuterium 
exchange mass spectrometry. 
3.2.1.1. Specificity of peptide A4 binding to AGR2 
Peptide A4 with the sequence HLPTTIYYGPPG was previously shown to bind 
AGR2 with high affinity [209].  We further evaluated the specificity of the peptide to 
see whether it can bind to and affinity purifies monomeric or dimeric AGR2 protein 
from human cell lysates. MCF-7 cells which express endogenous AGR2 were left 
untreated or treated with a cell-membrane permeable cross-linker that stabilises AGR2 
dimer via a K95-K95 homodimeric cross-link [97]. When lysates from untreated cells 
are incubated with streptavidin beads coated with peptide A4, monomeric AGR2 
protein can be affinity purified from the crude lysate (Figure 3.3A, lane 4 vs Load, 
Flow-though, and wash, lanes 1-3). In addition, the chemically stabilised AGR2 dimer 
(Figure 3.3A, lane 5) can also be affinity purified using the peptide A4 coupled beads 
(Figure 3.3A, lane 8 vs 5-7).  
 
We then further assessed the specificity of the peptide in affinity capture of 
AGR2 protein from beads without peptide (Figure 3.3B, lane 2) and beads with peptide 
(Figure 3.3B, lane 3). These data indicate that peptide A4 can be used to affinity purify 
dimeric or monomeric protein and suggest the bioactivity of this peptide motif in crude 
lysates to AGR2 is relatively specific. However, the silver stain gel does reveal high 
molecular mass proteins that can bind to the peptide directly or through association 
with AGR2. This fraction containing potential AGR2 binding proteins were not 
evaluated. Nevertheless, the relative specificity of this peptide for AGR2, as defined 
by its ability to affinity purify the protein from crude lysates, suggests that this feature 
of AGR2 can selectively drive (some of) its protein-protein interaction functions. 
Thus, we continued to characterise this specific peptide binding activity in an attempt 
discover bonafide client proteins which harbour this peptide motif.  
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Figure 3.3 Peptide aptamer affinity purification of in vivo cross-linked AGR2 protein from crude 
lysates. MCF7 cells grown in media with 10% FCS were incubated with DMSO (lanes 1-4) or with a 
fixed concentration of DSS (lanes 5-8) for 1 hour at 37oC.  Cells were harvested, lysed using a Tris-HCl 
(pH 8.0) buffer containing 1% NP-40, lysates were incubated with an optimised biotinylated peptide 
aptamer (named A4) linked to streptavidin beads, which can be used to affinity purify the AGR2 protein 
in crude cell lysates (18). The input lysate (Load, lanes 1 and 5), flow-through (lanes 2 and 6), wash 
(lanes 3 and 7), and eluate (lanes 4 and 8) was separated by electrophoresis.  The protein in the 
polyacrylamide gel was (A) immunoblotted to determine whether intermediary species of cross-linked 
AGR2 could be affinity purified and (B) stained with silver to examine total protein capture. The 18 
kDa and 36 kDa cross-linked and affinity purified silver-stained proteins (arrows, lane 3 vs lane 2) were 
excised using trypsin and AGR2 protein was confirmed present by MALDI-TOF mass spectrometry 
(data not shown).  
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3.2.1.2. Hydrogen-deuterium exchange mass spectrometry as tool to 
map peptide A4 binding to AGR2 
Hydrogen deuterium exchange (HDX) is a powerful technique which utilises 
the exchange of hydrogen atoms in the protein with deuterium (D2O) when protein is 
diluted into a solution of deuterium (Figure 3.4A).  The approach is based on the fact 
that hydrogen bonding between amino acid side chains and protein backbone amides 
retard exchange whereas amides that are located in regions that are not stabilised by 
hydrogen [210]. The degree of protection is indicative of local structure and dynamics. 
Mass spectrometry is used for determining the mass shifts induced by the exchange of 
hydrogens by deuteriums with time, as a consequence of changing environments, 
structure, and complex formation. Thus, this technique is useful for investigating 
conformational dynamics and interactions in proteins, protein-ligand and protein-
protein complexes. When a target protein solution is diluted in D2O, the protein mass 
will increase, owing to the exchange between backbone hydrogens and the deuterium 
in the solution. In a typical HDX experiment, the relative deuterium uptake rates are 
measured and compared to the protein under different conditions, most commonly with 
or without ligands.  
 
In the case of the protein-ligand complex is diluted in D2O, the extent of HDX 
decreases for regions involved in ligand binding which occurs due to decrease in 
solvent accessibility in the bonding regions. By comparing changes in deuterium 
uptake between ligand-free and ligand-bound states of the protein, ligand binding 
regions can be identified. The global deuteration also can be assessed by measuring 
the mass of the protein in the presence and absence of ligand which resolves the overall 
extent of binding under specific experimental conditions. Binding can be probed in a 
variety of conditions such as altering salt concentrations, changing pH, adding other 
molecules (e.g., DNA), or mutating a protein [211]. 
 
Our lab has previously set up hydrogen-deuterium exchange using Mouse 
double minute (MDM2) protein as a model system to define effects of ligand binding 
on the exchange reaction [182].  Purified full-length MDM2 (1 M) was incubated 
with DMSO or the ligand Nutlin-3 (a small molecule inhibitor of the MDM2/p53 
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interaction) for one hour, diluted in a 20-fold excess of D2O, and processed with pepsin 
to define changes in deuteration. The data showed expected suppression of deuteration 
at the N-terminal drug-binding pocket, with internal suppression from amino acids 
245-265 that might reflect allosteric effects of the small molecule inhibitor of MDM2 
protein (Figure 3.4B). In this study, we aimed to use the same method to monitor 
deuteration changes of AGR2 protein with and without ligand (peptide A4) to map 
where Peptide A4 binds to AGR2. 
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Figure 3.4 Establishing methodology for measuring the effects of a ligand on the target protein 
MDM2 using hydrogen-deuterium exchange mass spectrometry.  MDM2 was assembled with 
DMSO or with Nutlin-3 in the molar ratio 1 : 4 and cultivated at room temperature for 60 minutes, as 
described previously for the N-terminal domain of MDM2 (aa 1-126) (26). Deuteration of MDM2 was 
initiated by sequentially adding D2O with 1% DMSO. The protein concentration during EpCAM/D 
exchange was      2 μM. The exchange was quenched by acidification to pH 2.3 at eight-time intervals 
from 40 to 18,000 seconds. The samples were immediately frozen in liquid nitrogen. Thawed samples 
were processed for pepsinisation as described in the materials and methods. The deuterium exchange 
rates of individual peptides are summarised using the HDX exchange plots for the 300 second 
deuteration time course. 
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3.2.1.3. AGR2 purification for hydrogen-deuterium exchange 
In order to perform a hydrogen-deuterium exchange, AGR2 protein needs to 
be first purified to allow formation complex with its ligand. AGR2 was previously 
cloned into the pDEST17 vector using Gateway cloning containing hexahistidine tag 
at N-terminal (Figure 3.5A). As a result, the recombinant protein can be purified using 
His-tag affinity chromatography. The AGR2 cDNA sequence cloned into the 
expression plasmid lacked the disordered N-terminal cleavable signal peptide, such 
that the expressed product would be a representation of the mature form of protein 
(amino acid 21-175) (Figure 3.5B). Following transformation into E. coli BL21 (AI) 
bacteria and selection, isolated colonies were cultured in LB and induced with IPTG. 
The induced his-tagged AGR2 fusion product, with a molecular mass of 20 kDa, was 
evident in crude bacterial lysate (Figure 3.5C, see first lane CL). Following clearing 
of the bacterial lysate of membrane fragments and unlysed cells, the bacterial slurry 
was incubated with nickel-agarose beads. Beads were washed and eluted as described. 
The eluted protein was pooled and buffer exchange to remove imidazole and high salt 
content. Purified AGR2 was assessed by SDS-PAGE and immunoblot analyses using 
specific AGR2 polyclonal antibody. By coomassie staining, AGR2 showed a major 
band at 20 kDa and a minor band around 40 kDa (Figure 3.5C). The 40-kDa band was 
attributed to a dimeric form of His-AGR2 that persisted even under reductive SDS-
PAGE conditions. Overall, following the purification protocol of AGR2, AGR2 was 
highly expressed with an expected band in bacteria and that the recombinant protein 
was functional having the N-terminal fusion tag and extra amino acids from the 
homologous recombination when cloned into pDEST17 using Gateway cloning. The 
purified AGR2 also is immunoreactive as it can be detected by the AGR2 polyclonal 
antibody (data not shown).  
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Figure 3.5 Purification of recombinant His-AGR2.  A) Schematic representation of His-AGR2 
protein and plasmid constructs highlighting essential motifs of N- terminal His-epitope tagged, the 
dimer interface, thioredoxin motif CXXS and ER retention site KTEL. AGR2 construct for bacterial 
expression was previously cloned into pDEST17 via Gateway cloning.(B) His-AGR2 DNA and Protein 
sequences highlighted with AGR2 essential motifs C) Coomassie Blue staining of purified His-AGR2 
showing the major band at 20 kDa under reducing SDS-PAGE condition. Diffused AGR2 dimer band 
can also be seen (arrow). 
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3.2.1.4. Analysis of deuterium exchange on AGR2 in the presence 
and absence of peptide-A4 
AGR2 protein (3 M) was incubated without ligand or with peptide A4 
(SGSGHLPTTIYYGPPG; 10 M) to allow complex formation. The samples were then 
diluted 10 fold in D2O over a time course from 30 to 10800 seconds, reactions were 
quenched by acidification and freezing, then the thawed samples were subjected to 
pepsin digestion (Appendix 1 contains all of the primary raw graphical data). The 
peptic coverage of a representative experiment using ligand-free AGR2 is shown in 
Figure 3.6. Peptic cleavage is not completely random throughout the sequence and can 
generally be grouped into four distinct domains. These domains contain (i) the N-
terminal domain from amino acids 21-53 that harbour intrinsically disordered 
sequences that negatively regulate dimer formation [61] [97]; (ii) the central domain 
containing amino acids 54-108 that harbor the dimer interface [61], the thioredoxin 
fold, and the Reptin docking site [105]; (iii) a region N-terminal to the specific peptide-
binding domain (aa 109-130; this study); and (iv) the specific peptide binding domain 
and ER retention site (Figure 3.6).  
 
Preferred cleavage sites or hotspots of pepsin cleavage can be visualized such 
as Thr23 (highlighted as an N-terminal disordered region; Figure 3.6), Tyr63 (within 
the dimer interface of 60-EALYK-64), Ile74 (N-terminal to the CxxS motif), and 
Val110 (highlighted with Reptin binding motif [105]; Figure 3.6).  The existence of 
four regions with a degree of peptic resistance, suggests some secondary/tertiary 
conformation is maintained upon acidification. It is interesting to note that very few 
peptides were obtained covering the complete dimerization motif from amino acids 
60-64 (Fig 3C; highlighted by dimer interface). In fact, a hotspot of cleavage is at 
Tyr63 (within the dimer interface of 60-EALYK-64) suggesting this region is 
relatively more susceptible to proteolysis when in the acidified and denatured state.  
 
Upon peptide binding by AGR2, peptic fragments within the intrinsically 
disordered N-terminal domain exhibited marginal changes in deuteration (Figure 
3.7A-D),suggesting that this region is not significantly impacted upon peptide binding.
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Figure 3.6 Peptic peptides recovered from ligand-free mature AGR2 protein (with the N-terminal 20 amino acids containing the hydrophobic ER leader 
sequence removed. The proteolytic peptide fragments can be grouped into four regions based on extents of recovery after mass spectrometry; (i) The N-terminal region 
containing the poly his-tag and amino acids Arg21-Leu52 containing the intrinsically disordered region that plays a negative regulatory role in dimer stability (17) (7); 
(ii) a central grouping from Ile53 to Asn108, containing the beginning of the dimerization motif (60-EALYK-64), the CxxS thioredoxin fold, and the Reptin binding 
motif (104-FVLLNLVY-111); (iii) a third pepsin resistant region from aa 109-130; and (iv) a region of a cluster of overlapping peptic fragments including the specific 
peptide binding domain (this study) and the degenerate KTEL endoplasmic  reticulum retention site. 
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Such small mass peptic fragments included the N-terminal tag (YKKAGFEGDRT;  
Figure 3.7A) and a peptic fragment N-terminal to the dimerization interface (45-
SRGWGDQL-52; Figure 3.7B). Interestingly, over the time course of deuteration, the 
peptide 53-IWTQTYE-59 just adjacent to the dimerization motif was attenuated in its 
deuteration (Figure 3.7E) and small deuterium suppression over the time course from 
aa 62-LYKSKTSSKPLM-73 (Figure 3.7F).  These latter data suggest that peptide A4 
binding can impact on this dimeric interface. There is a degree of specificity in this 
deuterium suppression around the dimeric interface since the peptide 74-
IIHHLDECPHSA-85 containing the thioredoxin fold does not exhibit significant 
deuteration changes in the presence of peptide A4 (Figure 3.7C).  Nor does a small 
mass peptic fragment adjacent to the Reptin docking site, 97-IQKLAEQF-104, exhibit 
significant changes in deuteration (Figure 3.7D).  
 
The C-terminal domain showed the most significant global changes in 
deuteration after peptide binding across the time course (Figure 3.8). For example, 
peptide 138-RADITGRYSNRL-149 exhibited consistent suppression of deuteration 
throughout the entire time course (Figure 3.8A) similar to the peptides surrounding the 
dimer interface. However, the most significantly suppressed minimal peptic fragment 
over the entire time course of deuteration was 131-VDPSLTVRA-139 (Figure 3.8B).  
By comparison, the minimal peptide fragment 150-YAYEPADTAL-159 exhibited 
minimal deuteration changes upon peptide binding (Figure 3.8C). A visualisation of 
the global changes in peptide deuteration (from Figure 2) deuteration after 30 seconds 
(Figure 3.8D) or 10,800 seconds (Figure 3.8E) further highlights the most dominant 
impact of peptide A4 on the structural loop from aa 131-135 (Figure 3.8D-E and A). 
Presumably, once AGR2-peptide complexes reach some equilibrium after diluting 10 
fold with D2O for 10,800 seconds, there is enhanced deuteration within the 
dimerization motif (compare Figure 3.8E to Figure 3.8D). This suggests that specific 
peptide binding might destabilise the dimer into the monomeric state. 
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Figure 3.7 Representative deuteration rates of peptides derived from the N-terminal domain of 
AGR2 after binding of peptide A4. Ligand-free AGR2 or AGR2-peptide A4 complexes were 
deuterated over a 7-point time course from 30 seconds to 10,800 seconds followed by acidification, 
pepsinisation, and separation of fragments using mass spectrometry. (A-C). Representative segments of 
AGR2 protein that do not exhibit significant changes in deuteration after peptide A4 binding over the 
time course are highlighted including; (A) YKKAGFEGDRT from the N-terminal HIS tag; (B) a peptic 
fragment N-terminal to the dimerization interface containing aa 45-SRGWGDQL-52; (C) a peptide 
containing the thioredoxin fold, from aa 74-IIHHLDECPHSA-86; and (D) a peptic fragment adjacent 
to the Reptin docking site, containing aa 97-IQKLAEQF-104. Segments of AGR2 protein that do show 
a degree of deuterium suppression over the entire time course included; (E) a peptide containing aa 53-
IWTQTYE-59 just adjacent to and N-terminal to the dimerization motif; and (F) peptide containing half 
of the dimerization motif from aa 62-LYKSKTSSKPLM-73.  The data are plotted as % of deuteron 
exchange as a function of time (log10 in seconds; from 30, 60, 180, 600, 1800, 3600, and 10800). 
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Figure 3.8 Representative deuteration rates of peptides derived from the C-terminal domain of 
AGR2 after binding of peptide A4.  Ligand-free AGR2 or AGR2-peptide A4 complexes were 
deuterated over a 7-point time course from 30 seconds to 10,800 seconds followed by acidification, 
pepsinisation, and separation of fragments using mass spectrometry. The C-terminal domain showed 
the most significant global changes (suppression) in deuteration of individual peptic fragments after 
peptide A4 binding across the time course are highlighted, including: (A) peptide containing aa 138-
RADITGRYSNRL-149, and (B) the peptide contiguous and N-terminal to (A) containing aa 131-
VDPSLTVRA-139. (C) The peptide contiguous and C-terminal to (A) containing aa 150-
YAYEPADTAL-159 exhibited minimal deuteration changes upon peptide A4 binding. (D and E). A 
visualisation of the global changes in peptide deuteration without (blue) and with peptide A4 ligand 
(red) after (D) 30 seconds of incubation in D2O or (E) after 10,800 seconds of incubation in D2O. The 
data are plotted as % of deuteron exchange as a function of time (log10 in seconds; from 30, 60, 180, 
600, 1800, 3600, and 10800). 
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3.2.1.5. Effect of mutating AGR2 peptide ‘docking site’  
The most significantly suppressed deuteration was shown in the peptide 
fragment 131-VDPSLTVRA-139 and this region also showed consistent suppression 
at early and late time points which most likely to be the binding site for AGR2 peptide 
motif (Figure 3.9A). Based on the AGR2 crystal structure, the position 131-
VDPSLTVRA-139 consists of the two B-sheets and the core VDPSL makes the turn 
between the B-sheets B). We then decided to mutate the core VDPSL motif (Figure 
3.9B) from the his-tagged wt-AGR2 at the positions of D132, P133, and S134 to 
determine if alterations in PTTIYY peptide binding occur (Figure 3.9C-E). The 
proteins were purified (Figure 3.9C-E, lower panel) the same way as the wt-AGR2 and 
tested for changes in consensus site peptide binding. Protein purifications showed the 
different stability of the mutant’s protein in bacteria. AGR2P133A and AGR2S134A were 
stable and highly expressed and the yield was relatively the same as the wt-AGR2 
(Figure 3.9D-E). The mutant AGR2D132A, on the other hand, exhibited a high degree 
of proteolysis and instability in bacteria and its yield was lower than wt-AGR2 
suggesting it might have a different conformation (Figure 3.9C, compare the yield of 
elution fractions). The mutant proteins were purified in at least three different 
independent experiments and showed relatively same constancy and yield. Despite low 
yield of AGR2D132A, it was still used to evaluate in consensus site peptide binding 
assays.  
 
Biotinylated peptide A4 was captured on the streptavidin solid phase (Figure 
3.9F). The wild-type and docking-site mutated AGR2 proteins were titrated to 
determine whether these mutations increase, decrease, or have no effect on peptide 
binding. AGR2S134A exhibited wild-type levels of peptide binding, AGR2D132A 
exhibited attenuated levels of peptide-binding, and the AGR2P133A exhibited the lowest 
amounts of peptide binding (Figure 3.9G). The attenuated activities of the AGR2 
mutants encoded by the P133A and D132A alleles suggest that these two amino acids 
play more dominant roles than the S134 side-chain in sequence-specific peptide 
docking.  
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Figure 3.9 Mutations in the dominant deuteration responsive motif impact on AGR2 peptide 
binding activity in-vitro. (A) A secondary structure summary of changes in deuteration in the presence 
of the consensus peptide. The diagram shows the full amino acid sequence of mature AGR2 protein (aa 
21-175) with the alpha helices and β-sheets highlighted.  The block colours highlight the changes in 
fold deuteration after 30 seconds or 10800 seconds, with dominant changes at the region 131-139 (in 
between two β-sheets) and the dimer interface (aa 50-60). (B) A representation of the minimal 
deuteration responsive motif from aa 131-135 motif (highlighted in pink) in AGR2 (PDB code:  2LNS) 
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that is most significantly suppressed by peptide A4 binding. The main amino acids of focus were D132, 
P133, and S134 flanked by the hydrophobic amino acids V131 and L135. (C-E) DNA sequencing 
chromatogram traces of three of AGR2 peptide docking site mutations at position Asp132 to Ala, 
Pro133 to Ala, and Ser134 to Ala (upper panel) and their corresponding protein purifications shown as 
Coomassie Blue gel showing the relative purity of the indicated mutant proteins expressed in E.coli 
after nickel affinity purification (lower panel). (F-G) An ELISA assay was developed to measure the 
binding of AGR2 to synthetic biotinylated peptide A4 captured on the streptavidin coated solid phase. 
Reactions were added to the solid phase to measure binding to biotinylated peptide A4 on the solid 
phase.  The data plot the binding of AGR2 in relative light units (RLU) as a function of increasing wt 
or mutant AGR2 protein isoforms, as indicate (in µg) that was quantified using AGR2 specific antibody. 
12-mer negative peptide F3 which showed no binding specificity to AGR2 from previous studies was 
used as negative control and ELISA (data not shown). The experiment was carried out in triplicate in 
three independent experiment, and data is representative of twice replicated experiments. 
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The results may suggest that aspartic acid (D) residue which is negatively 
charged amino acid is essential for AGR2 binding and substituting it with uncharged 
alanine, significantly perturb the binding of AGR2. Proline (P) residue is a unique 
amino acid that can function to introduce a kink in alpha helices. Proline substitution 
to alanine is thought to remove the ‘kink effect’ or ‘binding pocket’ existed in the wt-
AGR2 thus showed loss-of-function binding to the peptide. 
 
3.2.2. Developing a consensus peptide-binding motif for AGR2 
AGR2 is an ER-resident molecular chaperone that plays a role in the 
maturation of cysteine-rich receptors such as MUC5 [104] and EGFR [83].  To our 
knowledge, AGR2 protein is relatively unique as a chaperone in possessing a 
sequence-specific peptide binding activity [209] and as discussed in 3.2.1.1. Therefore, 
it is vital to determine whether such a protein-protein interaction plays any role in 
binding to potential client proteins. If so, this would place a potential filtering step for 
client proteins with such a motif on AGR2-dependent processing. Previously, peptide 
A4 was shown to affinity purify monomeric or dimeric AGR2 protein and suggest the 
bioactivity of this peptide motif in crude lysates to AGR2 is relatively specific. A series 
of deletions and alanine scan mutagenesis of the 12-mer linear peptide A4 
HLPTTIYYGPPG narrowed down the essential binding residues to only PTTIYY 
[209]. The originally optimised AGR2-binding peptide, PTTIYY, was subjected to 
mutagenesis in this study to produce a synthetic peptide library in which each of the 
six positions was mutated to a range of amino acids that are either charged, 
hydrophobic (bulky), and hydrophobic (small) (Figure 3.10A).  AGR2 binding was 
measured by capturing biotinylated versions of the peptides onto streptavidin-coated 
plates and then assaying the extent of AGR2 binding. Relative to the positive control 
of AGR2 binding to the WT-peptide PTTIYY (Figure 3.10, far left bar), mutating each 
position resulted in the production of the consensus Tx[IL][YF][YF] (Figure 3.10B).  
For example, mutation of threonine at position 2 to any substitution abrogated activity 
(Figure 3.10A) suggesting a critical role for Threonine. Similarly, mutation Tyrosine 
at position 5 or position 6 was only tolerated by substitution to the bulky hydrophobic 
residues Phenylalanine and Tryptophan (Figure 3.10A). Mutation of Isoleucine at 
position 4 was only tolerated by a Leucine substitution (Figure 3.10A). By contrast, a 
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large set of amino acid substitutions were tolerated at Proline position 1 or Threonine 
position 3 (Figure 3.10A).  
 
Using the optimised stringent consensus site Tx[IL][YF][YF], the human 
proteome was searched against the motif using ScanProsite11 tool to identify potential 
human proteins that harbour the binding motif (Figure 3.10B). This database search 
resulted in 409 hits when splice variants or multiple isoforms of the same protein were 
excluded (Figure 3.10C-D). Interestingly out of 409 proteins, over 40% were predicted 
to be membrane associated (Figure 3.10C-E and Appendix 2). Among other hits were 
cilia-associated proteins, secreted proteins, protein-folding and transport-associated 
proteins, glycosylases, solute transporters and ion channels, and cancer-associated 
proteins. When gene enrichment tool was applied to the protein hits using FunRich 
[212], molecular functions related to membrane activity such as G-protein coupled 
receptor (GPCR) was among the highest (Figure 3.11A and Appendix 3). In the 
context of biological processes, proteins involved in transport, cell communication and 
signal transduction were enriched (Figure 3.11B). Signalling of GPCR and Olfactory 
were enriched in term of biological pathway (Figure 3.11C). This result suggests that 
AGR2 might involve in chaperoning lots of membrane class proteins and secreted 
proteins pathway. This is also consistent with previous studies which showed that 
AGR2 chaperone a number of secreted proteins such as MUC2 and MUC1 and also 
recently published paper showed binding to membrane bound protein EGFR. 
Furthermore, a large number of all the hits from the search were large, cysteine-rich 
proteins that undergo wide-ranging posttranslational modifications in accordance to 
proteins such as MUC2 and MUC1.  
  
                                                 
11 http://prosite.expasy.org/scanprosite/ 
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Figure 3.10 Mining of the human proteome for proteins containing the AGR2 linear peptide 
consensus motif. (A) The PTTIYY hexapeptide was previously defined as a minimal peptide sequence 
that binds to AGR2 (19). A mutational scan library was synthesised containing a subset of amino acid 
substitutions at positions 1-6, from left PTTIYY. The substitutions included small hydrophobic (L, V, 
I, M, A, G), bulky hydrophobic (EpCAM, F, P), charged (D, C) and hydrophilic (S, T) of the linear 
peptide motif. The peptides sequences created are shown on the X-axis.  Biotinylated peptides were 
bound to the streptavidin-coated solid phase and fixed amounts (1 µg) of AGR2 protein was added.  
AGR2 was detected using a secondary antibody and binding is measured in as RLU.  The data revealed 
that amino acids at positions 2, 4, 5, and 6 are relatively fixed whilst changes at positions 1 and 3 can 
be relatively well tolerated. B). Schematic illustrating strategy to find novel AGR2 client proteins using 
linear peptide motif database mining. The AGR2 linear peptide consensus motif was used as input using 
a ScanProsite tool (http://prosite.expasy.org/scanprosite/) and the human proteome database was 
screened to identify proteins containing the motif. C). The scan resulted in 409 protein hits when splice 
variants were excluded (Supplementary Tables 1 and 2). The hits were scored as subcellular localisation 
using FunRich where the majority of the proteins found were membrane proteins (Appendix 3). A large 
proportion of the hits were membrane-related proteins, which foreshadows AGR2 function in receptor 
maturation, D). Representatives of possible AGR2 binding proteins are shown containing the consensus 
peptide-binding motif.  
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Figure 3.11 Functional enrichment analysis of AGR2 linear peptide motif hits using FunRich 
[212]. (A) Bar graph of molecular function overrepresented in AGR2 linear peptide motif hits. (B). Bar 
graph of biological processes overrepresented in AGR2 linear peptide motif hits (C) Bar graph of 
biological pathway overrepresented in AGR2 linear peptide motif hits. Proteins attributed to these 
enrichment were listed in Appendix 3. 
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As such, we focused on validating a key Tx[IL][YF][YF] motif-containing 
transmembrane receptor in this list that also possesses oncogenic activity to form a 
model protein to validate the role of this linear motif on AGR2 binding. This will help 
to understand the role of AGR2 in the secretory landscape of cancer by looking at 
functional consequences of interaction with protein for destined for secretory pathway. 
The receptor EpCAM fits these criteria as it contains a TLIYY motif in its extracellular 
stalk structure near the plasma membrane Figure 3.12A-B).  Positions of the disulphide 
bonds in relation to the single pass transmembrane region and the TLIYY motif are 
shown in Figure 3.12C. Recent proteomics screen of 14 oesophageal adenocarcinomas 
versus two normal tissues biopsies by the Hupp lab identified EpCAM as the most 
independent validated “target” in human cancer as this protein was found to be 
overproduced proteins oesophageal adenocarcinoma [Personal Communication, 213]. 
EpCAM is a type I transmembrane 39–42 kDa glycoprotein that functions as a 
homophilic, epithelial-specific intercellular cell–adhesion molecule [214]. The 314 
amino acid-long EpCAM protein comprises a large extracellular domain with an 
epidermal growth factor (EGF)-like domain and a putative thyroglobulin (TY) domain, 
a single transmembrane region, and a short (26 amino acids) cytoplasmic tail. The 
extracellular domain is sometimes referred to as EpEX, and the intracellular domain is 
sometimes referred to as EpICD. EpCAM has been shown to play role in cell-cell 
adhesion, cell motility, proliferation, survival, carcinogenesis and metastasis 
formation [215]. Overexpression of EpCAM in several types of cancer has been 
associated with poor prognosis [216]. EpCAM has been used as targeted cancer 
immunotherapy. For example, catumaxomab (Removab®) is a monoclonal bispecific 
trifunctional antibody which targeted EpCAM and T-cell receptor CD3 and this was 
approved to be used in the European Union in 2009 [217] for the treatment of patients 
with malignant ascites due to epithelial carcinomas. EpCAM was also used as 
circulating tumour cells (CTC) biomarker [214, 215, 218]. Altogether, this further 
favours EpCAM as a key putative AGR2 interacting protein and if so would shed the 
light the role of AGR2 in maturing membrane-bound proteins destined for secretory 
pathway. 
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Figure 3.12 EpCAM as a candidate for AGR2 client proteins. (A) The secondary structure of 
EpCAM which consists of an N-domain (ND, green), Thyroglobulin type-1 domain (TY, blue) and C-
domain (CD, dark pink) which altogether make up for extracellular part (EpEX), transmembrane 
domain (TM, grey) and intracellular part (EpIC, yellow). B). Three-dimensional cartoon representation 
of extracellular part of human EpCAM (PDB code: 4MZV) highlighting the AGR2 linear peptide motif 
at amino acid position Thr247 to Tyr251 9 (grey). Colour coding is the same as in (A). C). Schematic 
representation of full-length EpCAM protein sequence highlighting the i) extracellular part (EpEX) 
containing thyroglobulin type-1, N domain, C-domain, and AGR2 linear peptide motif ii) 
intramembrane iii) and intracellular part (EpIC). Arrows indicate cleavage site for signal peptide 
between position 23Ala and 24Gln by signal peptidase in the ER lumen and previously reported 
cleavage at Arg80 and Arg81. EpCAM contains three N-glycosylation sites (Asn74, Asn111 and 
Asn198) which are abolished in the crystal structure. EpCAM structure is stabilised by three closely 
spaced intramolecular disulphide bridges (Cys27-Cys46, Cys29-Cys59 and Cys38-Cys48).  
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3.2.3. Validating EpCAM as a specific AGR2 interacting protein 
3.2.3.1. Solid-phase ELISA binding assay 
To test whether AGR2 can interact with EpCAM, we chose to perform in-vitro 
solid phase binding assay which is a protein-protein interaction assay based on  ELISA 
that was previously used as described in Figure 3.8. However, one of the binding 
protein is noncovalently coated by adsorption directly to the well surface of a 96-well 
polystyrene assay plate. The portion of the partner protein bound to the immobilised 
protein is quantified through antibody against the soluble partner protein using 
enzyme-linked immunosorbent assay (ELISA). This binary assay format ideally 
required a  purified form of proteins. Since we have purified AGR2 successfully, we 
plan to purify EpCAM with the same affinity purification method. 
 
3.2.3.2. Purification of EpCAM 
EpCAM is a single-pass membrane protein which consists of an extracellular 
domain (242 amino acids) with an epidermal growth factor (EGF)- and thyroglobulin 
repeat-like domains, a single transmembrane domain (23 amino acids), and a short 
intracellular domain (26 amino acids). Since purifying the entire membrane proteins 
like EpCAM are challenging, only the extracellular part of the protein (first amino acid 
to 265 amino acid) was cloned. This extracellular part (termed EpEX) comprises the 
AGR2 peptide motif ‘TLIYY’ at position 247 to 251 that are sufficient for assaying 
protein-protein interaction in the solid-phase binding assay (Figure 3.13A-B). EpEX 
also was cloned without the N-terminal signal peptide which will be removed during 
EpCAM translation by a signal peptidase in the ER lumen. EpEX was first cloned into 
cleavable His-tag at N-terminal pEHISTEV vector which is expected to be at 32kDa. 
Following transformation into E. coli BL21 (DE3) bacteria and selection, isolated 
colonies were cultured in LB and induced with IPTG. Induction with IPTG at 370C for 
3 hours yield low results (data not shown). The culture was then induced with IPTG at 
room temperature for 4 hours which give slightly better results. Coomasie staining of 
His-EpCAM when induced at room temperature for 4 hours and following his-tag 
affinity purification, showed bands in the elution fraction, however, the protein was 
not highly pure as the elution fractions contain multiple bands (Figure 3.13C). This 
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may be due to post-translational modification, specifically N-glycosylation of the 
protein which can occur in three potential N-linked glycosylation sites as highlighted 
in Figure 3.12C. However, western blot using EpCAM specific antibody showed that 
His-EPCAM is immunoreactive as it can be detected in the elution fractions with the 
correct expected size (Figure 3.13D). There was also a lower minor band that maybe 
corresponds to EpCAM cleavage when running under reductive SDS-PAGE 
conditions possibly at Arg-80/Arg-81 that can be detected by EpCAM antibody 
(antibody epitope at C-terminal of EpCAM) as described by Schnell and colleagues 
[214].  
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Figure 3.13 Purification of recombinant His-EpCAM. (A) Schematic representation of his-tagged 
EpCAM construct highlighting the extracellular domain (EpEX), the TEV cleavage site, and the TLIYY 
motif. (B) DNA and amino acid sequence of His-EpEX construct (C) Coomassie Blue staining of 
purified His-EpCAM showing multiple bands under reducing SDS-PAGE condition. (D) Western blot 
of purified His-EpCAM detecting His-EpCAM at 32kDa. CL= Crude lysate; FT= Flow Through; 
EpCAM=wash; E; Elution. 
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After having a poor EpCAM yield and purity upon affinity purification, we 
decided to use codon optimisation approach which can eliminate codon usage bias in 
certain host organisms such as bacteria. Codon optimisation has been proved to boost 
the levels of mRNA stability and productivity which in turn leads to higher yields of 
the protein [219]. We chose to chemically synthesise EpCAM and have a bacterial 
codon optimisation using GeneArt12 gene synthesis. This technology combines gene 
optimisation where it calculates optimal DNA sequence needed to encode the protein 
of interest and codon optimisation where it uses optimal codon usage of the gene to 
the codon preferences of the selected expression organism. The software evaluates up 
to 50 factors that can compromise mRNA stability, such as extreme GC content, 
ribosomal binding sites, consensus and cryptic splice sites, repeats, and secondary 
structures. The codon optimisation algorithms have shown to increase five different 
classes of protein including membrane protein [219].  
 
EpEx was chemically synthesised and designed to be cloned into pET151/D-
TOPO, harbouring EpEx with N-terminal His-tag (Figure 3.14A). The clone was then 
transformed into E. coli BL-21 (DE3) and the bacterial culture was induced with IPTG 
for 4 hours at room temperature. We also decided to harvest bacterial cells expressing 
EpEx with urea lysis buffer as described in (Material and methods) to maximise 
extraction of EpEx from the cells. Protein purification of His-EpEx showed 
significantly increase in protein yield and purity as Coomasie-blue staining showed a 
major single band at the expected size of 32kDa and the protein was also overexpressed 
in the crude lysates (Figure 3.14C). The  His-EpEx fraction was also functional and 
immunoreactive as it can be detected with specific monoclonal EpCAM antibody in 
western blot despite having undergone harsh lysis buffer during purification (Figure 
3.14D). This proves that the gene optimisation in a specific host organism can result 
in better protein production. 
 
                                                 
12  https://www.thermofisher.com/uk/en/home/life-science/cloning/gene-synthesis/geneart-gene-
synthesis.html# 
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Figure 3.14 Purification of recombinant codon optimized His-EpCAM. (A) Schematic 
representation of chemically synthesized codon optimized his-tagged EpCAM construct highlighting 
the extracellular domain (EpEx), the TEV cleavage site, and the TLIYY motif. (B) DNA and amino 
acid sequence of the bacterial codon optimized His-EpEx construct (C) Coomassie Blue staining of 
purified His-EpCAM showing single major band at 32 kDa under reducing SDS-PAGE condition. (D) 
Western blot of purified His-EpEx detecting His-EpEx at 32kDa. CL= Crude lysate; FT= Flow 
Through; EpCAM=wash; E; Elution. 
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3.2.3.3. Solid-phase binding assay of EpCAM and AGR2 
After having EpCAM and AGR2 purified we can then examine the binding of 
AGR2 and EpCAM in solid-phase ELISA binding assay. First, to make sure that the 
protein is properly coated on the 96-well polystyrene assay plate,  His-AGR2 or  His-
EpCAM were coated overnight in carbonate buffer  at 40C (Materials and methods) 
and the presence of the protein was directly detected by primary antibody followed by 
secondary antibody coupled peroxidase and quantification by chemiluminescence 
(Figure 3.15A-B, see first bar graph on the left and cartoon). The presence of 
immobilised His-AGR2 and His-EpCAM can be observed. Next, His-EpCAM was 
immobilised to the plate and AGR2 was added in the mobile phase and the binding 
was detected by the AGR2 polyclonal antibody (Figure 3.15A). Negative control wells 
were prepared without the addition of AGR2 primary antibody or His-AGR2 in the 
mobile phase to ensure that the binding is not due to unspecific binding of the primary 
antibody or secondary antibody respectively (Figure 3.15A). The results suggest that 
AGR2 was able to bind EpCAM in the solid phase. AGR2 binding to EpCAM also 
was observed when His-AGR2 was immobilised in the plate with EpCAM in the 
mobile phase followed by detection by the AGR2 polyclonal antibody (Figure 3.15B). 
However, the relative light signals were poorly detected compared to when EpCAM 
in the solid phase. We then decided to choose the format when EpCAM is coated to 
the solid phase for assaying binding to AGR2. The results showed that a dose-
dependent titration of AGR2 in the mobile phase with increasing EpCAM protein on 
the solid phase demonstrated that the proteins form stable protein-protein interactions 
(Figure 3.15C). Polyclonal AGR2 antibody K47 was used throughout the thesis unless 
otherwise stated. The specificity of the antibody is validated and shown in Chapter 4 
(Section 4.2.1 and 4.2.2).  
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Figure 3.15 Solid phase ELISA binding assay to measure AGR2 binding to EpCAM protein. Solid 
phase ELISA binding assay was performed to detect the presence of His-AGR2 (A) or His-EpCAM (B) 
adsorbed on a solid phase. When soluble EpCAM (B) or AGR2 (A)  is added to immobilise AGR2 or 
EpCAM respectively, binding activity is observed as a relative light unit. Controls were run to ensure 
the binding is not due to unspecific binding of the secondary or primary antibody to AGR2 as shown in 
the schematic. (C) Increasing amounts of EpCAM were immobilised on the surface of a microtiter plate 
(0-1 µg). AGR2 (0-1 µg) was titrated in the mobile phase and AGR2 binding to immobilised EpCAM 
was quantified using AGR2 specific antibody. The binding of AGR2 is plotted as the extent of protein-
protein complex formation as RLU as a function of increasing protein in the mobile phase. The 
experiment was carried out in triplicate in four independent experiments, and data are representative of 
one experiment. The bars represent standard error of the mean (SEM).   
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Previously, AGR2 original phage display binding peptide was a 12-mer 
HLPTTIYYGPPG [209].  Truncation of the 12-mer from the N-terminal showed that 
the presence first Pro (P) residue was critical for AGR2 binding. However, this 
position was adaptable in its identity, where alanine scan showed that mutation of Pro 
(P) to Ala (A) did not significantly affect binding to AGR2. Similarly,  truncation of 
the 12-mer from the C-terminal demonstrated that hydrophobic amino acid  Tyr-Tyr 
(YY) is required for AGR2-binding, reducing the core binding motif to hexapeptide 
PTTIYY. When the 12-mer was mutagenized from tyrosine (Y) at the last position of 
hexapeptide to Ala (HLPTTIYAGPPG) dramatically reduce binding to AGR2 [209]. 
However, when the minimal peptide PTTIYY was mutagenized (Y to A) mutation at 
position 6 in this study can attenuate, but not abrogate, AGR2 binding to the synthetic 
hexapeptides (Figure 3.10A). Since EpCAM was found based on this motif with the 
sequence TLIYY, it is interesting to see if the mutation has the same effect as the 
AGR2 binding motif. His-EpCAM was then subjected to site-directed mutagenesis in 
which the Tyr-251 was mutated to alanine to create the TLIYA motif (Figure 3.16A, 
upper panel).  His-EpCAMY251A was then purified the same way as its wild-type 
counterpart. Purification of His-EpCAMY251A showed relatively similar yield and 
purity and produced a major single band at 32kDa when stained with coomasie blue 
(Figure 3.16A, lower panel) and the proteins can also be detected with EpCAM 
antibody as analysed using western blot (Figure 3.16B). A titration of AGR2 against 
the wt-EpCAM or EpCAMY251A demonstrated that AGR2 binding was also attenuated 
on EpCAMY251A (Figure 3.16C). These data highlight at least one-binding site on 
EpCAM for AGR2 protein.  
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Figure 3.16 Mutagenesis, purification of His-EpCAMY251A and binding to His-AGR2. (A) Top 
panel - DNA sequencing chromatogram traces of EpCAMY251A. Bottom panel- Coomassie Blue 
staining of purified His- EpCAMY251A mutant protein showing a major band at 32 kDa under denaturing 
SDS-PAGE and western blot detected the same protein (B). CL= Crude lysate; FT= Flow Through; 
EpCAM=wash; E; Elution. (C) His-EpCAM or His-EpCAMY251A (1 µg) was immobilised onto the well 
surface of a microtiter plate. His-AGR2 WT (0-1 µg) was titrated in the mobile phase. AGR2 binding 
to immobilised EpCAM was quantified using AGR2 specific antibody. The binding is plotted as the 
extent of protein-protein complex formation as RLU as a function of increasing protein in the mobile 
phase. 
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3.2.3.4. Effect of mutation of the peptide-docking site on AGR2 in 
EpCAM protein binding. 
The three docking site AGR2 mutants (D132A, P133A, and S134A) that 
exhibit neutral or attenuated binding to the synthetic peptide PTTIYY were evaluated 
in EpCAM protein binding to determine the effects of these mutations on the 
AGR2:EpCAM protein-protein interaction. The AGR2:EpCAM binding reaction 
revealed a gain-of-function of all three mutants relative to wt-AGR2, with AGR2S134A 
exhibiting the most elevated gain-of-function activity (Figure 3.17A). As AGR2 has a 
thioredoxin domain that can form covalent bonds with client receptors such as mucins 
[60], it can be expected that we evaluate the impact of reductant on its biochemical 
function. For example, the AGR2C81S mutant is as active as wt-AGR2 in stimulating 
ex-vivo cell growth [180]. Dithiothreitol (DTT) is a reducing agent which can be used 
to reduce the disulphide bond. The addition of DTT can determine whether disulphide 
bond contributes to the binding of AGR2 and EpCAM. The inclusion of DTT into 
reactions at the AGR2-binding stage (Figure 3.17A and B), surprisingly, exacerbated 
the differences between the mutants and wt AGR2, with the S134A followed by the 
D132A mutants exhibiting the most pronounced gain-of-function activity (Figure 
3.17B and C). 
 
We next staged this effect of reductant by including DTT only in the blocking 
stage, after EpCAM absorption, but before AGR2 binding (Figure 3.17D). This 
addresses whether this effect is due to an altered redox-imposed conformation of the 
substrate, EpCAM or the chaperone, AGR2.  The incubation of DTT in the blocking 
step (Figure 3.17D, upper panel) is the stage at which the effect of the S134A mutant 
of AGR2 shows the most dramatic difference compared to wt-AGR2 (Figure 3.17D, 
lower panel).  These data suggest that oxidised EpCAM, rather than AGR2, attenuates 
the impact of peptide docking site mutations on AGR2 functions. These data also 
suggest that the conformation of AGR2S134A is altered to drive it into a “docking-
independent” activity towards a second, oxidation-sensitive binding site on EpCAM. 
For example, this alternate AGR2-binding site on EpCAM is apparently sensitive to 
its redox state.  
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Figure 3.17 Effect of AGR2 peptide docking mutants binding to EpCAM. (A) His-EpCAM was 
immobilised onto the well surface of a microtiter plate. Titration of AGR2 WT and mutants (0-0.5 µg) 
were added in mobile phase and AGR2 binding without (A) and with 1mM DTT (B) to immobilised 
EpCAM was quantified using a specific AGR2 antibody. The binding is plotted as the extent of protein-
protein complex formation in RLU as a function of increasing protein in the mobile phase. Reactions in 
(A) have no DTT included in the AGR2-binding reactions and (B) includes DTT at the stage of addition 
of AGR2 binding to reveal any effects of potential cysteine oxidation on protein-protein interactions (as 
highlighted in C where both AGR2 and EpCAM should be in the reduced state). (D) Staging the effects 
of DTT by including reductant in the blocking step to determine whether the DTT effect (from B) on 
the reaction is due to EpCAM substrate and not AGR2 itself.  (E) A titration of wt-AGR2 and 
AGR2S134A in the presence or absence of reductant in the blocking stage.  As in (A and B), the binding 
was plotted as the extent of protein-protein complex formation in RLU as a function of increasing 
protein in the mobile phase.  
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3.2.3.5. Evaluation of AGR2S134A conformational change by 
hydrogen-deuterium exchange mass spectrometry  
To evaluate whether AGR2S134A does in fact, have an altered conformation, 
hydrogen-deuterium exchange mass spectrometry was used to probe its overall 
interaction with solvent. The wild-type and AGR2S134A mutant proteins were diluted 
with D2O and quenched from 30 seconds to 10,800 seconds post dilution.  Relative to 
wt-AGR2, there was enhanced deuteration at several regions throughout the mutated 
AGR2S134A protein (Figure 3.18 A-F for representative peptic fragments and Appendix 
4). The most pronounced changes were observed at the dimer interface (aa 51-71) and 
at the peptide-docking site (aa 131-141) (Figure 3.18 G-I).  For instance, the relatively 
selective and enhanced deuteration of the peptide-binding domain at the 30-second site 
point (Figure 3.18G) suggests the region is intrinsically more solvent exposed, 
although this does not prevent binding to the PTTIYY peptide. However, the 
pronounced exposure of the dimer interface at later time points (Figure 3.18H and I) 
to solvent suggests allosteric effects of the AGR2S134A mutation impact on a monomer-
dimer equilibrium that in turn expose the dimer motif to solvent. Indeed, at early time 
points after deuteration, when the protein is diluted 10 fold into D2O, there is little 
difference in deuteration at the dimer interface. Thus, we would suggest that allosteric 
effects in the AGR2S134A peptide-docking site could impact on monomer-dimer 
equilibrium. For example, the 10-fold dilution of AGR2 (at a starting concentration of 
3 M before dilution with D2O and 0.3 uM after dilution) will take its final 
concentration lower than its published Kd of 8.8 M [61]. Thus, such a dilution that is 
intrinsic to the deuterium exchange methodology will shift AGR2 into its monomeric 
state. Consequently, in the ELISA reaction measuring EpCAM binding, the wt-AGR2 
and AGR2S134A proteins are diluted to a final concentration from 0.01 to 0.2 M where 
we would expect AGR2S134A to be more conformationally altered and explaining in 
part its gain-of-function activity towards EpCAM. Together, our biochemical data 
define a dominant peptide-binding pocket on AGR2 and highlight that mutation of this 
motif is not localised but it can impact on heterologous protein-protein interaction such 
as EpCAM protein.  
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Figure 3.18 Measuring conformational changes in the gain-of-function mutant AGR2S134A using 
hydrogen-deuterium mass spectrometry. Wt-AGR2 or AGR2S134A was deuterated over a 7-point time 
course from 30 seconds to 10,800 seconds followed by acidification, pepsinisation, and separation of 
fragments using mass spectrometry (Supplementary Figure 3) (A-C). Representative peptic ions of 
AGR2 protein that do not exhibit significant changes in deuteration between wt and mutant AGR2S134A 
(D-F). Representative peptic ions of AGR2 protein that do exhibit significant changes in deuteration 
between wt and mutant AGR2S134A. The data are plotted as % of deuteron exchange as a function of 
time (log10 in seconds; from 30, 60, 180, 600, 1800, 3600, and 10800). The deuterium exchange rates 
of individual peptides are summarised using the HDX exchange plots for (G) 30 seconds (H) 600 
seconds, and (I) 3,600 seconds time course. In (G), we highlight that the most noticeable difference is 
enhanced deuteration at the “peptide binding domain”, including aa 131-135. However, at elevated 
times of deuteration (H-I), there is apparent exposure of the dimerization domain and the peptide-
binding loop to solvent, suggestive of a global conformational change induced by the S134A mutation.  
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3.3. Discussion 
To understand the diverse biological functions of AGR2, the discovery of 
AGR2 interacting proteins is required to provide mechanistic insights. Yeast-two 
hybrid methods have identified potentially important AGR2-binding proteins. The first 
yeast-two hybrid identified the membrane receptor and pro-metastatic protein 
Dystroglycan/C4.4a as an AGR2 interactor [58] and that the newt homologue of AGR2 
was shown to bind to the receptor Prod1 [54].  These data are consistent with the 
paradigm that AGR2 stimulates receptor maturation linked to growth or adhesion [94].  
Another yeast-two hybrid screen revealed that AGR2 could bind not only to membrane 
receptors but many nuclear proteins such as RIP140 and Reptin, which might reflect a 
role for the form of AGR2 that escapes the endoplasmic reticulum through its non-
canonical KDEL retention sequence [220].  The most well characterised AGR2 
binding interactor is the AAA+ superfamily chaperone protein Reptin [105] [221] [97]. 
However, perhaps the most intriguing biochemical interaction function for AGR2 is in 
its intrinsic sequence-specific peptide binding activity [209]. In this chapter we exploit 
this specific “peptide-binding” function of AGR2 to propose a consensus-binding 
motif for its client proteins. 
 
The majority of protein sequence information in higher eukaryotes is encoded 
by the “linear motif”; perhaps millions of such motifs are comprised of small stretches 
of amino acids that drive weak but specific protein-protein interactions. A powerful 
tool to define the linear motif repertoire for a protein is the peptide-phage 
combinatorial library [222]. This methodology has been used to define the peptide 
consensus motif for the peptide binding groove of the oncoprotein MDM2 [223]. This 
information stimulated the development of peptide mimetics that inhibit MDM2 in-
vivo [224] [225].When AGR2 was subjected to a peptide-phage library screen, a 
pentapeptide docking motif emerged as TTIYY [209].  There were two distinct 
peptides selected in this study, but we have only focused on the one with the TTIYY 
motif.  Synthetic peptides with this TTIYY motif could affinity purify AGR2 from cell 
lines (Figure 3.3) or human tissue biopsies with a high specificity [209] suggesting it 
could act as a highly specific recognition motif for AGR2 target proteins. This suggests 
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that the peptide could act as a highly specific recognition motif for AGR2 target 
proteins.     
 
In this chapter, we apply hydrogen-deuterium exchange mass spectrometry to 
determine whether we can identify a specific binding site of the TTIYY containing 
peptide on AGR2. We identify a small region from aa 131-135 in AGR2 as the likely, 
primary binding site for TTIYY motif-containing peptides since it is here we see the 
most significant deuterium suppression after peptide binding (Figure 3.8 and Figure 
3.9). Additional residues C-terminal to the 131-135 aa motif, including 
RADITGRYSNRL, also show deuterium suppression by the consensus site peptide 
A4, however, this region was not evaluated. We focused on aa 131-135 since this 
represents an exposed surface unstructured turn that might form a binding finger into 
hydrophobic TTIYY docking sites. To further validate this data, we found that upon 
mutating the motif, we could create a set of mutants with the loss of function on 
synthetic peptides (Figure 3.9), suggesting that this motif is the major peptide-docking 
site. By contrast, the same series of AGR2 mutant proteins exhibited an inverse gain-
of-function activity on the client protein EpCAM (Figure 3.19) whose interpretation is 
complicated due to the oxidation-dependent resilience of EpCAM to this AGR2 
mutant series (Figure 3.17). Nevertheless, the ability to create a loss or gain-of-
function mutations in this region suggests that it not only provides a major primary 
interaction site but that the conformation of this region can allosterically affect other 
regions that impact on monomer-dimer equilibrium. The enhanced binding of EpCAM 
to this S134A mutant, in particular, suggests that AGR2 might have a secondary 
binding site on EpCAM that is stabilised by the altered conformation of the S134A 
mutant. This potential secondary site appears to play only a minor role on wt-AGR2 
protein since the EpCAMY251A mutation attenuates wt-AGR2 (Figure 3.16).   
 
The human proteome was scanned for proteins containing this motif in order 
to produce a set of potential AGR2-client proteins and there was a relative enrichment 
in transmembrane proteins (Figure 3.10). There is a degree of specificity in this peptide 
motif, as a prior selection of peptides from phage libraries to p300 identified PxxP 
motif proteins that predominate in transcription factors like SMAD4 and p53 [226]. 
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However, none of the AGR2 client proteins identified in previous studies overlap with 
our method of identification, suggesting that our method is exclusive in determining 
novel AGR2 client proteins. This provides a complementing approach to the yeast-two 
hybrid and immunoprecipitation methodology to identify new interacting proteins by 
exploiting the linear peptide motif as a common type of protein-protein interaction 
[196].Most of the membrane proteins identified from the database mining possess the 
motif at their extracellular domain. Nascent protein chains that translocate into the ER 
associate with specific ER luminal proteins, which in turn ensures proper folding and 
post-translational modifications. Since AGR2 localises in the ER lumen, AGR2 might 
be one of the key proteins in aiding protein maturation suggesting that protein-protein 
interaction may occur in the ER.  
 
EpCAM was chosen as the target of choice and its paralogue (TACD2) also 
shows identity in this region (Figure 3.11). In this chapter we only showed using 
ELISA that purified AGR2 and EpCAM can interact with each other. It is also 
noteworthy in the future to perform Circular Dichroism (CD) spectroscopy studies of 
EpCAM and its tyrosine mutant in binding to AGR2 in the future. CD is a biophysical 
quantitative technique in which the CD of molecules is measured over a range of 
wavelengths.  This method can determine whether there are changes in the structural 
integrity of proteins when they interact by looking at the changes in CD spectra which 
gives evidence that there is a direct binding. However, CD requires relatively large 
amounts of proteins for such biophysical studies which could be optimised by 
purification in insect cells. The consensus motif within EpCAM forms a β-strand 
within the main α-β fold in the EpCAM structure defined by PDB (4MZV) and this 
located in the extracellular region. It has been noted that linear motifs can reside within 
intrinsically disordered domains or they can reside within structural domains [206]. In 
the case of the linear motif within disordered regions, it is known that they can acquire 
distinct secondary structures depending upon the nature of the protein-interaction. If 
the linear motif resides within a structural domain, the protein-protein interaction 
presumably requires an alternate conformation at the target site. Using EpCAM as a 
model, we can speculate that AGR2 might interact with an unfolded version of 
EPCAM as the receptor is being assembled in the ER. This is also consistent with our 
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in-vitro protein-protein interaction assay using ELISA in which we used non-
glycosylated EpCAM. This is because we used bacterial host (E. coli) which lacks an 
N-glycosylation system for our protein purification. We chose this purification as it is 
easy to make rather than using mammalian insect cells, and perhaps since AGR2 is 
also purified from the bacterial host system. Based on ELISA results, AGR2 can bind 
to non-glycosylated EpCAM which suggests that the interaction occurs in the ER prior 
to glycosylation. However it is also possible that carbohydrate attached to glycosylated 
EpCAM is involved in the interaction since EpCAM possesses three N-linked 
glycosylation sites. The presence of carbohydrate can modify its tertiary structure or 
its presence obscures parts of the protein to which AGR2 protein would bind in its 
absence.  In addition EpCAM was shown to be hyperglycosylated in carcinoma tissue 
as compared with autologous normal epithelial, and glycosylated EpCAM 
demonstrated a degree of tissue specificity [227] and was shown to be crucial for 
tumour stability [228]. Therefore, it would be appealing to establish whether EpCAM 
glycosylation has any effect in binding to pro-oncogenic AGR2 or whether AGR2 has 
any role in the glycosylation of EpCAM in the future. In addition, EpCAM can be 
cleaved producing intracellular domain (EpICD) and extracellular part (EpEx) by an 
intramembrane proteolysis [229, 230]. The EpEx fragment has been found in 
microvesicles (e.g., exosomes) which represent potential signals that can migrate from 
cell to cell inside of the same organ or circulate into the bloodstream to distant organs. 
Since EpEx fragment contains AGR2 peptide motif and the fact that AGR2 can be 
secreted, it would be interesting to study the relationship of the extracellular role of 
AGR2 and EpCAM in tumour signalling. Intriguingly, a recent study described the 
unexpected role of an extracellular AGR2 (eAGR2) as a regulator of epithelial 
tumorigenesis and morphogenesis [180] suggesting another role of AGR2 in cancer 
development.   Alternatively, AGR2 might interact with the receptor as receptor 
conformation is altered especially as the peptide-docking site is near single-pass 
transmembrane domain.  We can also speculate that since the docking site is in the C-
terminus of EpCAM N-terminal to the single pass transmembrane domain,   if AGR2 
binds to this inside the ER, the motif could impact upon how the protein folds as the 
C-terminus is synthesised into the ER membrane. The docking site might facilitate a 
lower off-rate for AGR2 on EpCAM inside the ER to allow the correct formation of 
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key disulphide bonds. Alternatively, the docking site might facilitate AGR2-mediated 
transport of EpCAM cargo as it is transported to the plasma membrane.  A key 
observation is that in cells, the EpCAMY251A mutant protein fails to reach its normal 
plasma membrane destination, but is present in the cytosol or nuclear membrane (will 
be discussed in Chapter 4). There is a redox component to this docking site in-vitro 
(Figure 3.18), suggesting that disulphide bridge formation in the EpCAM protein can 
impact on how AGR2 binds in cells, although cell-based disulphide shuttling assays 
might be more difficult to reconstitute in cell systems.  Future cell-based assay 
developments can impact on understanding how the EpCAM docking site (aa 247-
251) facilitates its maturation or trafficking and how the AGR2-peptide binding motif 
impacts upon client protein maturation.  For example, it would be interesting to 
generate a gain-of-function AGR2S134A or cysteine-mutated EpCAM cell line using 
CRISPR/Cas9 gene editing cancer to measure changes influx of EpCAM receptor 
maturation as a result of such mutations.  
 
To conclude, we have provided a methodology to exploit the linear peptide 
motif as a tool to discover new protein-protein interactions for a target protein This 
includes mapping a specific site on AGR2 protein implicated in sequence-specific 
peptide binding and suggest a function for this motif in client proteins is to ensure 
proper maturation for its final destination. Transmembrane proteins are proposed to be 
the dominant class of proteins with such a motif and it will be interesting to stratify 
such “PTTIYY” motif containing proteins for AGR2-dependent maturation. Although 
these data provide an intracellular function for AGR2, it is interesting to note that on 
EpCAM, the AGR2 docking site is extracellular (Figure 3.12). Given the recent 
extracellular role for AGR2 in cancer cell growth [180], these data also suggest that 
AGR2 might function as an extracellular ligand to impact on EpCAM signalling in 
cells. Most of the work in this chapter utilises in-vitro biochemical approaches and 
there is no evidence whether AGR2 and EpCAM are indeed interacted with each other. 
Therefore, it is important to find such evidence in-vivo. This also serves as proof that 
our method of discovering client proteins is valid. In the next Chapter, we discuss 
protein-protein interaction assays in cells and utilises some of the techniques to further 
validate our AGR2-EpCAM interaction. 
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Figure 3.19 . Summary of the biochemical properties of the peptide-docking site mutations in 
AGR2 produced based on hydrogen-deuterium exchange mapping. Based on the hydrogen-
deuterium exchange mapping data (Figure 4 and 5), we focused on creating three alanine substitutions 
mutations in the VDPSL loop motif, from aa 131-135, residing between two β-sheets (Figure 6). The 
mutant proteins exhibit inverse trends in their specific activity. Consensus peptide binding reactions 
demonstrate that wt-AGR2=S134A>D132A>P133A with two mutants showing a loss-of-function. 
Whilst in EpCAM binding, S134A>D132A>P133A=wt-AGR2 with two mutants showing a gain-of-
function. These data suggest that although mutating some amino acids in the VDPSL motif can impact 
on specific peptide binding, the global conformation changed induced by loop mutation (for example in 
the gain-of-function S134A mutation (Figure 11) results in binding to a distinct site on the EpCAM 
molecule. These data thus suggest that one purpose of the VDPSL motif is to not only drive specific-
peptide binding by AGR2 but to allosterically constrain the conformational dynamics (or monomer-
dimer equilibrium) of AGR2 so as to minimise its “binding to other sites” on its client protein
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CHAPTER 4: Cell-Based Analysis of AGR2 and EpCAM 
Interaction 
4.1. Introduction 
4.1.1. Protein-protein interaction networks 
The completion of the human genome project has provided an immense 
amount of information that aimed to generate a comprehensive picture of all relevant 
genotypic variations in the human population. For example, many polymorphisms 
associated with disease have been linked to Mendelian disorders [231]and over one 
hundred thousand alleles have been implicated in at least one disorder [232]. In 
addition, a large number of susceptibility loci have been identified for hundreds of 
complex traits [233]. Despite the massive information of genomics sequences, the 
connection between genotype and phenotype is still not fully understood [234], 
especially for multifaceted trait loci and cancer-associated mutations. Even if the 
phenotype is known, the mechanism of how mutation perturbs the function of the 
corresponding gene or gene product is not fully understood. To understand the 
genotype-phenotype relationship, functions and context must be assigned to large 
numbers of genotypic changes. 
 
Cellular systems are connected through interactions among genes and gene 
products, or interactome networks, which represent most cellular functions [234]. 
Thus, to understand a comprehensive understanding of genotype-phenotype 
relationships in human, mechanistic descriptions of how interactome networks are 
distressed as a result of genomic susceptibilities are necessary. This may be achieved 
by building high quality and extensive genome and proteome-scale maps of 
macromolecular interactions such as protein-protein interactions (PPIs), protein-
nucleic acid interactions, and post-translational modifiers and their targets. 
 
Initial analysis of human genome estimated about 30,000–40,000 protein-
coding genes existed in the human genome [235] and a subset of 10 000 proteins can 
be produced by the cell at any given time (termed proteome) [109]. This number could 
be underestimated due to alternative splicing that could create a larger number of 
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protein products. The functions of numerous of these proteins are not known to 
understand the dynamics of the human organism. 
 
Protein-protein interactions (PPIs) are intrinsic to virtually every cellular 
process. Proteins are products of intertwined DNA and RNA regulations that facilitate 
most biological processes in a cell, including gene expression, cell growth, 
proliferation, nutrient uptake, morphology, motility, intercellular communication and 
apoptosis. Cells can respond to a numerous of external stimuli, which in turn dictates 
the expression or activation of specified proteins to perform the biological tasks. In 
addition, cells are varied, and many proteins are expressed in a cell type-dependent 
manner. Hence, these basic properties of proteins suggest a complexity that can be 
difficult to investigate, especially when trying to understand protein function in 
broader biological context. 
 
Conventionally, protein function analyses were mainly focused on single 
isolated species [236]. However, this is not the case. It has been revealed that over 
80% of proteins operate in complexes for proper function [109]. Therefore, the study 
of PPIs is imperative to fully understand protein function within the cell. For example, 
the functionality or behaviour of unknown proteins can be foretold on the evidence of 
their interaction with a known protein function.  Phizicky and Fields describe several 
important outcomes of PPIs [110] and these include; (i) altering the kinetic properties 
of proteins; (ii) permitting substrate channeling; (iii) creating new binding site for 
small effector molecules;(iv) inactivating or suppressing a protein; (v) changing the 
specificity of a protein for its substrate through interaction with different binding 
partners; (vi) or providing an upstream or downstream regulatory role.  
 
One of the advantages of studying protein-protein interaction is that it led to 
the identification of drug targets [237]. Proteins can involve a larger number of 
interactions built up by highly connected nodes (hubs) which can include families of 
enzymes, transcription factors, and intrinsically disordered proteins and many poorly 
connected nodes [238, 239]. Each node receives inputs and produces one or more 
specific outputs. This suggests that the latitude of PPIs regulation is large and may 
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represent more diverse processes. To accurately understand their importance in the 
cell, various interactions of a particular protein and the outcome of the interactions 
need to be taken into account. 
 
The technology advancement has been driven by the high-throughput 
experimental methods, which has made the identification of proteins a relatively 
simple task. This high-throughput experimental approach includes mass spectrometry, 
yeast two-hybrid system, combinatorial phage-display and protein chip technology. 
Mass spectrometry, for example, can be used not only to identify individual proteins 
but also to characterise protein complex [240]. However, the massive discovery of 
these newly protein binders has not been fully validated. Conceivably, in recent years, 
computational analysis (in-silico approach) has gradually becoming popular to predict 
client proteins and to understand the function of unknown proteins[241].  
 
4.1.2. AGR2 Protein-protein interaction networks. 
Yeast-two hybrid (Y2H) and co-immunoprecipitation, two commonly used 
assays to study protein-protein interaction, have largely driven the comprehensive 
discovery of AGR2 binding proteins. For example, MUC2, a large, cysteine-rich 
glycoprotein that forms the protective mucus gel lining the intestine, was found by 
immunoprecipitation with AGR2, suggesting AGR2 involvement in mucin processing 
[60]. Studies using Y2H showed that human AGR2 can interact with the metastasis-
associated GPI-anchored C4.4a protein and extracellular alpha-dystroglycan (DAG-1) 
[58] and membrane receptor Prod1 [54]. These data showed that AGR2 plays a pivotal 
role in the secretion of the receptor protein that is linked to adhesion and cell growth. 
The majority of studies only focused on the direct interaction of AGR2 and its client 
proteins, without fully interrogating the molecular mechanism of the interaction. It is 
important to note that Y2H is prone to error as numerous false positive discovery have 
been pointed out, thus detailed validation of partners is necessary to demonstrate 
biological significance [242]. Perhaps, there are many proteins identified as an AGR2 
binding partner from Y2H studies but only a few were thoroughly validated [94]. 
Reptin is the AAA+ ATPase protein and the only AGR2 client protein found in the 
Y2H screen that has been thoroughly studied [105]. The AGR2:Reptin interaction is 
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based on ATP-de-stabilising manner, was mapped to a peptide interface comprising 
the proposed substrate-binding loop on AGR2, within amino acids F104 to Y111,  that 
is shared with a binding loop of ERP18. Amino acid mutagenesis at that positions 
attenuates Reptin binding to the AGR2. Later it was shown that Reptin participated in 
the cytosolic regulatory protein-folding complexes through the chaperone-dependent 
R2TP activity  [106] and in cilia complex assembly at the plasma membrane [107] that 
may drag AGR2 involvement.  
 
In this study, we exploited the high-affinity AGR2 binding peptide from 
previous phage-peptide library data to expand potential AGR2 client proteins. We 
further characterised the binding peptide, in which we mapped the peptide docking site 
using hydrogen-deuterium exchange mass spectrometry, suggesting aa 131-135 on 
AGR2 is the primary peptide docking site (Chapter 3). We then developed a consensus 
site (TxIL[YF][YF]) for its activity and performed human proteome database mining 
using to identify potential cellular proteins that harbour this motif as potential AGR2 
client proteins. Transmembrane/receptor proteins were identified as a dominant type 
of proteins with potential AGR2 docking sites. These findings are consistent with the 
concept that AGR2 can mediate secretion of receptors linked to adhesion and cell 
growth[94, 116]. We validated one key protein-protein interaction, represented by 
AGR2 and the oncogenic receptor EpCAM (containing TLIYY motif) and suggested 
one function for this sequence-specific peptide binding is to drive an interaction with 
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4.1.3. Aims of Chapter 
In the previous chapter, a membrane-bound EpCAM protein was validated as 
an AGR2 interacting partner using in-vitro biochemical cell-free systems. This 
technique such as an ELISA is rather a simple and direct method for the analysis of 
protein-protein interactions. However, the dynamics of protein-protein interaction in 
cellular context might be more complex. Therefore, in this chapter, we aim to find 
evidence that AGR2 and EpCAM interact in cell system and if so, we aim to further 
characterise the interaction. This will help us understand the molecular role of AGR2 
in trafficking a protein destined for secretory pathway and find a mechanism of such 
interaction. A panel of cancer cell lines was screened to establish cell lines that express 
or do not express AGR2 and/or EpCAM to serve as cancer models. Cell-based PPIs 
methods such as an in-situ proximity ligation assay and colocalisation of fluorescently-
tagged AGR2 and EpCAM using confocal microscopy were performed. We also aim 
to exploit the FLO-1 cells (AGR2-/EpCAM-) in a reconstitution studies. The FLO-1 
cells were used to reconstitute AGR2 and EpCAM expression to assess the localisation 
of each protein, and investigate how an ER-resident protein AGR2 can regulate and 
determine EpCAM expression and localisation. The final aim of this chapter was to 
assess the expression of AGR2 and EpCAM in tumour clinical samples and find 
evidence that two proteins are co-expressed using immunohistochemistry.  
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4.2. Results 
4.2.1. Identification of AGR2 expressing cell lines as cancer models 
 Human cell lines derived from tumour biopsies are the most frequently 
employed models in cancer research and their use has facilitated the understanding of 
cancer biology. Cell lines offer the advantages such as easy to maintain and 
propagated, relatively inexpensive, and accessible to high-throughput testing of 
therapeutic agents [243]. Data generated from cell lines can then be extrapolated to in-
vivo human and provide models for drug testing and translational study. In fact, AGR2 
was first identified in mammalian studies in oestrogen receptor-positive breast cancer 
cells [126]. Therefore, it is important in this study to establish a cell line for proper 
expression of the specific protein  (i.e whether the cell line expresses a target protein 
where its pathway is intact or vice versa) in order to fundamentally study the cellular 
pathways and to unveil critical genes especially those relating to its interactome in 
cancer.  
 
A panel of cell lines containing breast cancer cell line MCF-7 and oesophageal 
adenocarcinoma; OE19, OE33 and FLO-1 were tested to assess the basal expression 
level (if any) of AGR2 and its putative binding partner EpCAM using specific AGR2 
and EpCAM antibodies in western blot (Figure 4.1A). Western blot using rabbit 
polyclonal AGR2 K47 (Moravian Biotechnology) exhibited that MCF-7, OE33 and 
OE19 expressed AGR2 while FLO-1 cells did not express detectable expression of 
AGR2 (Figure 4.1A). OE19 relatively showed the highest expression of AGR2 
followed by OE33 and MCF-7. Western blot analysis using EpCAM mouse 
monoclonal antibody (Calbiochem), EpCAM showed a similar pattern of expression 
in the cancer panels, where MCF-7, OE33 and OE19 are positive for EpCAM (Figure 
4.1A). Interestingly, FLO-1 cells were also absent for EpCAM and this can serve a 
very good negative control or can be used for reconstitution complex studies for 
manipulating AGR2 and EpCAM protein-protein interaction assays in cells.  Mouse 
monoclonal p53 (DO-1) antibody was also used on the same blot to examine p53 status 
in relation to AGR2 and EpCAM expression (Figure 4.1A). All the oesophageal 
adenocarcinoma cell lines contain mutated p53 while MCF-7 breast cancer cell lines 
have wild-type p53 [244, 245].  
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 The specificity of AGR2 antibody was validated using short interfering RNA 
(siRNA) that targets AGR2. A set of siRNA to AGR2 (FlexiTube GeneSolution 
GS10551, Qiagen) and siRNA control was acquired (AllStars Negative Controls 
FlexiTube siRNA, 1027280, Qiagen) and transfected into a panel of cell line (Figure 
4.1B). After incubation of 72 hours, the cells were analysed using western blot using 
AGR2 K47 antibody. AGR2 can be knocked down using siRNA 1 and 2 and to some 
extent siRNA 4 in MCF-7 and OE-33, where most knockdown was seen in MCF-7 
compared to control siRNA or non-transfected controls (Figure 4.1B). However, 
AGR2 cannot be knockdown in OE-19 using the same siRNA set. As shown in western 
blot, OE19 expressed a high amount of AGR2 which might need a higher amount of 
siRNA and longer incubation to bypass the positive steady-state regulation of 
AGR2(Figure 4.1B). This data altogether, validated the use of AGR2 rabbit polyclonal 
K47 and band correspond to western blot was AGR2-specific. 
 
 We next examined the localisation of AGR2 and its client protein EpCAM in 
MCF-7 using immunofluorescence (Figure 4.1 C-D). MCF7 cells lines were stained 
with the same antibody anti-AGR2 K47 polyclonal and anti-EpCAM monoclonal 
antibodies. Using confocal microscopy, the localisation of endogenous AGR2 showed 
diffuse distribution and observe as punctate in the cytoplasm or specifically in the ER 
as previously shown [Fourtouna et al., 2009] (Figure 4.1 C). EpCAM was seen to 
localise mainly in the cell membrane and partially in the cytoplasm which consistent 
of a typical membrane protein localisation (Figure 4.1 D). These results served further 
evidence that the AGR2 and EpCAM antibodies were specific. 
 
4.2.2. AGR2 and EpCAM interaction using in situ proximity ligation 
assay 
Proximity ligation assay (PLA) is a recent development of detecting protein-
protein interactions (Figure 4.2). It was first described by Fredriksson and colleagues 
in 2002 [246] and modified by Söderberg and colleagues et al. [247]. The PLA 
technique utilises simultaneous recognition of oligonucleotide labelled antibodies 
binding in close proximity (30-40 nm apart) by pairs of affinity probes of the same 
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protein or two proteins in a complex. Thus, the advantage of the proximity ligation 
assay is that it can detect an authentic endogenous protein-protein complex in situ and 
it does not rely on transfected or non-physiologically-tagged protein vectors. The assay 
can also be used to quantify protein and modification of proteins in fixed cells and 
tissue samples. Two primary antibodies raised in different species (such as one mouse 
and one rabbit antibody) are used to detect two target antigens (Figure 4.2). Two 
additional species-specific secondary antibodies are then introduced. The secondary 
antibodies are attached to unique DNA strands that serve as a template for 
hybridization of added oligonucleotides. If the two proteins are in close proximity (30-
40nm) the oligonucleotides are ligated by ligase, leading to the formation of a circular, 
single-stranded DNA molecule. The DNA circles, in turn, provide templates for rolling 
circle amplification (RCA) by DNA polymerase. The addition of fluorescent probes 
then allows individual interacting pairs of protein molecules to be visualised with a 
fluorescent microscope. The main disadvantage of PLA is cross-reactivity and 
nonspecific adsorption, which sets the limit for the selectivity of such assays. Another 
drawback of PLA is that the concentration of proximity probes must be kept minimal 
in order to prevent unwanted background signals originating from accidental 
proximity of non-bound probes. Furthermore, since PLA can permit identification of 
pairs of antibodies located within less than approximately 40 nm which is higher than 
standard light microscopy (approximately 200nm), this resolution is still lower than 
that of FRET which detects molecular interactions at a distance of even below 0.5 nm 
[248]. This suggests that the two interacting proteins might be in a larger protein 
complex in which there are other interconnecting proteins in between. 
 
Prior to evaluating the impact of AGR2 on EpCAM expression in cells, we first 
determined whether endogenous, authentically expressed AGR2 and EpCAM can 
form protein-protein interactions in situ using PLA. First, we required the use of cancer 
cell lines where AGR2 and EpCAM show mutual expression and where their pathways 
are presumably intact.  In screening for cell lines that contain AGR2 and 
EpCAM (Figure 4.1A), we focused on the use of MCF7 cells since they express both 
proteins and have a wt-p53 pathway allowing for future impacts of AGR2 on p53 
activity [249].   
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Figure 4.1 Expression of pro-oncogenic AGR2 and its putative binding partner EpCAM in a panel 
of cancer cell line. (A) Breast cancer cell line (MCF-7) and oesophageal cancer cell line (FLO-1, OE33 
and OE19) was analysed by western blot using AGR2 polyclonal antibody K47 (Moravian 
Biotechnology) and EpCAM monoclonal antibody (Calbiochem). Tumour suppressor protein p53 status 
was also analysed p53 monoclonal antibody (Moravian Biotechnology). β-actin was used as loading 
control. B) Indicated cell lines were treated with four different siRNAs to AGR2 (50 µm) incubated for 
72h and knockdown was detected by western blot using AGR2 polyclonal antibody K47. Control siRNA 
or non-transfected cells served as negative control (C) MCF-7 cells were immunostained with AGR2 
polyclonal antibody K47 with a combination of Alexa 594 (red) secondary antibodies and detected using 
confocal microscopy. Scale bar 10 µm. (D) MCF-7 cells were immunostained with EpCAM monoclonal 
antibody with a combination of Alexa 488 (green) secondary antibodies and detected using confocal 
microscopy. Scale bar 10 µm. 
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Figure 4.2 In situ proximity ligation assay. (A)Two primary antibodies raised in different species- for 
example, red protein is mouse monoclonal antibody and blue is rabbit polyclonal antibody- use to detect 
target antigen of interest. (B) Different short DNA strand is attached to each species-specific secondary 
antibody (Duolink kit) (green and blue, respectively). (C)When the secondary antibodies are in close 
proximity (30-40nm), the DNA strands can interact through a subsequent addition of two other circle-
forming DNA oligonucleotides (black). (D) After joining of the two added oligonucleotides by 
enzymatic ligation, they are amplified via rolling-circle amplification using a polymerase. Amplification 
reaction results in several hundred replications of the DNA circle being made and labelled fluorescent 
probes (added as detection solution) highlight the product (red). The resulting high concentration of 
fluorescence in each single-molecule amplification product is easily visible as a distinct spot in a 
fluorescence microscope. 
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In addition, AGR2 has an apparently elevated dynamic in MCF7 cells since siRNA 
targeting AGR2 can deplete its steady-state levels (Figure 4.1B), whereas AGR2 in the 
p53 mutated cell lines OE19 and OE33 is more stable and perhaps less manipulated 
by synthetic manipulations. MCF-7 also was previously used in our lab for AGR2 
studies and in fact was widely used worldwide for research purposes [250].  
 
PLA was performed in MCF7 cells (AGR2+/EpCAM+) where the cells were 
incubated with antibodies to the two proteins (Figure4.3A). We tested two sets of 
AGR2 and EpCAM antibodies. The first pair of antibody was the antibody previously 
validated above in western blot and immunofluorescence which was AGR2 K47 rabbit 
polyclonal and EpCAM mouse monoclonal (Figure 4.3A, upper panel). The second 
set of antibody was AGR3 4.1 mouse monoclonal antibody (Moravian biotechnology) 
which showed cross-reactivity with AGR2 (Argyro Fourtouna PhD Thesis 2009) and 
EpCAM rabbit polyclonal (Sigma). Incubation with either pair of antibodies showed 
punctate foci representative of protein-protein interactions as detected by green 
fluorescent probes (Figure 4.3, middle panel). As a control, MCF-7 was not incubated 
with the antibody pair but incubated with PLA probes which showed no or few foci 
(Figure 4.3A, lower panel). PLA spots per cell were counted as shown in Figure 4.3C. 
PLA was also performed in FLO-1 cells that do not express AGR2 and EpCAM 
(Figure 4.3B). When authentic non-transfected FLO-1 were incubated with AGR2 and 
EpCAM antibodies demonstrated no significant amount of foci (Figure 4.3B and C). 
There are no detectable AGR2-EpCAM foci at the plasma membrane in both cell 
MCF-7 and FLO-1, suggesting that AGR2 interactions are confined to prior events in 
the maturation of the EpCAM receptor. These data together highlight that AGR2 and 
EpCAM can be co-expressed in cell lines (Figure 4.1 and Figure 4.2) and that a 
proportion of the proteins can interact in cells (Figure 4.3). These data are consistent 
with the prior biochemical study that mapped the in-vitro protein-protein contacts 
between AGR2 and EpCAM in Chapter 2.  
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Figure 4.3 Proximity ligation assays demonstrate that AGR2 and EpCAM form protein-protein 
interactions in situ. (A) Representative image of a proximity ligation assay performed with antibody 
pair of AGR2 mAB and EpCAM pAb (upper panel) or AGR2 pAb and EpCAM mAb (middle panel) 
in MCF-7 cells. PLA probes (Anti-rabbit PLUS probe and anti-mouse MINUS probe) were then added 
to the samples. Following ligation and amplification, protein-protein interaction complex was detected 
with green fluorescent probes (Duolink). Green fluorescence foci indicate the interaction between the 
two proteins. As a control, MCF-7 was not incubated with the antibody pair but incubated with PLA 
probes (lower panel) which showed no or few foci. Scale bar 25 µm (B) PLA also was also performed 
in cells that do not express AGR2 and EpCAM (FLO-1). AGR2 pAb and EpCAM mAb was used and 
protein-protein interaction complex was detected with red fluorescent probes (Duolink). Transfected 
AGR2 and EpCAM in FLO-1 cells showed foci indicative of protein-protein interaction while 
authentically non-transfected FLO-1 demonstrated no significant amount of foci. Scale bar 10 µm. 
Nuclei were counterstained with DAPI and cells were visualised with an epifluorescence microscope. 
(C) Signals were quantified in randomly selected 20 cells using ImageJ software (analyse particles) and 
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4.2.3. Co-localisation analysis of AGR2 and EpCAM by fluorescence 
microscopy 
We next aim to see if AGR2 and EpCAM can be seen co-localise in cells. Co-
localisation is defined as the presence of two or more different molecules residing at 
the same physical location in a cell. If proteins interact in-vivo they are expected to be 
co-localised or, at least, they will display overlapping distribution within the cell. The 
intracellular localisation of two (or more) proteins can be studied by fluorescence 
microscopy. In the classical immunofluorescence, cells are incubated with two primary 
specific antibodies, followed by incubation with secondary antibodies conjugated to 
two different fluorophores. Co-localisation is a function of two fluorophores display 
different emission maxima, the intracellular localisation of the proteins can be 
monitored by fluorescence microscopy. Therefore, if the two proteins are co-localised 
the fluorescent probes will also be co-localised which are represented by pixels from 
fluorescence microscope containing both colour distributions.  
 
The most commonly used method to comprehend co-localisation is 
immunofluorescence (IF) where specific antibodies for protein and its binding partner 
were incubated in cells followed by secondary antibody conjugated with two different 
fluorophores. However, there are two important problems related to this method. First, 
many antibodies can bind non-specifically to other proteins or show cross-reactivity 
with other proteins. Second, the method requires antigen retrieval which involves the 
fixation and permeabilization of the cells that can potentially cause artefacts that can 
affect the localisation observed. Many studies have conveyed different results in 
protein distribution depending on the antigen retrieval protocol used [251]. Since in-
situ localisation of proteins is a function of maintaining ‘in-vivo’ protein distribution 
after immunostaining, protein redistribution needs to be avoided and extraction of the 
antigen during experimental needs to be augmented.  
 
Although we have shown the specificity of the AGR2 and EpCAM using 
western blot and immunofluorescence studies (Figure 4.1C and D), the use of fusion 
protein will ensure minimum artefacts during immunolabelling and eliminates the use 
of antigen retrieval protocol which could necessitate protein distribution. Full-length 
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AGR2 (FL-AGR2) was previously cloned into mCherry vector and a gift from Dr 
Veronika Brychtova (Brno, Czech Republic) (Figure 4.4A). mCherry is a mutant 
fluorescent protein derived from the tetrameric Discosoma sp. red fluorescent protein, 
DsRed. Full-length EpCAM (FL-EpCAM) was cloned into a pEGFP-N1 vector which 
encodes a red-shifted variant of wild-type GFP which has been optimised for enhanced 
fluorescence and higher expression in mammalian cells (Figure 4.4A). pEGFP-N1 
encodes the GFPmut1 variant which contains the double-amino-acid substitution of 
Phe-64 to Leu and Ser-65 to Thr. Both FL-AGR2 and FL-EpCAM harbour C-terminus 
tagged of mCHERRY and EGFP respectively. From herein, we use AGR2-CHERRY 
and EpCAM-GFP for describing these constructs. 
 
The expression of the fusion proteins was then observed in cells using western 
blot to make sure they expressed properly. AGR2-CHERRY or EpCAM-GFP DNA 
constructs were transfected into MCF-7 cells. As a control, MCF-7 cells also were 
transfected with mCHERRY and GFP-expressing vectors and were immunoblotted 
using an mCHERRY antibody or GFP antibody respectively. Data showed that full-
length mCHERRY-AGR2 was expressed (arrow). However, we noticed the 
reproducible small molecular mass “cleavage” or synthesis product when mCHERRY 
was transfected into cells (asterisk). The immunoblotting of GFP and EpCAM-GFP 
transfected cells using GFP antibody highlights the expression of GFP alone marked 
by an asterisk (lane 1) and full-length EpCAM-GFP fusion protein marked by an arrow 
(lane 2). Interestingly, The EGFP was not subjected to the production of smaller 
molecular mass adducts as was the mCHERRY protein, which suggests that GFP 
fluorescent tags are more stable in cells. 
 
Using confocal microscopy, transfection of AGR2-CHERRY into MCF-7 
showed cytosolic expression. This localisation of the tagged AGR2 was consistent 
with IF data, but with tagged-AGR2 the punctate are more vivid and clear (Figure 
4.5C). Transfected EpCAM-GFP in MCF-7 showed major localisation in the 
membrane consistent with the nature of the protein being a transmembrane protein 
(Figure 4.5D) and consistent with IF results. The mCHERRY controls and GFP 
controls are shown in Figure 4.5 A and B, respectively which showed non-specific 
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localisation. When both DNA constructs were co-transfected in MCF-7 cells, a 
variable degree of colocalisation was observed (Figure 4.6 A). Two representative 
cells were pooled to showed the different co-localizations. AGR2 and EpCAM showed 
partial co-localisation in the cytoplasmic region (Figure 4.6A). By contrast, the 
EpCAMY251A-GFP mutant with an attenuated AGR2 binding previously shown using 
in-vitro biochemical study in Chapter 3 expressed cytosolically (Figure 4.5E). Co-
transfection of the mutant EpCAM and AGR2-CHERRY showed that co-localisation 
is still retained but to a lesser extent (Figure 4.6B). However, there is also the 
observation that there is more co-localisation of the mutant EpCAM and AGR2 (Figure 
4.6B, upper panel). We think that maybe this is due to mutant EpCAM is unfolded and 
therefore accumulating in the ER where AGR2 predominantly resides. 
 
Altogether, these data suggest that the transfection of AGR2 and EpCAM can 
result in transient interactions and is consistent with the pool of endogenous 
interactions identified using proximity ligation (Figure 4.3). Co-localisation of AGR2 
and EpCAM in the cytoplasmic region suggest that the interaction event could either 
be in the ER, the first compartment of the secretory pathway, where AGR2 chaperone 
EpCAM for proper folding or co-localisation events occur during trafficking (e.g Golgi 
apparatus, endosome constituents) for eventual EpCAM membrane delivery. Using 
this cell line with a dynamic AGR2 protein expression, we first noted using confocal 
microscopy that the majority of AGR2 is cytosolic and EpCAM is plasma membrane 
(Figure 4.5C and D), which is the expected dominant localisation of the proteins. By 
contrast, the EpCAMY251A mutant with attenuated AGR2 binding in-vitro is distributed 
away from the plasma membrane but still reveals co-localisation with AGR2 (Figure 
4.5E and Figure 4.6B). When the mutant EpCAM was tested on binding to AGR2 in-
vitro, the binding was not fully abolished, which explained why there is still evidence 
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Figure 4.4 Constructions of AGR2-CHERRY and EpCAM-GFP fusion proteins. (A) Schematic 
representation showing constructs of fluorescently labelled versions of AGR2-CHERRY and EpCAM-
GFP. Both proteins contain the full-length sequences. (B) The immunoblotting of mCHERRY and 
mCHERRY-AGR2 transfected cells highlights the expression of mCHERRY alone (lane 1) and 
mCHERRY-AGR2 (lane 2). Blots were incubated with an anti-mCHERRY antibody. The arrow marks 
the location of full-length mCHERRY-AGR2 and the asterisk marks the location of mCHERRY. We 
noticed the reproducible small molecular mass “cleavage” or synthesis products when mCHERRY was 
transfected into cells. (C) The immunoblotting of EGFP and EpCAM-GFP transfected cells highlights 
the expression of EGFP alone (lane 1) and EpCAM-GFP (lane 2). Blots were incubated with a GFP 
antibody. The arrow marks the location of full-length EpCAM-GFPand the asterisk marks the location 
of GFP. The GFP was not subjected to the production of smaller molecular mass adducts as was the 
mCHERRY protein. NT= Non-transfected. 
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Figure 4.5 Expression and localisation analysis of AGR2-CHERRY and EpCAM-GFP in MCF-7 
cells using confocal microscopy. A) MCF-7 cells transfected with mCHERRY vector or GFP vector 
demonstrate non-specific expression. C) MCF-7 cells transfected with AGR2-CHERRY. AGR2-
CHERRY localised in the perinuclear region and cytoplasm as punctate. D) MCF-7 cells transfected 
with EpCAM-GFP showing partial cytoplasmic localisation and but mainly localise in the cell 
membrane. E) Effect of AGR2 peptide docking site loss-of-function mutation. EpCAM-GFP were 
mutated at Y251A. Transfected EpCAMY251A-GFP de-localize to the cytosol. All cells were analysed 
24-hours after transfection and cells were fixed using 4% PFA. Nuclei were counterstained with DAPI. 
Scale bar 25 µm.  
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Figure 4.6 Co-localisation of AGR2-CHERRY and EpCAM-GFP using confocal microscopy. (A) 
MCF-7 cells were transfected with AGR2-CHERRY and EpCAM-GFP and visualised using confocal 
microscopy. Two representative images were shown to show a degree of co-localisations. Scale bar 
10um. (B) MCF-7 cells were transfected with AGR2-CHERRY and EpCAMY251A-GFP and visualised 
using confocal microscopy. Two representative images were shown to show a degree of co-
localisations. Scale bar 10 µm. All cells were analysed 24-hours after transfection and cells were fixed 
using 4% PFA. 
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4.2.4. Reconstitution of an AGR2-EpCAM pathway dynamics using cell-
based assays.    
Next, we aimed to exploit FLO-1 cells, which has no detectable AGR2 or 
EpCAM expression (Figure 4.1A), as a potential assay that can reconstitute AGR2 
impacts on EpCAM expression. We ask whether AGR2 docking to EpCAM has a 
positive or negative role in receptor maturation, expression, or localisation. The 
mislocalisation of the EpCAM-Y251A mutant suggests that attenuated binding results in 
this mislocalisation of EpCAM from going to the plasma membrane. So, we might 
expect to develop an assay whereby AGR2 transfection can stimulate EpCAM 
membrane localisation.  The same approach was used recently to study AGR2 and its 
binding partner, epidermal growth factor receptor (EGFR) [111]. Like EpCAM, EGFR 
is a membrane protein. This served another good example of how an ER-based 
thioredoxin AGR2 is able to direct signalling activity by influencing whether EGFR is 
delivered to the plasma membrane from the secretory pathway. Dong and colleagues 
used AGR2 and EGFR negative cells (CHO-K1) to show AGR2-induced EGFR 
delivery to the plasma membrane [111]. Transient transfection of CHO-K1 cells with 
an EGFR-GFP construct alone resulted in cytosolic distribution. Co-transfection with 
EGFR-GFP and AGR2 cDNA resulted in EGFR cell surface expression. So, we ask 
whether this is the case with AGR2 and EpCAM after having found cell model that is 
negative for both proteins. 
 
Initially, we sought to transfect EpCAM-GFP alone with two different 
concentrations (low and high amount of DNA) to see if there any difference in 
localisation compare to EpCAM positive cells, MCF-7 (Figure 4.7). Initial transfection 
of low amount EpCAM-GFP in FLO-1 cells showed that the majority of the 
localisation is cytosolic (Figure 4.7, middle panel). Transfection of a higher amount of 
EpCAM-GFP DNA constructs showed almost similar results where most EpCAM-
GFP are cytosolic but there are some mixtures of cytosolic and diffused membrane 
staining (Figure 4.7, lower panel). There were no differences when AGR2 were 
transfected with the low and high amount of AGR2-CHERRY, where they showed 
typical cytosolic distribution near perinuclear region which was similarly seen in 
MCF-7 cells (Figure 4.7B, middle and lower panel). The empty vector encoding EGFP 
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 4 – Cell-Based Analysis of AGR2 and EpCAM Interaction 162 
 
control of mCHERRY were shown in (Figure 4.7A and B, upper panel) which showed 
non-specific distribution.  Co-transfection of an equal amount of AGR2-CHERRY and 
EpCAM-GFP DNA into FLO-1 cells resulted in more membrane expression of the 
EpCAM-GFP per field views (Figure 4.8B and enlarged image) compared to EpCAM-
GFP alone (Figure 4.8A). These initial data suggested that AGR2 is required for 
EpCAM delivery to the plasma membrane. Next, we ask whether we can optimise the 
assay to elevate EpCAM delivery to the plasma membrane by finding the best ratio of 
AGR2 to EpCAM DNAs transfected into FLO-1 cells. We performed several titrations 
of AGR2-CHERRY and EpCAM-GFP co-transfection, where EpCAM-GFP was kept 
at a lower concentration with increasing amount AGR2-mCHERRY to observe 
whether AGR2 has an impact on trafficking EpCAM to the plasma membrane. As the 
ratio of AGR2-CHERRY to EpCAM-GFP increased, EpCAM membrane staining was 
more evident(Figure 4.9A). We counted the cells with either; i) cytoplasmic positive 
and membrane negative or ii) membrane positive in a field containing at least 50 cells 
and the counts were plotted in Figure 4.9B. The graph shows a shift (%) from 
cytoplasmic staining to membrane staining as AGR2-CHERRY increases(Figure 
4.9B).The best ratio of AGR2-mCHERRY to EpCAM-GFP, where EpCAM-GFP was 
most seen in the plasma membrane, is at 3:1 (or 1.5 µg: 0.5 µg per 6 well plates). When 
the experiment was repeated using the ratio, EpCAM-GFP can be seen more evident 
in membrane compare to cytoplasmic localisation (Figure 4.9C), and also suggest 
reproducibility of EpCAM delivery to the membrane upon co-transfection with AGR2. 
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Figure 4.7 Localisation of AGR2-CHERRY and EpCAM-GFP in FLO-1 cells (AGR2 (-ve); 
EpCAM -ve). (A) FLO-1 cells were transfected with GFP vector only (upper panel) low amount of 
EpCAM-GFP,  0.2µg (middle panel) and high amount of EpCAM-GFP 1 µg (lower panel). Scale bar 
25 µm. (B) FLO-1 cells were transfected with mCHERRY vector only (upper panel) low amount of 
AGR2-CHERRY,  0.2µg (middle panel) and high amount of AGR2-CHERRY 1 µg (lower panel). Scale 
bar 25 µm. Nuclei were counterstained with DAPI and cells were visualised with an epifluorescence 
microscope.  
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Figure 4.8 Initial co-transfection of AGR2-CHERRY and EpCAM-GFP into FLO-1 cells. (A) 
FLO-1 were transfected with EpCAM-GFP only. Scale bar 10 µm (B) FLO-1 cells were co-transfected 
with an equal amount of AGR2-CHERRY and EpCAM-GFP DNA. EpCAM-GFP with more membrane 
localisation in the presence of AGR2-mCHERYY was shown in the enlarged image. Scale bar 10 µm. 
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Figure 4.9 EpCAM-GFP enhance membrane localisation with titration of AGR2-CHERRY in 
FLO-1 cells. (A) FLO-1 cells were co-transfected with a fixed amount of EpCAM-GFP (0.5 µg) and 
AGR2-CHERRY titration (0.5-1.5 µg). Scale bar 10 µm. (B) Graph showing the number of cells with 
either cytoplasmic positive/membrane negative or membrane positive with each titration as in (A). 
Widefield view of at least 10 cells per field was counted. (C) FLO-1 cells were -transfected in an 
independent experiment with AGR2-CHERRY (0.5 µg) and EpCAM-GFP (1.5 µg) or 3:1 ratio which 
showed enhanced membrane staining.  
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In addition, upon quantitation of the extent of EpCAM-GFP membrane vs 
cytosolic localisation, we noticed elevated fields of EpCAM-GFP expression in wide-
field views. To confirm this, we co-transfected very low amount of EpCAM-GFP 
(0.125 µg DNA) with titration of AGR2-CHERRY (0.25 µg- 1.5 ug DNA). The 
increasing amount of AGR2-CHERRY DNA elevates the production of lowly 
transfected EpCAM, while the transfection of the low EpCAM-GFP alone was poorly 
expressed (Figure 4.10A).  Quantitation of cells with EpCAM-GFP positive cells per 
field views confirm elevated EpCAM-GFP when co-transfected with increasing 
AGR2-CHERRY expressed (Figure 4.10B). This suggests that AGR2 can elevate the 
steady-state levels of EpCAM. This EpCAM elevation was confirmed using 
immunoblotting (Figure 4.11). When the same experiment was repeated and the 
lysates were subjected to immunoblotting, the bands corresponding to EpCAM 
increased as AGR2-CHERRY increases (Figure 4.11A, upper panel) and confirmed 
when the integrated intensity of bands was quantified (Figure 4.11A, lower panel).  We 
also evaluated whether the sole cysteine (Cys-81) within the thioredoxin domain on 
AGR2 has any role in AGR2: EpCAM interaction. The cysteine residue was 
previously shown to form mixed disulphide bridge with AGR2 client proteins such as 
MUC2 and EGFR [60, 111]. We mutated AGR2-CHERRY at its sole cysteine within 
the to Cys81 to Ser (AGR2-C81S-CHERRY).  However, there was no significant 
difference from WT-AGR2 in stimulating EpCAM production suggesting that a 
chaperonin function rather than a redox function is directly responsible for EpCAM 
elevation (Figure 4.11).  
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Figure 4.10 EpCAM-GFP expression in FLO-1 cells were elevated with increasing AGR2-
CHERRY. (A) FLO-1 cells were either transfected with relatively low amount of EpCAM-GFP alone 
or co-transfected with a fixed amount of EpCAM (0.125 µg) and titration of AGR2-CHERRY (0.25 µg 
– 1 µg). Transfection of EpCAM-GFP alone showed low expression and barely detectable. Upon 
titration of AGR2 co-transfected with EpCAM, the expression of EpCAM is greatly increased. Scale 
bar 25 µm. Nuclei were counterstained with DAPI and cells were visualised using epifluorescence 
microscope. 
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Figure 4.11 Western blot showing EpCAM-GFP expression in FLO-1 cells were elevated with 
titration of AGR2-CHERRY. FLO-1 cells were either transfected with a low amount of EpCAM-GFP 
alone or co-transfected with a fixed amount of EpCAM (0.125 µg) and in a combination with increasing 
amount of mCHERRY, AGR2-CHERRY or AGR2C81S-CHERRY (0.25 µg, 0.5 µg, 1 µg) and analysed 
using western blot with Anti-GFP antibody to detect the presence of EpCAM-GFP. Only the band 
correspond to full-length AGR2-GFP was shown. The anti-mCHERRY antibody was used to detect the 
presence of mCHERRY, AGR2-CHERRY or AGR2C81S-CHERRY. β-actin was used as loading control. 
Integrated intensity corresponding to the full-length EpCAM-GFP band was scored as a bar graph 
(lower panel).  
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4.2.5. Construction of recombinant untagged-AGR2 and untagged-
EpCAM in weak and strong promoter vectors 
We have shown that AGR2 can elevate the steady-state level of EpCAM using 
fluorescence microscopy and western blot using fusion proteins where both proteins 
were fluorescently tagged. We asked whether the fluorescent tags could have an effect 
to the elevation of EpCAM. Hence, we thought of making the assay cleaner by 
removing the tags in both proteins to ensure that genuine AGR2 causing the effect of 
elevating EpCAM expression. We cloned AGR2 and EpCAM into two different 
mammalian vectors: strong and weak constitutive promoters. This represents the low 
and high expression of AGR2 or EpCAM and also eliminates the need of titration. The 
strong constitutive promoter contains human cytomegalovirus (CMV) promoter (pSF-
CMV) which is by far the strongest mammalian and the most commonly used promoter 
(Figure 4.12B). The weak constitutive promoter was derived from Rous sarcoma virus 
(RSV) promoter (pSF-RSV) (Figure 4.12B). Both of the vectors were bought from 
Oxford Genetics which the expression levels of different mammalian promoters have 
been tested. Figure from Oxford Genetics 13  showed that CMV demonstrated the 
highest transient expression level in mammalian cells whereas RSV showed the 
weakest expression level (Figure 4.12A). While all the DNA sequences are similar, 
the two vectors were only differing in the promoter region and antibiotic selection gene 
where the pSF-CMV vector has ampicillin resistance gene while the pSF-RSV has 
kanamycin resistance gene (Figure 4.12B).  
                                                 
13 www.oxfordgenetics.com 
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Figure 4.12 Comparison of the transient expression level of different mammalian promoters. (A) 
Bar Graph showing relative expression levels of different mammalian promoters tested in 293A cells 
(reproduced from OxfordGenetics.com). (B) pSF-RSV vector which contains Rous sarcoma virus 
(RSV) promoter that drives gene expression in mammalian cells with a kanamycin resistance cassette. 
This promoter is one of the weaker constitutive promoters as shown in (A). (C) pSF-CMV vector which 
contains human cytomegalovirus (CMV) promoter that drives gene expression in mammalian cells with 
an ampicillin resistance cassette. This promoter is one of the strongest constitutive promoters as shown 
in (A). Both vectors contain few important sites within the multiple cloning sites (MCS). These include 
the NcoI site the XbaI site and the BsgI and BseRI sites. The NcoI site contains a start codon that is 
immediately downstream of both a Kozak and Shine-Dalgarno ribosomal binding site which allow for 
optimal positioning of genes when the start codon is placed in this location. The XbaI site contains a 
stop codon. This stop codon is positioned in a specific position in relation to the BsgI and BseRI sites 
that are immediately downstream. When either BseRI or BsgI cleave the plasmid they produce a TA 
overhang from the stop codon in the XbaI site.  
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4.2.5.1. Cloning and expression of structural variants of untagged-
AGR2  
We also interested to see if different structural variants or molecular 
arrangement of AGR2 published in the literature have a positive or negative impact on 
EpCAM expression. Based on previous studies, full-length and mature form (signal 
peptide aa 1-21) of AGR2 showed different localisation in cells. Mutagenesis of ER 
retention site of KTEL to more optimise KDEL showed more ER distribution in cells 
[81]. The mature form of AGR2 with deletion of KTEL showed that AGR2 is secreted 
outside the cells [81, 96]. When the intrinsically disordered N-terminal region (aa 21-
45) was deleted, AGR2 exists in a more stable and spontaneous dimer when in the 
purified form [97]. Based on this information, we decided to test four different AGR2 
forms on EpCAM activity in which we designed vectors containing i) full-length 
AGR2 WT (FL-AGR2 WT); ii) full-length AGR2 with T173D mutation (FL-AGR2 
KDEL - enhanced ER); iii) mature AGR2 + KTEL deletion (mAGR2 ΔKTEL- 
enhanced secretion); iv) N-terminal deletion aa 20-40 of AGR2 + KDEL (ΔNterm 
AGR2 KDEL - enhanced ER dimer). Schematic representation of these AGR2 forms 
and their description were shown in Figure 4.13A and B. The cDNAs of these were 
chemically synthesised along with restriction enzymes for directional cloning into low 
(pSF-RSV) and high expression (pSF-CMV) vectors. The 5’ and 3’ ends of each 
cDNA contain NcoI and XbaI restriction sites respectively and cloned into the multiple 
cloning sites containing the same restriction sites in pSF-RSV and pSF-CMV. 
Resulting recombinant AGR2 constructs were named as shown in Figure 4.13B. 
 
We then checked how these different forms of AGR2 express in the cells and 
whether the weak and strong promoters give different level of expression. We used 
FLO-1 cells as this cells will be used for assaying AGR2: EpCAM interaction. FLO-1 
cells transfected with FL-AGR2 WT and FL-AGR2 KDEL under weak RSV promoter 
and analysed in western blot using AGR2 antibody gave a single band, with the later 
showed a higher band intensity (Figure 4.13C). The mAGR2 ΔKTEL showed almost 
undetectable band while ΔNterm AGR2 KDEL demonstrated two bands (Figure 
4.13C). AGR2 constructs under the control of the strong promoter, CMV showed a 
similar pattern of bands but with increased band intensities (Figure 4.13C). This 
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suggests that the two promoters indeed showed the expected level of expression, where 
RSV promoters drive weaker expression of AGR2 while CMV gives higher AGR2 
expression.  
 
 The higher expression of FL-AGR2 KDEL suggests that this form is more 
stable and that it might be retained intracellularly in the ER while the FL-AGR2-WT 
might be partially secreted even in its full-length form [180]. The very weak expression 
of mAGR2 KTEL suggests that this form is less stable or it is secreted. However, the 
secretion of AGR2 in the spent culture media was not immunoblotted to confirm these 
hypotheses. The two bands detected from N-term AGR2 KDEL could mean that 
AGR2 is cleaved possibly by a signal peptidase to remove its signal peptide aa 1-20 
that is not made when it is matured and perhaps the signal peptide is fused to aa 41 
which is not natural for the protein (due to the deletion aa Δ20-40). Note that N-term 
AGR2 KDEL in the weak promoter RSV, only one band was predominant (lower 
band) but in the stronger promoter CMV, the second upper bands were equally visible 
(Figure 4.13C, compare RSV and CMV). This may suggest that the strong promoter 
AGR2 can bypass the post-translational modification leading to the expression of full-
length N-term AGR2 KDEL.  
 
4.2.5.2. Cloning and expression of structural variants of untagged-
EpCAM 
EpCAM also was cloned into the RSV and CMV promoter vectors so that our 
assay would be more accurate (i.e all genes were cloned into the same vectors). We 
cloned the full-length EpCAM (FL-EpCAM) and also the mature EpCAM (mEpCAM) 
which is without its signal peptide aa 1-23) (Figure 4.14A). These EpCAM cDNAs 
were also chemically synthesised harbouring NcoI and XbaI restriction sites at 5’ and 
3’ ends respectively at each cDNA form and cloned into the multiple cloning sites 
containing the same restriction sites in pSF-RSV and pSF-CMV. Resulting 
recombinant EpCAM constructs and their description was designated in Figure 4.14B.  
 
FLO-cells transfected with low FL-EpCAM expression vector showed very 
weak band while FL-EpCAM in strong promoter vector showed increased in 
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expression (Figure 4.14D) as detected with EpCAM antibody in western blot. 
However, the expression of mEpCAM in both low and high expression vectors was 
not detectable (Figure 4.14D). The different level expression of FL-EpCAM in the two 
expression promoters, again showed that the promoter can drive gene expression as 
expected. The FL-EpCAM showed multiple minor bands which correspond to 
cleavage of intracellular and extracellular cleavage consistent with previous studies 
[214, 229, 252]. mEpCAM was unable to express suggest that it is not stable and 
suggest that the signal peptide is crucial for EpCAM maturation.  
 
Although FL-EpCAM was shown to express in FLO-1, the expression is 
relatively low as it needs high exposure for the band to be seen in western blot. As a 
backup, we construct a full-length EpCAM which was human codon optimised 
(Thermo Scientific) which was proven to increase EpCAM expression in bacteria. 
Codon optimised EpCAM was chemically synthesised and designed to be cloned into 
pCDNA3.1 (+) which is under the control of CMV promoter (Figure 4.14C). The 
expression of the construct (FL-EpCAM-CO) as transfected in FLO-1 cells showed an 
elevated EpCAM in western blot (Figure 4.14D). As such, we plan to omit the 
mEpCAM as it is not express and use either FL-EpCAM cloned into CMV vector or 
FL-EpCAM-CO for subsequent experiments. 
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 4 – Cell-Based Analysis of AGR2 and EpCAM Interaction 175 
 
 
Figure 4.13 AGR2 constructs clone into weak and strong promoter vector and their respective 
expression in cells.  (A) Schematic representation of different AGR2 variants clone into both weak 
(RSV) and strong (CMV) promoters vector for mammalian expression. AGR2 cDNAs were chemically 
synthesised containing NcoI at 5’ end and XbaI at 3’ end and cloned into a generic holding vector pMA-
T (ThemoFisher Scientific). The cDNAs were then subcloned into RSV and CMV vectors using NcoI  
and XbaI. Plasmid names and description corresponding to different constructs were shown in (B).  (C) 
FLO-1 cells were transfected with weak and high expressing AGR2 constructs and analysed by western 
blot using AGR2 polyclonal antibody K47. β-actin was used as loading control. 
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Figure 4.14 EpCAM constructs clone into weak and strong promoter vector and their respective 
expression in cells (A) Schematic representation of different EpCAM variants clone into both weak 
(RSV) and strong (CMV) promoters vector for mammalian expression. EpCAM cDNAs were 
chemically synthesised containing NcoI at 5’ end and XbaI at 3’ end and cloned into a generic holding 
vector pMA-T (ThemoFisher Scientific). The cDNAs were then subcloned into RSV and CMV vectors 
using NcoI and XbaI. Plasmid names and description corresponding to different constructs were shown 
in (B). (C) Schematic representation of wild-type full-length EpCAM which was chemically synthesised 
and human codon optimised for mammalian expression. This construct was designed to be cloned into 
a pcDNA3.1 (+) vector which under CMV promoter to drive gene expression. (D) FLO-1 cells were 
transfected with weak and high expressing or codon-optimized EpCAM constructs and analysed by 
western blot using EpCAM monoclonal antibody. β-actin was used as loading control. 
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4.2.6.  Effect of AGR2 structural variants on EpCAM expression 
Having successfully cloned and expressed the untagged-AGR2 and untagged-
EpCAM, we reconstituted their expression in FLO-1 cells and see whether the 
structural variants of AGR2 have a negative or positive impact on EpCAM expression. 
We used weak (RSV promoter) and strong expression (CMV promoter) of AGR2 as 
means of low and high expressing AGR2, cotransfected with a constant amount of 
EpCAM without the need of titration. First, we tested the effect of AGR2 structural 
variants on FL-EpCAM/CMV and analysed in western blot.  The low expression FL-
AGR2-WT showed to elevate FL-EpCAM/CMV nearly two-fold as compared to 
transfected FL-EpCAM/CMV only (Figure 4.15A). However, the high expression FL-
AGR2-WT did not significantly increase EpCAM expression. Similar results were 
observed for three other AGR2 forms, where the FL-AGR2-KDEL, mAGR2 ΔKTEL 
nor ΔNterm AGR2 KDEL significantly impact the expression of EpCAM/CMV 
(Figure 4.15A).  
 
Next, we examined the effect of AGR2 structural variants on codon-optimized 
FL-EpCAM CO. Western blot analysis of co-transfected FLO-1 cells with AGR2 and 
codon optimised showed that all AGR2 variants in both low and high expression 
vector, elevate codon optimised EpCAM (Figure 4.15B). The enhanced ER form of 
AGR2 (FL-AGR2 KDEL) showed the most impact on EpCAM. The different level 
expression of AGR2 in all forms correlate to the expression of EpCAM; i.e the higher 
the expression of AGR2, more EpCAM expression was seen. The results obtained 
were different than the EpCAM cloned into CMV vector. We hypothesised that in the 
case of FL-EPCAM/CMV, only small amount of AGR2 is needed to achieve the FL-
EpCAM/CMV steady-state levels while increasing the amount of AGR2 is toxic or 
there is a feedback mechanism to reduce the production of EpCAM. In the case of 
codon-optimized EpCAM, more AGR2 is needed to achieve the steady-state level of 
this form of EpCAM. Nonetheless, these data showed that AGR2, especially the FL-
AGR2 WT when co-express with EpCAM in AGR2/EPCAM-null cells, was able to 
elevate the expression of EpCAM.  
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We also titrated the untagged FL-EpCAM CO in combination with AGR2-
mCHERRY and co-transfected both constructs into FLO-1 cells. Western blot analysis 
showed that FL-AGR2-CHERRY but not mCHERRY was able to elevate the untagged 
EpCAM protein production Figure 4.16 which was similarly seen with EpCAM-GFP 
(Figure 4.10 and Figure 4.11). These data suggest that AGR2 functions in a positive 
role in EpCAM activity.  
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Figure 4.15 Effect of AGR2 structural variants on EpCAM expression. (A) (Upper panel) FLO-1 
cells were transfected with FL-EpCAM/CMV alone or co-transfected with AGR2 structural variants 
(both low (L) and high (H) expression. An equal amount of lysates were electrophoresed and 
immunoblotted with anti-EpCAM to monitor the effect of EpCAM/CMV expression upon co-
transfection with AGR2 constructs. The expression level of AGR2 constructs was blotted with anti-
AGR2. β-actin was used as loading control. (lower panel) Integrated intensities correspond to FL-
EpCAM/CMV bands were plotted in a bar graph (A) (Upper panel) FLO-1 cells were transfected with 
codon optimised EpCAM (FL-EpCAM CO) alone or co-transfected with AGR2 structural variants (both 
low (L) and high (H) expression. An equal amount of lysates were electrophoresed and immunoblotted 
with anti-EpCAM to monitor the effect of EpCAM/CMV expression upon co-transfection with AGR2 
constructs. The expression level of AGR2 constructs was blotted with anti-AGR2. (Lower panel) 
Integrated intensities correspond to FL-EpCAM CO bands were plotted in a bar graph β-actin was used 
as loading control.  
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Figure 4.16 Western blot showing untagged FL-EpCAM CO expression in FLO-1 cells were 
elevated with titration of AGR2-CHERRY. (Upper panel) FLO-1 cells were either transfected with 
a low amount of untagged-EpCAM-CO (0.125 µg)  alone or co-transfected with a fixed amount of 
EpCAM (0.125 µg) and in a combination with increasing amount of mCHERRY, AGR2-CHERRY 
(0.25 µg, 0.5 µg, 1 µg) and analysed using western blot with anti-EpCAM antibody to detect the 
presence of EpCAM. Only the band correspond to full-length AGR2-GFP was shown. The anti-
mCHERRY antibody was used to detect the presence of mCHERRY, AGR2-CHERRY. β-actin was 
used as loading control. (Lower panel) Integrated intensity corresponding to untagged FL-EpCAM CO 
band was scored as a bar graph. 
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4.2.7. Immunohistochemistry using AGR2 and EpCAM antibody on 
oesophageal adenocarcinoma tissue microarray   
Tissue microarray (TMA) is a high-throughput molecular pathology technique 
that allows assessment of biomarkers expression simultaneously on hundreds of 
multiple specimens at the same time [253]. It also allows simultaneous and parallel 
molecular profiling of clinical samples at the DNA, RNA, and protein level and also 
provides utmost preservation and use of limited collection tissue samples. TMA is 
produced by extracting microscopic tissue cores from different paraffin donor blocks 
and re-embedding these into a single recipient (microarray) paraffin block at defined 
array coordinates. First, the donor blocks containing invariably stored paraffin blocks 
are retrieved and sectioned to produce standard microscopic slides that are stained with 
hematoxylin and eosin. An experienced pathologist examines the slides to mark the 
area of interest (Cancer or normal tissues), after which the samples can be arrayed. Up 
to 1000 tissue samples can then be arrayed into a single paraffin block. This method 
gives several advantages for researchers [254]. First, it decreases assay volume as 
hundreds of biopsies can be assayed from a single microscope slide and in turn save 
time and cost. It also allows amplification of a limited tissue resource of biopsies and 
allows simultaneous analysis of a very large number of specimens as each tissue 
microarray paraffin block can be sectioned and cut multiple times and permits different 
individual assay from the same source. TMA also reduces experimental variation as 
each tissue sample in the array is treated in an equal manner and allow analysis of the 
entire cohort in one batch on a single slide. Thus, variables such as antigen retrieval, 
temperature, incubation times, washing procedure, and reagent concentration are 
consistent for the entire cohort. It is a practical and effective tool for high-throughput 
molecular analysis of tissues that is helping to identify new diagnostic and prognostic 
markers and targets in human cancers and has a range of potential applications in basic 
research, prognostic oncology and drug discovery. 
 
We evaluated the expression of AGR2 and EpCAM and assess whether there 
is any evidence for the two proteins being co-expressed in human cancer clinical 
samples. A TMA containing 115 cores of oesophageal adenocarcinoma tissues was 
processed for immunohistochemistry using antibodies to AGR2 or EpCAM (Figure 
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4.17A). AGR2 and EpCAM were scored using a modified Allred method [255] which 
is based on the sum of intensity and area of staining (Figure 4.17B). Not all cores could 
be scored due to loss of material during experimental setup or lack of appropriate tissue 
type in the core. A total of 91 cores were intact and subjected to analysis. A summary 
of the expression of both AGR2 and EpCAM in the same tumour sample as a function 
of % cells per sample and intensity per sample was shown in Figure 4.17C. The scores 
showed that majority of the tissues stained for AGR2 and EpCAM. Nearly half of the 
populations, 46% (42/91) showed the highest expression (score 7) of EpCAM and 
AGR2. Tissues with at least a total of score 2 for EpCAM or AGR2 which we deemed 
to be the minimal score for positive staining were 90% (82/91) of the samples. This 
suggests that AGR2 and EpCAM were highly expressed in clinical tissue samples such 
as oesophageal adenocarcinoma. Only 9% (9/91) of samples exhibited no detectable 
expression of either protein and only one cancer exhibited high EpCAM expression 
with no detectable AGR2 protein expression. There is also a significant positive 
relationship between EpCAM expression and AGR2 expression (Pearson’s correlation 
coefficient r(89)=.8204, p<0.0001)  suggesting that the two proteins are highly co-
expressed in oesophageal adenocarcinomas. Representative images of 
immunohistochemistry using AGR2 and EpCAM in TMA containing oesophageal 
adenocarcinoma were shown in Figure 4.18. AGR2 and EpCAM showed relatively 
similar staining coverage of staining as shown in representative images in Figure 4.18. 
Since the TMA cores were derived from the same samples but with different cuts, the 
same staining coverage of  EpCAM and AGR2 suggests that the two proteins are co-
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Figure 4.17 Immunohistochemistry of tumour microarray (TMA) containing oesophageal 
adenocarcinoma tissue cores using EpCAM and AGR2 antibody. (A) Image of a slide containing 
sections of TMA containing 115 cores of oesophageal adenocarcinoma tissue stained using antibodies 
to AGR2 (left) or EpCAM (right) (B) Scoring method for IHC using a modified Allred method [255]. 
Intensity was graded from 0-3 and area of staining was scored from 0-4. The sum of the intensity and 
area was calculated for each scorable core. (C) Bar graph summary of the expression of both AGR2 and 
EpCAM in the same tumour sample as a function of area and intensity per same sample. Only 91 out of 
115 cores could be scored due to loss of material during IHC or lack of tissue type in the core. (Samples 
preparation and staining were performed by Dr Robert O’Neill).(D) Regression line showing a 
correlation of AGR2 and EpCAM scoring in the same tumour sample. Data were analysed using 
Pearson’s correlation coefficient r(89)=.8204, p<0.0001. The size of the bubble indicates number of 
occurrences of the scoring. 
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Figure 4.18 Representative images of immunohistochemistry using AGR2 and EpCAM in TMA 
containing oesophageal adenocarcinoma. (A) I-III Three representative images of typical high-level 
expression of both AGR2 and EpCAM.  All three images have the highest score (7) of AGR2 and 
EpCAM. (B) Image of high-level of expression of EpCAM but no detectable AGR2 expression. (C) 
Image of no detectable expression of both proteins. 
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4.3. Discussion 
Functions of AGR2 are not well defined since AGR2 is not only found in ER 
but also in other subcellular localisation such as nucleus [81, 83], cell surface and 
extracellular space [100]. AGR2 can form mixed disulphide bonds with 
transmembrane protein MUC2, in which AGR2 play a role in mucin processing [60]. 
AGR2 can interact with the metastasis-associated GPI-anchored C4.4a protein and 
extracellular alpha-dystroglycan (DAG-1) [58] and membrane receptor Prod1 [54]. 
Besides, AGR2 was found to be secreted during the development of pancreatic cancer 
[143] and was detected in the urine of prostate cancer patients [152] as well as in the 
blood of ovarian cancer patients [135]. A recent study describes the physiological role 
of extracellular AGR2 (eAGR) using organoid model derived from human lung 
epithelial cells. The study highlights that eAGR2 is a novel and unexpected 
microenvironment regulator in epithelial tumorigenesis and morphogenesis [180]. 
Altogether, this suggests that AGR2 can sculpt the cellular secretome. We have shown 
that AGR2 protein has a unique property for a protein disulphide isomerase in that it 
can bind sequence-specifically to a TxIL[YF][YF] peptide-docking motif present in 
client proteins such as receptor EpCAM in the previous chapter. 
Transmembrane/receptor proteins are the predominant class of proteins with such a 
motif suggesting that their maturation depends on AGR2 signalling. In this chapter, 
we further characterised the AGR2: EpCAM interaction using cell-based assays to 
extend the understanding how the motif on EpCAM (aa 247-25) facilitates its 
maturation or trafficking. Additionally, protein-protein interaction in-vivo may involve 
large, multidomain, and complex, and undergo many posttranslational modifications, 
which may influence maturation process like AGR2:EpCAM interaction [256].  
 
First, by using PLA in MCF-7 cells, AGR2 and EpCAM can form complex in 
cells which are represented by PLA punctate foci (Figure 4.3A) but not in FLO-1 null 
cells (Figure 4.3B). Second, we used fluorescently tagged AGR2 and EpCAM for co-
localisation assays in fixed cells. Paraformaldehyde fixation was used in this study as 
it has been widely used to preserved cell morphology prior to immunofluorescence 
staining. Fixed cells are no longer living which may create artefacts due to the 
disruption of cellular structures or lowering of protein antigenicity [257] and this may 
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lead to misinterpretation of localisation. However, using this methodology, GFP-
tagged wt-EpCAM for example can localise to the plasma membrane, where it has 
been published to reside [258]. These data indicate that the GFP-tag does not preclude 
membrane localisation of EpCAM. The advantage of this GFP-tag expression assay 
was that we could also mutate EpCAM at Y251 to create an attenuated AGR2-
interacting mutant that in turn demonstrated its’ mislocalisation in cells. The 
disadvantage of the GFP-tag expression methodology is that it relies on using tagged 
proteins that might alter protein functions. Upon transfection of AGR2-CHERRY into 
cells, we discovered that there are some cleavages of the mCHERRY tag but not on 
GFP tag on EpCAM (Figure 4.4). The cleavage of mCherry has been documented in 
other studies as well. For example, one study showed that C-terminal mCherry fusion 
protein showed significant proteolytic cleavage [259] though the full-length mCHerry 
fusion protein can still be obtained. The studies also showed that different linkers 
connecting the parent protein and the fluorescent tag also may affect cleavage 
suggesting the instability of the mCherry tag. In addition, the addition of mCherry at 
the C-terminal of AGR2 (after KTEL sequence) might also affect protein targeting. 
The addition might obscure the recognition by KDEL receptor for retrieval from Golgi 
apparatus by retrograde transport to the ER lumen. A recent study showed that the 
addition of extra residues after KTEL sequence causes AGR2 to be secreted into cell 
media [68], suggesting that the addition of sequences upstream the ER retention 
sequence can disrupt protein localisation which may be due to KDEL receptor fail to 
recognise KTEL motif. We think that it would be better in the future if the construct 
is designed with the mCherry tag is placed before the KTEL for proper protein 
localisation. However, to do this, multiple sequential cloning needs to be performed. 
Since the same construct has been used previously used [260] (though with C-
terminally DsRed tag) by our lab, and the fact that our construct produced active full-
length AGR2 fusion protein as shown in western blot and cytoplasmic staining by 
fluorescence microscope, we think that this construct is still relevant to use in this 
studies. Co-transfection of AGR2-CHERRY and EpCAM-GFP proteins into MCF-7 
cells showed that AGR2 localisation is cytosolic (Figure 4.5C) while EpCAM is 
largely plasma membrane bound (Figure 4.5D). Upon co-transfection of AGR2-
CHERRY and EpCAM-GFP, a degree of colocalisation of the two proteins is observed 
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in the cytosol, suggesting that the two proteins can partially form stable interactions 
in-vivo (Figure 4.6). This finding is consistent with the PLA data where the foci seen 
in MCF-7 cells are also cytosolic which suggest that AGR2 interactions are confined 
to prior events in the maturation of the membrane-bound EpCAM. We next evaluated 
whether the TLIYY motif on EpCAM plays a role in its localisation and/or binding to 
AGR2 in MCF7 cells. If so, this would place more significance on its physiological 
relevance for further study. 
 
Mutation of the peptide-docking motif loss-of-function, EpCAMY251A-GFP 
was not expressed at the plasma membrane when transfected into MCF7 cells (Figure 
4.5E). Upon AGR2-CHERRY co-transfection, the EpCAMY251A-GFP mutant 
remained localised predominantly to the cytosol and/or nuclear membrane and did not 
exhibit a distribution of wt-EpCAM-GFP (Figure 4.6B). These data suggest that this 
protein-protein interaction pair has impacts on each other in cell systems. Thus, we 
conclude from the cell-based validation that, although that there is not a strikingly 
“stable” co-localisation of AGR2-CHERRY and EpCAM-GFP in every co-transfected 
cell, the key results are: (i) a degree of “transient” co-localisation of AGR2-CHERRY 
and EpCAM-GFP and (ii). Mislocalisation of EpCAMY251A-GFP suggests that the 
AGR2 docking site is important, in cells, for the appropriate trafficking of EpCAM to 
its destination.  
 
This chapter showed that AGR2 act as a regulator of EpCAM signalling by 
promoting receptor presentation from the endoplasmic reticulum to the cell surface. It 
is possible that the docking site of AGR2 in EpCAM can stimulate EpCAM 
glycosylation for its plasma membrane representation. However, based on mobility in 
an SDS-PAGE, EpCAM stimulated for delivery to the plasma membrane in FLO-1 
cells is in the non-glycosylated state, suggesting that AGR2 interaction with EpCAM 
occurs prior to EpCAM post-translational modification or without the help of glycans. 
This is consistent with our previous data in Chapter 3 which showed that AGR2 binds 
to a non-glycosylated form of EpCAM which takes place in the ER before it is released 
for subsequent maturation steps in the secretory pathway. This study also presents a 
mechanism for controlling EpCAM-mediated signalling. We demonstrate that AGR2 
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is able to dictate signalling activity by determining whether EpCAM is delivered to 
the plasma membrane from the secretory pathway. We reconstituted EpCAM 
expression in FLO-1 cells which are negative for both AGR2 and EpCAM expression. 
Transient transfection of FLO-1 cells with recombinant EpCAM-GFP alone resulted 
in an intracellular distribution (Figure 4.8). Upon co-transfection with EpCAM-GFP 
and AGR2-CHERRY cDNA, EpCAM-GFP cell surface expression is greatly 
stimulated (Figure 4.8 and  
 
Figure 4.9). AGR2 has been shown to regulate another membrane-bound 
protein namely EGFR [111]. Similarly, EGFR-mediated signalling was shown to be 
dependent on AGR2 expression and is required for receptor delivery to the plasma 
membrane and thus EGFR signalling. However, the study showed that the AGR2 acts 
a novel post-translational regulator of EGFR-mediated signalling which suggests that 
AGR2 can escape ER and has different roles in regulating membrane bound proteins. 
We also found that AGR2 can elevate the expression of EpCAM protein by chance. 
Titration of AGR2-CHERRY with fix amount EpCAM-GFP co-transfected into FLO-
1 cells increase the fluorescence staining of EpCAM-GFP (Figure 4.10) and the 
increased level of EpCAM protein is confirmed by western blot (Figure 4.11). Based 
on these findings, we hypothesise that AGR2 may serve as a regulatory factor, if not 
major, in EpCAM-mediated signalling. EpCAM molecule has been targeted for cancer 
immunotherapy such as Catumaxomab [261] which target cell surface EpCAM. 
Therefore, EpCAM cell surface representation is necessary for the drug recognition 
which can be achieved by the AGR2 expression, so any manipulation of AGR2 
expression is relevant for the effectiveness of current therapy. Current data can be 
further strengthened to show that EpCAM signalling is dependent on AGR2 
expression. For example, FACS experiment can be used to count the number of cells 
with EpCAM membrane staining in the presence or absence of AGR2. This can be 
done by staining cells with antibodies recognising extracellular EpCAM (which is used 
in this study) on unfixed FLO-1 cells in the presence and absence of exogenous AGR2. 
In addition, it would be interesting in the future to deplete AGR2 by short-hairpin RNA 
(shRNA) or knockout AGR2 cell models which can then be used to check whether 
EpCAM cellular distribution is affected by the altered level of AGR2 expression. It is 
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also important to establish the rate of EpCAM synthesis and maturation in the presence 
of absence of AGR2 which can be done by radiolabel pulse-chase experiment. 
 
Protein folding and assembly in the ER is largely facilitated by chaperones and 
devoted ER-resident enzymes like the heat shock proteins and protein disulphide 
isomerases [262]. AGR2 belongs to protein disulphide isomerase superfamily 
containing thioredoxin domain. This domain is responsible for interaction of AGR2 
client proteins through the formation of mixed disulphide bonds which were seen in 
MUC2 [60] and EGFR [111]. Mutating the single cysteine within the thioredoxin 
domain, C81S still showed stimulation of EpCAM-GFP cell surface expression, 
suggesting that a chaperonin function rather than a redox function is directly 
responsible for EpCAM elevation (Figure 4.11).  
 
Proteins destined for conventional secretory pathway enters ER and undergo 
stringent quality control before they can proceed to the Golgi apparatus, and 
subsequently to the final destination [256]. EpCAM contains N-terminal signal peptide 
which suggests that the protein is targeted to the ER and secretory pathway. Following 
the ER quality control (ERQC), correctly folded EpCAM is then able to exit the ER 
and subsequently to the plasma membrane where signalling is transduced [256]. The 
ability of AGR2 to transport membrane-bound EpCAM suggests that it impacts cell 
signalling. Although generally reside in the ER, AGR2 also can leak through the 
cytosol or is secreted, suggesting that AGR2: EPCAM interaction can occur outside 
the ER. Mutating the C-terminal ER retention site on AGR2 to a more canonical ER 
retention motif (KTEL to KDEL), showed a slight increase in stimulating (compared 
to wt-AGR2 stimulation) the production of codon-optimized EpCAM (Figure 4.15B) 
implying that protein-protein interaction occurs inside the ER for proper folding and 
assembly of EpCAM. We also cloned various forms of AGR2 based on previously 
published data to check whether any of these AGR2 variants on EpCAM signalling 
(Figure 4.13). Based on the western blotting experiment, these AGR2 variants have 
minimal impact on EpCAM expression (Figure 4.15). Nevertheless, these constructs 
can be further manipulated for future cell-based assays. 
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A recent finding by our group using quantitative shotgun proteomics in 
oesophageal adenocarcinomas vs. normal tissues biopsies, have identified EpCAM as 
one of the most independent validated “target” in the tumour sample (Dr Robert 
O’Neill Thesis, and manuscript in preparation).  Immunohistochemistry on a TMA 
containing 91 cores of oesophageal adenocarcinoma tissues in this study confirmed 
that EpCAM is highly expressed (Figure 4.17). Similarly, AGR2 was also found to be 
highly expressed in the vast majority of this type of adenocarcinomas. Interestingly, 
tissue samples with the maximum scoring of EpCAM and AGR2 are represented by 
nearly half of the population (Figure 4.17). Another set of immunohistochemistry 
analysis using normal squamous tissues showed that AGR2 expression was absent but 
exhibited low expression in normal gastric. EpCAM expression, however, was 
observed in both normal squamous and normal gastric epithelia but the expression was 
relatively low compared to the expression in adenocarcinoma tissues (Dr Robert 
O’Neill Thesis, and manuscript in preparation). The staining pattern and coverage of 
AGR2 and EpCAM on the tissues suggest that both proteins are co-expressed in 
tumour samples at least in the case of oesophageal adenocarcinoma (Figure 4.18). The 
absence of AGR2 protein in most normal tissues but high expression in tumour tissues 
implies that AGR2 expression represents a novel and probably a dominant post-
translational mechanism for regulating EpCAM-mediated cell signalling. There is also 
a significant positive relationship between EpCAM expression and AGR2 expression 
(Pearson’s correlation coefficient r(89)=.8204, p<0.0001)  suggesting that the two 
proteins are highly co-expressed in oesophageal adenocarcinomas (Figure 4.17). Since 
we have yet to receive the patient’s data, we were unable to correlate with patient’s 
cancer progression specifically patient’s survival in which we will incorporate in near 
future. 
 
In conclusion, we presented data showing AGR2 and EPCAM can interact in 
cells consistent with our in-vitro biochemical results in the previous chapter. We also 
developed a cell-based protein-protein interaction assay for studying AGR2 and 
EpCAM interaction by reconstituting their expression in FLO-1 cells (AGR2-
/EpCAM-). Using this reconstituted complex, EpCAM delivery to the plasma 
membrane was shown to be dependent on AGR2 expression showing that AGR2 act 
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as a major regulator in EpCAM signaling Finally, AGR2 and EpCAM were highly 
expressed in vast majority clinical tissues and we provided data using oesophageal 
adenocarcinomas tissues that showing AGR2 and EpCAM was indeed highly 
expressed in this type of cancer and showed positive relationship. This suggests that 
both proteins may serve as physiologically relevant candidates for oesophageal 
adenocarcinoma biomarker for early diagnosis and for future therapeutic intervention.  
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CHAPTER 5: Analysis of AGR2 Reprogramming Cancer 
Cell Using Quantitative Proteomics 
5.1. Introduction 
5.1.1. Genetic screen to study gene function 
The exploration of a gene often begins with a DNA sequence. As previously 
discussed, the main challenge is to translate the DNA sequence into a function or 
distinct phenotype. The standard genetic approach to decipher gene function is to 
disrupt normal gene expression and study the resulting phenotypes. This technique is 
called classical forward genetics which has been performed for more than 100 years 
[263]. This method determines gene that is responsible for a phenotype of an organism 
(i.e mutant phenotype  sequence). This was initially done by using naturally 
occurring mutations or inducing mutants with radiation, chemicals, or insertional 
mutagenesis using a virus. Subsequently, mutant individuals are isolated, and then the 
gene is mapped. However, this approach is painstaking due to numerous technical 
challenges to map random and superficially small changes in an enormous genomic 
DNA.  
 
With large volumes of genomic sequence data that move rapidly in the past 
decades, many genetic sequences are discovered in advance without knowing their 
biological function. Therefore, instead of going from phenotype to sequence as in 
forward genetics, geneticist used so-called reverse genetics that works in the opposite 
direction, which determines the function of a gene by analysing the phenotypic effects 
of altered DNA sequences (sequence  mutant phenotype). This approach begins with 
a known gene and experimentally investigates the effects of altering the sequence or 
expression of that gene to infer gene function [264]. The alteration of the sequence can 
either be targeted specifically (e.g gene silencing or homologous recombination) or 
non-specifically (e.g., chemical mutagenesis, transposon-mediated mutagenesis) 
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5.1.2. New genome editing technologies to study gene function 
Gene targeting by homologous recombination was first described by Capecchi 
et al. which integrates exogenous repair templates that contain sequence homology to 
the target site [266]. HR-mediated targeting has simplified the generation of isogenic 
animal models via manipulation of germline-competent stem cells that precisely alter 
target gene, advancing many types of biological research. However, the desired 
recombination events can be very challenging due to the low efficiency of a 
recombination event, presenting enormous challenges for large-scale applications of 
gene-targeting experiments [266] and generating knockin or knockout animal model 
can be very time-consuming. This, in turn, encouraged scientists to develop new tools 
for reverse genetics.. Reverse genetics complete loss-of-function approaches became 
available with the discovery of programmable nucleases which enable precise genome 
editing by introducing DNA double-strand breaks (DSBs) at specific genomic loci. 
DSBs subsequently recruit endogenous repair machinery for either non-homologous 
end-joining (NHEJ) or homology-directed repair (HDR) to the DSB site to mediate 
genome editing[265]. To date, four major classes of nucleases have been developed 
for sequence-specific genome editing: i) meganucleases and their derivatives, ii)zinc 
finger nucleases (ZFNs) iii) transcription activator–like effector nucleases (TALENs) 
and iv) (clustered regularly interspaced short palindromic repeats-CRISPR associated) 
CRISPR/Cas9 [266].Since  these nucleases differ in their mode of DNA recognition, 
they can be generally classified into two categories: i) ZFNs, TALENs and 
meganucleases achieve specific DNA binding via protein-DNA interactions, whereas 
ii) Cas9 is targeted to specific DNA sequences by a short guide RNA molecule that 
base-pairs directly with the target DNA and by protein-DNA interactions. Description 
of the genome editing tools is summarised in Table 5.1 
 
Once the DSB has been made, the lesion may be repaired by either one of the 
two major DNA repair machinery: Non-homologous end joining (NHEJ) or 
homology-directed repair (HDR). NHEJ may repair the lesion by direct re-ligation of 
the two DSB ends in a process that does not require a repair template. Although NHEJ-
mediated DSB repair can be accurate, repeated repair of the same DSB by NHEJ 
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machinery eventually results in the formation of small insertion/deletion (indels) 
mutations bridging the break site. Indels introduced into the coding sequence of a gene 
can cause frameshift mutations or premature stop codon that lead to mRNA 
degradation by nonsense-mediated decay or result in the production of nonfunctional 
truncated protein, hence a gene knockout [267]. Alternatively, DSB can be repaired by 
the high-fidelity HDR, by introducing exogenous DNA repair template that can 
mediate the repair and precisely edit the target gene. Thus, NHEJ and HDR may be 
used to suppress gene function similar to RNAi, but it may lead to permanent 
suppression by introducing loss-of-function mutations into the genome of targeted 
cells. 
 
Together, these powerful tools offer a new assurance to decipher any gene’s 
function in a rapid and efficient way. These programmable nucleases have been shown 
to achieve effective genome editing in a wide range of model organisms and 
mammalian cells, and investigators are now focusing on to developing these tools as 
therapeutics [268, 269].  
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5.1.3. Aims of chapter 
The aim of this chapter is to employ protein knockdown strategy to study AGR2 
function. Our primary focus is to employ current genome editing technology to 
knockout AGR2 in a cell line followed by quantitative proteomics screen to identify 
dominant proteins, subcellular components and pathways affected by AGR2 depletion. 
This chapter serves as a second paradigm to identify potential AGR2 client proteins 
and to define the AGR2 regulatory network. However, our attempts to knockout AGR2 
using the CRISPR/Cas9 gene editing tool was not successful. This led to a different 
strategy in which we utilised protein overexpression strategy to study AGR2 function. 
We utilised a AGR2-negative cell line that we identified earlier (Chapter 3) in which 
we reconstitute the cell as a function of AGR2 transient overexpression followed by 
quantitative proteomics screen. We have shown in Chapter 3 that AGR2-specific 
peptide motif dominantly exists in membrane proteins suggesting that AGR2 has a 
tendency to bind to this class of proteins. We have established that AGR2 can bind and 
mature one protein of this class represented by EpCAM using both in-vitro (Chapter 
3) and cell based assays (Chapter 4), and showed that AGR2 act as a major regulator 
in EpCAM signalling by promoting receptor presentation from the endoplasmic 
reticulum to the cell surface. Thus, this chapter was also aimed to check whether 
proteomic screens showed large perturbation of membrane proteins or those pertaining 
to secretion and trafficking to support our working hypothesis that AGR2 could largely 
bind to and help in the maturation of membrane proteins destined for secretory 
pathway. 
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5.2.1. Establishing AGR2 knockout isogenic cell line using genome 
editing CRISPR/Cas9 
5.2.1.1. CRISPR/Cas9 technology 
CRISPR-Cas is an adaptive immune system that uses RNA-guided nucleases 
to cleave exogenous genetic elements and is found in roughly 50% of bacteria and 
90% of archaea [270]. There are three types (I-III) of CRISPR systems found in 
bacterial and archaeal hosts[268]. The Type II CRISPR system derived from 
Streptococcus pyogenes is one of the best and widely used. This system consists of the 
nuclease Cas9, the CRISPR RNA (crRNA) array that encodes the guide RNAs and a 
required auxiliary trans-activating crRNA (tracrRNA) that facilitates the processing of 
the crRNA array into discrete units. Each crRNA unit then contains a 20-nt guide 
sequence and a partial direct repeat, where the former directs Cas9 to a 20-bp DNA 
target via Watson-Crick base pairing (Figure 5.1A). The crRNA and tracrRNA can be 
fused together to create a chimeric, single guide RNA (sgRNA). The target DNA must 
possess a 5’-NGG protospacer adjacent motif (PAM). The PAM is a critical feature of 
the Cas9 system which dictates Cas9 nuclease to DNA target and mediates DSB at the 
3’ upstream of the PAM  (Figure 5.1A). Cas9 nucleases can be mutated and exploited 
for an additional function such as to carry out strand-specific cleavage. For example, 
an aspartate-to-alanine (D10A) mutation in the RuvC catalytic domain allows the Cas9 
nickase mutant (Cas9n) to nick rather than cleave DNA to produce single-stranded 
breaks. With the introduction of HDR, a more precise gene editing can be performed. 
A pair of sgRNA with Cas9n targeting each double-stranded DNA can be used 
simultaneously to mediate DSB, thus increasing the specificity of target recognition. 
Gene editing occurs during the DSB repair. The DSB at a target genomic locus 
typically undergoes one of two endogenous DNA repair mechanisms: Non-
homologous end joining (NHEJ) or the homology-directed repeats (HDR) as described 
before (Figure 5.1B). 
 
5.2.1.2. Guide RNA design for AGR2 knockout 
The specificity of the Cas9 nuclease is determined by the 20-nt guide sequence 
within the sgRNA.. Since CRISPR/Cas9 is relatively new, we decided to outsource the 
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designing and cloning of gRNA for knocking out AGR2 to a biotechnology company 
Horizon Discovery14.  
 
We decided to use sgRNA-expressing plasmids to minimise experimental error 
as the gRNA is inserted within the same plasmid with the remainder of the sgRNA 
scaffold immediately following Cas9, and this only requires a single transfection.The 
gRNA designed for AGR2 knockout was also designed for AGR2 knockin mutation 
(AGR2 C81S), where this mutation will have defective oxidoreductase activity on its 
sole cysteine within the thioredoxin domain. This AGR2 mutation is chosen because 
most PDI-like AGR2 interactions are thought to occur via the disulphide bridge 
through the cysteine. Thus, it is interesting to introduce this mutation into cells to 
comprehend what proteins are affected as a result of the C81S knocking following 
quantitative proteomics. As the knockin require gRNA to target DNA sequence and 
introduce DSB, therefore the knockin gRNA can also be used for the knockout 
experiment. However, for a knockin to take place, it requires an extra donor template 
containing the knockin mutation. The AGR2 knockout/knockin gRNA (gRNA218) 
targets exon 4 of AGR2 (as the DNA sequence containing the Cys81 is in exon 4). 
This gRNA scored the highest quality score (for targeting exon 4) based on Horizon 
Discovery design tool and contains the least off-targets compared to other gRNAs. 
Therefore, we chose this gRNA initially in an attempt to knockout AGR2. Horizon 
discovery cloned the gRNA into a GE6-002 plasmid. This plasmid contains a U6 
promoter, expressing wild-type Cas9 which is under the control of CMV promoter. 
This plasmid also contains a 2A puromycin resistance gene to allow screening and 
selection of transfected cells. 
                                                 
14 https://www.horizondiscovery.com/ 
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Figure 5.1 RNA-guided Cas9 nuclease and DSB repair that promotes gene editing. (From [271] 
(A) Schematic of the RNA-guided Cas9 nuclease. The Cas9 nuclease from S. pyogenes (in yellow) is 
targeted to genomic DNA) by a sgRNA consisting of a 20-nt guide sequence (blue) and a scaffold (red). 
The sgRNA sequence pair with the DNA target (blue bar on top strand), directly upstream of a requisite 
5′-NGG adjacent motif (PAM; pink). Cas9 mediates a DSB ~3 bp upstream of the PAM (red triangle). 
B) DSBs induced by Cas9 (yellow) can be repaired in one of two DNA repair machinery. In the NHEJ 
pathway, the ends of a DSB are re-ligated, which can result in random indel mutations at the site of the 
junction. Indel mutations occurring within the coding region of a gene can result in frameshifts and the 
creation of a premature stop codon, resulting in gene knockout. Alternatively, HDR is another DNA 
repair machinery which can generate precise gene editing in the presence of an exogenously introduced 
repair template. Single-stranded nicks to the DNA can also induce HDR. 
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Figure 5.2 gRNA design for AGR2 knockout. (A) The 20-nt gRNA for AGR2 knockout is designed 
by Horizon Discovery. The gRNA targets the locus exon 4 of AGR2 genomic sequence. It as the lowest 
number of off-target binding. It can also be used to knockin C81S provided that the repair template is 
introduced alongside this gRNA. (B) The gRNA is cloned into GE6-002 which  contains a U6 promoter, 
expressing wild-type Cas9 which is under the control of CMV promoter. This plasmid also contains a 
2A puromycin resistance gene to allow screening and selection of transfected cells. 
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5.2.1.3. Experimental design for AGR knockout 
We followed the general protocol suggested by Horizon discovery and the 
experimental design is summarised in Figure 5.3. We chose the breast cancer model 
cell line, MCF-7 as the target cell line where AGR2 protein expression level can be 
manipulated as used in previous experiments in Chapter 3-5. To deliver the plasmid 
into the cell line, we used transfection method using Attractene (Qiagen) as this is the 
routine transfection reagent used in our lab and was also proven to be the best 
compared to some commercial transfection reagents in term of cell viability and 
transfection efficiency. The transfected cells were incubated for 72 hours prior to 
single cell dilution into 96-well plates in standard cell culture media to obtain isogenic 
clonal population. After several days, each well of 96-well plates were checked and 
marked if they contained a single colony, while wells containing more than one colony 
(which may contain contaminating clonal line) were excluded. The clonal lines were 
then incubated in the incubator for several weeks to expand as described in Materials 
and Methods followed by characterisation and validation of the isolated clones as 
discussed below. 
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Figure 5.3 Experimental design for generating AGR2 knockout cell line. 
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5.2.1.4.  Characterization of AGR2 knockout clones 
To check whether the isolated clones carry AGR2 knockout, we initially used 
western blot to check AGR2 protein level as this is a quick and simple method to see 
the loss-of-function of a gene. If homozygous knockout is successfully carried out, 
there will be no detectable AGR2 band in western blot. Heterozygous knockout can 
also be obtained, where one of the AGR2 alleles are edited while the other allele is 
intact which may or may not affect the AGR2 protein expression level. 
 
Upon expanding the clones, we noticed that the clonal lines have different 
growth levels, and these cells were harvested and labelled as followed: i) fast growth; 
ii) moderate growth iii) slow growth. Initially, more than 100 clones were successfully 
isolated to contain single colony, however, some cells died suggesting some clonal 
lines cannot tolerate single cell dilution. At the end, we only managed to isolate ~40 
clonal lines. Western blot analysis of the AGR2 clonal lines using AGR2 antibody 
showed a variable degree of AGR2 expression (Figure 14b). One clonal line did not 
show any detectable AGR2 (Clone 11) that could potentially have an AGR2 knockout.  
Some clonal lines showed reductions of AGR2 (e.g Clones 15, 16, 19 and 20) 
compared to unedited non-transfected cells. This reduction of AGR2 expression could 
mean that the clones carry heterozygous knockout. Clonal lines with no detectable or 
reduced AGR2 expression were further grown and harvested for a second western blot 
analysis to make sure that their expression can be maintained. Second western blot 
analysis, however, showed that all clones including clone 11, our main candidate for 
AGR2 knockout showed AGR2 expression. 
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Figure 5.4 Western blot analysis of AGR2 knockout clonal line candidates. (A) Expanded clonal 
lines were harvested according to their cell growth levels: i) fast growth; ii) moderate growth iii) slow 
growth. The cells were harvested using urea lysis buffer and immunoblot using AGR2 K47 antibody. 
(B) The candidate clonal lines for AGR2 knockout were allowed to grow further and passaged several 
times before harvesting for a second western blot analysis using AGR2 K47 antibody. Β-actin antibody 
was used as loading control. 
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5.2.1.5. Genotyping and sequencing of AGR2 knockout clonal lines 
SURVEYOR nuclease assay is a method to detect a specific DNA mismatch 
caused by mutation, micro-deletion, inversion, or indels in heteroduplex DNA. This 
makes possible by the use of SURVEYOR nuclease, an endonuclease that cleaves 
DNA with high specificity at sites of base-substitution mismatch and other alterations. 
This method starts with the isolation of genomic DNA from the heterogeneous 
population of Cas9-targeted cells that is amplified by PCR. Amplicons are then 
denatured and re-hybridised slowly to generate heteroduplexes. The reannealed 
heteroduplexes containing indels are cleaved by SURVEYOR nuclease, whereas 
homoduplexes are left intact and these fragments can be resolved by DNA gel 
electrophoresis. Cas9-mediated cleavage efficiency (% indel) is then calculated on the 
basis of the fraction of cleaved DNA following analysis of integrated intensity of 
electrophoresed bands.  
 
SURVEYOR primers for AGR2 knockout were designed from the genomic 
DNA region within AGR2 exon 4 that will give 586 bp long amplicon, where one of 
the primers is roughly one-third of the Cas9 target so that the cleavage fragments can 
be clearly distinguished in electrophoresis. SURVEYOR nuclease will recognise the 
indels occurring near Cas-9 cleavage site (3’ bp PAM site) which will produce two 
more fragments; ~311 bp and ~275 bp in length.  SURVEYOR nuclease assay requires 
a single PCR product to avoid non-specific cleavage during the digestion process. We 
examined the AGR2 SURVEYOR primers by performing PCR from the isolated 
genomic DNA of the non-transfected MCF-7 cells. DNA gel electrophoresis showed 
that the primers were able to produce a single PCR product with expected band size 
(586 bp). We next, extracted the genomic DNA from the AGR2 knockout clonal line 
candidates and assayed using SURVEYOR nuclease assay. Unfortunately, no 
cleavages were observed on all clonal lines suggesting that AGR2 knockout was not 
successfully carried out. Positive control was included in the assay kit where the DNA 
contains a single nucleotide polymorphism (SNP, GC) in the reannealed 
heteroduplex DNA, which is recognized by the SURVEYOR nuclease, which 
produced the expected three bands (Uncut- 633bp*, G-G mismatch- 416 bp**, and C-
C mismatch- 217 bp***). This also suggests that SURVEYOR nuclease works well 
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and is sensitive in detecting an SNP but not in the case of AGR2 knockout clonal line 
candidates. We further confirmed the results by analysing the PCR amplicons with 
DNA sequencing. The results showed that the genomic DNA of the clonal lines were 
intact with no alteration around the Cas9 target (3 bp upstream PAM site marked by 
red arrow) which confirm that the clonal lines did not carry AGR2 knockout.  
 
We postulated that the gRNA has poor gRNA cleavage efficiency which can 
vary from cell line to cell line. To measure this, MCF-7 cells were transfected with 
gRNA218 and incubated for 72 hours before the cells were harvested for SURVEYOR 
assay. These transfected cells contain a pool of both edited and unedited genome which 
can be assayed by SURVEYOR nuclease. SURVEYOR nuclease assay on these mixed 
populations showed no cleavage of the genomic DNA on AGR2 exon 4 signifying that 
the sequence-specific guide gRNA218 did not direct the Cas9 nuclease to cleave the 
target locus.  Another gRNA (gRNA219) provided by Horizon Discovery which 
showed the second best quality score to target AGR2 exon 4 (data not shown) was also 
assessed for its cleavage efficiency and the result was the same where no cleavage was 
seen. The combination of both gRNA218 and gRNA219 co-transfected into MCF-7 
cells yield the same result. These data suggest that neither gRNAs were efficient for 
editing AGR2 gene. Though variable protein expression of AGR2 was seen in the 
clonal lines which may due to selection pressure from a single cell dilution and 
expansion. 
 
A second attempt was made to knockout AGR2 by another student in the lab. 
This time, the gRNA was designed from the available CRISPR Design Tool15 from 
the Feng Zhang lab at Massachusetts Institut of Technology (MIT) which was deemed 
to be the ‘gold standard’ at the time for designing gRNA. The MIT output colour codes 
the guides (green, yellow, red) designating high quality, mid quality and low quality. 
Guides which are categorised ‘green’ in the MIT output and that have the fewest off 
target sites specified in exons should be preferably chosen. The newly designed gRNA 
for AGR2 knockout targets exon 7 of AGR2 and has a high-quality score with 
minimum off-targets (Figure 5.7A). The gRNA was cloned in-house into 
                                                 
15 http://crispr.mit.edu/  
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pLentiCRISPRv2 using BsmBI and the resulting clone was subjected to DNA 
sequencing to check the presence of the 20-nt gRNA (Figure 5.7B). We made some 
modifications in the experimental design (Figure 5.7C) where we used: i) Barrett's 
oesophagus cell line, CP-A which is positive for AGR2 and ii) fluorescence-activated 
cell sorting (FACS) to sort for single cell dilution.  CP-A cells were chosen because 
they are routinely used in the lab and they are near-diploid cell line which could be 
manipulated relatively easier for gene editing. We also notice that our MCF-7 cell line 
is an aneuploid which maybe of hypertriploid or hypotetraploid which means that three 
of four copies of AGR2 needs to be depleted for complete homozygous knockout, 
which may also explain the difficulty of knocking out AGR2 in this cell line. For FACS 
single cell sorting, CP-A cells were co-transfected with gRNA construct and GFP-
expressing plasmid (pmaxGFP, Lonza) and were sorted for GFP-positive cells. 
Following the expansion of the clonal lines and analysis by western blot, the results 
were disappointing as no cells produced any depleted AGR2 (data not shown). Again, 
like our first experimental layout, there were some clonal lines that showed reduced 
AGR2 expression, but SURVEYOR nuclease assay and DNA sequencing yield 
negative results as there were no evidence of genomic editing. This implied that there 
were selection pressures during single cell dilution and expansion that can give 
variable gene/protein expression levels. The inability to knockout AGR2 in two 
different cell lines with two different gRNA design sources might also suggest that 
knocking out AGR2 is lethal for the cells. Another explanation would be that the 
gRNA might have successfully directed Cas9 nuclease to introduce DSB in target 
genes but due to lethality, these edits cannot be assayed. Another possibility is that the 
gRNA bind to off-target sites (e.g gRNA218 has 30 off targets). However, these off-
target sites were not checked because of time constraint (i.e primers need to be 
designed for each off-target for sequencing or for SURVEYOR assay).   
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Figure 5.5 Schematic of SURVEYOR nuclease assays for genotyping clonal lines. (reproduced 
from [271]). (A) Schematic of the SURVEYOR nuclease assay. First, genomic DNA from the 
heterogeneous population of Cas9-targeted cells is isolated and amplified by PCR producing amplicons 
around 200-800 bp surrounding the Cas9 target site. PCR products are then reannealed to generate 
heteroduplexes. The reannealed heteroduplexes are cleaved by SURVEYOR nuclease, whereas 
homoduplexes are left intact. Cas9-mediated cleavage efficiency (percentage indel) is calculated on the 
basis of the fraction of cleaved DNA, as determined by the integrated intensity of gel bands. (b) An 
example of SURVEYOR nuclease assay. Two sgRNAs (orange and dark blue bars) are used to target 
the human GRIN2B and DYRK1A loci. SURVEYOR gel shows modification at both loci in transfected 
cells. Coloured arrowheads indicate expected fragment sizes for each locus. 
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Figure 5.6 SURVEYOR nuclease assay of AGR2 knockout clonal line candidates. (A) The design 
of SURVEYOR primers (yellow) for AGR2 knockout within AGR2 exon 4 where the gRNA218 is 
located (green) that will amplify 586 bp long. SURVEYOR nuclease will recognise the indels occurring 
near Cas-9 cleavage site (3’ bp PAM site) which will produce two more fragments; ~311 bp and ~275 
bp fragments. (B) Examination of SURVEYOR primers for gRNA218 from non-transfected MCF-7 
cells, which produce a single band at the expected size 586bp. (C) SURVEYOR nuclease assays of the 
clonal line candidates for AGR2 knockout. Positive control was run from the SURVEYOR assay kit 
which detects SNP in the heteroduplex suggesting the nuclease is functional and sensitive. (D) The 
selected clonal lines were subjected to DNA sequencing using forward SURVEYOR primer, and the 
sequences were aligned to see any cleavage site around the 3’ upstream PAM (red arrow) (E) MCF-7 
cells were transfected with gRNA218 or gRNA219 or in combination of both and incubated for 72 hours 
before the cells are harvested for SURVEYOR assay. These transfected cells contain a pool of both 
edited and unedited genome which can be assayed by SURVEYOR nuclease. 
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Figure 5.7 New gRNA design for AGR2 knockout and experimental pipeline (Courtesy of Lee 
Puay Ling). (A) New gRNA design using Feng Zhang lab gRNA design tool at Massachusetts Institute 
of Technology (MIT) (http://crispr.mit.edu/) targeting exon 7 of AGR2 genomic DNA. The gRNA has 
a high-quality score and few off-targets. (B) The gRNA was cloned in-house into pLentiCRISPRv2 
using BsmBI. The vector contains a U6 promoter, expressing wild-type Cas9 which is under the control 
of CMV promoter. This plasmid also contains a 2A puromycin resistance gene to allow screening and 
selection of transfected cells. (C) New experimental pipeline for knocking out AGR2. 
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5.2.1.6. Generation of stable AGR2 expressing cells. 
Due to unsuccessful attempts to knockout AGR2 using CRISPR/Cas9 
technology, we next aim to use gain-of-function analysis to understand AGR2 function 
in cells. This can be done by overexpressing AGR2 in cells which in turn can 
reprogram the cells that can involve inhibition or activation of a protein, a complex, or 
a pathway by different molecular mechanisms. The changes in global proteome 
triggered by AGR2 overexpression can be monitored by the use of quantitative 
proteomics and the outputs can be used to create interaction network. 
 
Transfection into a cell can be in either two forms; transient or stable. In 
transient transfection, the plasmid DNA is inserted into the nucleus of the cell but does 
not get integrated into the chromosome. The foreign gene in the nucleus will be 
temporarily be expressed. Since the gene is not integrated into the genome, the 
transfected gene does not pass to future generations of the cell. Stable transfection, on 
the other hand, does incorporate the plasmid DNA into the genome and gets passed on 
to future generations of the cell. For stable transfection to take place, the plasmid DNA 
must carry selectable marker (e.g antibiotic resistance) on the DNA construct or on a 
separate vector that is co-transfected into the cell. Then appropriate selective pressure 
is applied to the cells after a short recovery period. 
 
We initially sought to establish a stable cell line expressing AGR2 and its client 
protein EpCAM in two different cell lines; MCF-7 (AGR+/EpCAM+) and FLO-1 
(AGR2-/EpCAM-) cells. These stable cell lines can be then used to manipulate AGR2 
and EpCAM interaction and pathways, especially in null FLO-1 cells. For example, 
by making stable EpCAM expressing cells in FLO-1 (AGR2-/EpCAM-), we could ask 
how the introduction of AGR2 ectopically will impact the expression and localisation 
of membrane-bound EpCAM? Will it be the same as the transient reconstitution of 
AGR2 and EpCAM were previously seen? What are the effects on growth, adhesion 
and metastasis? 
 
We chose EpCAM-GFP and AGR2-CHERRY constructs for making stable 
cell lines in MCF- and FLO-1, as both vectors contain a selectable neomycin antibiotic 
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resistance gene. These constructs also express fluorescently-tagged proteins that can 
be visualised directly by fluorescent microscope, so any manipulation of the cells can 
be assayed quantitatively. MCF-7 and FLO-1 cells were transfected with each of the 
following; i) GFP-expressing vector; ii) mCHERRY-expressing vector; iii) EpCAM-
GFP or iv) AGR2-CHERRY and incubated for 72 hours before selection process by 
adding G418 (an analogue of neomycin). Five colonies of each transfected DNA from 
each cell line were then transferred into new wells and expanded. Analysis of the stable 
cell lines in both FLO-1 and MCF-7 expressing EpCAM-GFP and AGR2-CHERRY 
by fluorescence microscopy demonstrated that most cells did not express the fusion 
proteins except for cells transfected with GFP and mCHERRY-expressing vectors. 
There were few colonies that express the fusion proteins but the number of cells 
expressing the fusion proteins were relatively low (~<5% cells from total cells). This 
suggests that creating the stable cell line expressing either EpCAM-GFP or AGR2-
CHERRY were not expressed well or perhaps both proteins were secreted resulted in 
a low percentage of cells having the fluorescent proteins. 
 
5.2.1.7. Real-time visualisation and quantification of cells 
expressing EpCAM-GFP and AGR2-GFP 
We then investigated the cells expressing EpCAM-GFP or AGR-CHERRY in 
real-time quantitative live-cell analysis from the point of the transfection until 3 days 
post-transfection. This analysis can help us to determine the number of cells expressing 
the fusion proteins over time and explain why a generation of the stable cell line 
expressing both proteins was failed. For this analysis, we used IncuCyte® ZOOM 
System (Essen Bioscience) which can monitor and quantify cell behaviour over time 
and also supports HD phase-contrast, green fluorescence and red fluorescence 
automated imaging modes. We used AGR2-GFP instead of AGR2-CHERRY so that 
the image acquisition (green fluorescence) can be done simultaneously with EpCAM-
GFP, and these were transfected into cells using a 96-well plate.  
 
MCF-7 and FLO-1 cells were transfected with each of the following; i) GFP-
expressing vector; ii) EpCAM-GFP, and iii) AGR2-GFP and incubated for 72 hours. 
The cells were transfected with the same amount of DNA but with three different cell 
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densities, each in triplicates; 4000, 8000 and 12000 cells per well of 96-well plate 
(Figure 5.8). Image acquisition of the cells (HD phase contrast and green fluorescence) 
were taken every 3 hours for a total of 72 hours. After 72 hours, the images were 
analysed as a function of the percentage of green fluorescence confluency (GFP) of 
the transfected cells (Number of GFP cells/Total number of cells (phase-contrast) over 
time. In FLO-1 cells, the number of cells with AGR2-GFP expression was very low or 
non-existent in all the three densities (Figure 5.8A-C). For EpCAM-GFP, the cells 
with green fluorescence increased after about 24 hours’ post-transfection but then 
gradually decreased over the time period (Figure 5.8A-C). Although there was an 
increased number of cells with EpCAM-GFP, the highest percentage of GFP 
expression was approximately 5% (Figure 5.8C). In contrast, the GFP-expressing 
vector only, the GFP expression increased over time in all cases and reached as high 
as 20% (Figure 5.8A-C).  Almost the same observations were seen with MCF-7 cells. 
Cells with AGR2-GFP expression showed a slight increase of GFP fluorescence after 
20 hours (~2%) but then dropped to nearly zero (Figure 5.8D-F). The EpCAM-GFP 
expression was maximum after 24 hours’ post-transfection and then plateaued for the 
rest of incubation period (Figure 5.8D-F). MCF-7 cells transfected with the GFP-
expressing vector showed similar observation in FLO-1 cells, where the expression 
increased over time (Figure 5.8D-F).  
 
This data suggest that AGR2-GFP expression is not well maintained in either 
AGR2-negative cells (FLO-1) or AGR2-positive cells(MCF-7). This may be because 
the AGR2-GFP is secreted as described before. AGR2 has also been shown to have 
adhesive property where it can be coated to the plastic substratum, and the coated 
AGR2 protein was able to promote cell adhesion of rat mammary tumour cells [61]. 
This finding leads us to another hypothesis where AGR2 expression is ‘sticky’ to the 
cells which can prevent cells to proliferate. The low expression of AGR2-GFP in our 
real-time analysis explains why we could not isolate stable cell clone expressing 
AGR2-GFP. In the case of EpCAM-GFP, the expression is not well-maintained in 
FLO-1 which is EpCAM negative-cells, probably due to no authentic EpCAM 
synthesis pathway and overexpressing the protein could be toxic to cell over a period 
of time (expression decrease after 20 hours Figure 5.8A-C). In contrast in EpCAM-
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positive cells, MCF-7, EpCAM-GFP expression is maintained after 20 hours, 
suggesting that there is a feedback mechanism to maintain the steady-state level of 
EpCAM-GFP expression. This is not the case with GFP-vector control only where its 
expression is comparatively high in both FLO-1 and MCF-7 cells, implying that that 
AGR2 and EpCAM have different growth characteristics.  
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Figure 5.8 Real-time visualisation and quantification of cells expressing EpCAM-GFP and AGR2-
GFP. MCF-7 and FLO-1 cells were transfected with either: i) GFP-expressing vector; ii) EpCAM-GFP, 
or iii) AGR2-GFP and incubated for 72 hours in incubator equipped with IncuCyte® ZOOM System. 
The cells were transfected with the same amount of DNA but with three different cell densities, each in 
triplicates; (A and D) 4000, (B and E) 8000 and (C and F) 12000 cells per well of 96-wellplate. Image 
acquisition of the cells (HD phase contrast and green fluorescence) were taken every 3 hours for a total 
of 72 hours. After 72 hours, the images were analysed as a function of the percentage of green 
fluorescence confluency (GFP) of the transfected cells (Number of GFP cells/Total number of cells 
(phase-contrast) over time.The experiments were performed in three independent experiments in 
triplicates and  data presented here are representative of one experiment. Error bars represent SEM from 
three biological replicates from one experiment.  
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5.2.3. Live-cell fluorescence imaging of FLO-1 transfected with AGR2-
CHERRY 
We also evaluated the expression of AGR2-CHERRY in FLO-1 cells using live-
cell fluorescence microscopy to further assess AGR2 expression and to monitor its 
localisation and movement in the AGR2-null cell. FLO-1 cells coated on coverslips 
were transfected with AGR2-CHERRY construct and incubated for 24 hours. The 
coverslips containing the transfected cells were then subjected to live-cell imaging 
using epifluorescence microscopy equipped with incubation chambers set at 
physiological conditions. The results demonstrated that AGR2-CHERRY showed 
cytoplasmic localisation and a subset of the population showed puncta staining (Figure 
5.9, left panel). When AGR2-CHERRY was subjected to live-recordings, the puncta 
moved rapidly in the cell suggesting that AGR2-CHERRY localised in secretory 
vesicles. The movement of the vesicles corresponding to AGR2-CHERRY were 
tracked and colour-coded as a function of time (0-50ms) (Figure 5.9, right panel). The 
image analysis proved that these vesicles moved at a high-rate throughout the cell. 
These are unusual features of an ER-resident protein (i.e localisation of ER-resident 
protein like calreticulin or Sec61β generally show tubular or flat sheet structure) and 
further suggest that AGR2 can escape the ER or ‘bud off’ the ER for its secretion or 
perhaps AGR2 involve in chaperoning proteins destined for secretory pathway.  
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Figure 5.9 Live-cell fluorescence imaging of AGR2-CHERRY in FLO-1 cells. FLO-1 cells grown 
in 25mm coverslip in 6-well plate (SLS Cat No. MIC3350) were transfected with AGR2-CHERRY 
construct (2µg) and incubated for 24 hours. Cells on coverslips were transferred onto coverslip chamber 
onto microscope incubation chamber set at 370C and 5% CO2. Images and live-recordings (100x time 
lapse) were captured in widefield using Olympus IX81 epiflourescence microscopy with 63X objective. 
Vesicles tracking and analysis was performed using Imaris by Dr Alison Dun, Heriot-Watt University.  
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5.2.4. Reconstitution of AGR2 by transient transfection 
5.2.4.1. Expression of AGR2 by electroporation 
After having unsuccessful attempts to generate isogenic cell line by knocking 
out AGR2 by CRISPR/Cas9 tool and to generate stable cell line overexpressing AGR2, 
we decided to reconstitute AGR2 into AGR2-null cells (FLO-1) using transient 
transfection and process for mass-spectrometry. Live-imaging of AGR2-CHERRY in 
FLO-1 cells suggests the cells can express AGR2-CHERRY and has intact ER in 
which AGR2 can ‘bud off’ for its dedicated function.  The reconstitution of AGR2 in 
FLO-1 results in transient overexpression that can be used to study AGR2 gain-of-
function. We chose to deliver the DNA constructs using mammalian electroporation 
system. This is to ensure that the cells are free from any lipids that associated with 
most transfection reagents like Attractene and Lipofectamine 2000 which are lipid-
based that could complicate mass spectrometry quantitation. Also, electroporation 
offers higher transfection efficiency compared to traditional lipid-based transfection 
reagents which we have confirmed in our lab. We compared the transfection efficiency 
of GFP-expressing vector (pEGFP-N1 and pmaxGFP) using Attractene and 
electroporation system (Nucleofector® Device, Lonza) after 24 hours incubation and 
counted the GFP- positive cells using a flow cytometry. The transfection efficiency 
was about 4-fold higher using electroporation (data not shown).  
 
We opted to use untagged-AGR2 and not the fluorescently-tagged AGR2 to 
make sure that AGR2 is responsible for reprogramming the cells when we screen for 
any proteomic changes. We have cloned AGR2 in two different vectors with different 
promoters as described in Chapter 4; CMV (strong promoter) and RSV (weak 
promoter). Both AGR2 constructs expressed well and as expected in cells where the 
AGR2 in CMV vector express higher than its RSV counterpart. Since AGR2 
expression is poor in FLO-1 cells and the fact that AGR2 can be ‘adhesive’, we decided 
to choose the low expression promoter RSV so that overexpression of AGR2 is not 
toxic to the cell. The introduction of low expressing AGR2 into cells also ensures true 
representative of AGR2-reprogrammed cells, as any dramatic changes in cells can lead 
to induction of unexpected pathways that could complicate our proteomics screen 
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analysis. We also showed that AGR2 structural variant with the more classic ER 
retention motif (C-terminal KTEL mutated to KDEL) can also stimulate AGR2 client 
protein EpCAM production and delivery to the plasma membrane (Chapter 4) and 
included in our proteomic screen.  
 
FLO-1 cells were transfected in biological triplicates with each of the following 
constructs in a 6-well plate; i) RSV empty vector (pSF-RSV) ii) wt-AGR2 (pAM1L) 
iii) AGR2-KDEL (pAM2L). The cells were incubated for 72 hours. The cells were 
then harvested as described in Materials and Methods and lysed using urea lysis buffer. 
One of the triplicates were subjected to western blot analysis to confirm the expression, 
while the other two were prepared for mass spectrometry and were only performed 
once. Western blot analysis confirmed the expression of wt-AGR2 and AGR2-KDEL 
in FLO-1 cells, while the empty vector RSV (negative control) showed no expression 
of AGR2 (Figure 5.10). The AGR2-KDEL showed higher expression than the wt-
AGR2 which we previously observed in Chapter 4. This is also due to the fact that the 
wt-AGR2 can be secreted into media hence the lower expression, while AGR2-KDEL 
with enhanced ER localisation is retained intracellularly, therefore higher expression. 
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Figure 5.10 Western blot analysis of FLO-1 cells expressing wt-AGR2, AGR2-KDEL, or RSV 
empty vector. FLO-1 cells were transfected with 2 µg of either: i) RSV empty vector (EV) ii) wt-
AGR2-RSV or iii) AGR2-KDEL-RSV in a 6-well plate in triplicates using mammalian electroporation 
system. The cells were incubated for 72 hours and one of the triplicates were harvested using urea lysis 
buffer and subjected to western blot as showed here using anti-AGR2 K47 and anti-β-actin as a loading 
control. 
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5.2.5.  The application of quantitative proteomics using tandem mass tag 
mass spectrometry 
Tandem mass tag (TMT) mass spectrometry is a quantitative proteomics 
approach to accurately determine peptides and proteins in a complex sample (Figure 
5.11). During sample preparation, fractionated peptides are labelled with TMT tag. 
Each tag comprises a sensitization group and a mass differentiated group that together 
comprise the TMT fragment which is actually detected [272]. TMT tags consist of an 
amine reactive, N-hydroxysuccinimide ester (NHS-ester), balancing carbonyl linker 
and reporter ion components. The tags also comprise a reactive functionality (R) to 
enable the tag to be coupled to any peptide which forms amide linkages with the label 
peptides via N-termini or lysine residues. TMT mass spectrometry allows 
multiplexing, where multiple tags with different reporter ions can be used 
simultaneously for each different samples and all the samples are mixed prior to 
fractionation and analysed using tandem mass spectrometry (MS). TMT-tagged 
peptides are chemically identical and have the same total mass and chromatographic 
separation and therefore the liquid chromatography (LC) retention time and 
mass/charge (m/z) separation of each labelled peptides do not split into different peaks 
during the MS1 scan [273]. TMT strategy relies on dissociation of the TMT fragment 
by a number of methods of dissociation. One such method involves colliding the ions 
with a stream of inert gas, which is known as collision-induced dissociation (CID) or 
higher energy collision dissociation (HCD) to produce ionised labelled peptide in the 
MS2 mode (Figure 5.11). The peptide fragments are detected by generating mass 
spectra in the usual manner fragment. The reporter ions are detected and as peaks at a 
predefined m/z. For a TMTsixplex experiment, the reporters are detected at 
126.1,127.1, 128.1, 129.1, 130.1 and 131.1 m/z [272]. TMT offers better signal-to-
noise ratios and permits untagged material to be discounted which significantly 
improving data quality.  
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Figure 5.11 Flowchart of experimental design for TMT mass spectrometry. FLO-1 cells were 
transfected either: i) RSV empty vector (EV) ii) wt-AGR2-RSV or iii) AGR2-KDEL-RSV in a 6-well 
plate in biological triplicates using mammalian electroporation system. The cells were incubated for 72 
hours and two of the triplicates were analysed by MS and MS was only performed once. Cells were 
lysed, reduced, alkylated and trypsin digested using FASP protocol. Peptides were labelled using 
TMTsixplex isobaric tags as illustrated. Labelled peptides were mixed and analysed using Orbitrap LC-
MS/MS before data analysis. Labelled peptide ions are indistinguishable in the full MS. Quantification 
is based on low m/z reporter fragment relative ion intensities after a target ion is isolated and fragmented 
(CID/HCD) in MS2 experiment. 
 
  
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 5 – Analysis of AGR2 Reprogramming Cancer Cell Using Quantitative 
Proteomics 
223 
5.2.5.1. TMT quantitation of proteome of cells with incorporated 
AGR2 
    The TMT methodology allows a degree of multiplexing of the experiment 
design, to incorporate relevant controls for the analysis of the function of the AGR2 
gene of interest. We employed TMTsixplex™ (Thermo Fischer Scientific) technique, 
allowing quantitation of three different samples/conditions in duplicates to be 
compared concurrently which are; cells with the RSV empty vector, cells with wt-
AGR2, and cells with AGR2-KDEL. Any modification from the cell with empty vector 
suggests a potential role of the introduced gene in the reprogramming of the cell. This 
also allows us to see if there are any overlaps of dysregulated proteins from proteomics 
screen between the two variants, where wt-AGR2 represent ER-localised and secreted 
form while AGR2-KDEL represent enhanced ER-localised form. 
 
Proteins extracted from transfected FLO-1 cells in biological duplicates are 
reduced, alkylated and digested as described in Materials and Methods. Samples were 
labelled with the TMT Reagents as illustrated in Figure 5.11. Each biological duplicate 
was labelled with TMT labels; EV with 126 and 127; wt-AGR2 with 128 and 19; and 
AGR2-KDEL with 130 and 131. Labelled peptides were then mixed following by 
sample fractionation and clean up. Samples were then analysed by high-resolution 
Orbitrap LC-MS/MS before data analysis to identify peptides and to quantify reporter 
ion relative abundance, thanks to Dr Lenka Hernychova. The total number of proteins 
identified in the spectral files were 1224 (Appendix 5). The quantitation of peptides 
was further analysed and the relative abundance of the peptides was measured by 
comparing the peptide pairs labelled with different TMT tag (e.g 128/126 for wt-
AGR2/Control) followed by statistical evaluation on the peptide ratios to infer protein 
levels. The fold changes of quantified proteins in biological duplicates were 
normalised by calculating the geometric mean of the of the fold changes. The fold 
changes of all quantified proteins for each AGR2 expressing cells over control were 
plotted against the TMT scores (Figure 5.12A-B). The majority of protein expression 
levels quantified across all conditions were not dramatically altered from the control 
AGR2-null cell line. However, we noticed that for wt-AGR2 expressing cells the 
global proteins seem to be clustered to the left quadrant suggesting most proteins were 
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downregulated. On the other hand, the more enhanced ER-localised AGR2, AGR2-
KDEL expressing cells showed most proteins clustered to the right quadrant 
suggesting that most proteins were upregulated. This suggests that the two AGR2 
variants have specific distinct signalling pathways consistent with the theory that both 
proteins have different localisations in the cells. We also plotted the fold changes of 
wt-AGR2 and AGR2-KDEL against each other so we can determine overlapping 
proteins between the two populations (Figure 5.12C). The plot shows clustering of 
proteins towards the second quadrant (upper left) suggesting that most proteins were 
upregulated in AGR2-KDEL but the same set of proteins were downregulated in wt-
AGR2 cells. Only a few proteins were found to be upregulated in both conditions and 
the key proteins were highlighted in green (Figure 5.12C, first quadrant) such as AGR2 
itself, AK3, MRPS28, RAB6A and DCD. Two proteins were found to be the dominant 
downregulated outliers and these are KRT17 and PAX highlighted in blue (Figure 
5.12C, third quadrant). 
 
The database mining of proteins containing AGR2 docking motif shows 
enrichment in transmembrane proteins (Chapter 3), suggesting that AGR2 involve in 
the maturation of this class of protein, at least in the case of transmembrane EpCAM.  
Therefore, we expect that introduction of AGR2 will yield upregulation of this class 
of proteins. However, when we ranked the differentially expressed proteins, the top 10 
most upregulated and downregulated proteins in wt-AGR2 or AGR2-KDEL 
expressing cells listed were not enriched in transmembrane proteins.    This might be 
that the transmembrane proteins were not properly extracted during sample 
preparation due to highly hydrophobic and water-insoluble nature of membrane 
proteins the fact that they are present at low abundance and the absence of polar side 
chains in amino acid residues [274].  The use of shotgun proteomics or enrichment of 
glycoproteins during sample preparation might be a better idea to resolve identification 
of membrane protein landscape [275, 276].  
 
 We further analysed the top 40 most upregulated proteins in wt-AGR2 and 
AGR2-KDEL expressing cells and subjected to functional enrichment tools using 
FunRich [212]. When the top 40 proteins upregulated in wt-AGR2 expressing cells 
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were scored based on subcellular components, the majority of the proteins have 
localisation in the exosomes and lysosomes.  The AGR2-KDEL expressing cells also 
showed the same enrichment and additionally displayed protein localisations in the 
cytoplasm.   
  
 We also looked at the overlapping proteins of the top 40 upregulated genes in 
both cases of AGR2-expressing cells. There are 15 overlapping proteins suggesting 
potential AGR2 client proteins. These 15 proteins mainly enriched in lysosomal 
proteins such as SEC24 family member C (SEC24C) and superoxide dismutase 1 
(SOD1). However, these proteins, are not validated in this study. We chose dermcidin 
(DCD) protein as a potential AGR2 binding protein. DCD is upregulated in both wt-
AGR2 and AGR2-KDEL expressing cells and the fact that DCD is also found in 
another proteomic screen in the lab where it was identified in label-free SWATH 
(sequential window acquisition of all theoretical fragment ion spectra) mass 
spectrometry analysis of ELMO1 pull-down assay from FLO-1 and OE19 cells (Ali 
Alsaadi Thesis 2016, and personal communication). ELMO1 was shown to form 
protein-protein interaction complex with AGR2 as well as DCD in cells using in situ 
PLA, suggesting that AGR2 may potentially bind to DCD.  
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Figure 5.12 Quantitative mass spectral data of wt-AGR2 and AGR2-KDEL expression subtly reprograms the proteome of the cell. (A) Distribution of fold 
changes of all proteins quantified in wt-AGR2 compared to EV control FLO-1 cells that are plotted as a function of TMT scores. Most proteins showed downregulation 
of the proteome as they are clustered to the left quadrant, while few proteins were upregulated showing in the right quadrant. (B) Distribution of fold changes of all 
proteins quantified in AGR2/KDEL compared to EV control FLO-1 cells that are plotted as a function of TMT scores. Most proteins showed upregulation of the proteome 
as they are clustered to the right quadrant, while few proteins were upregulated as plotted in the left quadrant. (C) Distribution of fold changes of all quantified proteins 
in AGR2-KDEL/Control on the y-axis and wt-AGR2/Control on the x-axis plotting against each other, indicating common genes upregulated (quadrant 1, top right) or 
downregulated (quadrant 3, bottom left) in both conditions. In all plots, key upregulated proteins were annotated and marked with green colour for upregulated proteins 
while downregulated proteins with blue colour.   All identified proteins were summarised in Appendix  5. 
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Figure 5.13 Ranked TMT expression data presenting the ten most upregulated and downregulated protein expression changes as a result of wt-AGR2 or AGR2-
KDEL genes introduction into AGR2-null FLO-1 cells. The proteins are tabulated by protein ID, TMT score and fold changes. 
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Figure 5.14 Functional enrichment of the top 40 most upregulated proteins in wt-AGR2 and  AGR2-KDEL expressing cells using Funrich [212].   The top 40 
most upregulated    proteins in (A) wt-AGR2 expressing cells and  (B) AGR2-KDEL expressing cells were scored as cellular components. (C) Venn diagram showing 
overlapping proteins from the top 40 upregulated proteins between wt-AGR2 and AGR2-KDEL expressing cells. (D) List of overlapping proteins in (C). 
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5.2.6. Dermcidin as a potential AGR2 binding partner 
Dermcidin (DCD) is a secreted protein that is subsequently processed into 
mature peptides with distinct biological activities [277]. In normal cell physiology, 
DCD play a role in the antimicrobial activity, innate immunity and embryogenesis. In 
cancer cells, DCD has been shown to promote cancer cell survival and responsible for 
disease progression. For example, DCD was found to be in a high concentration in the 
blood of breast cancer patients and associated with poor prognosis [278]. It was also 
identified in a subset of invasive breast cancers and found that its expression enhanced 
cell proliferation and has been reported to make cells more resistant to oxidative stress 
compared to control cell lines [279]. The unprocessed precursor DCD is an 110 aa 
long, and the protein can undergo proteolytic processing forming functional 
domains with different functions (Figure 5.15). The functional domain generally 
can be divided into two groups: prodomain and antimicrobial peptide (AMP) 
domain [280]. The AMP domain, for example, can give rise to a functional peptide 
that started with 47 aa long which is constitutively expressed in sweat glands and, 
secreted into the sweat, and transported to the epidermal surface. This peptide fragment 
of DCD was named as DCD-1 which play a role in antimicrobial defence [277]. The 
prodomain, on the other hand, can be spliced to encode Y-P30 which results in 30 
aa peptides which were previously named as diffusible survival evasion peptide 
(DSEP) and was shown to increase resistance to oxidative stress [277].  
 
DCD function and localisation seems to mirror AGR2 since DCD is secreted 
and also found in extracellular vesicles, implicated in cancer cell survival. Therefore, 
DCD is a highly-relevant ‘dominant’ pro-oncogenic signalling target which can be a 
potential AGR2 client protein. Studying the interaction can also help us understand the 
role of AGR2 in secretion and trafficking pathways. 
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Figure 5.15 Overview of dermcidin gene and the gene products with distinct biological functions. 
(reproduced from [277]). Mature dermcidin RNA codes for a precursor protein with 110 amino acid 
residues and molecular weight of 11.2 kDa. DCD can be divided into two functional domains; 
Prodomain and antimicrobial peptide (AMP) domain. Prodomain can be spliced for example producing 
30 aa peptides Y-P30 or 47 aa DCD-1 or 48 aa DCD-1L peptides. The resulting peptides have different 
biological roles in a cell. 
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5.2.6.1. Western blot analysis of AGR2-expressing cells to check 
DCD expression levels 
We first assessed whether the DCD expression is indeed changed as a result of 
ectopically expressing AGR2.  We repeated the transfection of RSV empty vector, wt-
AGR2 and AGR2-KDEL into FLO-1 cells and incubated for 72 hours the same way 
we did for mass spectrometry analysis. The cells were harvested using urea lysis and 
subjected to western blot analysis. There were two peptides detected by mass 
spectrometry analysis and these are; dAVEDLESVGk and aVGGLGk where the 
former is a unique peptide. Both peptides attributed to AMP domain of the C-terminal 
DCD. Thus, we obtained the DCD antibody which recognises the C-terminal epitope 
of DCD (anti-Dermcidin E-7, #sc-393728, Santa Cruz Biotechnology). However, this 
antibody did not detect any band at the expected size of around 12 kDa even after long 
exposure and high concentration of lysates (data not shown). We then obtained a 
second antibody from a different commercial source which can detect endogenous 
DCD (anti-Dermcidin, #ab175519, Abcam) and also binds to C-terminal of DCD (aa 
81-110). Immunoblotting using this antibody on the transfected cell lysates detected 
bands around 12 kDa and also a second upper band around 25 kDa which we assumed 
is the dimer form of DCD, and this band also appeared in manufacturer's datasheet. 
However, the corresponding ‘monomeric’ 12kDa band looks relatively higher in the 
control RSV empty vector expressing FLO-1 cells compare to wt-AGR2 or AGR2-
KDEL cells. The 25kDA ‘dimeric bands’ appearance was more apparent, where in 
both wt-AGR and AGR2-KDEL cells, the bands were more reduced compared to the 
RSV control. This data contradicts with our mass spectrometry data suggesting that 
DCD is upregulated in both cases. We hypothesised that the DCD is secreted into 
media as DCD-1L/DCD-1 processed peptide form (the 48/47 aa long peptide 
respectively) during post-translational modification hence the lower expression was 
seen in western blot. Thus, we collected the media of the transfected cells, concentrated 
it 40 times and subjected to immunoblot analysis using DCD antibody. However, we 
could not detect any expression of DCD in the media (Figure 5.16B). Another 
explanation would be that, although fold changes in peptide ions identified from TMT 
quantitation can be used to translate protein changes as being “up or downregulated”, 
this does not necessarily mirror changes in the absolute steady‐state protein levels. The 
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fold changes might also reflect the extractability, post-translational modification, and 
trypsinisation capacity that give rise to peptide ion identification and then quantitation 
using MS. Since DCD is highly susceptible to post-translational modification 
(proteolytic processing to form functional peptides with as illustrated in Figure 5.15, 
this can affect quantitation using MS yielding such a result.   Despite contradictory 
data (mass spec vs. western blot), the DCD level was altered as a result of AGR2 
expression, suggesting that mass spectrometry was highly sensitive to detect any 
proteomic changes  
 
5.2.6.2. AGR2 and DCD protein interaction using in situ proximity 
ligation assay 
As mentioned previously, one member of the lab showed that DCD was one 
of the pulled-down proteins associated with ELMO1 protein as detected by 
SWATH MS (Ali Alsaadi Thesis 2016). Also, ELMO1 was shown to form protein-
protein interaction with DCD and AGR2 as analysed using PLA. Thus, we 
evaluated whether AGR2 can form a protein complex with DCD in cells using 
PLA. We utilised the Duolink In-situ based PLA assay that we have used before to 
detect the AGR2 and EpCAM protein-protein interaction (Chapter 4).. We used the 
mouse monoclonal AGR2 antibody (AGR3 4.1) and rabbit polyclonal DCD 
antibody (Abcam).  FLO-1 cells were first transfected with RSV empty vector (EV 
Upper panel), wt-AGR2 (middle panel) or AGR2-KDEL (lower panel) and 
incubated for 24 hours and processed for PLA using the antibody pair. Following 
addition of PLA probes, ligation and amplification, protein-protein interaction 
complex was detected with red fluorescent probes (Duolink). However, we could 
not detect any PLA foci in cells expressing either wt-AGR2 or AGR2-KDEL, 
suggesting that the two proteins did not interact with each other in cells (Figure 
5.17, middle and upper panel). Based on these data, we hypothesised that AGR2 
does not bind DCD directly but may bind through ELMO1 protein or its cofactors.  
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Figure 5.16 Western blot analysis of AGR2 reconstituted FLO-1 cells using DCD antibody. (A) 
(Upper panel FLO-1) Cells were transfected with RSV empty vector (EV), wt-AGR2 or AGR2-KDEL 
using electroporation and incubated for 72 hours, the same condition as our previous mass spectrometric 
analysis. The lysates were harvested using urea lysis buffer and immunoblot using anti-DCD (Abcam). 
(Lower panel) The 12kDa band intensities in all conditions were measured using ImageJ and plotted as 
a bar graph. (B) Media from cells transfected with constructs in (A) were collected and concentrated 
40X using Amicon concentrating column with 30,000 da cutoff filter (Millipore). Concentrated media 
were mixed with SDS sample buffer and subjected to western blot using anti-DCD. 
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Figure 5.17 Proximity ligation assays demonstrate that AGR2 and DCD did not form protein-
protein interaction in situ. Representative image of a proximity ligation assay performed with antibody 
pair of anti-AGR2 mAb (AGR3 4.1) and anti-DCD pAb (Abcam). FLO-1 cells were first transfected 
with RSV empty vector (EV Upper panel), wt-AGR2 (middle panel) or AGR2-KDEL (lower panel) and 
incubated for 24 hours before processed for PLA using the antibody pair. PLA probes (Anti-rabbit 
PLUS probe and anti-mouse MINUS probe) were then added to the samples. Following ligation and 
amplification, protein-protein interaction complex was detected with red fluorescent probes (Duolink). 
Red fluorescence foci indicate the interaction between the two proteins, which was not observed in any 
of the cells. Scale bar 10 µm. 
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5.3. Discussion  
Methods to study protein-protein interactions have been improved over the 
years. A typical protein-protein interaction study usually begins with an initial screen 
for novel binding partners. It has been shown previously that knockout of a protein 
which has a central role in many networks tends to be lethal [281]. This phenomenon 
has been observed in many organisms [282, 283] and is commonly referred to as the 
centrality-lethality rule. The current view that most, if not all, cellular proteins are 
directly or indirectly coupled to a large cellular protein–protein interaction network 
has implications for the way we define cellular pathways.  
 
The emerging programmable nucleases for a precise genome editing has 
enabled scientists to produce rapid and complete loss-of-function gene knockout in 
cells [268, 270, 284] to study gene function. In this chapter, we aimed to develop an 
isogenic cancer cell line by knocking out AGR2 using the latest CRISPR/Cas9 genome 
editing technology to infer AGR2 function and use the AGR2-null cell to screen for 
global proteome changes using quantitative proteomics.   We have previously shown 
that the database mining of proteins containing AGR2 docking motif shows 
enrichment in transmembrane proteins (Chapter 3), suggesting that AGR2 is involved 
in the maturation of this class of protein. Further analysis of AGR2 with one of the 
proteins of this class, EpCAM showed that EpCAM’s plasma membrane expression is 
dependent on AGR2 expression. Immunohistochemistry using OAC tissues showed 
that the two proteins were highly co-expressed (Chapter 4). We aimed to study AGR2 
function by a complete loss-of-function which is then coupled with quantitative 
proteomics analysis to identify the dominant pathways or co-factors associated with 
AGR2. Our goal was also aimed to find evidence that AGR2 engages in trafficking 
and secretion pathways to complement our previous data suggesting that AGR2 
involve largely in the maturation of proteins destined for secretory pathway. 
 
We first attempted to generate a complete loss-of-function by knocking out 
AGR2 in MCF-7 cell line using CRISPR/Cas9 technology. We targeted the exon 4 of 
the AGR2 genomic locus for DSB. However, we were unable to generate AGR2 
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knockout cell line as confirmed by western blot analysis and DNA sequencing (Figure 
5.4and Figure 5.6). A different experimental strategy was employed by using a 
different algorithm for designing the 20-nt gRNA, a different cell line, and FACS 
sorting to isolate individual clones yield the same results, where no clonal line carrying 
AGR2 knockout was isolated (Figure 5.7). However, in both experimental approaches, 
we observed variable AGR2 expression in the clonal lines compared to the parental 
cell line, suggesting that there were selection pressures during single cell dilution and 
expansion that can give variable gene/protein expression levels (Figure 5.4). There 
was no published data thus far showing AGR2 knockout in a cell line by the 
CRISPR/Cas9 technology though partial knockdowns by RNAi have been widely 
successful [144, 161]. There are several aspects that affect CRISPR/Cas9 technology 
and this includes efficiency and specificity, including Cas9 activity, target site 
selection and sgRNA design, delivery methods, off-target effects and the incidence of 
NHEJ/HDR repair. One of the main problems we encountered was the delivery of the 
plasmid encoding the sgRNA and Cas9 since different cells have different transfection 
efficiency. We utilised both transfection and electroporation methods coupled with 
FACS sorting to isolate clonal lines. The electroporation method for example only 
yield 20% efficiency as counted by FACS for cells with GFP staining. Additionally, 
once transfected, plasmid DNA can also persist inside the cells for several days, which 
may exacerbate off-target effects in this small population of transfected cells. To 
circumvent these pitfalls, studies have emerged to improve this technology for 
example, by improving sgRNA design by extending PAM sequence [285]. Moreover, 
the delivery method by viral vectors have been used as this vector is an active, 
receptor-dependent process that allows control over the amount of DNA transfected 
with greater efficiency and less cytotoxicity and viral vector can enter into large 
numbers of cell types efficiently [286].  Researchers are also looking to microbes to 
find endonucleases that have different sequence requirements than Cas9 so that they 
can expand the flexibility in modifying the number of sequences. One study has found 
an endonuclease which is called Cpf1 [287]. This enzyme is smaller than Cas9, has 
different sequence requirements and is highly specific. Another enzyme, called C2c2 
has been found that can targets RNA rather than DNA and holds the potential to 
develop into new RNA-targeting tools [288]. 
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 




The inability to knockout AGR2 suggests that AGR2 may play a central role 
in the cell, and complete loss-of-function of the gene may be lethal. This observation 
was seen in mice model, where conditional AGR2 knockout (Agr2 -/-) resulted in 
premature death due to gastrointestinal obstruction showing consistent phenotype 
featuring hyperplasia of the glandular stomach [289]. Two other studies using 
conditional (Agr2 -/-) null mice experiments showed that the mice were viable but with 
histologic changes, if not severe changes, in the stomach and intestines [60, 63]. The 
different results from Agr2 null mice may be due to conditional knockout that 
implements floxed Agr2 exons whose deletion were dependent on the constitutive 
expression of Cre recombinase. In addition, there might be some residual AGR2 
expression at early developmental stages, hence the increased in viability. A more 
recent study by Dong et al., generated a non-conditional AGR2 null mouse with 
germline deletions of Agr2 exons 2–8 [111]. The study showed that only two out of 52 
mice with homozygous AGR2 knockout is viable but one of them died after 3 weeks 
while the other suffered from weight loss and displayed many of the gastrointestinal 
obstructions. This suggests that AGR2 may belong to highly connected proteins in the 
cell that is important for its survival, and also explains why we were unable to generate 
AGR2 knockout in cell line using CRISPR/Cas9 technology. AGR2 was found to be 
overexpressed in our proteomics screen in tissues of OAC compared to normal 
adjacent tissues (Robert O’Neill Thesis 2014) and confirmed using 
immunohistochemistry of tumour microarray earlier in the thesis (Chapter 4) 
signifying that AGR2 is needed for cancer cell survival. Inducible knockdown of 
AGR2 in a cell line has never been done before. Inducible knockdown RNAi System 
may be performed in the future to determine the lethality of AGR2 knockdown in cells 
as this has been proven useful in cases where suppression of a gene may be lethal, 
preventing its analysis [290] and this can support our current hypothesis. This system 
use an expression vector for example, lentiviral expression system to express the and 
this system is induced when either tetracycline (Tc) or doxycycline (Dox; a Tc 
derivative) is added to the culture medium of an appropriately engineered cell. 
Induction of the shRNA results in suppression of the gene targeted by the shRNA 
through RNAi. Thus, the system allows for tight regulation of the expression of a 
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shRNA in a time-dependent manner suitable for studying lethality of a gene when Tc 
or Dox is added to the medium. 
 
Our attempt to generate an overexpressed AGR2 by creating a stable cell line 
expressing AGR2-GFP were also unsuccessful. Real-time visualisation of transfected 
AGR2-GFP in both cell lines showed that AGR2-GFP expression declined to almost 
non-existent after about 24 hours post-transfection (Figure 5.8). As AGR2 protein has 
been shown to promote cell adhesion [61], we hypothesised that AGR2 expression 
stimulates ‘adhesive properties’ which can prevent cells to proliferate. However, when 
AGR2-CHERRY was subjected to live-cell fluorescence imaging in FLO-1 cells, the 
expression was observed as puncta or secretory vesicles which implied that the AGR2-
CHERRY can be expressed in this AGR2-null cell. These vesicles move rapidly 
throughout the cells suggesting that AGR2 not only reside in the ER, but can escape 
or ‘bud off’ from the ER to be secreted or perhaps involve in trafficking of secretory 
proteins as we hypothesised (Figure 5.9).  
 
This led us to find a new strategy to study AGR2 function in which we utilised 
protein overexpression strategy to study AGR2 function. We utilised AGR2-negative 
cells, FLO-1 that we identified earlier in which we reconstitute the cell as a function 
of AGR2 transient overexpression and process for mass-spectrometry analysis. 
Overexpression of AGR2 can promote changes in the AGR2-interactome by either 
dissociating existing PPIs or induction of new AGR2 interactions especially in cells 
that do not express AGR2. We delivered the weaker expression of AGR2 under the 
control of Rous sarcoma virus (RSV) promoter into FLO-1 cells, which was one of the 
commercially weakest promoter previously cloned (Chapter 4) to ensure that its 
expression is not too overwhelm that can be toxic to cell and also warrants the true 
representative of AGR2-reprogrammed cells for our proteomics screen analyses. 
Quantitative proteomics mass spectrometry was used to look for a  global view of 
proteomic dynamics to unravel dominant proteins and pathways of wt-AGR2 and 
AGR2-KDEL expressing FLO-1 cells compared to RSV empty vector FLO-1 cells.  
Progress in mass spectrometry instruments and data analysis currently can be carried 
out using both label and label-free approaches to quantify the protein expression 
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landscape of the experimental condition (Table 5.2 Summary of quantitative 
proteomics strategies). Quantitative proteomics can be split into two forms: relative 
and absolute. Relative quantitation methodologies compare two or more samples to 
one another (e.g to a control) as a function of relative fold change of protein abundance. 
Absolute quantitation is the determination of the precise amount or mass concentration 
of a protein. In its simplest form, 2-dimensional gel electrophoresis (2-DIGE) coupled 
to fluorescent dyes, fluorophores or radioactivity label allow protein levels to be 
quantified using the intensity of the incorporated labels to the same spot from a control 
lysate. In MS-based proteomics, the reliance is based on stable isotope dilution theory, 
which states that a stable isotope-labelled peptide is chemically identical to its native 
counterpart; therefore the two peptides also behave identically during chromatographic 
and mass spectrometric analysis. The sensitivity of an MS detector means that the mass 
difference between the labelled and unlabelled isoforms of the peptide can be 
differentiated, and quantification can be achieved by comparing their relative signal 
intensities. Isotope labels can be introduced into the sample in several ways: (i) 
metabolically, (ii) through chemical reactivity, (iii) enzymatically or (iv) as an external 
standard of the spiked synthetic peptide to normalise to [291]. Recently, label free 
strategies have begun to emerge, such as spectral counting where the number of spectra 
acquired of a specific peptide/protein is used as an estimate of abundance in the 
sample. The stable isotope labelling by amino acids (SILAC) method for example use 
the metabolic labelling of cells in growth medium [292] incorporating light and heavy 
forms of arginine or lysine allowing labelling of all nascent proteins in the 
experimental condition. This makes proteins from the light and heavy cells 
distinguishable by MS after the cell lysates are mixed and the proteins separated. 
However, multiplexing is limited in SILAC in which three isotopically labelled SILAC 
allows comparison of three cell populations in a single experiment [293]. SILAC also 
is only restricted to cultured cells and depends on full incorporation of amino acids in 
growth medium for mass spectrometric analysis. The development of isobaric mass 
tags such as tandem mass tag (TMT) [272] and isobaric tags for relative and absolute 
quantification (iTRAQ) [273] allows for the comparison of up to ten samples in 
parallel, which is particularly useful in studies of time courses or in providing 
biological replicates. TMT used in this study is based on the introduction of isobaric 
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tags to label peptides which do not influence chromatographic nature. The LC-MS/MS 
analysis yields peptide fragment ion spectra generated in MS1 for peptide 
identification and the cleaved tag spectra generated in MS2, which are used for relative 
quantitation. The ratio of detection of the tags can then be used as a relative 
quantitation measure to detect the difference between the levels of proteins from 
different samples. Assuming complete peptide labelling with TMT isobaric tags of 
each sample, the more abundant peptides within each sample will incorporate more 
label. When equal amounts of each sample are mixed and subjected to LC-MS/MS 
analyses, those samples with a higher concentration of peptide will produce higher 
reporter ion peak intensities in the MS2 scan. By comparing the relative reporter ion 
intensities, the relative peptide and therefore protein abundances in the original 
samples can be determined [294]. Therefore TMT methodology provided the most 
appropriate platform for this study as we can perform the TMTsixplex™ experiment 
which permits comparison of not only AGR2-null and AGR2-expressing cells in 
biological duplicates, but also the comparison with the enhanced ER-localised AGR2, 
AGR2-KDEL to control for ER/intracellular specificity. 
 
 TMT relative quantitation showed differences in the proteome dynamics of wt-
AGR2 and AGR2-KDEL expressing cells compared to RSV empty vector cells 
(Figure 5.12). The overall protein expression levels quantified across the two 
conditions were not significantly altered as the fold changes were largely between 0.5-
1.5 region (Figure 5.12A-B). However, the proteome of reconstituted wt-AGR2 cells 
showed that most proteins were downregulated while the AGR2-KDEL cells showed 
that most proteins were upregulated suggesting that the two AGR2 variants have 
specific distinct signalling pathways. This also suggests that the localisation of AGR2 
gives different cellular reprogramming outcomes. The wt-AGR2 has been shown to 
localise intracellularly (mainly in the ER) as well as extracellularly [94, 260]. The 
AGR2-KDEL, with more classic ER retention motif, was shown to localised 
intracellularly, more specifically in the ER where it colocalises with ER-marker PDI 
[260]. A large number of downregulated proteins identified in the wt-AGR2 
expressing cells may correlate to our real-time analysis (Figure 5.8), where the wt-
AGR2-GFP expression in FLO-1 cells was not well- maintained or was almost non-
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existent in FLO-1 cells. Possibly, the wt-AGR2 is secreted to an extracellular milieu 
which can play a role in autocrine/paracrine signalling giving such results. The 
enhanced ER-localised AGR2-KDEL, on the other hand, may act as general molecular 
chaperone, assisting in the proper endogenous protein folding and maturation in the 
ER, yielding many proteins exiting the stringent ER quality control, hence many 
upregulated proteins quantitated by mass spectrometry. 
 
In Chapter 3, AGR2 has propensities to bind transmembrane proteins as this 
type of proteins were found to be dominant using our motif-based approach. This leads 
to another hypothesis in this chapter where proteomics approach could show that 
membrane proteins or perhaps secretory proteins may increase globally when AGR2 
is expressed.  However, our results did not show dominant upregulation of membrane 
proteins (Figure 5.13). We hypothesised that the transmembrane proteins were not 
properly extracted during sample preparation due to its hydrophobic and water-
insoluble nature, therefore mainly soluble proteins were extracted for mass 
spectrometric analysis. This experiment can be repeated in the future by performing 
an enrichment and fractionation of subcellular compartments prior to mass-
spectrometric analysis to increase the detection limits of analysis and this also can 
determine the localisation of identified proteins. In our case, the membrane fraction 
can be extracted for mass spectrometric analysis to check whether membrane proteins 
are upregulated in the presence of AGR2 to support our hypothesis. Alternatively, 
proteome analysis of a specific subcellular fraction that has been post-translationally 
modified for example, protein glycosylation-targeting enrichment can be performed. 
Protein glycosylation analysis has become an important target in the proteomic 
research field and has great potential for clinical applications like the development of 
biomarkers. Many protein biomarkers that are known to be cancer biomarkers are also 
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Methodology Labelling  
strategy 
Quantitation Advantages Disadvantages 










Isobaric labelling Relative Allows 
multiplexing up 
to 10 samples 
Additional chemical 
modification step 






in cultured cells and 
limited to in in-vivo use 
18O Labelling Heavy oxygen 
isotope labelling 
Relative Labelling during 
trypsin digestion 
Complete labelling is 
rare and poor coverage 
Spectrum 
count 
None Relative No labelling Inaccurate for low 
abundance 





Only suitable for known 
targets 
Table 5.2 Summary of quantitative proteomics strategies 
 
Functional analysis of the top 40 upregulated proteins in both AGR2 variants 
expressing cells showed that they were enriched in exosomal proteins (Figure 5.14). 
This result is consistent with previous studies that showed AGR2 upregulates 
exosomal marker TSG101 whose expression induced p53-dependent activity 
suppression whose expression attenuates p53 signalling [297], and strongly suggest 
that AGR2 can sculpt cellular secretome. The top overexpressed proteins are also 
enriched in lysosomal proteins. Lysosomes are membrane-bound organelles that 
receive and degrade macromolecules from the secretory, endocytic, autophagic and 
phagocytic membrane-trafficking pathways through the activity of lysosomal 
hydrolases [298]. Additionally, lysosome also has been linked with various 
physiological processes, such as cholesterol homoeostasis, plasma membrane repair, 
bone and tissue remodelling, pathogen defence, cell death and cell signalling, 
suggesting possible roles of AGR2 in any of these processes. The AGR2-KDEL, but 
not wt-AGR, expressing cells were enriched in cytoplasmic proteins, which is 
consistent with our hypothesis that ER-localised form of the AGR2 act as a protein 
folding catalyst releasing properly folded protein from ER to cytoplasm. There are 15 
common proteins in the top 40 upregulated proteins suggesting possible AGR2 client 
proteins. One interesting protein include superoxide dismutase 1 (SOD1) which is 
upregulated in both wt-AGR2 and AGR2-KDEL samples, also referred to as Cu/Zn 
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superoxide dismutase, which is an antioxidant enzyme that binds copper and zinc ions 
and forms a homodimer whose main known function is as a dismutase removing toxic 
superoxide radicals (O2
−) radical into either molecular oxygen (O2) or hydrogen 
peroxide (H2O2). SOD1 mutations have been associated with the neurodegenerative 
disease amyotrophic lateral sclerosis (ALS) [299]. Since AGR2 has an oxidoreductase 
activity through its thioredoxin motif, it is interesting to explore how SOD1 and AGR2 
control the cellular redox state, particularly in the ER. The increased expression of 
SOD1 in both wt-AGR2 and AGR2-KDEL suggested that the levels of oxidised 
proteins are elevated. However, this theory is not tested and the interaction of AGR2 
and SOD1 can be validated in the future.  
 
We chose DCD protein as potential AGR2 interacting protein as this protein 
was upregulated in both AGR2 conditions. The fact that DCD is secreted and 
implicated in cancer cell survival serves the protein as a highly relevant AGR2 client 
protein candidate. Studying the interaction can also help to identify cofactors involved 
in secretion and trafficking pathways. There were two peptides detected in our mass 
spectrometry analysis, and these peptides belong to the C-terminal AMP domain, and 
these peptides have homology with all 13 known processed AMP peptides (Figure 
5.18). AMP domain is responsible for a broad range of antimicrobial activity against 
pathogens and was constitutively secreted in eccrine sweat. We analysed the cells 
transfected with wt-AGR2 and AGR2-KDEL using western blot, to see if the DCD is 
indeed elevated in these reconstituted cells. However, we have difficulties in finding a 
good antibody to detect the presence of DCD. We obtained two antibodies that detect 
the C-terminal of DCD. The first antibody from Santa Cruz Biotechnology did not 
detect any band in western blot. The second antibody detects the expected full-length 
DCD at 12 kDa and also a ‘dimeric band’ (Figure 5.16). The expression of DCD as 
detected by the relative intensities of both the 12kDa and dimeric band showed that 
the empty vector control has elevated expression compared to the AGR2 expressing 
cells. This is inconsistent with our mass spectrometry data which suggest that DCD is 
more abundant in both AGR2 variants expressing cells (Figure 5.12C). Western blot 
analysis of the concentrated spent culture media from AGR2 transfected cells did not 
detect the presence of secreted DCD (Figure 5.16B). Despite the contradictory data, 
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mass spectrometry quantitation showed that the DCD is perturbed in both wt-AGR2 
and AGR2-KDEL expressing cells proving that mass spectrometry is sensitive to 
detect proteomic changes. The contradictory data (MS vs western blot) has been 
observed in our lab recently in a proteomic screen study to detect changes identify 
Nutlin‐3 responsive MDM2‐binding proteins [300]. Thus, the fold changes may not 
necessarily reflect protein abundance but may reflect post-translational modification 
(in our case). DCD has a high susceptibility for proteolytic processing forming 
functional peptides with distinct biological roles. In eccrine sweat, 14 proteolytically 
processed DCD peptides are found, one peptide derived from the N-terminal 
prodomain named YDP-42 (can be further processed to PIF or Y-P30) and 13 peptides 
derived from the C-terminal AMP domain (Figure 5.18). The AMP domain is derived 
from the C-terminal region of the precursor protein, DCD-1L (consisting of 48 amino 
acids) and DCD-1 (47 amino acids, lacking the last leucine) and this can be further 
processed by post-secretory processing. Thus, selection of the antibody must be highly 
specific depending on the peptide of interest, and the lack of antibodies detecting all 
peptides makes detection difficult.  It is also possible to check mRNA level of DCD in 
the future as upregulation of DCD at transcriptional level may suggest upregulation of 
DCD at protein translational level. This could be tested by using quantitative real-time 
PCR (qRT-PCR) comparing DCD mRNA expression levels in cells with AGR2-
transfected cells and AGR2-negative control cells. If the mRNA is indeed upregulated, 
this suggests that DCD protein level is subjected to the post-translational modification 
that is difficult to detect. 
 
DCD was shown not to interact with AGR2 in cells as tested using PLA (Figure 
5.17).  DCD was also found in another proteomics screen in the lab using SWATH 
mass spectrometry analysis of ELMO1 pull-down assay from FLO-1 and OE19 cells 
(Ali Alsaadi thesis 2016, and personal communication). ELMO1 was shown to form 
protein-protein interaction complex with AGR2 as well as DCD in cells using PLA. 
Since we do not have evidence that AGR2 interacts with DCD, we speculate that 
AGR2 may bind DCD through the interaction with ELMO1 or with one of ELMO1 
signalling proteins. It remains to be determined the effect of AGR2-induced DCD 
expression and secretion in tumour development. It is also interesting to establish 
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whether AGR2 contributes to the sensitivity of proteolytic processing of DCD. The 
crystal structure DCD-1L peptide from the AMP domain has been established showing 
that the peptide exists as hexameric bundle formed by elongated α-helices and 
stabilised by the presence of zinc [301]. DCD forms highly efficient channels to disrupt 
the bacterial transmembrane potential that is essential for cell survival. Therefore, it is 
fascinating to explore in the future if there is any relationship of AGR2 in the 
oligomerization of DCD-1L peptide to form the ion channels and its contribution in 
the antimicrobial barrier. 
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Figure 5.18 Processed peptides identified from the different domains of the dermcidin precursor 
protein. (Adapted from [280]) The dermcidin precursor protein has a high susceptibility for proteolytic 
processing. After cleavage of the 19-amino-acid N-terminal signal peptide and secretion into sweats, 
the 91-amino-acid dermcidin precursor protein can undergo further proteolytic processing, generating 
13 functional peptides. 
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CHAPTER 6: Developing Synthetic Models to Dissect 
AGR2 Function 
6.1. Introduction 
6.1.1. Antibodies and the emerging of recombinant antibodies 
Antibodies are specialised immune glycoprotein secreted by B cells which are 
produced by the mammalian immune systems to protect against foreign antigens such 
as pathogenic organisms or toxins and has the ability to neutralise them. Also known 
as immunoglobulins (Igs), can be divided into two categories: polyclonal (pAbs) and 
monoclonal antibodies (mAbs). Polyclonal antibodies are a collection of antibodies 
from different B cells recognising multiple epitopes on the same antigen, while 
monoclonal antibodies are derived from a single B cell lineage and therefore only bind 
to one unique epitope of the target antigen. Thus, mAbs promise high-specificity 
compared to pAbs counterpart in which pAbs may possess cross-reactivity to different 
biomolecules with similar epitopes. Consequently, mAbs have been the highly-
favoured pharmaceutical molecules and are the fastest growing component used in 
immunotherapy identifying targets in wide-range of diseases and conditions [302] . 
 
Antibodies come in different forms known as isotypes. There are five antibody 
isotypes in mammals: IgM, IgD, IgG, IgA, and IgE [303]. They differ in the type of 
heavy chains that the antibody possesses, with each heavy chain class named 
alphabetically: α (alpha), γ (gamma), δ (delta), ε (epsilon), and μ (mu). IgG is the most 
abundant form of immunoglobulins, and it provides the majority of antibody-based 
immunity against invading pathogens. IgG also is most extensively used molecule in 
therapeutic antibodies [304]. Moreover, it is the only class that crosses the placenta 
and is further subdivided into 4 different classes: IgG1, IgG2, IgG3 and IgG4 which 
confer distinctive functional properties at the C-terminal part of the heavy chain. All 
antibody molecules, however, are constructed the same way, having a Y-shaped 
signature consisting of four polypeptide chains; two identical heavy chains (VH) and 
two identical light chains (VL) connected by disulphide bonds (Figure 6.1, top panel). 
Each chain is further classified into variable and constant domains. Antibodies are 
large molecules with a size of approximately 150 kDa. The variable region (Fv) amino 
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acid sequence varies greatly among different antibodies, and it is located in the Y tips. 
This variable region, composed of 110-130 amino acids, give the antibody its 
specificity by serving as an antigen contact site making each antibody molecule at least 
bivalent. The variable region is further subdivided into complementarity determining 
regions (CDRs) and framework regions (FR). The constant region (Fc) determines the 
mechanism used to destroy antigens such as binding to various cell receptors, 
activation of the classical complement pathway, and phagocytosis [305]. Soon, it was 
discovered that the structure is not suitable for some applications due to some effects 
triggered by the Fc domain. For instance, Fc-mediated effects can lead to toxicity due 
to cytokine release and have a long serum half-life results in reduced discrepancy in 
imaging applications [304]. Initially, researchers attempted to remove Fc domain by 
using proteolytic treatments with enzymes such as papain or pepsin. This yield 
fragment antigen binding (Fab) or two Fab arms linked together F(ab’)2 fragments 
(Figure 6.1, bottom panel) [306, 307]. The cleaved Fc domain, however, does not have 
any variation and triggers the biological effector functions of the antibody [308]. Later, 
advances in recombinant DNA technology and genetic engineering directed the 
development of a large variety of recombinant antibody (rAb) fragments with 
unlimited potential for research, diagnostics and therapy, and have emerged over the 
last two decades as the fastest growing class of therapeutic proteins [302]. The 
fragments include single chain variable fragment (scFv), V-domain molecules as well 
as camelid VHH and shark V-NAR fragments (Figure 6.1, bottom panel). The 
minimised monoclonal antibodies retain specificity as the full-length IgG. In addition, 
they offer several advantages such as better tissue penetration, rapid blood clearance 
and tumour uptake [304]. The rAb fragments can also be easily and cost-effectively 
cloned and expressed in large quantities in a wide range of hosts [309]. This has led to 
the new generation and innovative antibodies that have been implemented in research 
studies and therapeutics such as antibodies coupled to radioactive tags for cell imaging, 
therapeutic ligands, enzymes and pro-drugs for treatments such as Antibody 
Dependent Enzyme Prodrug Therapy (ADEPT) [310]. The mAb-fragment repertoires 
can be applied and manipulated to better suit the future application of the fragments 
such as the proteomic discovery of new cancer biomarkers, and development of 
nanosensors for the diagnostic purpose [304]. 
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Figure 6.1 Schematic representation of antibody structure and antibody fragments. (Top panel) 
The basic structure of antibody molecule represented by full-length IgG consists of the Y-shaped 
structure. The molecule is composed of two identical heavy and light chains. Each of these chains 
contains multiple constant (C) and one variable (V) regions linked by disulphide bonds. The antigen 
binding site is located in the N-terminal of variable domains of both chains. Variable domains contain 
complementary determining regions (CDRs) and framework regions (FR) that highly assist in antigen 
recognition. Heavy chain constant domain is divided into three parts i.e. CH1, CH2 and CH3 where 
both CH2 and CH3 from the Fc portion of the antibody responsible for its effector functions. (Bottom 
panel) Antibody fragments resulted from proteolytic digestion producing Fab and F(ab)2 region 
containing variable and constant domains from heavy and light chains with no Fc portion of an antibody. 
Also shown scFv containing only variable heavy and light chain domains connected by a flexible linker, 
and single-domain containing heavy or light chain. 
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6.1.2. Phage display 
Antibody generation has been dramatically accelerated by in-vitro selection 
systems, particularly phage display. Phage display technology is a commonly used 
method for the selection of monoclonal antibodies against various antigens. The 
concept of fusing foreign DNA fragments with gene encoded for pIII coat protein of a 
non-lytic filamentous phage was first revealed by Smith in 1985 [311]. Five years later, 
McCafferty et al. established for the first time that scFv could be displayed on the 
surface of the phage surface as a functional protein retaining its antigen binding 
capacity [312]. Since then, the technology has been applied for the selection of diverse 
molecules such as Fab fragments, polypeptides, peptides, zinc fingers as well as 
enzyme modules. The display of the monoclonal antibodies on a filamentous 
bacteriophage allow rare clones to be screened and isolated from a large-scale phage 
library against any antigen of interest. A single phage library can contain up to billions 
of distinct clones. Phage and phagemid are two vectors used for expression, where the 
latter is most commonly used. Phagemid requires additional proteins called helper 
phage for packaging necessary gene products to make functional phage particles 
displaying recombinant protein on the surface of a phage.  
 
There are three types of phage display libraries which are categorised based on 
the origin of antibody genes; immune, naïve, and synthetic libraries [309, 313]. 
Immune libraries are constructed from variable domain originated from B cells 
obtained from immunised animals such as mice, sheep, rabbit, camel as well as humans 
with the target of interest. As compared to a library made from hybridoma cells, library 
made from spleen might give better diversity but also contain non-specific antibodies. 
This library can result in high-affinity selection of antibodies as it is biased only 
towards the antigen of interest used for immunisation. Thus, a new phage library has 
to be constructed for each antigen which can be very time-consuming. Secondly, naïve 
libraries are created from B cells of non-immunized donors. Unlike an immune library, 
this library has the advantage that it can be used for a large number of antigens and 
beneficial for the construction of antibody fragments which are difficult to generate 
using hybridoma technology. The affinity of an antibody towards a specific target is 
thought to be proportional to the size of the library [314]. Construction of variable 
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domains involve PCR amplification from IgM mRNA or total mRNA, as building 
libraries from IgG mRNA do not perform well due to unrelated immune response 
[315]. Thirdly, synthetic libraries are also derived from the nonimmune donor but are 
built artificially by the in-vitro assembly of heavy and light chains gene segments and 
introducing complementarity determining the region (CDRs) of varying loop lengths 
using PCR and randomised oligonucleotide primers [316]. Most structural and 
sequence diversity is found in the CDR3 region of the heavy chain and essentially 
responsible for antigen contact, with the other CDRs possessing limited variation 
[317].  
 
6.1.3. Aims of chapter 
Based on our prior report using biochemical approaches (Chapter 3) and the 
cell system analysis (Chapter 4), we hypothesised that AGR2 functions to elevate 
EpCAM protein levels occur via docking to the TxIYY binding site on the EpCAM 
receptor. The objective of this chapter is to deconstruct this hypothesis using synthetic 
protein modules. We wanted to explore if we could isolate synthetic scFv antibody 
fragments that bind to AGR2 with high-affinity from a massively diverse phage-
display library, express the isolated scFv targeting AGR2 in mammalian cells and 
assess whether such high-affinity binding protein positively or negatively regulated by 
AGR2.  We also aim to exploit the AGR2-binding peptide motif (TxIYY) previously 
isolated from peptide phage-display by making a synthetic AGR2-binding mini-
protein, consisting the TxIYY docking site motif and allow its destination to reside in 
the endoplasmic reticulum and test the fate of such an AGR2-binding protein. We also 
seek to generate synthetic membrane protein, which contains a transmembrane domain 
and AGR2-binding motifs TxIYY. This provides an optimal ‘artificial AGR2 client 
protein’ and test the fate of such a membrane protein (e.g whether it can be regulated 
by AGR2 or whether AGR2 has any influence in the delivery of the synthetic 
membrane protein to the cell surface).  
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6.2. Results 
6.2.1. Development of scFv antibody fragments targeting AGR2 
6.2.1.1. scFv antibody fragments format for selection of monoclonal 
antibodies targeting AGR2 
ScFv fragments represent the smallest functional antibody in which the VH and 
VL domains are joined with a flexible polypeptide linker preventing dissociation and 
retain the ability to bind to the antigen in high-affinity. It was first developed by Huston 
and co-workers [318] and refined by Whitlow group [319]. Nowadays, scFv is the 
most popular rAb fragment due to their versatility. These antibodies are much smaller 
in size ranging from 26-30 kDa and still retain affinity to bind target antigen [319]. 
The scFv antibody consists of one VH and one VL chain connected by a flexible peptide 
linker. The orientation could be in either VL-linker-VH or VH-linker-VL orientation, 
but the latter is the most common. The orientation can influence scFv stability binding 
to the antigen [320] and expression efficiency [321]. The length of the flexible linker 
also can affect the correct folding of scFv proteins and it was estimated that the linker 
is optimum at 3.5 nm resolution [322]. The most extensively used linker was the one 
that made up of glycine and serine stretch residues which offer great flexibility and 
combination with glutamic acid and lysine can increase solubility [323]. As scFv 
fragments bind monovalently to their target and they often present in low functional 
affinity (also termed avidity) and a short in-vivo half-life [324]. These properties can 
be useful for diagnostics imaging applications, for example, but they can compromise 
the efficacy as therapeutics agents as these may require higher retention times on the 
target antigen or engagement of multiple receptors in order to activate signal 
transduction and/or apoptosis [325, 326]. In order to overcome this drawback, scFv 
antibodies are engineered into different types of multimeric complexes for greater 
binding avidities and improved pharmacokinetic properties [327, 328]. The multimeric 
complexes include minibodies, diabodies, triabodies, tetrabodies and bispecific scFv 
fragments. ScFv antibody fragments can be selected and affinity matured by three 
different molecular displays, namely phage-display [312], ribosome display [329] and cell 
surface display [330, 331]. All three formats share the same basic principle in term of 
library construction of display libraries, which are created by cloning a massive collection 
of rAb genes and these libraries are screened for target antigen binding. Multiple selection 
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rounds of the polyclonal pools are performed to enrich for high-affinity monoclonal scFvs 
binding to target antigen. Here, we used phage display format to select for high-affinity 
scFv antibody fragments binding to AGR2 (Figure 6.2). 
 
6.2.1.2. Isolation of high-affinity scFv antibody fragments binding 
to AGR2 from phage-display library  
AGR2 was previously purified using affinity chromatography containing N-
terminal His-tagged epitope (Chapter 3) and used as an antigen to select for high-
affinity monoclonal scFv antibodies. The resulting His-AGR2 protein was highly pure 
showing a major monomeric band at 20kDa and a minor dimeric band as detected by 
coomasie blue staining and also immunoreactive in western blot analysis. His-AGR2 
or coating buffer (negative control) was coated onto microtitre wells and a phage-scFv 
library was used to isolate individual AGR2 binding scFv fragments (Figure 6.2) in a 
screening process called biopanning. Briefly in biopanning, a phage display library is 
constructed which involves inserting foreign desired gene segments into a region of 
the bacteriophage genome, so that the peptide or antibody product will be displayed 
on the surface of the bacteriophage virion. The library is then incubated with a target 
molecule. The library can be incubated directly with an immobilised target or pre-
incubated target prior to capture on a solid support. As in affinity chromatography, 
only specific peptides or antibodies are bound to the target while the non-interacting 
peptides or antibodies are washed away. The interacting phage display peptides or 
antibodies are then eluted and can be amplified by bacterial infection to increase their 
copy number. This screening and amplification process can be repeated several times 
to enrich higher-affinity phage display peptides or antibodies. The scFv library was 
constructed by cloning scFv genes into phagemid vectors by PCR amplification of 
RNA from a canine naïve library derived from canine spleen, and these were provided 
by Dr Euan Murray (Prof. Hupp lab). This library encodes both the heavy (VH) and 
light(VL) chains ligated together and connected via a linker of 15 amino acids, forming 
scFv fused to a gIII protein expressing on the surface of M13 bacteriophage (Figure 
6.3). For the initial round of panning, the phage-scFv library was pre-cleared on a non-
targeted His-tagged protein Reptin (a kind gift from Lucy Remnant) to exclude phages 
binding to the His-tagged epitope. Three rounds of biopanning were performed to 
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enrich for scFv-phages targeting AGR2 (Figure 6.4A). In each round biopanning, the 
phage-scFv library pool binding to the immobilised target was detected using M13-
HRP monoclonal antibody in ELISA as relative light unit (RLU). The biopanning was 
carried out successfully, as the scFv phage pool binding to immobilised His-AGR2 
was enriched in each round but not to negative control wells containing coating buffer 
(Figure 6.4A). The result also suggests that the scFv antibody library is bioactive that 
it can bind the target antigen immobilised in a microtiter plate.   
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Figure 6.2 A schematic representation of the biopanning procedure in the scFv-phage display. 
The scFv library was made by inserting the scFv sequences into the phagemid that also encodes a 
recombinant phage coat protein gene III (at the C-terminus of the scFv). Infection of these transformed 
bacteria with helper phage enabled them to make a collection of functional phage particles expressing 
the scFvs fused to the surface protein pIII. A phage particle displaying a functional antibody fragment 
in the form of scFv as a fusion protein with the coat protein pIII. Next, the scFv-phage library is 
incubated with immobilised antigen coated onto a solid phase. The unbound phage antibodies are 
removed, and the bound ones are eluted and amplified in bacteria. These phages are then extracted and 
used for the next round of biopanning. Several rounds of panning are usually performed to enrich the 
population of scFV-phage binds to the antigen. Then, individual antibodies directed against a specific 
antigen are selected from the enriched library for subsequent characterization. 
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Figure 6.3 Construction of scFv antibody fragment library. The scFv fragments derived from canine 
naïve phage library build from dog spleen. The heavy chain (VH) and light chain (VL) variable fragments 
were PCR amplified and inserted into pCaHv9 and pCaLv9 holding phagemid vector respectively. The 
vector containing the heavy chain fragments digested using AscI and NotI and ligated and the vector 
containing the light chains were digested with NotI and MluI and ligated in the presence of AscI and 
MluI which were lost in the final phagemid vector, pCaScFV9. The final phagemid vector contains VH 
and VL domain DNAs joined by a 15 aa linker peptide as a single-chain Fv segment (scFv) and fused 
to M13 gIII coat protein. The scFv library was provided by Dr Euan Murray.  
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At the end of the third round of biopanning, the enriched phage-scFv library 
binding to AGR2 was used to infect E. coli TG1 cells which were plated out in LB 
agar plates to isolate individual phage displaying scFv antibody fragment producing 
plaque (monoclonals) that binds to AGR2. Forty phage producing plaques were 
randomly selected and grown overnight, and the scFv-phage in the supernatant was 
PEG precipitated. The phage-bound scFvs were screened for binding to AGR2 as 
quantified using the M13-HRP antibody as RLU in an ELISA. Nine high-affinity scFv 
were identified to bind to AGR2, and this was numbered from 1 to 9 (Figure 6.4B).  
 
The nine high-affinity scFv binding to AGR2 were selected, grown overnight, 
and the scFv-phage in the supernatant was PEG precipitated. The binding of the scFv-
gIII-fusion phages to a target His-AGR2 was re-assayed in an ELISA to make sure 
that the newly amplified phage binds to His-AGR2. The ELISA results showed that 
all nine phage-scFvs bound to His-AGR2 but not to negative control wells containing 
coating buffer (Figure 6.5A). We also tested the nine high-affinity scFv to AGR2 
binding against a different His-tagged protein, His-MDM2 Ring domain (a kind gift 
from Dr Fiona Lickiss Prof Hupp Lab) to ensure that the phage-scFv is AGR2-specific. 
The PEG-precipitated phage-scFv showed binding only to AGR2 protein but not to 
MDM2 Ring domain (Figure 6.5B). This result also implied that the scFv did not bind 
to the N-terminal His-tagged epitope that is fused to the N-terminal of MDM2 Ring 
domain suggesting specificity to AGR2. 
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Figure 6.4 Screening of scFv-phage library binding to His-AGR2 in ELISA. (A) Enrichment of 
scFV-phage targeting AGR2 in a biopanning procedure. His-AGR2 (1μg in 50 μl per well) was coated 
onto the solid-phase of a microtiter well and used as an antigen in the selection of scFv-phage that bound 
to the His-AGR2. Active scFv-gIII-fusion phage binding to target antigen was detected using mouse 
monoclonal M13-HRP antibody as relative light units (RLU). Three rounds of panning were performed 
to enrich for phage library that binds to His-AGR2. The data was a representative of one experiment 
done in three triplicates and repeated in three independent experiments. Bars represent mean of the 
triplicates and and error bars show SEM.  (B) Colonies (40) from rounds 3 of panning were randomly 
selected and grown in 200 μl of LB media and the supernatant was PEG-precipitated. The precipitated 
phage-bound scFV binding to immobilised His-AGR2(0.1 μg in 50 μl per well) was quantified using 
M13-HRP antibody as RLU. Nine high-affinity scFv-phage binding to AGR2 were identified which 
were numbered from 1 to 9. The experiment was performed in two independent experiments in 
triplicates. The data was a representative of one experiment and error bars show SEM.  
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Figure 6.5 Assessing the specificity of the isolated high-affinity scFv to AGR2.  (A) Phage producing 
plaques from nine high-affinity scFV to AGR2 were re-amplified by transfection into TG1 cells, and 
the scFv-phage in the supernatant was PEG precipitated, and assayed in an ELISA using His-AGR2 
(0.1 µg in 50 µl per well) coated onto a solid phase. The re-amplified scFv-gIII-fusion phage was 
assayed using an M13-HRP phage antibody as RLU to ensure binding to AGR2 and reproducibility (B). 
The PEG-precipitated scFV-gIII-fusion phages were assayed for activity as in (A) using a different his-
tagged protein, His-MDM2 ring domain (0.1 µg in 50 µl per well) as a negative control to ensure 
specificity of the scFv to AGR2 but not to His-tag or other protein. The experiment was performed in 
two independent experiments in triplicates. The data was a representative of one experiment and error 
bars show SEM. 
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6.2.1.3. Epitope mapping of high-affinity scFv antibody fragments 
on AGR2 protein 
We then asked which region on AGR2 does the scFv fragments bind to. In 
order to do so, we mapped the epitopes on individual scFv modules on AGR2 (Figure 
9A-D). Identification of binding sites of an antibody is physiologically important as it 
can aid in the future manipulation of the antibody and may contribute to the discovery 
and development of new pharmacological interventions. We used an overlapping 
synthetic peptide library derived from an AGR2 open reading frame (ORF). The 
overlapping synthetic peptide library is composed of 15 amino acids with 5 amino 
acids overlap, and each peptide contains an N-terminal biotin-SGSG linker (Figure 
6.6A). The biotinylated peptides were captured onto streptavidin coated microtiter 
plate, followed by incubation with the phage-scFv clones and binding was quantitated 
by probing with M13-HRP antibody. Incubation of the combined phage-scFv clones 
(polyclonals) with the biotinylated AGR2 peptide library showed that the phage-scFv 
pool bind with high-affinity to peptide 1, and to some extent peptide 5 and peptide 13 
(Figure 6.6B). We then tested all nine individual scFv (monoclonals) binding to these 
three selected peptides to determine which scFv clones were responsible for binding 
to the peptides. ELISA results showed that one clone, namely scFv4 bound with high 
affinity to peptide 1 and also showed binding affinity to peptide 5 and 13 (Figure 6.6B). 
The other scFv clones seem to bind moderately to peptide 5 and peptide 13. It is 
important to note that the phage bound scFvs used were the crude lysates that obtained 
by PEG-precipitation, and were not normalised to the same concentration when 
assayed in the ELISA, so the assay may not be a true representative to measure the 
extent of high-affinity binding. We did not isolate scFv in its soluble form where the 
scFv is unfused to gIII M13 coat protein, as this scFv form is not stable in which our 
lab has observed previously [332] and this was true in our study as well, where our 
initial ELISA analysis  from scFv clones isolated at the end of the third round of 
biopanning did not produce any detectable binding to AGR2.As such, the activity of 
the scFv was tested as an intact scFv bound to the phage. We then assayed high-affinity 
AGR2-targeting scFv4 binding to the entire AGR2 peptide library, and the result 
showed that the scFv4 bind to peptide 1 in high affinity and negligible binding to 
peptide 5 and 13 consistent with the previous ELISA results (Figure 6.6D).  
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6.2.1.4. Sequencing of AGR2-binding scFv antibody fragments 
We sequenced all nine scFv antibody fragments to ensure that the clones are 
not the same and to certify that they are monoclonal scFvs, with no other 
contaminating scFv fragments. The primer was designed in the M13-gIII region that 
is fused downstream the light chain modules in the phagemid. The DNA sequencing 
of all nine clones demonstrated a single population of scFv indicating they are 
monoclonal clones but some of the scFV sequences were the same. The DNA 
sequences were translated using ExPasy16 translate tool, and the deduced amino acid 
sequences were aligned and compared with the previously sequenced scFv phage 
library. This comparison helped us to determine the framework (FR) and 
complementary determining region (CDR) and to define areas of presumed similarity 
since some scFv fragments seem to bind peptide 5 of AGR2. Overall, there were five 
different classes of scFv antibody fragments that bind to AGR2 (Figure 6.7A). In 
general, the FR regions showed a high degree of homology across all scFv fragments 
with most of the different amino acids having been exchanged by groups with similar 
properties. The CDR regions in both heavy and light chain demonstrated high 
variations among all five classes of scFv, especially in the CDR3 heavy chain 
suggesting hypermutation events of both heavy and light chains during library 
construction. Interestingly, scFv 4 which has the highest binding affinity to purified 
AGR2 protein and the N-terminal AGR2 peptide is unique as it has a slight 
dissimilarity in the FR region and has shorter CDR3 identity implying that this region 
contributes to the antigen contact. The amino acids sequence comprising functional 
scFv4 was illustrated in Figure 6.7B which follow the direction ‘heavy chain-Linker- 
Light chain’ (VH-L-VL). 
 
  
                                                 
16 http://web.expasy.org/translate/  
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 6 – Developing Synthetic Models to Dissect AGR2 Function 263 
 
Figure 6.6 Epitope mapping of the scFv antibody fragments binding to AGR2 protein. (A) An 
overlapping synthetic peptide library derived from AGR2 open reading frame. The overlapping 
synthetic peptide library is composed of 15 amino acids with 5 amino acids overlap, and each peptide 
contains an N-terminal biotin-SGSG linker (pictured in lower panel). The peptides were numbered as 
illustrated along with the protein sequence composition. (B) The biotinylated peptides were captured 
onto streptavidin coated microtiter plate. The nine high-affinity scFv-phage clones were combined, 
making polyclonal antibodies and the phage pool was incubated with the immobilised biotinylated 
peptides. Blocking buffer (3% BSA) was used as negative control. Binding was quantitated by probing 
with M13-HRP antibody as RLU. (C) AGR2 peptides that can be recognised by the phage pool was 
selected. The binding of individual nine scFv-phages was tested on these peptides (Pep 1, 5 and 13) and 
blocking buffer as a negative control and detected as in (B). (D) scFv4 phage which showed high-
affinity to the N-terminal of AGR2 (Pep 1) was selected and assayed on all 15 AGR2 overlapping 
peptides to ensure epitope specificity. All data were representative of one experiment from three 
independent experiments done in three technical replicates. Error bars show SEM. 
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Figure 6.7 Multiple sequence alignment of the deduced amino acids obtained from DNA 
sequencing of AGR2-targeting scFv antibody fragments. (A) Phagemid encoding the scFv fragments 
were isolated and sequenced using a primer designed in the M13 gIII region. The DNA sequences were 
translated into protein sequence and subjected to multiple sequence alignment using Clustal Omega17. 
The amino acid sequences were compared to previously sequenced scFv heavy and light chains during 
library construction to determine the framework regions (FR), complementary determining regions 
(CDR) and linker. The scFv sequences follow the direction ‘heavy chain-Linker- Light chain’ (VH - L-
VL). Different blocks of FR and CDR were coloured differently. ‘:’ (colon) indicates conservation 
between groups of strongly similar properties, scoring >0.5 in the Gonnet PAM 250 matrix; ‘.’ (period) 
indicates conservation between groups of weakly similar properties, scoring ≤ 0.5 in the Gonnet PAM 
250 matrix. (B) Amino acids sequence of high-affinity scFv 4 targeting AGR2 highlighting FRs and 
CDRs of VH and VL.  
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6.2.1.5. Construction of monoclonal AGR2-binding scFvs into 
mammalian expression vector 
 So far, we have successfully isolated 5 different classes of scFv from the 
massively diverse scFv library and the scFv library contains bioactive antibodies that 
can detect both purified full-length protein and peptide fragments. One particular 
clone, namely scFv4 exhibited high-affinity binding which is epitope mapped on the 
N-terminal of AGR2. Significantly, the N-terminal region of AGR2 is an intrinsically 
disordered domain which may not interfere with AGR2 core activity, for example, the 
thioredoxin domain is located centrally, and the peptide binding loop is towards the C-
terminal region. However, it could impact on AGR2 dimerization as deletion of the N-
terminal intrinsically disordered domain can allow AGR2 to form a stable dimer 
[97].  We selected the high-affinity scFv4 antibody fragment to be cloned into a 
mammalian expression vector to see whether its expression has any impact on AGR2 
or whether it can be positively or negatively by AGR2 expression. The scFv4 sequence 
was engineered to contain an N-terminal ER-leader sequence from AGR2 and a KDEL 
ER-retention site, with the control being scFv with truncated signal peptide and 
without the ER postcodes (Figure 6.8A).  A none-AGR2-binding scFv was used as a 
control that also has the same AGR2 leader sequence and KDEL (ER retention 
motif). This scFv was derived from the screening of scFv that binds to C-terminus of 
HSC70-Interacting Protein (CHIP), and the isolated scFv has been validated to bind 
CHIP and CHIPK30A mutant (scFv-CHIP (clone 11F) sequences kindly provided by 
Professor Kathryn Ball, unpublished data). We also engineered a CD20 epitope to 
monitor the production of the protein. This epitope tag is a 20 amino acids peptide 
derived from canine CD20, that can be recognised by a mouse monoclonal CD20 
antibody (NCD1.2) previously developed in our lab [332] and this was fused upstream 
the ER retention motif KDEL (Figure 6.8A). The three scFv constructs were human 
codon optimised and chemically synthesised by GeneArt synthesis (Thermo Fischer 
Scientific) and contain 5’ NcoI and 3’ XbaI restriction sites. The cDNA constructs 
were then subcloned into a pSF-CMV mammalian expression vector which we have 
extensively used in cloning AGR2 and EpCAM cDNAs in Chapter 4, where the vector 
is under the control of the strong CMV promoter to drive gene expression. The protein 
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sequences of the synthetic scFv constructs using ProtParam18, which can compute both 
physical and chemical parameters of a protein and the analysis is summarised in Figure 
6.8B. All the synthetic scFv proteins have molecular weights between 28 kDa to 30 
kDa and in general, the instability index classifies the proteins as stable.  
 
6.2.1.6. Expression of the synthetic monoclonal scFv antibody 
fragments in mammalian cells 
Using these vector constructs we asked whether the steady-state levels of these 
synthetic scFv proteins in cells can be impacted in an AGR2-dependent manner. We 
used two different cell lines that endogenously express AGR2 (MCF-7) and do not 
express AGR2 (FLO-1 cells). The transfection of the three scFv fragments resulted in 
a defined steady-state level of production in FLO-1 cells (AGR2-) (Figure 6.9). Both 
scFv4-ER and scFV4-NoER produced a single expected band at 30kDa and 28 kDa 
respectively as analysed by western blot. The scFv-CHIP-ER also produced a single 
band at 30kDa, but the expression is significantly higher suggesting that it has a more 
defined protein steady-state level. By contrast, in MCF7 cells (AGR2+) the scFv4-ER 
was substantially lower expressed and needed higher exposure for the appearance of 
the corresponding band in western blot (Figure 6.9). On the other hand, the expression 
of the scFv4-No-ER and the negative control scFv-CHIP-ER showed relatively similar 
expression across the two cell lines.  These data suggest that the expression of the 
scFv4 was depended upon the ER entry/retention sequences. Intriguingly, the presence 
of AGR2 in MCF-7 cells can suppress the production of a high-affinity binding protein 
when it is destined for the ER. The scFv scaffold with an additional epitope tag and 
ER postcodes were able to be expressed in mammalian cells and immunoreactive as 
detected by western blot. 
  
                                                 
18 http://web.expasy.org/protparam/  
A Novel Role of an ER-Resident Chaperone Pathway in Cancer Signalling 
Chapter 6 – Developing Synthetic Models to Dissect AGR2 Function 267 
 
Figure 6.8 Construction of scFv antibody fragments into mammalian expression vectors. (A) The 
20 aa of AGR2 signal peptide (blue) was fused to scFv4 scaffold (pink), and 20 aa CD20 epitope 
(chocolate) and ER retention motif KDEL (yellow) was fused at scFv4 C-terminal as illustrated in (1). 
As a negative control truncated N-terminal AGR2 signal peptide and deletion of KDEL was introduced 
to the scFv scaffold (2). A non-AGR2 binding scFv (scFv binding to CHIP protein) is constructed the 
same way as in (1) and serve as a second negative control (3). All constructs were human codon 
optimised, chemically synthesised, and sub-cloned into a high expression mammalian vector, 
pSF_CMV using restriction enzyme NcoI (5’) and XbaI (3’) which was incorporated as part of the 
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Figure 6.9 Expression of scFv modules in mammalian cells. FLO-1 or MCF-7 cells were transfected 
with 1 µg DNA encoding the scFV4-ER and the scFV4-NoERin a 6-well plate. As a negative control, 
cells were transfected with pSF-CMV empty vector (EV). Twenty-four hours post-transfection, cells 
were harvested and lysed using urea lysis and subjected to western blot analysis. Anti-CD20 (NCD1.2) 
was used to detect the presence of the scFv proteins. AGR2 was detected with anti-AGR2 K47 and anti-
β -actin was used as loading control. 
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6.2.2. Development of synthetic mini protein containing minimal AGR2 
peptide motif 
6.2.2.1. Construction of synthetic mini-proteins containing AGR2 
linear peptide motif repeats 
Next, we aim to further manipulate the AGR2 linear peptide motif TxIYY by 
expressing it in mammalian cells.  Our previous results using biochemical approaches 
and the cell-based assay analysis suggests that AGR2 function is to elevate its client 
protein EpCAM protein levels and this occurs via docking to the TxIYY binding site 
on the EpCAM receptor. We asked whether the synthetic protein expression containing 
TxIYY components in mammalian cells can be positively or negatively regulated by 
AGR2 as observed with AGR2-targeting scFv modules.  We sought to deconstruct this 
using synthetic mini protein the same way we constructed the AGR2-targeting scFv 
since this construct was expressed successfully. Since the AGR2 docking motif is 
short, we engineered three copies of the docking motif in tandem separated by a 4 
amino acids linker (Figure 6.10A) which may also increase binding affinity to AGR2. 
We included the original minimal hexapeptide, PTTIYY from peptide-phage display 
data that maintain high-affinity binding to AGR2 [209]. Like the scFv construct, the 
N-terminal of the docking motif modules are fused to 20 amino acids encoding AGR2 
signal peptide and the C-terminal contains ER retention motif, KDEL and a CD20 
epitope tag to monitor its expression. As a negative control, we designed the mutant 
version of the mini protein in which the linear peptide motifs were mutated to PKTIGS. 
In designing this, we avoided amino acid with similar property with the AGR2 
consensus peptide docking motif  Tx[IL][YF][YF], so that the mutant form has no 
binding affinity to AGR2. All the DNA encoding the mini-protein scaffolds were 
human codon optimised and chemically synthesised and subcloned into pSF-CMV 
using restriction enzyme NcoI and XbaI which were incorporated at 5’ and 3’ 
respectively of the DNA fragments. The pSF-CMV mammalian expression vector is 
under the control of the strong CMV promoter to drive gene expression, which we 
have extensively used in cloning AGR2 and EpCAM cDNAs in Chapter 4. ProtParam 
analysis of the mini-proteins showed that the wild-type AGR2 synthetic mini protein 
which we named as synPROwt has a molecular weight of 8.14 kDa and its mutant 
counterpart (synPROmut) has a slightly shorter molecular weight, 7.6 kDa despite 
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having the same amino acids length suggesting that they have different protein 
conformation (Figure 6.10B). Another notable difference is the theoretical pI where 
the synPROmut  has a higher pI synPROwt. Both synthetic proteins were deemed stable 
as the instability index was below the suggested limit.  
 
6.2.2.2. Expression of the synPROmut  and synPROwt  in mammalian 
cells 
We utilised the same set of cell lines, MCF-7 and FLO-1 cells, to see if there 
is any difference in the expression of synthetic mini-proteins in the absence or presence 
of endogenous AGR2. Western blot analysis of the cells transfected with the DNA 
constructs encoding the mini-protein using NCD1.2 monoclonal antibody detected the 
expression of artificial mini protein synPROmut in both MCF-7 and FLO-1 cells (Figure 
6.11A). The synPROwt can only be detected in MCF-7 cells (AGR2+) but not in FLO-
1 cells (AGR2-). However, the expression of the synPROwt was substantially lower 
and required longer exposure for detection in western blot. The band corresponding to 
the synPROwt was also slightly higher than its mutant counterpart which is consistent 
with the ProtParam analysis. Since the synthetic mini-proteins were small in size, they 
may not be efficiently detected by immunoblotting which may be the case of the  
synPROwt. However, the detection of the synPROmut expression in both cell lines 
suggest that the expression of the synPROwt has lower protein steady-state level and 
dependent on cell types. Nevertheless, we tried to improve the detection of the 
synPROwt by incubating the blotted membrane after gel transfer with 0.4% PFA which 
was proven to increase detection of endogenous protein like α-synuclein [333]. 
However, the synPROwt  expression is still weak compared to the synPROmut (data not 
shown).  
We titrated the amount of DNA transfected into the MCF-7 cells to see if we 
can increase the expression of the synPROwt. Since the expression of the synPROmut is 
higher we lower the amount of DNA for transfection into the cells so that we can see 
a window in which the expression can be equilibrated with synPROwt. Titration of the 
DNA encoding the synPROwt from 0.5 µg to 4 µg showed an increased synPROwt 
expression at higher DNA concentration (Figure 6.11B). Lowering the amount of the 
DNA expressing the synPROmut (titration from 0.0625 µg to 0.5 µg) did not affect its 
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expression and the protein expression can still be seen at the very low level of DNA 
transfection. We also probed the blot for AGR2 expression to see if the endogenous 
AGR2 expression is affected by the expression of the mini-proteins. The result showed 
that the AGR2 binding peptide modules stabilise the expression of AGR2 but not in 
the case of the mutant binding peptide (Figure 6.11B).  
Altogether, these data demonstrated that first, we were able to express the 
artificial mini protein in cells. The expression of the mini-protein can be seen regulated 
by AGR2 in cells showing different protein steady-state levels. In the case of the mini-
protein containing the wild-type AGR2 binding peptide motifs, a higher amount of 
transfected DNA was needed for its expression to be perceived, while the mutant 
AGR2 peptide motif only required a small amount of DNA material for protein 
expression. Based on the western blot analysis, the ratio of DNA amount required for 
the mini-protein expression synPROwt:synPROmut is approximately 8:1. Transfection 
of the optimised DNA concentration for the synPROwt in FLO-1 cells (AGR2-) did not 
produce any corresponding band in western blot (data not shown) which further 
implied that synPROwt expression dependent on AGR2. The stabilisation of AGR2 
when the wild-type mini-protein is expressed (but not the mutant mini-proteins) 
suggests that they interact with AGR2 in cells presumably through the peptide docking 
interface (aa 131-135) on AGR2 which we have mapped earlier (Chapter 3) using 
hydrogen-deuterium exchange mass spectrometry.  
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Figure 6.10 Construction of mini-protein containing AGR2 binding peptide repeats into a 
mammalian expression vector. (A) The minimal AGR2 binding peptide (PTTIYY, green) was 
synthetically constructed in tandem (3x PTTIYY) separated with GSGS linker which is fused to AGR2 
signal peptide at N-terminal (blue) and CD20 epitope tag (light chocolate) and endoplasmic reticulum 
(ER) retention motif at C-terminal (yellow) to direct the scFv to endoplasmic reticulum where AGR2 
normally resides. As a negative control, a mutant version of the AGR2 binding peptide (PKTIGS, light 
green) was synthesised the same way as the AGR2 ‘WT’ binding peptide counterpart. All constructs 
were human codon optimised, chemically synthesised, and sub-cloned into a high expression 
mammalian vector, pSF_CMV using restriction enzyme NcoI (5’) and XbaI (3’) which was 
incorporated as part of the synthetic constructs. (B) Physical and chemical parameters of the mini-
proteins using ProtParam analysis.  
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Figure 6.11 Expression of synthetic mini-protein encoding AGR2 binding peptide repeats and its 
mutant form in mammalian cells. (A) FLO-1 or MCF-7 cells were transfected with 1 µg DNA 
encoding the AGR2 binding peptides synPROwt and the mutant form synPROmut in a 6-well plate. As a 
negative control, cells were transfected with pSF-CMV empty vector (EV). Twenty-four hours post-
transfection, cells were harvested and lysed using urea lysis and subjected to western blot analysis. Anti-
CD20 was used to detect the presence of the mini-proteins. Expression of synPROwt is marked by (*) 
and synPROmut  (**). β-actin antibody was used as loading control. (B) MCF-7 cells were transfected 
with titration of indicated DNA encoding the synPROwt and synPROmut proteins in a 6-well plate. The 
amount of transfected DNA is normalised with pSF-CMV empty vector. Twenty-four hours post-
transfection, cells were harvested and lysed using urea lysis and subjected to western blot analysis. Anti-
CD20 (NCD1.2) was used to detect the presence of the mini-proteins and also probed for AGR2 using 
anti-AGR2 (K47). β -actin antibody was used as loading control. 
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6.2.2.3. AGR2 and synthetic mini protein interaction using in situ 
proximity ligation assay 
We evaluated whether the mini-protein containing AGR2 peptide motif repeats 
can form a complex in cells using proximity ligation assay (PLA) whose interaction 
has been established previously using in-vitro biochemical assays. Since the mini-
protein containing the wild-type AGR2 peptide repeats only express in the cells that 
endogenously express AGR2, we utilised MCF-7 cells as a model for the PLA assay. 
Based on our prior result, transfection of the same amount of DNA give different 
expression of the wild-type and mutant mini-proteins levels. Therefore, we transfected 
the cells according to the optimised DNA amount that achieves the same protein 
expression level of the wild-type and mutants mini-proteins so we can assay the 
protein-protein interaction accurately (Figure 6.11B). We utilised the Duolink In-situ 
based PLA assay that we have used before to detect the AGR2 and EpCAM protein-
protein interaction (Chapter 4). This assay requires two primary antibodies each 
directed against one of the targets of interest and the two primary antibodies must be 
raised in different species. We used the mouse monoclonal CD20 (NCD1.2) for 
detecting the transfected mini-proteins and rabbit polyclonal AGR2 (K47) directed 
against the endogenous AGR2 in MCF-7 cells. PLA assay incubated with the antibody 
pair showed PLA signals in cells transfected with synPROwt (Figure 6.12, upper panel). 
This suggests that the mini-protein containing repeats of AGR2 binding peptide form 
complex with endogenous AGR2 indicating protein-protein interaction in cells 
consistent with our previous in-vitro biochemical assay. On the other hand, the mutant 
form of the mini-protein, synPROmut did not produce PLA foci indicating that there is 
no protein-protein interaction taking place in the cells Figure 6.12, middle panel). As 
a control, MCF-7 cells were transfected with pSF-CMV empty vector (EV) and 
incubated with the antibody pair in PLA which exhibited no foci (Figure 6.12, lower 
panel). 
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Figure 6.12 AGR2 and synthetic mini-proteins interaction using in situ proximity ligation assay. 
(A) MCF-7 cells were transfected with DNA encoding synPROwt (4µg, upper panel); synPROmut (0.5 
µg), or pSF-CMV empty vector (2 µg). These DNA concentrations were according to optimised starting 
DNAs to give equal protein expression of synPROwt and synPROmut .After 24 hours transfection, the 
cells were processed by Duolink In situ proximity ligation assay using mouse monoclonal CD20 
(NCD1.2) and rabbit polyclonal AGR2 (K47) antibody pair. Following ligation and amplification, 
protein-protein interaction complex was detected with Duolink red fluorescent probes. Red fluorescent 
foci indicate the interaction between the two proteins. Nuclei were counterstained with DAPI and cells 
were visualised with an epifluorescence microscope. Scale bar 10 μm.  
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6.2.3. Development of synthetic membrane protein containing AGR2 
peptide motif repeats 
6.2.3.1. Designing and construction of synthetic membrane protein 
containing AGR2 peptide motif repeats 
Our results so far suggest that AGR2 can bind synthetic mini-protein 
containing its linear peptide motif in cells, complementing our in-vitro protein-protein 
interaction assay. AGR2 was shown to elevate its client protein level containing such 
motif, EpCAM which occurs via docking to the TxIYY binding site on the EpCAM 
receptor. We also showed that the delivery of EpCAM to the plasma membrane is 
mediated by AGR2. Therefore, we wanted to create an artificial membrane protein 
containing a transmembrane domain and AGR2 binding peptide motif to see whether 
the artificial membrane exhibits the same activity as the EpCAM membrane protein. 
The synthetic membrane protein consists of the same composition of the mini-protein 
containing AGR2 binding peptide repeats but with an addition of transmembrane 
domain (Figure 6.13A). This domain comprises of 23 amino acids that are derived 
from the EpCAM transmembrane helix (amino acid 266-288). We added the 
transmembrane domain downstream of the epitope tag upstream in which we predict 
that the epitope tag will appear in an extracellular orientation which as illustrated in 
Figure 6.13C. Our prediction is based on the EpCAM structure where the TLIYY motif 
is located in the extracellular stalk. This orientation allows us to visualise plasma 
membrane localisation using CD20 antibody recognising the extracellular side in 
immunofluorescence study. We also analysed the synthetic membrane protein 
sequences using TOPCONS19 which can predict membrane protein topology and can 
efficiently separate signal peptides from transmembrane regions [334].  The analysis 
results were in agreement with our membrane topology models which suggest that the 
epitope tag is on the extracellular side (Figure 6.13D). However, it is also important 
not to rule out that there is a possibility that the orientation can be in the reversed 
orientation. ProtParam analysis of the proteins suggests that the proteins are more 
hydrophobic (positive value of hydrophaticity) which is consistent with the addition 
of the transmembrane domain (Figure 6.13B). The synthetic membrane protein 
containing the AGR2 binding peptide repeats or the mutant form was human codon 
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optimised and chemically synthesised. These were subcloned the same way as the 
AGR2 mini-proteins into pSF-CMV via restriction site NcoI (5’) and XbaI (3’). 
 
6.2.3.2. Expression of the synthetic membrane proteins 
We utilised the same set of cell models MCF-7 (AGR+) and FLO-1 (AGR2-) 
for the expression of the synthetic mini-proteins. Since we have shown that synthetic 
mini-proteins without the transmembrane domain are dependent on endogenous 
expression of AGR2, we ask whether the synthetic membrane proteins have the same 
activity and whether the presence of AGR2 can influence the delivery of the synthetic 
membrane protein to the plasma membrane as in the case of EpCAM, since the 
synthetic proteins have EpCAM’s transmembrane domain. Western blot analysis of 
the MCF-7 (AGR2+) cells transfected with equal amount DNA constructs encoding 
the synthetic wild-type or mutant membrane proteins showed different protein steady-
state levels (Figure 6.14A). The synMEMwt is substantially lower compared to the 
synMEMmut. Transfection into FLO-1 (AGR2-) showed much lower expression of 
both membrane protein (Figure 6.14B). These data suggest that the expression of the 
membrane proteins were regulated by AGR2 consistent with the expression of the 
synthetic mini-protein (synPRO) we have previously observed. The lower expression 
of the wild-type membrane protein may indicate that it interacts with AGR2 via 
docking to the PTTIYY for proper maturation and trafficking to the plasma membrane 
or possibly secreted into media, hence lower total protein load upon harvesting for 
western blot. The mutant, however, cannot bind to the AGR2 which may be 
predominant in soluble form in the cytosol, therefore, more abundance in the cells 
when harvested for western blot analysis. 
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Figure 6.13 Construction of synthetic membrane proteins containing AGR2 binding peptide 
repeats and EpCAM transmembrane domain. (A) The synthetic membrane proteins contain the 
same structure of the synthetic mini-protein (synPRO) but with an addition of EpCAM transmembrane 
domain (orange). This is inserted downstream the CD20 epitope tag which is flanked by a small stretch 
of linker. All constructs were human codon optimised, chemically synthesised, and sub-cloned into a 
high expression mammalian vector, pSF_CMV using restriction enzyme NcoI (5’) and XbaI (3’) which 
was incorporated as part of the synthetic constructs. (B) Physical and chemical parameters of the 
synthetic membrane proteins using ProtParam analysis. The wild-type synthetic membrane protein was 
named synMEMwt and the mutant counterpart. (C) Schematic representation of membrane topology 
model based on EpCAM structure, where the transmembrane domain embedded in the plasma 
membrane, while the epitope tag and the AGR2 binding motifs are in the extracellular stalk orientation. 
(D) Membrane protein topology TOPCONS prediction analysis which supports our model topology in 
(C) for synMEMwt (upper panel) and synMEMmut (lower panel) suggesting the epitope tag and the 
binding motifs are extracellular and recognise EpCAM transmembrane domain as a helix.  
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Figure 6.14 Expression of synthetic membrane protein containing EpCAM transmembrane helix 
and AGR2 binding peptide repeats. MCF-7 (A) or FLO-1 (B) were transfected with 1 µg od DNA 
encoding synMEMwt, synMEMmut or  pSF-CMV empty vector (EV) in a 6-well plate. Twenty-four 
hours post-transfection, cells were harvested and lysed using urea lysis and subjected to western blot 
analysis. Anti-CD20 was used to detect the presence of the wild-type or mutant synthetic membrane 
proteins. β-actin antibody was used as loading control. 
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6.2.3.3. Localisation analysis of the synthetic membrane proteins 
using immunofluorescence  
Next, we examined the localisation of the synthetic membrane protein in the 
cells using immunofluorescence. We ask whether if there are different localisations of 
the wild-type and mutant membrane proteins, in which the expressions are regulated 
by AGR2. We hypothesised that in the presence of AGR2, the wild-type synthetic 
membrane protein synMEMwt is predominantly localised in the plasma membrane 
while the synPROmut is more abundance in the cytosol.  MCF7 or FLO-1 cells lines 
transfected with the synthetic membrane proteins were stained with mouse monoclonal 
CD20 (NCD1.20) recognising the epitope tag predicted to be at the extracellular side. 
Cells were then fixed and permeabilised and visualised using epifluorescence 
microscopy.  Immunofluorescence staining of the synMEMwt demonstrated a mixture 
of localisations in MCF-7 cells, where there was a pool of plasma membrane 
localisation and also a cytosolic distribution appearing as puncta (Figure 6.15A, upper 
panel). On the other hand, the synMEMmut localisation was largely cytosolic Figure 
6.15A, middle panel). Interestingly, the synMEMmut appeared as puncta and in some 
cells seemed more granular/vesicle-like distribution. In FLO-1 cells, both the wild-
type and the mutant synthetic membrane proteins exhibited cytosolic distribution 
(Figure 6.15B, upper and middle panel). However, the wild-type synMEM distribution 
was more ‘spotty’ or as puncta, while the mutant synMEM localisation looks more 
diffused. As negative controls, there were no positive staining in cells transfected with 
CMV empty vector only (Figure 6.15A, and B, lower panel). 
 
Overall, we were able to express the artificial membrane protein containing 
AGR2 binding peptide motifs, synMEMwt and remarkably the synthetic protein was 
seen to localise partially in the plasma membrane in MCF-7 cells (AGR2+). It is 
important to point out that we engineered a ‘strong’ canonical ER retention motif 
KDEL in the synthetic membrane protein (Figure 6.13). This suggests that some 
proteins may be retained in the ER which explained why we observed some puncta 
staining for synMEMwt. Nevertheless, the synMEMwt plasma membrane distribution 
suggests that the protein can bind to endogenous AGR2 in the ER via docking to the 
PTTIYY repeats which drive the protein to enter secretory pathway or to escape ER 
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and finally to the plasma membrane. There was no plasma membrane localisation seen 
in FLO-1 cells (AGR2-) for synPROwt suggesting that the protein was unable to 
interact with AGR2 for its protein maturation, which may be trapped in the ER or 
subjected to proteasomal degradation. The synPROmut controls exhibited similar 
distribution where they are largely cytosolic in both MCF-7 and FLO-1 cells. 
However, there was a notable difference in the pattern of staining where synPROmut 
demonstrated more puncta/granular staining in MCF-7 cells, whilst in FLO-1 
displayed diffused staining suggesting that the proteins have different regulations in 
different cells. Importantly, the mutant membrane protein was not delivered to plasma 
membrane indicating that AGR2 was not able to recognise the mutant peptide motif 
for docking and processed for its maturation through the secretory pathway.  
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Figure 6.15 Localisation of synthetic membrane proteins containing AGR2 binding peptide motif 
using immunofluorescence analysis. (A) MCF-7 cells were transfected with DNA encoding 
synMEMwt (upper panel); synMEMmut (middle panel) or; CMV empty vector (EV) (lower panel) and 
incubated for 24 hours. The cells were then immunostained with CD20 monoclonal antibody (NCD1.2) 
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with a combination of Alexa 594 (red) secondary antibodies and detected using epifluorescence 
microscopy. Scale bar 10 μm. (B) FLO-1 cells were transfected with DNA encoding synMEMwt (upper 
panel); synMEMmut (middle panel) or; CMV empty vector (EV) (lower panel) and incubated for 24 
hours. The cells were then immunostained with CD20 monoclonal antibody (NCD1.2) with a 
combination of Alexa 594 (red) secondary antibodies and detected using epifluorescence microscopy. 
Scale bar 10 μm. Nuclei were counterstained with DAPI.  
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6.3. Discussion 
It has been more than 30 years since the first monoclonal antibodies were 
generated. Monoclonal antibodies (mAbs) were first generated by Kohler and Milstein 
in 1975 using hybridoma technique and this founding work has embraced the area of 
clinical research and has been acknowledged as the magic bullet against tumour 
antigens as well as several other diseases because of their inherent capacity for 
specificity [335]. The monoclonal antibody industry has expanded exponentially ever 
since and is the fastest growing component used in immunotherapy identifying targets 
in wide-range of diseases and conditions [302]. With major advances in molecular 
biology and biomedical research, much research into monoclonal antibodies now 
focuses on identifying new targets for development and maximising their efficacy for 
use in clinical practice. Currently, there are approximately 30 mAbs that have been 
approved for use in clinical practice while much more waiting in the pipeline and being 
tested in clinical trials. 
 
mAbs have been used extensively in cancer therapeutics which target a wide 
variety of antigens expressed on the surface of cancer cells [8]. There are different 
mechanisms of actions of mAbs targeting cancer cells and these dependent on the 
mAbs construct and the nature of tumour malignancy. Some tumours specific mAbs 
have a direct effect on tumour cells upon binding cell surface antigen which induces 
apoptosis by direct transmembrane signalling [336]. There was also evidence that 
mAbs involved in immune-mediated effects which are called complement-mediated 
cytotoxicity (CMC) which directly result in target cell death through the development 
of a membrane attack complex (MAC) [337]. Another immune-mediated effect upon 
mAbs antigen contact is by inducing antibody-dependent cellular cytotoxicity (ADCC) 
[338] which result in enhancing phagocytosis and lysis by monocytes and 
granulocytes. 
 
A key criterion to be considered for development of antibody therapeutics is to 
identify a suitable target in the disease and to reduce immunogenicity [339]. Other 
limitations include side-effects, inefficient models for mAb generation and a lack of 
efficacy. Different manipulative forms of antibodies have been developed such as 
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humanised, chimeric and fully human antibodies which aim to overcome the issues 
such as human anti-mouse antibody response raised by mouse monoclonal antibodies 
[25].  
 
 As discussed previously, AGR2 has emerged to be a potential drug target in 
cancer. It was found to be overexpressed in various type of cancers [94, 116]. AGR2 
showed pro-oncogenic features, where its overexpression, for example, can enhance 
cancer cell survival, rather than inhibit cell growth in the premalignant Barrett 
oesophagus and oesophageal cancer models [87]. In addition, high levels of AGR2 are 
associated with poor prognosis in ER-positive breast cancer and was shown to promote 
metastasis of breast epithelial cells in an in vivo metastasis assay [120, 139], suggesting 
AGR2 as a potential drug target and biomarker. The clinical relevance of AGR2 is 
strengthened by the finding that AGR2 showed resistance to major cancer drug 
therapies such as Tamoxifen [171].  
 
 In this chapter, we aim to develop monoclonal antibodies targeting AGR2 in 
the format of scFv antibody fragments, in which we screened from a massive scFv-
phage display library which roughly contains 109 scFv sequences. Antibody fragment 
in the format of scFv has been successfully modified in several applications, for 
example, scFv fragments were fused with radioisotopes for cancer imaging [340], scFv 
conjugated with enzymes in antibody-directed enzyme prodrug therapy (ADEPT) 
[341], scFv as immunotoxins for targeted tumour cell targeting [342] and biosensors 
for real-time detection of target molecules [343]. The phage library used here was 
constructed by in-house cloning of massive collection of scFv genes derived from the 
canine naïve library and cloned into phage display vectors to determine whether single 
chain antibody domain fusions can be packaged in bioactive form (Figure 6.3). We 
were able to isolate five classes of high-affinity scFv antibody fragments that bind to 
specifically to purified His-AGR2 and this as well suggests that the scFv antibody 
library is bioactive that it can bind the target antigen (Figure 6.4 and Figure 6.7). 
Epitope mapping using 15-mer overlapping peptides of AGR2 ORF demonstrated that 
all five scFvs have an affinity towards centrally located peptide no 5 (aa 61-75) and to 
some extent to peptide 13 (aa 141-155) (Figure 6.6B-CFigure 6.8). One particular scFv 
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however, showed high-affinity binding to peptide 1 which is the N-terminal 
intrinsically disordered region of AGR2 (aa 21-35). This epitope is away from the core 
domain of AGR2 such as the thioredoxin domain CPHS (aa 81-84), peptide binding 
loop (aa 104-111) or peptide docking site we have mapped in Chapter 3 (aa 131-135) 
but however may affect AGR2 dimerisation [97]. We selected this scFv4 and cloned 
it into a mammalian expression vector which was engineered to contain ER postcodes 
for entry into ER where AGR2 normally resides and CD20 epitope to monitor its 
expression (Figure 6.8). We were able to express the scFv scaffolds in mammalian 
cells and were immunoreactive as they can be detected with a CD20 antibody (Figure 
6.9). Our results showed that the expression of the scFv with ER postcodes (scFV4-
ER) was regulated by the presence of AGR2 and the expression of the ER-directed 
scFv4 depended upon the ER entry/retention sequences, where the scFv without ER 
postcode showed the same expression levels in MCF-7 and FLO-1 cells. This suggests 
that the production of high-affinity scFv targeting AGR2 can be suppressed by AGR2 
when destined for the ER. However, we have not yet checked whether the proteolytic 
activity is involved in regulating the scFv expression which can be done by the 
treatment of proteasomal inhibitor MG132 in the cells transfected with these scFv 
constructs. Strikingly, the expression of AGR2 remains unchanged when the AGR2-
targeting scFv is expressed. One explanation is that scFv expression does not effect on 
the total protein load of AGR2, but may affect AGR2 function and signalling (such as 
enhancing the unfolded protein response or relieving ER stress) and AGR2 cellular 
distribution (since AGR2 can escape ER and can be secreted). There is also a 
probability that there might be a negative feedback loop maintaining its expression, 
which could be investigated in the future. This finding also expands current 
monoclonal AGR2 antibodies since there are only a few AGR2 mAbs available 
commercially. Our group has been trying to generate in-house monoclonal AGR2 
antibodies using hybridoma techniques from the purified AGR2 protein as antigen 
were nor fruitful. Some of the isolated monoclonal antibodies showed cross-reactivity 
with its homologue AGR3 and cannot be used in immunoprecipitation. We are 
planning to express and purify these monoclonal antibodies in the future and test their 
potential and specificity in assays like immunoprecipitation. It is also interesting to see 
the effect of these scFvs expression on AGR2 client proteins in the future. In addition, 
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these scFvs can be translated into immunotherapy use for example as a recombinant 
bioconjugate system for ADEPT. 
 
 Since we were able to express functional high-affinity scFv that binds to AGR2 
in cells, we ask if we can repeat the experiment by exploiting the AGR2 linear peptide 
motif previously isolated from peptide phage-display and construct it the same way as 
the synthetic scFv modules but with three copies of AGR2 linear peptide motif 
PTTIYY motif in tandem (Figure 6.10). The expression of the synthetic mini-protein 
containing AGR2 linear motifs (synPROwt) was also regulated by AGR2, where the 
production of synPROwt was only expressed in AGR2-expressing cells (MCF-7) but 
not AGR2-null cells (FLO-1) (Figure 6.11). Compared to the mutant form of mini-
protein (synPROmut), the expression of synPROwt requires a higher amount of starting 
DNA to achieve steady-state level. Importantly, the AGR2-binding protein synPROwt 
stabilises AGR2 expression suggesting that they interact with each other. However, 
we showed using western blot only that titration of synPROwt but not its mutant 
counterpart stabilises AGR2. This data could be further strengthened by looking at the 
stability of the synPROwt and it mutant counterpart in MCF-7 and FLO-1 cells by using 
pulse-chase experiment and to check whether proteasomal degradation causes the 
lower expression of the synPROwt. We showed using PLA that AGR2 can interact with 
the wild-type synthetic protein but not the mutants which complement our in-vitro 
protein-protein interaction assays in Chapter 3 (Figure 6.12). This data highlight the 
importance of peptide-protein interactions that regulate the magnitude of signal 
amplification in a signal transduction pathway which may fundamentally serve as 
regulatory switches. We also provided evidence using a cell-based system which may 
be further tested in animal models for potential peptide lead in the development of 
peptide therapeutics to disrupt pro-oncogenic AGR2 protein-protein interactions in 
cell systems. Such peptide therapeutics (peptide-mimetics) have been successfully 
developed in that past that exploit the respective peptide-binding grooves of, for 
example, Cyclin A [344], MDM2 [224] and HSP90 [345]. 
 
 We expanded the synthetic tools to produce EpCAM-like synthetic membrane 
protein containing the same composition as the synthetic AGR2 binding mini-protein 
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and the addition of transmembrane helix of EpCAM Figure 6.13). The expression of 
the synthetic membrane protein containing wild-type AGR2 peptide motifs 
(synMEMwt) follows the same rule as the synPROwt, where the expression is dependent 
on AGR2 expression (Figure 6.14). Remarkably, immunofluorescence analysis 
showed that the synMEMwt partially localised in the plasma membrane in AGR2-
expressing cells MCF-7 but not AGR2-null cells (FLO-1). This data provides another 
strong evidence that such sequence-peptide peptide motif in binding to AGR2 that 
result in protein maturation and delivery to its destined location and this can be 
recapitulated using artificial membrane proteins. Further experiment should be done 
to further prove this for example by counting the number of cells with plasma 
membrane expression using FACS in unfixed cells. Based on the immunofluorescence 
studies, we only observe partial plasma membrane staining and there is a degree of 
puncta staining in the cytoplasm. Based on the immunofluorescence studies, we only 
observe partial plasma membrane staining and there is a degree of puncta staining in 
the cytoplasm. We thought that this could be due to the incorporation of the KDEL 
sequence which is a strong ER localisation signal and this sequence also is absent in 
membrane protein like EpCAM. We hypothesized that if we remove this canonical ER 
retention motif KDEL we would expect more plasma membrane distribution. It is also 
interesting to assess the effect of reconstituting AGR2 and synMEMwt in FLO-1 cells 
(e.g whether AGR2 can help in maturation and trafficking of synMEMwt to the plasma 
membrane, or perhaps help the production of (synMEMwt) like we did with EpCAM 
in Chapter 4.  
 
All in all, we were able to isolate high-affinity scFv fragments that bind to 
AGR2 which can be further manipulated towards more innovative biologic drugs of 
mammalian disease. We also demonstrated using a cell-based assay that the AGR2 
sequence-specific peptide binding activity is to drive an interaction with proteins 
destined for the secretory pathway. AGR2 can function as an oncogene by virtue of 
binding to and regulate intracellular localization of not just EpCAM but synthetic 
membrane protein containing such sequence-specific peptide motif.  
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CHAPTER 7: Summary and Future Perspectives 
 
AGR2 protein has emerged in the past ten years as a major pro-oncogenic and 
metastatic player in cancer largely due to the emergence of clinical-OMICS [94] [116]. 
In human, AGR2 was first discovered as an overexpressed gene in ER-positive breast 
cancer cell lines [126] and has since been shown to be overexpressed in breast cancers 
and many other adenocarcinomas, including colorectal, oesophageal, lung, ovarian, 
pancreatic, and prostate carcinomas [94]. The mechanism of how AGR2 involves in 
cancer and how it is regulated is vaguely understood. AGR2 can involve in the 
pathways for endoplasmic reticulum stress, protein folding, transcription regulation, 
and exosome formation, as well as in biologically important pathways including limb 
regeneration, inflammatory bowel disease, and asthma [54, 60, 117]. There are small 
genomic variants found, and mostly AGR2 is associated with overexpression, 
suggesting its expression is vital for cancer cell survival. Indeed, its expression is 
linked to resistance to some current chemotherapeutic compounds, predicts poor 
prognosis and has a suppressive effect on the p53 response to DNA damage. AGR2 
also involve in tumour dissemination as it has been found to induce metastasis; found 
in circulating tumour cells (CTC) from breast, colon and prostate cancer patients [346]; 
found in higher concentration in the blood of patients with ovarian cancer [135] and 
ectopic endometriotic lesions [347]. Very little is known about the dominant pathways 
through which AGR2 signals in cancer, and therefore we are currently not able to 
embed AGR2 in any channel. Current objectives of this emerging AGR2 field, 
therefore, are to characterise and identify the protein interactions that mediate its 
function which include identification of the signalling pathways through which it can 
stimulate cell growth or drug-resistance [185, 186], and determining whether these 
pathways are “druggable”[187].  
 
We aim to investigate the biology of AGR2 using a combination of 
interactomics to identify functionally relevant binding partners. We reasoned that 
expanding the AGR2 interactome and placing “AGR2 node” in the complex network 
of cellular interactions could help to unravel its functions in normal and tumour 
samples. We began by addressing an intriguing and ill-defined core function of AGR2 
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in which AGR can bind sequence-specifically to a peptide isolated from a massive 
peptide-phage library [209]. The peptide can affinity purify monomeric and dimeric 
AGR2 from crude lysates which suggest that the peptide is highly-specific and this 
feature of AGR2 can selectively drive some of its protein-protein interaction functions. 
Using hydrogen-deuterium exchange mass spectrometry, the peptide binding site was 
found to be in the exposed unstructured turn in the region of aa 131-135 on AGR2. 
Based on the previous multiple sequence alignment of AGR2 homologs and related 
families [57, 61] including our own alignment showed that this region is highly 
conserved, indicating the likely importance of binding to the peptide interface for 
protein function. We then developed a consensus site (Tx[IL][YF][YF]) for its activity, 
and use this knowledge to identify potential cellular proteins that harbour this motif as 
potential AGR2 client proteins. Interestingly, transmembrane proteins predominated 
containing such a motif using web-based informatics approach. The implication of this 
data is that the specific docking site of AGR2 is used to interact with client proteins 
that enter the endoplasmic reticulum; in which we have validated one key protein-
protein interaction, represented by AGR2 and the oncogenic receptor EpCAM using 
biochemical assays and mutagenesis. We suggest that AGR2 has a novel function in 
which the AGR2 sequence-specific peptide binding is driving the interaction with 
proteins that are dominantly destined for the secretory pathway (Figure 7.1). In cancer 
cells overexpression of AGR2 may suggest that AGR2 is needed to promote cell 
survival by allowing the cell to withstand excess protein production associated with 
transformed cells and many of these proteins could be largely membrane proteins. In 
addition, many of the proteins identified by our database mining analysis have 
functions associated with cell growth, metastasis, and ER-stress responses. AGR2 can 
also be found in other cellular localisations such as in the cytoplasm and nucleus of 
some cell types, indicating the contribution of AGR2 to cell proliferation, survival, 
metastasis and drug resistance may be complex and mutli-faceted. Another member of 
the lab has also validated protein-protein interaction with another membrane-bound 
Meckelin protein (MKS3) which contains more divergent motif (TPIFY) using 
immunoprecipitation and colocalisation analyses which further supported the validity 
and specificity of the peptide motif, and this peptide is not simply due to a bias 
selection during peptide-phage display. Unfortunately, we could not find any 
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overlapping protein with the previously published AGR2 interacting partners, 
indicating a different AGR2-dependent processing or the identification could be 
missed using the classical approaches such as yeast two-hybrid and 
immunoprecipitation. In a yeast two-hybrid for example, proteins of the secretory 
compartments or integral membrane proteins often do not interact in the environment 
of the yeast nucleus, and it might not be possible to identify interaction that is 
dependent on post-translational modifications [348]. Thus, our data provide a different 
way of identifying interacting proteins using in which we used data-driven approach. 
Future cell-based assay developments should be directed at determining the impact on 
understanding how the EpCAM docking site (aa 247-251) facilitates its maturation or 
trafficking and how the AGR2-peptide binding motif impacts upon client protein 
maturation. For example, it would be interesting to generate a gain-of-function 
AGR2S134A (AGR2 docking site mutant that showed gain-of-function binding to 
EpCAM) or cysteine-mutated EpCAM cell line using CRISPR/Cas9 gene editing 
cancer to measure changes influx of EpCAM receptor maturation because of such 
mutations. Since both AGR2 and EpCAM can be secreted, it would also be interesting 
to check if AGR2 has an extracellular function in the future since the peptide motif in 
EpCAM is extracellular (also extracellular in MKS3). The recent establishment of 
AGR2 crystal structure showed that AGR2 exist in homodimer [61]. In addition, our 
group showed that the single cysteine of AGR2 is responsible for regulating oxidation 
state and determine its monomeric-dimeric state [99]. It remains unclear what role of 
AGR2 monomer-dimer equilibrium plays in the normal and pro-oncogenic properties 
of AGR.Thus, follow-up studies could also be directed to assess the AGR2 
dimer/monomer equilibrium, and how destabilisation will affect characteristics such 
as interaction partner binding.  
 
We further characterised the AGR2: EpCAM interaction using cell-based 
assays to understand how these two proteins can promote tumorigenesis since both 
proteins are major players in cancer development. It is also important to note that there 
is a targeted cancer immunotherapy drug targeting EpCAM (Catumaxomab, a 
monoclonal bispecific trifunctional antibody) which was approved to be used in the 
European Union [217]. Thus, studying EpCAM signalling and its maturation are 
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physiologically significant which can lead to the identification of converged pathway 
interconnecting AGR2 and EpCAM and may increase the future efficacy of drug 
development (e.g. EpCAM cell surface representation is important for recognition by 
an antibody for tumour clearance).  We demonstrated that AGR2 and EpCAM could 
bind in cells using PLA and confocal microscopy co-localisation analysis. Mutation of 
the motif on EpCAMY251A (TLIYY to TLIYA) impaired its membrane localisation in 
MCF-7 cells (AGR2+/EpCAM +) and remained in the cytosol which implied that the 
AGR2 docking site is important in cells for the appropriate trafficking of EpCAM to 
its destination. We also presented a mechanism for controlling EpCAM-mediated 
signalling using reconstitution studies in FLO-1 cells (AGR2-/EpCAM-). AGR2 can 
dictate signalling activity by determining whether EpCAM is delivered to the plasma 
membrane from the secretory pathway. Also, AGR2 could elevate EpCAM production 
as confirmed by fluorescence microscopy and western blot analysis. Evaluation of 
AGR2 and EpCAM clinical tissues of oesophageal adenocarcinomas exhibited that the 
two proteins were highly co-expressed and showed significant positive correlation 
suggesting physiologically relevant biomarker candidates for this type of cancer for 
early diagnosis and for future therapeutic intervention. As discussed earlier, the next 
step is to establish whether EpCAM glycosylation has any effect in binding to pro-
oncogenic AGR2 or whether AGR2 has any role in the glycosylation of EpCAM in 
the future. Our results thus far showed that AGR2 binds EpCAM in the ER, therefore 
it remains to be determined whether AGR2 can interact with EpCAM post-ER or at 
later steps in the secretory pathway (Figure 7.1).  Intriguingly, a recent study described 
the unexpected gain-of-function of an extracellular AGR2 (eAGR2) as a regulator of 
epithelial tumorigenesis and morphogenesis [180] suggesting another role of AGR2 in 
cancer development. Since EpCAM can also be cleaved to produce extracellular 
fragment (EpEx) and in this fragment that EpCAM harbours AGR2 peptide motif, it 
would be interesting to study the relationship of the extracellular role of AGR2 and 
EpCAM in tumour signalling.  
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Figure 7.1 Model of AGR2 role in the secretory landscape.  
AGR2 has a novel function in which AGR2 binds to a subset of client proteins containing AGR2 linear-
peptide motif that are destined for secretory pathway. Many proteins that harbour the linear-peptide 
motif belong to membrane type proteins. In this thesis, we have validated one member of this type of 
protein represented by oncogenic EpCAM. Our data showed that AGR2: EpCAM interaction occurs in 
the ER, the first compartment of the secretory pathway, possibly through its PDI family chaperone 
function in which AGR2 help in folding client protein like EpCAM. It remains to be determined if the 
interaction occurs at later steps in the secretory pathway. Our database mining approach expands AGR2 
interactome and suggests a biological role for AGR2 in the secretory pathway.  
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During this study, we attempted to make a mouse monoclonal antibodies 
targeting EpCAM. We sent the purified codon-optimised extracellular part of EpCAM 
(His-EpEx) for immunisation in mice. Three initial clones showed a weak affinity 
binding to EpCAM in western blot, and these were selected and grown further. 
Eventually, only one clone can be produced, however, this clone of EpCAM 
monoclonal antibody was not able to detect purified EpCAM nor EpCAM in cell 
lysates in western blot analysis (data not shown). Currently, we are in the process of 
characterising the localisation of AGR2-CHERRY and EpCAM-GFP using live-cell 
fluorescence imaging. We briefly showed in Chapter 5, that AGR2 movement 
resembles secretory vesicle and has a high rate of mobility throughout the cells as 
analysed with live-cell fluorescence imaging, which quite unusual for ER-resident 
protein. Our preliminary data exhibited that, when AGR2-CHERRY and EpCAM-
GFP were co-expressed in cells, the movement of AGR2-CHERRY was reduced 
suggesting that EpCAM impacted on AGR2 signalling and there is a positive feedback 
interaction exists between the two pathways. This also further supported that AGR2 
and EpCAM interact in cells. However, we are yet to find a mechanism for such 
observation.  
 
We sought to generate isogenic cell lines that carry AGR2 knockout using the 
latest CRISPR/Cas9 technology. This study aimed to use this isogenic oesophageal 
cell model (AGR2 knockout vs. wt-AGR2) to screen for global proteomic changes 
using quantitative proteomics which serve as another paradigm to identify potential 
AGR2 interacting partners and to define AGR2 regulatory network in cancer 
signalling. However, we were unable to generate a cell line with AGR2 knockout after 
two different attempts. We postulated that AGR2 edited knockout cell line was lethal 
which was supported by a few pieces of evidence in mouse knockout models showing 
lethality as a result of AGR2 knockout as discussed previously [60, 63, 289]. We then 
opted to reconstitute AGR2-null cells, FLO-1 using transient AGR2 overexpression 
and process for mass-spectrometry analysis. TMT mass spectrometry quantitation 
showed that the proteome of reconstituted wt-AGR2 cells exhibited many 
downregulated proteins while the AGR2-KDEL showed many upregulated proteins 
suggesting that the two AGR2 variants have specific distinct signalling pathways. 
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There were overlapping proteins between the two AGR2 variants expressing cells 
which can be potential AGR2 interacting partners and can be integrated into AGR2 
‘signalling pathways’. Both AGR2 reconstituted cells showed enrichment in exosomal 
and lysosomal proteins suggesting AGR2 role in cancer signalling in this oesophageal 
cancer model and this also complemented our current hypothesis that an ER-resident 
protein AGR2 involve in the secretion of proteins destined for secretory pathway. We 
chose one protein, DCD, which is a secreted protein and has been implicated in cancer, 
as a potential AGR2 interacting protein. Our initial data showed that the level of DCD 
was downregulated in both AGR2-expressing cells compared to non-reconstituted 
cells, which contradicted the mass spectrometry data. The fact that DCD is rarely 
found in its full-length form due to high-susceptibility cleavage by proteases to form 
functional peptides, and the lack of antibodies, complicates our analysis to detect DCD 
changes in our cell models. DCD was also found in another proteomics screen in our 
lab SWATH mass spectrometry analysis of ELMO1 pull-down from FLO-1 and OE19 
cells (Ali Alsaadi thesis 2016, and personal communication). ELMO1 was shown to 
form protein-protein interaction complex with AGR2 as well as DCD in cells using 
PLA. Since we do not have evidence that AGR2 interacts with DCD, we speculate that 
AGR2 may bind DCD through the interaction with ELMO1 or with one of ELMO1 
signalling proteins. The next steps of this study are to define the mechanism whereby 
AGR2, predominantly an ER-resident molecular chaperone, promotes the expression 
and secretion of DCD and then to link to changes in key cellular phenotypes (e.g., does 
AGR2 affect DCD proteolysis proteolytic processing). We recently obtained some 
DCD drugs in which we can test on our cell models. For example, we asked whether 
AGR2 expression in FLO-1 cells (since AGR2 increase production of DCD) can 
sensitise DCD to these drugs. We also aimed to repeat the experiment by performing 
protein glycosylation-targeting enrichment prior to mass spectrometric analysis to test 
our hypothesis that AGR2 can bind and mature membrane-bound proteins. In addition, 
most of the membrane or transmembrane proteins identified from database mining in 
Chapter 3 are known to be post-translationally modified particularly glycosylation and 
most contained a large number of cysteine residues. 
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Along with the identification of AGR2 interacting proteins, synthetic tools 
were devised and engineered to dissect the pro-oncogenic AGR2 function further. This 
study, using synthetic scFv phage library, we have successfully isolated 5 different 
classes of scFv fragments that bind to both full-length AGR2 and AGR2 peptides. One 
particular scFv fragment (scFv4) bind with high-affinity to the N-terminal of AGR2. 
Expression of the scFv4 in mammalian cells showed that its expression are regulated 
by AGR2, but AGR2 expression itself remain unchanged. Therefore, next study can 
be focused on finding the mechanism of how this AGR2-specific scFv can affect 
AGR2 expression. Currently, we are in the process of purifying the AGR2-binding 
scFv4 from bacteria so that we can further characterise the antibody (e.g., how scFv 
binding to AGR2 influence AGR2 structure, and affect AGR2 interactome) and 
determine its pharmacokinetics properties. Experiments are underway to clone scFv 
into an imaging vector that fused the scFv with EGFP protein, so we can analyse its 
localisation, and check if the expression has an impact on AGR2 expression or AGR2 
interacting protein in cells. This scFv can be potentially translated for the specific 
probe for in-vivo fluorescence imaging, for example, use in the detection of cancer-
specific cancer since AGR2 was selected as biomarkers for some cancer types. We 
also developed a synthetic mini protein containing AGR2-peptide docking motif 
(synPROwt) to show the specificity of the peptide in cells. The mini-protein expression 
in mammalian cells was negatively regulated by AGR2 and its expression stabilised 
AGR2 protein levels. Also, PLA showed that the AGR2 and synPROwt form protein-
protein interaction in cells. These findings further supported our in-vitro data that 
AGR2 has a sequence-specific peptide binding activity that drives (some of) its 
protein-protein interaction. Finally, we engineered synthetic membrane protein 
(synMEMwt) containing AGR2 mini-protein and EpCAM transmembrane domain. 
Expression of the synthetic membrane protein was also regulated by AGR2 expression. 
Importantly, in the presence of endogenous AGR2, the expression of the synMEMwt 
was seen to localise partially in the plasma membrane as analysed by 
immunofluorescence, suggesting that AGR2 recognise the sequence specific peptide 
which then channels the protein to secretory pathway and to its final destination. Future 
cell-based assays can be performed to check if synMEMmut plasma membrane 
localisation can be rescued by ectopically expressing AGR2 in AGR2-null cells (FLO-
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1). This will further support our data that there is a sequence-peptide peptide docking 
motif in AGR2 activity. The specific docking site of AGR2 is used to interact with 
client proteins that enter the endoplasmic reticulum which is then processed for proper 
maturation and delivery to its destined location. 
 
In conclusion, our data highlight an unusual feature of a “molecular chaperone” 
class of proteins that exist in the endoplasmic reticulum (sequence-specific peptide 
binding). We discovered that proteins containing the consensus AGR2-peptide 
docking motifs were highly enriched in transmembrane proteins. We suggest that 
AGR2 has a novel intracellular function in which the AGR2 sequence-specific peptide 
binding is driving the interaction with a subset of client proteins while they are 
trafficked into the secretory pathway. We also provided a working model of how 
AGR2 can function as an oncogene by virtue of binding to and regulating intracellular 
localisation of one member of membrane proteins which is an oncogenic receptor 
EpCAM.Such sequence-specific binding can also be recapitulated using synthetic 
membrane protein containing such a motif.  We presented data from proteomics 
screens suggesting that AGR2 showed upregulation for proteins involved in secretory 
pathways. We also developed synthetic tools such as high-affinity scFv fragment 
targeting AGR2 and mini-protein containing AGR2-peptide docking motifs that can 
be further manipulated to target AGR2 signalling pathway.
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CHAPTER 8: Appendices 
8.1. Appendix 1 
Raw graphical data summarising AGR2 ligand binding (peptide A4) effects on AGR2 
conformation analysed by hydrogen-deuterium exchange mass spectrometry.  
 
8.2. Appendix 2 
Protein hits list from database mining using AGR2 consensus peptide binding motif 
Tx[IL][YF][YF] in ScanProsite (http://prosite.expasy.org/scanprosite/).   Hits were 
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8.3. Appendix 3 
Excel file of functional enrichment analysis of motif hits list in Appendix 2 using 
FunRich. 
 
8.4. Appendix 4 
Raw graphical data summarising effects of the S134A mutation on the overall 
conformation of AGR2 protein analysed by hydrogen-deuterium exchange mass 
spectrometry.  
 
8.5. Appendix 5 
Excel file of TMT mass spectrometry quantitation of FLO-1 cells with transient 
overexpression of wt-AGR2, AGR2-KDEL, or EV control. 
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